<SEC-DOCUMENT>0001439222-20-000039.txt : 20200430
<SEC-HEADER>0001439222-20-000039.hdr.sgml : 20200430
<ACCEPTANCE-DATETIME>20200430094720
ACCESSION NUMBER:		0001439222-20-000039
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200430
DATE AS OF CHANGE:		20200430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGIOS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001439222
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36014
		FILM NUMBER:		20833580

	BUSINESS ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-649-8600

	MAIL ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AGIOS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20080703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>agio-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a02d1e66-dea3-48df-83b5-cb17f8e40104,g:f4811f45-5f64-498d-9bc7-c730ea92ab47,d:7c71c9a7a53d48458a969df1a7cd05a7--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:agio="http://agios.com/20200331"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>agio-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGFibGU6YTA5MzYxNTgwMmQxNGNjZDgxYWNmMTk4NDI2ZGI5ZGEvdGFibGVyYW5nZTphMDkzNjE1ODAyZDE0Y2NkODFhY2YxOTg0MjZkYjlkYV8zLTEtMS0xLTA_95a75c41-b3e2-41b4-a3e6-105dcad1302d">2020</ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGFibGU6YTA5MzYxNTgwMmQxNGNjZDgxYWNmMTk4NDI2ZGI5ZGEvdGFibGVyYW5nZTphMDkzNjE1ODAyZDE0Y2NkODFhY2YxOTg0MjZkYjlkYV80LTEtMS0xLTA_f5dd56ba-816f-4afb-9b8b-1a203deabf84">Q1</ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGFibGU6YTA5MzYxNTgwMmQxNGNjZDgxYWNmMTk4NDI2ZGI5ZGEvdGFibGVyYW5nZTphMDkzNjE1ODAyZDE0Y2NkODFhY2YxOTg0MjZkYjlkYV81LTEtMS0xLTA_e4f67d33-6980-44c3-8332-cee4f46f779b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGV4dHJlZ2lvbjplMDM0ZDI3NjRkZTA0MmVhYmNiYjVjZjZjNjBkZWZhOF84Ng_5555295e-b5d3-4b42-9c44-d48ac15a0aca">0001439222</ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGV4dHJlZ2lvbjplMDM0ZDI3NjRkZTA0MmVhYmNiYjVjZjZjNjBkZWZhOF84OA_17f3fd28-3dbb-4085-9a10-a42bfdc9c3d5">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531" name="agio:RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzI5ODUzNDkxMzg3MA_e91388f5-9090-44e2-9f63-c9d6bd473913">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531" name="agio:RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQ4NQ_1f9fa6ea-bf2b-47b0-80ab-ef3b836dafa9">P1Y0M0D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="agio-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i862ee064d0b64106a97a0864c5e2a292_I20200424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ieb4111aca4884f158039e11aeb841e7d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i35fda49bee8b485999b812e174739a48_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68cad50d747b48a7b8ceb77216e8aa02_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e999092fe5a47b995df7486ab8722ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02db62d3a5c6475eb891c555c988387c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41094e12553647d993f3c81751f72fe6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54eae18cd0904e9d906affdbfe7dceef_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82eaa651b994a398eb65997f0b11e71_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if879b8d640fd4528a046bfb43e105676_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4ece46885443dfb8b45982f5c1d81a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37911106fe1449f9034156faa5eb2a6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic89fcca3dd5745338d1cfd3260db99f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae2b4e4df79d4fe1bf3634518d64c589_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib08167bb5f1945769d6ee3657f77ca59_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0449bd3f63554820bbdfb7c723787243_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5089bb6eb61f47bd86313de5659a1590_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cbd70b0ea74776a5302b8c60f708dd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5ad1c314b54412beee6289ce701979_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06129accabc84db1998139916e3bfdce_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9781e5291b34a4b96ee6b85750b185a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22c76c636c44318bd5ddf5c65c4945e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8958bd3f29941f2aa800c1928252121_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db96c6a87374048ace2fc1cb33ea464_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b788f2270d84d63a475d1b2aecbeaf8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c76a8d5c9f047fdb64349f6cebc1f11_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62be91ce449047f7b038e5f03bcc8373_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a5f41773d3e4ddd9bceaac90793a7ee_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64beb8c427754afbbeb4323e2204e1ce_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfdf8a5d4f2b461cbcd4e7f10715380a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c9a056637214d5796f17b4822cda10e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a0427dc88004cdb9ad5b111ee121e8a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6971d4a30427440ba662d8d10de5fd9a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9f97f0add14e97ac35d6c17a93e045_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d5f65c2dfb44ce892a2a2a36fc23f81_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4edbcb8341ca4ae9a52de4dfbc7f3fa9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic285bdb5cfff4f9bb6e8c6aa8bd0aef6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2896d589cf7469a8775ecf2af7fef57_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d69f26b53ee4c3e8ba4149462acd30a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5ae1f4e6da4a40ab90e89f131655fc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980609409a6b4e13b07d000c6cdd7d2c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237b15fb46da4b59a1a6fac0feae116a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7da42c6aea42a087aa27c849a90448_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i852744abdf2745b18e0f60fa3df00339_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f8f8fda49a94e84b0a5c8d9bd24a8ef_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i635947295b764abfbbdea991d6fe54fc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6cbec674e741b4a873e845b45a4e31_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4fdeb9348b94b618851880b5c977d5d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9f32329914f4f5ba7b80bae3b347fda_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474102d2baee43179a37e278bb04cf73_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244896107f9d40bd82157d3c93e71bad_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3fe9a6e1ebc48a49cc37d47c38c8288_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e239c737d2f45488edacb7ef4b2bb95_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689b528c68d6471cbeca1282d66876f7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe05f5bb5bf340819df84fa9a1e20a30_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0502aed7c32c4db0853962e904c21847_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i108de68f38fd4fabbe1b522da2bfee56_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85ccd9c5271946ae8ea7524c2ea81976_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i554916221ecb43d4bad1bebdd455085e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba4c2b9d8104e2092c8a1578a072d33_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia264a24d96044bba896491152779474a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74269132e8824b1d9ae169ad9bcfd579_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf88bf362c84475c8e9b943d30632f1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4917f73e8bc4c0d8651d34dc493d64d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2183ebcadc4450b714435b21b5ba17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2021a05d78884df3b63427ad0ed8fbef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i985faa780d224792b8352dc1688c2523_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae56b3854004a2ab8062e84d6051194_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>agio:security</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie585f0844fac40089fdc45382188ce5a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="extension"><xbrli:measure>agio:extension</xbrli:measure></xbrli:unit><xbrli:context id="icf8e4931186847f7af3d6555eddb2ef4_I20160517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d39d16372b54ef7b70c6ceb2f6802c9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8cc725b4829480fa6c29d3f371c5ae3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d50ef5ca59c4f6d94a83843d5742328_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91175df5ecdd49638bd57d0783c41bdc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108d62e896fc49d1b83a96231e5bc13e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3447e34e86e4a2ea996f1ad6af3f411_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc256153a0dc460d8411bbd9eb5fbb40_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2a9618801f42c48cc8313f6b4cd731_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c90550dda24d7eb8b02c2f2c2f719e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d243dbfb39c481597c75558a4b5ffa9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d106c4df9564a3caf0ba3be633967df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i811057ddd1de4d0eb6492cfeadecbf6a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096066d9ee4641e1b8faebda2ab34627_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84fd2a101824c788fae2a197d74ffa9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04eae8cb5824809b789766bea430fe0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6726df3a7204f6b9e2e0d1efc7914f1_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da6969fb0f94cae987375f25efa45d4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b95111b950c47f2a99d64f7549560da_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9319d12250d4cd4816f3f7f9a1a58ec_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54283dcee9d43cf9fb07a1481b6d9dc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda041072edb42d2a45ab6f7a35301cf_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9f069f49404c26883dc94c9bf8bf4b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57699cbaff4472d9cf3ea62c0cbb2fb_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id861975ff87f4dbc8890a79d84ea157e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie310e674843d43f68873f2b9cc63f547_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f90389d1054ec5a3f958cb88835d5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280f176668304207a8331664a7bf1e74_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5252cae278436a972c726382d0b31e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i269bc734bdc446a984c9d2c5b91a592c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38711366192418d8c09c3d6abfa8e66_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e49459503f4101adaa3ac89788c0cc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e8393880f542d281e86b6aff922c87_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida454044d7e04cf78a0d3ed1df7dd45d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04dd698bbbf04386be79177cadfcb551_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72433a7819146b3a0daa5c98f8ffa28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7485735e584ad183fa3ab8df167007_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i458a6e5895e2457b9575fb921714653a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfe0ad5afa984d16ba94c0190f3a7bb7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc517a1325e3471bb6ee91315080f545_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ac445102f7441f9e4b8ba54ae46f21_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0177361b9c4b0b90dc4288e2d48078_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256d78b2b36e45f28bd9b75429058398_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i899a9e83495b4f28b410853e4bd3e1a9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d21d465e804cd7be91d92333466787_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8dacf8900174e15a3112799baf17da0_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e96f9d80bf045189e770a60c9426d0f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id544e772704d4df68d5aafeb2c9bb919_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00295454cded4864b99639e493192cdc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida2a85e29bc44bb4b78adcee2aa8a238_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b778fd9cd91494abee392de786ad04e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3964e595953c4f299314ea4efb11d354_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1c325e2dd54b6aa424bba94309ad67_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d3013b6a4c4bdbae10be0d1e36aeec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4533663f1404a6c94d173dbdd0d8fe6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc2e58225fba4370abf79603604d587c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f2e56eb9624864a6a945bcd372afda_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09bbe0bec9644d0bdb9f127f396b6ee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c6cd3484924f04bded7e03913923fb_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d93efc8a284556ab8f020edd3dc6e0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a127ee084474fe89e94f05cb952f47b_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091c1b621ade4bb9a85dbc64bfb48525_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7729db14fc3848fe915720a14a4de566_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a6e57a772564177acc7f7a661b71d0f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07875a2aa9f4507b1f46ea8b5fed18d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c7313c325334ec4b2e51b1fbd9a8afb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i429a7cb2f66d4ba1976785a1a8199946_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_1"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Washington, DC 20549</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:21.345%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY184Mg_f709a33e-75e7-454d-b0d8-3e9ea89d7cdc">10-Q</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:21.345%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6MzcxNDk4YmY2NjU4NDViZThhMTQxOWRlZGUxYWFhYjkvdGFibGVyYW5nZTozNzE0OThiZjY2NTg0NWJlOGExNDE5ZGVkZTFhYWFiOV8wLTAtMS0xLTA_06fa7edd-394c-4800-a0ea-55caf19df8a8">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xMzE_ebb92f6e-40ad-47b8-8fa8-c5d2455fe964">March&#160;31, 2020</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">OR</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6YWI5NWY1NjJjMzM1NGI1NWIzNjg1YmU4OTNlODczMjgvdGFibGVyYW5nZTphYjk1ZjU2MmMzMzU0YjU1YjM2ODViZTg5M2U4NzMyOF8wLTAtMS0xLTA_0412f77c-6f3f-4d4d-bcc1-5c0f329a5b5f">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xNjI_63f10415-149c-4ef9-bbd6-15bc16a47db6">001-36014</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:21.345%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xNjc_d3d03e58-fc41-4137-b425-3347180673d2">AGIOS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:21.345%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"><tr><td style="width:1.0%;"></td><td style="width:19.107%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.718%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.349%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8wLTAtMS0xLTA_6e37b1f5-9434-4d9f-b046-e394a351d169">Delaware</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8wLTMtMS0xLTA_32648baa-cc24-4794-9728-90fa5aacefc1">26-0662915</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or Other Jurisdiction of<br/> Incorporation or Organization)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S.&#160;Employer<br/> Identification&#160;No.)</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiN2UxZGU3NDI5ZTE0ZjM5OTQ3ZmViNzkxYWNlZjBiZl80_96101a1f-e460-4545-b6ec-44a9f8e13d1a">88 Sidney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiN2UxZGU3NDI5ZTE0ZjM5OTQ3ZmViNzkxYWNlZjBiZl84_3e6c99d3-d0e2-4749-b029-9d804cde53d8">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiN2UxZGU3NDI5ZTE0ZjM5OTQ3ZmViNzkxYWNlZjBiZl8xMg_cd825cf1-f90c-4171-84c4-c51a0c5e2526">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTMtMS0xLTA_ed55a258-2b65-4174-a501-159c5a678217">02139</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of Principal Executive Offices)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18yMzE_7e61a7bc-fb32-49f1-a787-389aba284827">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18yMzU_d0a59a0b-48ad-401a-88f1-091aa0d656e8">649-8600</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center;margin-top:12pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:21.345%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="margin-top:3pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.596%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.491%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.913%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzhmNTg4MTQ0NGNhNGYxZDg4YjhmZjIwMjY2NjNjNzYvdGFibGVyYW5nZTo3OGY1ODgxNDQ0Y2E0ZjFkODhiOGZmMjAyNjY2M2M3Nl8xLTAtMS0xLTA_e60bd73c-cdee-4d9d-8304-be0b59c4d2ab">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzhmNTg4MTQ0NGNhNGYxZDg4YjhmZjIwMjY2NjNjNzYvdGFibGVyYW5nZTo3OGY1ODgxNDQ0Y2E0ZjFkODhiOGZmMjAyNjY2M2M3Nl8xLTEtMS0xLTA_7eb3611d-5b53-4ef2-a1ac-dfce3988f28a">AGIO</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzhmNTg4MTQ0NGNhNGYxZDg4YjhmZjIwMjY2NjNjNzYvdGFibGVyYW5nZTo3OGY1ODgxNDQ0Y2E0ZjFkODhiOGZmMjAyNjY2M2M3Nl8xLTItMS0xLTA_88c4646e-061d-42fa-93ef-94c5b724bd59">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY183ODg_370b909f-8568-4613-8401-9dcfd35fb5a2">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:24pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xMTE1_a16acab4-fa5f-42a1-b679-7e7cc33fe382">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:24pt;margin-bottom:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:26.928%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.052%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.375%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.445%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzNhZTE1ODA2MmZiNDc1NzhlNmFiMjk1MjcwZWZhYTMvdGFibGVyYW5nZTo3M2FlMTU4MDYyZmI0NzU3OGU2YWIyOTUyNzBlZmFhM18wLTAtMS0xLTA_dc87e081-8298-4ae4-b185-981176c1a9ec">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzNhZTE1ODA2MmZiNDc1NzhlNmFiMjk1MjcwZWZhYTMvdGFibGVyYW5nZTo3M2FlMTU4MDYyZmI0NzU3OGU2YWIyOTUyNzBlZmFhM18xLTMtMS0xLTA_f474078a-b6eb-43b4-be31-2efb2ecaee47">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzNhZTE1ODA2MmZiNDc1NzhlNmFiMjk1MjcwZWZhYTMvdGFibGVyYW5nZTo3M2FlMTU4MDYyZmI0NzU3OGU2YWIyOTUyNzBlZmFhM18yLTMtMS0xLTA_8875a33c-17b9-44d0-8c6b-13bf9c16a4fa">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24pt;margin-bottom:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:24pt;margin-bottom:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xODU3_d4eccb1a-bca4-4a51-90d5-877f80d728f8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160;&#9746;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Number of shares of the registrant&#8217;s Common Stock, $0.001 par value, outstanding on April&#160;24, 2020: <ix:nonFraction unitRef="shares" contextRef="i862ee064d0b64106a97a0864c5e2a292_I20200424" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xOTU5_07044b9a-0634-4ce0-b0d5-c157d0ec7a41">68,889,380</ix:nonFraction> </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_7"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORM 10-Q</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FOR THE THREE MONTHS ENDED MARCH 31, 2020 </span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:6.797%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.017%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.186%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Page</span></div><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">No.</span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_10">PART&#160;I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_16">Condensed Consolidated Balance Sheets as of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_16">M</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_16">arch 31, 2020</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_16"> and December&#160;31, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_16">19</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_19">Condensed Consolidated Statements of Operations for the Three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_19">Months Ended </a>March 31<a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_19">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_19">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_19"> and 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_19">19</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_19">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22">Condensed Consolidated Statements of Comprehensive Loss for the Three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22">Months Ended </a>March<a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22"> and 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22">19</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_22">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25">Condensed Consolidated Statements of Stockholders' Equity for the Three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25">Months Ended </a>March<a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25"> and 201</a>9</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_25">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">T</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">hree</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28"> Months Ended </a>March<a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28"> and 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">19</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_28">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_67">18</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_88">26</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_91">26</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_94">PART&#160;II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_94">28</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_97">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_97">28</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_475">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_475">62</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_100">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_100">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_103">Signatures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_103">65</a></span></div></td></tr></table></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_10"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_13"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1.&#160;&#160;Financial Statements (Unaudited)</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_16"></div><div style="text-indent:36pt;text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;">(Unaudited)</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:76.070%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.674%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMy0xLTEtMS0w_c8e58068-2fb8-4c96-a656-00b4d2f0287e">89,093</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMy0zLTEtMS0w_eb3b624b-fc53-45a0-8409-24cb93e802db">80,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNC0xLTEtMS0w_986b6370-ba1e-4178-83f1-2839b2cdf0a0">439,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNC0zLTEtMS0w_0d8eead6-5525-4d1c-bf37-b77d72ca66b5">483,946</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNS0xLTEtMS0w_7ff21d76-742d-4604-b6c2-08baad7e1b44">11,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNS0zLTEtMS0w_aea298f3-8d49-4a94-8b16-79724cb21d5c">8,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration receivable &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNi0xLTEtMS0w_36bab38a-6ed6-43e5-b9b8-16044eacd462">2,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNi0zLTEtMS0w_114b4a7c-2913-4a37-bf2f-b8f5e4b16c67">1,539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration receivable &#8211; other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNy0xLTEtMS0w_8d4fb11e-24de-4df2-a695-018d68a0bb02">2,033</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNy0zLTEtMS0w_92308c6e-7965-4a15-813c-1eb6699a45b9">1,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty receivable &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:RoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOC0xLTEtMS0w_3ef0c084-ebd2-4410-9cca-768c683e3bf8">3,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:RoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOC0zLTEtMS0w_3efea33f-023c-4ba7-ae14-e423b88b85f0">2,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOS0xLTEtMS0w_f83b8471-d5d1-487c-ae78-9b0e58dcb64f">9,778</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOS0zLTEtMS0w_f1b569cf-9a9c-4609-bca0-aa30cf9b1249">7,331</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTAtMS0xLTEtMA_98e83f59-2eb3-4eb5-a9e5-fad10e6e637c">29,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTAtMy0xLTEtMA_426fea81-d61d-448f-a102-1f2b29c94c1a">24,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTEtMS0xLTEtMA_8501b195-ffd1-44cf-a07e-bfaa7de145c6">587,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTEtMy0xLTEtMA_c4245eda-51b2-4468-8f8e-02a4462e2401">611,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTItMS0xLTEtMA_8883f5c1-a920-4dee-bc9e-720aedc2f6f1">84,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTItMy0xLTEtMA_0226e0c6-cb9b-431d-82a2-a9d858b3e4b8">152,929</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTMtMS0xLTEtMA_0bc2b746-dfb2-44ae-a910-db630b07914e">91,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTMtMy0xLTEtMA_2a7e08bd-fd85-403e-b6ef-9273d4e5112b">93,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTQtMS0xLTEtMA_f4e4b858-5fdc-4008-ac38-078d6fe2b969">33,840</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTQtMy0xLTEtMA_a459bed0-84e6-42ca-8fc1-a2e2a5ae7dae">31,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing lease assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTUtMS0xLTEtMA_5c6fafc8-74a9-43df-b9d0-2e4971b8d2b9">881</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTUtMy0xLTEtMA_ec8b245e-2868-4b60-8173-f72bf0c0a334">993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMS0xLTEtMTc4OA_3bc150ed-2784-407d-8ea4-1ae667f1106c">1,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMy0xLTEtMTc5MQ_af26638a-3043-460d-9196-91f2145841a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMS0xLTEtMA_46256270-4fa9-4418-a6ee-9e92e6c0aba8">799,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMy0xLTEtMA_ba54614b-4610-41f4-ad09-98ee00872dde">890,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTktMS0xLTEtMA_85f0569e-9cdc-4b92-9e21-b75e1844cc4b">18,707</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTktMy0xLTEtMA_73e8e8ad-350a-4752-93b2-c27268279603">21,896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjAtMS0xLTEtMA_30c8951c-db79-4660-be3d-79bfbe1a33a9">39,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjAtMy0xLTEtMA_c66f959b-87f6-4862-98bf-a9089da98354">53,142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjEtMS0xLTEtMA_7b192c58-0c1c-4efb-88ad-d4a4eefb15a3">4,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjEtMy0xLTEtMA_8b39017a-6565-4b5a-b2db-471da12ae715">10,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjItMS0xLTEtMA_5149c70e-320d-4237-b74c-a2391c98e54c">6,466</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjItMy0xLTEtMA_46a29e11-da0d-4742-b25d-567a6c06e0b0">6,642</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjMtMS0xLTEtMA_8538fd9c-c358-45ab-b481-8b9c547b25ab">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjMtMy0xLTEtMA_32ed4e1c-ce22-499c-ba23-0301269294b4">273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjQtMS0xLTEtMA_71c1fb77-59bc-4ed8-bbd3-86ab3761cb26">69,858</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjQtMy0xLTEtMA_e3a20fe5-813e-4e85-89fa-3c6348b374f0">92,886</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjUtMS0xLTEtMA_96a25983-6892-442c-a374-9ec5044910a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjUtMy0xLTEtMA_06193a65-471a-4ddd-9566-68ee90ba90ba">50,580</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjYtMS0xLTEtMA_394fdc87-e860-4b51-af5d-51112463074e">104,010</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjYtMy0xLTEtMA_9d0a2c2e-49e2-4f0f-a08e-e8f4bfad21ed">106,074</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjctMS0xLTEtMA_fa2b0837-7506-4561-8b5d-d103d75074f1">571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjctMy0xLTEtMA_0a2c02a6-ec8e-41ca-91ca-f82f90bfd4cb">673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjgtMS0xLTEtMA_39d627af-26fb-4e09-a3b8-ff5ee501a6fd">174,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjgtMy0xLTEtMA_4e09f38b-1125-4cff-a395-7076a42c1cc1">250,213</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzIx_02e1e0c9-8178-4651-8c6a-25bebb492513"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzIx_3e785395-7102-4574-9c39-30d95596d0f5">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzM1_87d790af-cf2a-49b2-837c-a7cbb0ec7158"><ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzM1_da41ba03-6816-4869-a1ca-36a76ac10b81">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_06606bc1-f91e-442a-9750-46f57c07388b"><ix:nonFraction unitRef="shares" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_08b276db-0e5c-40da-9e8a-ea4a71788517"><ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_6d34a51b-f8b7-47d9-8f3c-134621ccbb11"><ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_ee55b380-1eca-4b0f-9e10-714596013e36">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at March 31, 2020 and December 31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMS0xLTEtMA_f3112198-d3af-4ab2-aa63-4a2c5c4d8dec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMy0xLTEtMA_e8e161fe-f2b3-4294-9a94-867adf9eefb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzE4_8306a027-359b-4b94-972b-abad230695dc"><ix:nonFraction unitRef="usdPerShare" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzE4_c4c1d208-f3c3-48dd-9c34-95943f8ebc48">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzMy_c3b22cbc-9f20-4603-8f20-1e29929f2f27"><ix:nonFraction unitRef="shares" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzMy_f9a8116a-5570-4b02-a3d0-2e1fc8678d5d">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzU0_4202f64b-d01d-46eb-90a6-e78032b05527"><ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzU0_b1852341-1adb-4dcd-b67b-1ba09dc74f80">68,789,925</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzYx_27f8fe79-ddb8-48e5-9928-cfa576628539"><ix:nonFraction unitRef="shares" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzYx_48e28be4-8943-4369-a8d1-043d637d8d83">68,401,105</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMS0xLTEtMA_0f94b124-c890-4ecc-acf4-2f30faff2a4b">69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMy0xLTEtMA_4f7d4f1e-16b2-4d9f-976c-fa6b630f95b5">68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzItMS0xLTEtMA_89cd6f6b-0f82-4908-9057-7cb90c4bc3a4">2,181,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzItMy0xLTEtMA_2eaf27da-2d66-4b27-8e55-f0884f867c59">2,156,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzMtMS0xLTEtMA_516ef55e-714c-41ef-bfd0-ee5bd9a1ccc8">74</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzMtMy0xLTEtMA_0740660b-7260-4478-aa24-80d6f0aa502e">202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzQtMS0xLTEtMA_5f2aa7aa-9782-4dae-8b35-f7667a3fcd6e">1,556,361</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzQtMy0xLTEtMA_edb358ce-d9f1-4a23-b923-2aa298f4a34f">1,516,105</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzUtMS0xLTEtMA_4a203df8-e4c8-4070-b510-65bc139c4229">625,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzUtMy0xLTEtMA_6ebaa8d4-de30-4f84-bba9-98678b0798f0">640,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzYtMS0xLTEtMA_af6df1bb-10c0-4cab-81b5-4ca9a69ccb5a">799,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzYtMy0xLTEtMA_e37b83ba-ee01-41b5-ac3e-b6d2cdd4b05a">890,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_19"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.830%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35fda49bee8b485999b812e174739a48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMy0xLTEtMS0w_e76ea54d-49c3-4221-8fd1-2116f8e5df71">22,674</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68cad50d747b48a7b8ceb77216e8aa02_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMy0zLTEtMS0w_771cb60d-38b7-48a7-9e8f-a5a074c1a4cf">9,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e999092fe5a47b995df7486ab8722ad_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNC0xLTEtMS0w_430bb797-dd93-4cb2-bad0-56ddb8529096">60,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02db62d3a5c6475eb891c555c988387c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNC0zLTEtMS0w_6b85b29e-bb9e-43e9-baa3-29c9e22c095b">17,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue &#8211; other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41094e12553647d993f3c81751f72fe6_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNS0xLTEtMS0w_926cbf29-6574-4b7b-9735-379d29563624">993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54eae18cd0904e9d906affdbfe7dceef_D20190101-20190331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNS0zLTEtMS0w_24bb7d3a-6097-4caf-9431-e92e01b47398">970</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty revenue &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic82eaa651b994a398eb65997f0b11e71_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNi0xLTEtMS0w_4c01b13c-2171-4d5a-a43d-45b2d37a8cc0">3,334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if879b8d640fd4528a046bfb43e105676_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNi0zLTEtMS0w_3743b21c-3e05-4c84-8168-272d35f4cf83">2,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNy0xLTEtMS0w_8a601348-d4a7-4d1e-88c3-678cf237d2c3">87,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNy0zLTEtMS0w_f4cf1a94-e1e6-40b4-88d2-5e015afe3466">30,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfOS0xLTEtMS0w_47d09b68-cfeb-487c-9b44-5cda6415f28d">533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfOS0zLTEtMS0w_42f866ff-b0af-42a6-b36b-9267b7b3c246">334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTAtMS0xLTEtMA_9a6bc720-8e24-490e-9cf4-52277ae33f6d">91,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTAtMy0xLTEtMA_50472083-d5fc-47bd-a1f9-c8d8279a0502">95,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTEtMS0xLTEtMA_e44d3b46-a953-4031-afab-d7fa725c5e79">38,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTEtMy0xLTEtMA_720d6cf3-f185-46b0-a13e-f829197b78a6">31,791</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cost and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTItMS0xLTEtMA_bb4e5eda-c1f2-4079-828b-34666e0f6a7a">130,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTItMy0xLTEtMA_0057b71f-3fdd-46f7-8b84-f3755f48adaa">127,710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTMtMS0xLTEtMA_53c07f43-7b49-428b-9017-865e8faa66be">43,192</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTMtMy0xLTEtMA_467773de-022c-41ff-ac06-60d0c176e796">97,483</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTQtMS0xLTEtMA_cd44194a-6f78-419a-a5c4-3a7d4a795779">2,936</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTQtMy0xLTEtMA_d60473ea-c9c8-4722-b4c7-868f93fbc1cf">4,405</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTUtMS0xLTEtMA_cecf5592-de19-43d9-baf5-b1010ebcb09e">40,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTUtMy0xLTEtMA_8da73c4a-f678-442c-9b4f-bbef609d45b5">93,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share &#8211; basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTYtMS0xLTEtMA_0eeaa883-0db9-4eb6-bb2f-91986730993b">0.59</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTYtMy0xLTEtMA_59887939-9492-40f0-b59a-d6ac62de65eb">1.59</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTctMS0xLTEtMA_30f0bbed-2d12-4f5b-9ff4-0ffa6c435ffe">68,608,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTctMy0xLTEtMA_6caf9831-83de-4ddd-8a44-e5e57087cd69">58,453,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_22"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.830%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">(In thousands)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfMi0xLTEtMS0w_cecf5592-de19-43d9-baf5-b1010ebcb09e">40,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfMi0zLTEtMS0w_8da73c4a-f678-442c-9b4f-bbef609d45b5">93,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (loss) gain on available-for-sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNC0xLTEtMS0w_af5a40ea-562c-4651-b2a2-1c8296ada092">128</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNC0zLTEtMS0w_5ef49a94-0eb9-4b1f-bf05-f89dbaae59e4">1,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNS0xLTEtMS0w_ff560841-a7c0-4167-b93c-0099069d5941">40,384</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNS0zLTEtMS0w_2d984111-410f-4e0e-b0e8-2030b16a9123">91,391</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_25"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:29.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.964%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.964%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.134%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.388%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share amounts)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0d4ece46885443dfb8b45982f5c1d81a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi0xLTEtMS0w_302c4626-8088-4778-a136-8287b2991133">68,401,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d4ece46885443dfb8b45982f5c1d81a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi0zLTEtMS0w_da2fff5c-e1d1-451f-92a6-92678fa9b244">68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id37911106fe1449f9034156faa5eb2a6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi01LTEtMS0w_d7e235eb-39bf-43db-ab94-49b74e98e8f9">2,156,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89fcca3dd5745338d1cfd3260db99f1_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi03LTEtMS0w_5dee418b-f0e0-4ede-aeed-e78009d5455e">202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iae2b4e4df79d4fe1bf3634518d64c589_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi05LTEtMS0w_0d5188f7-d085-4410-b2d7-066e23800006">1,516,105</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi0xMS0xLTEtMA_01bc103d-cae2-4c89-bd04-5eafaae2d15a">640,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib08167bb5f1945769d6ee3657f77ca59_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC0xLTEtMS0w_572bd038-82a0-41cd-97f2-57da155902f2">388,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib08167bb5f1945769d6ee3657f77ca59_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC0zLTEtMS0w_ec28894d-6b95-4b38-b568-5c3f9fa2d9a6">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0449bd3f63554820bbdfb7c723787243_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC01LTEtMS0w_49b5bd8a-e9c9-4435-8673-b18eb8b2099c">5,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC0xMS0xLTEtMA_7966cbc8-679b-47dc-8711-fccf94107732">5,465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0449bd3f63554820bbdfb7c723787243_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNS01LTEtMS0w_e840a15b-badf-48e6-b3f4-1eca1a2aacc4">19,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNS0xMS0xLTEtMA_b50f8ccc-be0e-4fe9-9513-04069340a537">19,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5089bb6eb61f47bd86313de5659a1590_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNi03LTEtMS0w_3ec63b0d-0a70-487f-acf1-9204e77c32b8">128</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNi0xMS0xLTEtMA_f549ac0e-2b5c-45c3-b274-dd35ee154f4d">128</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i05cbd70b0ea74776a5302b8c60f708dd_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNy05LTEtMS0w_8272c8c7-6933-4591-ac29-e393b881886b">40,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNy0xMS0xLTEtMA_40725a29-ff72-4f01-b382-ee722295f263">40,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7f5ad1c314b54412beee6289ce701979_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS0xLTEtMS0w_b270b2f0-a6b8-4f5b-80ef-50a8521fb873">68,789,925</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f5ad1c314b54412beee6289ce701979_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS0zLTEtMS0w_e37c43ca-f34d-4787-862e-1a495553b880">69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i06129accabc84db1998139916e3bfdce_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS01LTEtMS0w_a4aebdfe-3402-4e77-88f8-969975bf29d7">2,181,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9781e5291b34a4b96ee6b85750b185a_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS03LTEtMS0w_f493fa9e-dd59-491c-8d84-7819774b0386">74</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie22c76c636c44318bd5ddf5c65c4945e_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS05LTEtMS0w_df460be7-eabe-4498-9067-eb96ce1d185d">1,556,361</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS0xMS0xLTEtMA_87ed2230-016a-4111-bdbb-766cb60ceb66">625,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:29.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.964%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.964%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.134%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.388%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share amounts)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic8958bd3f29941f2aa800c1928252121_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi0xLTEtMS0w_b2016883-c841-4edb-9e40-616449bf19b2">58,218,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic8958bd3f29941f2aa800c1928252121_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi0zLTEtMS0w_5a282dd2-e551-4aea-81ff-9acf62e56812">58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6db96c6a87374048ace2fc1cb33ea464_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi01LTEtMS0w_f31bd5ff-4f98-4875-88a7-1e03d15fa862">1,794,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b788f2270d84d63a475d1b2aecbeaf8_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi03LTEtMS0w_2f4d7d6e-5a98-4e62-99c7-befee8c4eb3f">2,171</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5c76a8d5c9f047fdb64349f6cebc1f11_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi05LTEtMS0w_2c26a86d-726c-473e-af25-eb5ba1ff9bcf">1,104,633</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i62be91ce449047f7b038e5f03bcc8373_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi0xMS0xLTEtMA_51903e74-36b4-488e-85c4-a45cf665995e">687,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1a5f41773d3e4ddd9bceaac90793a7ee_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC0xLTEtMS0w_ffbe0ae5-505c-4a64-b450-e4e6b3f1dd4f">441,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a5f41773d3e4ddd9bceaac90793a7ee_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC0zLTEtMS0w_4ccde987-080a-4d0e-8bd2-64ccb06b040b">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64beb8c427754afbbeb4323e2204e1ce_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC01LTEtMS0w_206dc9f7-8383-49af-8611-e81a9c076773">6,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC0xMS0xLTEtMA_a78f4cb1-f80b-4648-b9da-fb3b8b286973">6,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64beb8c427754afbbeb4323e2204e1ce_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNS01LTEtMS0w_b6da4e2b-156f-4230-8897-3a016b3ed778">18,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNS0xMS0xLTEtMA_949baabe-2621-465e-a6d7-70e26e515cbb">18,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idfdf8a5d4f2b461cbcd4e7f10715380a_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNi03LTEtMS0w_aa4012b3-66a7-41f8-9e73-04ba857400bd">1,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNi0xMS0xLTEtMA_9485cf39-9819-4464-be5e-5979bd32e4ba">1,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3c9a056637214d5796f17b4822cda10e_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfOS05LTEtMS0w_955b3949-236a-4b00-a6cc-6d329003945b">93,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfOS0xMS0xLTEtMA_fd04e914-e170-43cd-8823-d265f8d0a319">93,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a0427dc88004cdb9ad5b111ee121e8a_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtMS0xLTEtMA_542313c7-3dab-4609-91bd-89b9bd26ed11">58,659,821</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a0427dc88004cdb9ad5b111ee121e8a_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtMy0xLTEtMA_1097e6d4-3b0a-4e62-9a4b-025e762d949e">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6971d4a30427440ba662d8d10de5fd9a_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtNS0xLTEtMA_5777dbf4-1194-4ce8-82e2-7bc31ac0488f">1,818,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8b9f97f0add14e97ac35d6c17a93e045_I20190331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtNy0xLTEtMA_701ed571-3412-4f51-97c5-430aff66445d">484</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d5f65c2dfb44ce892a2a2a36fc23f81_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtOS0xLTEtMA_c6a824d7-8dfb-42a9-bcfb-86f724c0003a">1,197,711</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4edbcb8341ca4ae9a52de4dfbc7f3fa9_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtMTEtMS0xLTA_e7e89cec-6190-4aff-8cd7-ab2220eec031">620,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_28"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-top:3pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:73.806%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMy0xLTEtMS0w_1b92ce9b-3730-480a-8a61-a98c8f44f2e3">40,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMy0zLTEtMS0w_c838272e-da2f-4ba1-adba-67aa29e8501e">93,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNS0xLTEtMS0w_aabdf972-97d5-4a1e-bc96-28da41ba4e63">2,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNS0zLTEtMS0w_057b7908-3c67-4fb6-8980-673409fcf1f9">2,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNi0xLTEtMS0w_f30580d6-4099-4f35-86be-9b53eeb396b5">19,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNi0zLTEtMS0w_c7b4f56b-ab47-4332-a653-ebaaa4181643">18,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net accretion of premium and discounts on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNy0xLTEtMS0w_b3697149-fbf2-483d-8635-e66291dc8137">126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNy0zLTEtMS0w_5228e1ff-868c-463c-a480-f590730b9d38">1,131</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash operating lease expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfOS0xLTEtMS0w_820a3724-2c48-4579-842d-459096c051ba">2,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="agio:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfOS0zLTEtMS0w_00137c90-9ddd-4752-a2b4-5da5a8d49ecb">2,085</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTEtMS0xLTEtMA_a6c2de4a-5059-4c71-a86e-4e8de04f82df">2,861</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTEtMy0xLTEtMA_9505698d-e7f5-4528-b6c6-ab01920dd4d5">721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration receivable &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTItMS0xLTEtMA_e4689313-1c5a-4ae1-b6ab-fecd228009b9">1,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" name="agio:IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTItMy0xLTEtMA_1b42e52d-0208-4ff1-9dca-3107b87848db">143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration receivable &#8211; other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="agio:IncreaseDecreaseinCollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTMtMS0xLTEtMA_b847f5ff-de00-423d-8cd9-84cae6cbe835">105</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" name="agio:IncreaseDecreaseinCollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTMtMy0xLTEtMA_b2a6aa8e-3152-4222-9bae-c8b2741debe6">970</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty receivable &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTQtMS0xLTEtMA_4c441501-d764-45a2-9280-a09ad32e3489">400</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" name="agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTQtMy0xLTEtMA_0448889e-87e1-42c1-b176-0547bc475048">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTUtMS0xLTEtMA_272ec9ce-5e17-4609-aae4-ad073bd059ff">2,447</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTUtMy0xLTEtMA_7a1ee955-6371-4123-8fea-f52e55d34761">1,459</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTctMS0xLTEtMA_1aaf201c-a0c9-4e3c-812e-dd3b434a496f">6,774</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTctMy0xLTEtMA_ad2b932f-a128-4321-8c1e-35be91ffd6fb">2,173</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTgtMS0xLTEtMA_b0392e79-3fb4-4121-9c28-9dc9f5dc32d4">2,009</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTgtMy0xLTEtMA_b4f0d2ca-cc20-462a-925a-99a726c4bb90">4,939</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTktMS0xLTEtMA_20c462b5-21ae-4acc-aee4-e76f4d2ba754">14,967</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTktMy0xLTEtMA_da7987f2-92c4-4188-bcd6-453c6b3aac7c">5,097</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue &#8211; related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjAtMS0xLTEtMA_69a287d6-57a0-47be-b7e4-ed1699719d94">56,765</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjAtMy0xLTEtMA_5aea0b56-4dce-4ae7-8c2f-36bac23a4341">15,391</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjEtMS0xLTEtMA_bc64a9c4-201c-46b4-a4b8-bd1992f478c8">2,229</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjEtMy0xLTEtMA_2f716df8-e0b4-43ed-bc81-8c629745f234">2,129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:42pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjMtMS0xLTEtMA_1981a037-bc92-42e9-9d46-87f9635f01b5">105,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjMtMy0xLTEtMA_df855812-cf9c-47db-b5b9-0bb57f2cc8a1">103,271</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjUtMS0xLTEtMA_7aa665aa-6314-43e4-880c-ab96d244eca3">54,911</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjUtMy0xLTEtMA_16ad0419-2a5e-49c2-b5e9-f4e22d8e306d">77,421</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturities and sales of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjYtMS0xLTEtMA_5ac3ef8f-420a-47f7-8a2c-4b1dbe61d50e">167,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjYtMy0xLTEtMA_0fc80ba7-932f-4ded-b0c8-9c5f8e423d44">210,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjctMS0xLTEtMA_f5aa15ba-dc89-4157-b24a-39ee6466f511">4,455</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjctMy0xLTEtMA_c952c7ca-7339-41d6-bf44-5080cd09935e">2,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:42pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjgtMS0xLTEtMA_74c66762-9474-4b23-ad01-63d94a17515a">108,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjgtMy0xLTEtMA_fcff0b29-8b00-4ea4-969e-44f251d421dc">131,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments on financing lease obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzAtMS0xLTEtMjE4OQ_40bd0ea0-9dba-4b9d-b94b-fb4ed7085585">80</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzAtMy0xLTEtMjU0NA_1059aa23-b413-4ea1-977f-1a14c62f8bf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net proceeds from stock option exercises and employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzItMS0xLTEtMA_8525ea46-29db-4b32-8709-55214f7b5c17">5,465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzItMy0xLTEtMA_1f2c0ad7-fd57-4af1-b5be-77685693df74">4,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:42pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzMtMS0xLTEtMA_7690e077-e845-439c-bf40-116c958e1a22">5,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzMtMy0xLTEtMA_a74ff30e-e1d2-472b-ac3c-0e1b64bd36c1">4,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzQtMS0xLTEtMA_342dc0a6-aeef-42aa-9f0f-27e5bf534eeb">8,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzQtMy0xLTEtMA_a23e8a04-bf3c-4dd5-aa00-e679e1d7a9ae">32,941</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzUtMS0xLTEtMA_7df61483-5324-4833-b320-8fca168a2491">80,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i62be91ce449047f7b038e5f03bcc8373_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzUtMy0xLTEtMA_e26d75bf-53a2-481e-88ba-b6e4a682e34f">70,502</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzYtMS0xLTEtMA_69382c70-f410-4cc3-915f-0cb68a4bb82c">89,093</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4edbcb8341ca4ae9a52de4dfbc7f3fa9_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzYtMy0xLTEtMA_8105afb6-8775-48fe-a655-67a0c93dbf37">103,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of non-cash investing and financing transactions</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to property and equipment in accounts payable and accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzgtMS0xLTEtMA_b87943f0-7ea0-4eeb-96d8-ec45d15f401f">5,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzgtMy0xLTEtMA_c9ed3a96-e1d4-45e4-9292-2263f7a7990f">727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from stock option exercises in other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="agio:ProceedsFromStockOptionsExercisedInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzktMS0xLTEtMA_4f3da7f8-25fd-464d-b7e8-a3e9e20c6c2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="agio:ProceedsFromStockOptionsExercisedInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzktMy0xLTEtMA_f30d2428-3e88-47b2-9ca6-8cf98541245a">1,149</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities arising from obtaining operating lease assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDEtMS0xLTEtMA_af6a943b-170b-45d6-b94e-6d6eaef0979b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDEtMy0xLTEtMA_c1d5a930-73c4-492c-b4fa-69dd37048f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing lease liabilities arising from obtaining financing lease assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDItMS0xLTEtMTgzMQ_671bc326-9815-4457-ae25-8095add9f559">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDItMy0xLTEtMTgzNA_d1b5ef75-0ca3-44bf-b9bf-54cb6bd1e3b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_31"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_34"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMjY3NA_c96aeccf-b1a0-40b6-9dd7-6d56cce3c0da" continuedAt="i237b30eedcdb4aec9df5f1781df03928" escape="true">Overview and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i237b30eedcdb4aec9df5f1781df03928" continuedAt="i909c54a18c86420a840104a9159d8902"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">References to Agios</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our Board of Directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company committed to the fundamental transformation of patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect. We are located in Cambridge, Massachusetts.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of presentation</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMzI5ODUzNDg4OTczNA_39bf2e50-fbaa-4c39-a685-0f6365758e27" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three months ended March 31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2020, our results of operations and stockholders' equity for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMzI5ODUzNDg4OTczNQ_7097e3b7-43a2-41f3-8381-cadce56568a4" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMjM1OQ_f9b7db24-4aa0-45c3-ba7d-ac5346d137d4">613.1</ix:nonFraction> million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i909c54a18c86420a840104a9159d8902">marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.</ix:continuation></span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_37"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNy9mcmFnOmQyNjEzYmMxNDM5MDQyNDA4ODEzMWFmNWY3MDYwM2QwL3RleHRyZWdpb246ZDI2MTNiYzE0MzkwNDI0MDg4MTMxYWY1ZjcwNjAzZDBfMzY0Mg_e3f9ed2d-a7df-4475-836d-a8cb6ec7a705" continuedAt="i4b32a4e45051463286315d9025f57946" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4b32a4e45051463286315d9025f57946"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNy9mcmFnOmQyNjEzYmMxNDM5MDQyNDA4ODEzMWFmNWY3MDYwM2QwL3RleHRyZWdpb246ZDI2MTNiYzE0MzkwNDI0MDg4MTMxYWY1ZjcwNjAzZDBfMzI5ODUzNDg5ODU0MA_873d8a61-f835-45d1-8fc1-5bc436f68f07" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant accounting policies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses (Topic 326),</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent accounting pronouncements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div></ix:nonNumeric></ix:continuation><div id="i7c71c9a7a53d48458a969df1a7cd05a7_40"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTk3OQ_695dc427-a01e-473a-91cb-0b2e44c031ef" continuedAt="if657b3d7dc4b42ca8dae32e9334e441f" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="if657b3d7dc4b42ca8dae32e9334e441f" continuedAt="i2aa04400f262420a9e9ed77460ce29d6"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTk3NQ_a0a98a13-2cd2-412f-aabf-00108d8df90d" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTk3Ng_33f7bc06-507b-42fd-84b1-475700aaab69" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of March&#160;31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:48.807%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.750%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic285bdb5cfff4f9bb6e8c6aa8bd0aef6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS0xLTEtMS0w_d98554b4-731e-452f-97f7-c92fbc127144">54,853</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2896d589cf7469a8775ecf2af7fef57_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS0zLTEtMS0w_f429283f-34ce-42a9-852d-b35c46660441">19,979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d69f26b53ee4c3e8ba4149462acd30a_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS01LTEtMS0w_263894de-08f2-4bbf-86e7-e2d1d32b88cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a5ae1f4e6da4a40ab90e89f131655fc_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS03LTEtMS0w_5e349fee-f8f5-4ec7-a499-60e11275a121">74,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i980609409a6b4e13b07d000c6cdd7d2c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi0xLTEtMS0zNzc_8558079c-0adf-4a2d-a616-faee64eacdd0">54,853</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i237b15fb46da4b59a1a6fac0feae116a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi0zLTEtMS0zNzc_3199eb9d-57f7-489a-8265-24799b821d52">19,979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi01LTEtMS0zNzc_0484a5c6-9884-4a9d-a761-d092a0dbe32a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d7da42c6aea42a087aa27c849a90448_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi03LTEtMS0zNzc_93e7af31-e19f-4c0d-a077-394cbc9a470a">74,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i852744abdf2745b18e0f60fa3df00339_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC0xLTEtMS0w_d2b46754-2214-487f-b408-f1365358c645">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f8f8fda49a94e84b0a5c8d9bd24a8ef_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC0zLTEtMS0w_e357e5d1-74aa-4f71-9280-e6df31a852e1">163,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i635947295b764abfbbdea991d6fe54fc_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC01LTEtMS0w_f3e8f7d1-3a64-4b4f-8f4b-b3af87cdd7e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief6cbec674e741b4a873e845b45a4e31_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC03LTEtMS0w_28fe0a29-badf-4de4-9b28-d7a3bf6d8c97">163,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4fdeb9348b94b618851880b5c977d5d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS0xLTEtMS0w_693bf8ad-31d2-4889-8d0e-d50f5698a927">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f32329914f4f5ba7b80bae3b347fda_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS0zLTEtMS0w_b55a5eb4-2772-4381-8e88-d1673a861778">100,492</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i474102d2baee43179a37e278bb04cf73_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS01LTEtMS0w_067610d8-918b-4831-a4db-3bb228b74ec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i244896107f9d40bd82157d3c93e71bad_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS03LTEtMS0w_cceceb1d-5307-43c0-bfd0-d5760bc2aa7d">100,492</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3fe9a6e1ebc48a49cc37d47c38c8288_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi0xLTEtMS0w_3183f581-9152-4733-af37-fa71e0277db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e239c737d2f45488edacb7ef4b2bb95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi0zLTEtMS0w_4caf435d-a6ea-46f5-a4d9-ee03a524eb14">259,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i689b528c68d6471cbeca1282d66876f7_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi01LTEtMS0w_fb50a935-c914-4267-b2af-cfd6078c8644">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe05f5bb5bf340819df84fa9a1e20a30_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi03LTEtMS0w_1c0977a6-8774-4b6d-b97b-33894ea3afc9">259,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i980609409a6b4e13b07d000c6cdd7d2c_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS0xLTEtMS0zODE_f8ed362b-db0d-4b2f-bd6a-c62c6c4f888a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i237b15fb46da4b59a1a6fac0feae116a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS0zLTEtMS0zODE_e28a5387-81c2-4acd-9086-dea841d3fc08">524,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS01LTEtMS0zODE_88255756-959a-4a20-aeb1-b21aeded1d48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d7da42c6aea42a087aa27c849a90448_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS03LTEtMS0zODE_3e2cf275-7b11-42eb-bce2-0aa0a2322d61">524,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i980609409a6b4e13b07d000c6cdd7d2c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy0xLTEtMS0w_6a9279c8-3000-4cc8-8a3e-3137f61034df">54,853</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i237b15fb46da4b59a1a6fac0feae116a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy0zLTEtMS0w_5cc914ff-a675-4330-aea4-9698120650ff">544,010</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331" decimals="-3" format="ixt:zerodash" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy01LTEtMS0w_a91cd460-a0df-4d0d-bcee-ea0bc74638ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d7da42c6aea42a087aa27c849a90448_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy03LTEtMS0w_09c418b9-11d6-4fc2-b197-6c5e479c0003">598,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of March&#160;31, 2020.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2aa04400f262420a9e9ed77460ce29d6">There have been no changes to the valuation methods during the three months ended March 31, 2020. We evaluate transfers between levels at the end of each reporting period. We have <ix:nonFraction unitRef="usd" contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueNetAssetLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTg4MQ_01240fd6-7ef8-46a4-a951-aec39aea5e30">no</ix:nonFraction> financial assets or liabilities that were classified as Level 3 at any point during the three months ended March 31, 2020.</ix:continuation></span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_43"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTc2NA_45ac4ec8-ee23-4b85-aa44-1a1f2281c318" continuedAt="i58648311edcf40bb964ab9c56595fcc9" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i58648311edcf40bb964ab9c56595fcc9" continuedAt="i617ac4fd033044e09b8ee7f3e7c1a199"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTc1OQ_a3dda6d1-c7a2-44a9-9e55-3c8cfa147a11" continuedAt="i939288797c9f47f7908d1c9d90d77818" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments &#8211; Debt and Equity Securities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses</span></ix:nonNumeric><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i939288797c9f47f7908d1c9d90d77818">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfNTUw_9dbd18c4-67d5-47d6-b715-7d6ff5d95660"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfNTUw_a1d11a58-4d41-4816-8a83-6b12d0d9c7f2">no</ix:nonFraction></ix:nonFraction> material realized gains or losses on marketable securities for the three months ended March 31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTc2MQ_8495b195-dfd5-4813-8ee1-f1540481e343" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities at March&#160;31, 2020 consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:48.807%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.750%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0502aed7c32c4db0853962e904c21847_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy0xLTEtMS0w_e3fd1b15-ca82-4d59-b561-8517ffaaba0f">141,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0502aed7c32c4db0853962e904c21847_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy0zLTEtMS0w_f99cb0af-029a-4c13-945e-0b23a0d06942">835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0502aed7c32c4db0853962e904c21847_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy01LTEtMS0w_621fac69-cd58-4118-a1d8-718cc36ceb41">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0502aed7c32c4db0853962e904c21847_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy03LTEtMS0w_f180685b-f736-48d5-9953-b8cbc2993486">142,325</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC0xLTEtMS0w_f7a6b918-599f-4e92-8316-1ad3d03ed8fb">89,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC0zLTEtMS0w_f07c0411-2ed9-42c4-9416-b58bf278ed20">256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC01LTEtMS0w_b53fbfa7-22be-4f8c-82d0-3e601a698d26">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC03LTEtMS0w_80aafb86-e1b2-4200-9a9a-4e7eb406d552">89,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS0xLTEtMS0w_922f443a-c013-4ddb-8467-d407ca6e1f9c">208,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS0zLTEtMS0w_a9669c26-88b5-447f-8172-ff24baa81329">82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS01LTEtMS0w_068feccc-3f01-408b-b73f-4531c2a97ef4">718</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS03LTEtMS0w_7fe00876-84ed-40c5-8a1c-e1eb4b6366c4">207,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi0xLTEtMS0zOTI_8f11cc43-38d3-4d67-bcc5-556d8ea25430">439,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi0zLTEtMS0zOTI_39fdfd89-455f-48ab-9bff-5ba370c506e8">1,173</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi01LTEtMS0zOTI_ae570c11-a2c1-4a19-9d4c-458ed17d170d">739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi03LTEtMS0zOTI_ce1e985a-2e8e-4033-a96d-136720b39fad">439,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMS0xLTEtMzk3_a7bab8a9-907c-49c1-8cc6-235cfd6aea83">21,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMy0xLTEtMzk3_ec440f48-5204-4699-8349-462dbaf972a8">271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNS0xLTEtMzk3_9dc0e243-37af-452c-b7f2-9231d5bcc0f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNy0xLTEtMzk3_767d0075-4b77-4e76-a490-cb4a7d1ebb8e">21,553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS0xLTEtMS0w_4047013e-7ec5-4b0e-bc21-40d2fee3a8f9">11,260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS0zLTEtMS0w_57348bad-f855-4e3e-a729-709ca2cec8b1">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS01LTEtMS0w_ce69225e-f8f4-4612-a023-f3d09450fbbd">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS03LTEtMS0w_0817c174-5239-429d-9ddb-c57fe747e466">11,249</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia264a24d96044bba896491152779474a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtMS0xLTEtMA_550a1286-8ef1-4547-a45c-0943ea2ce393">52,329</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia264a24d96044bba896491152779474a_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtMy0xLTEtMA_ad30c9bb-efda-4f9a-9792-9b417324a7e8">72</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia264a24d96044bba896491152779474a_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtNS0xLTEtMA_9e1c86ba-8882-4907-a276-42618055464b">700</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia264a24d96044bba896491152779474a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtNy0xLTEtMA_1f99195d-e481-44cb-9bc8-b5c3920b47b7">51,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtMS0xLTEtNDAw_1dc93b65-d85d-4618-a3b3-633c8b86ed62">84,871</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtMy0xLTEtNDAw_3de9da7c-9d7a-46dc-a014-85da77848b35">347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtNS0xLTEtNDAw_efefcdc3-8e3b-4f3a-85b0-fae34a7e4644">715</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtNy0xLTEtNDAw_5ef2d85c-3923-4cb9-9dda-614191c7dcc4">84,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMS0xLTEtMA_22b79d52-6301-4002-9ef5-664f04858b96">523,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMy0xLTEtMA_ba6939de-1fca-44e0-b502-a756bdc57962">1,520</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNS0xLTEtMA_c6dae1b2-3755-42a7-8b68-d9ff78d48531">1,454</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNy0xLTEtMA_8aa23d9c-eaf7-4331-834d-168e01e2b74e">524,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities at December&#160;31, 2019 consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:48.807%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.750%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy0xLTEtMS0w_b1474d10-e2f3-4b21-a7bd-ff0427781902">178,721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy0zLTEtMS0w_000c9f5e-76ee-44d7-acab-03d93f529867">58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy01LTEtMS0w_d10056f7-703c-44be-aa0a-88f9b2080440">38</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy03LTEtMS0w_160328f3-d9d5-4f93-bc1d-a6b18252d9e1">178,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC0xLTEtMS0w_65c235db-8e53-4eb6-bbf0-3106369eba0f">80,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC0zLTEtMS0w_3880df84-0974-41d5-9a57-aa42ca3fe7c8">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC01LTEtMS0w_639ae3d7-c33b-4a45-b4bb-3ed9f76b606e">16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC03LTEtMS0w_3488ebad-b7a0-4d6b-8dfc-27ff13214845">80,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0xLTEtMS0w_b2d6679e-8cbd-40bd-a6d6-c6acae9b2fe7">224,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0zLTEtMS0w_4142722a-ce6f-4df5-8110-bf45f48b0a98">139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS01LTEtMS0w_1eeab8ab-33a9-46b5-9be0-a6400a2dd63a">91</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS03LTEtMS0w_86efdb45-6d40-4a02-94b9-9eb557f549ac">224,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0xLTEtMS00MTM_7ff57bdd-abe7-4d05-b620-7f62efb57bb3">483,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0zLTEtMS00MTM_4c5f0e6c-597c-43a0-a83b-cc6e7b1affc3">214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS01LTEtMS00MTM_66464e96-f911-48c0-aef8-f9bab41cd8e6">145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS03LTEtMS00MTM_ec4d7c1b-a2fd-40cc-bf6e-e65b6b0e3333">483,946</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC0xLTEtMS0w_1458fa27-775d-470d-9937-e36afaf256b9">35,296</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC0zLTEtMS0w_1fe623d7-59a8-4413-98eb-5206672ae841">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC01LTEtMS0w_0fb10abb-413e-42e0-8edc-07d1ed0c05d6">13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC03LTEtMS0w_4c2b631b-5656-4187-b1d6-56b088e308bc">35,286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS0xLTEtMS0w_4d02fad1-6cfe-4c12-bb76-d65b6ec5b66f">17,587</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS0zLTEtMS0w_584b43fe-449d-4488-9f8c-74e118d48d96">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS01LTEtMS0w_022caca0-d26f-4ef4-aba6-51df4f844ab3">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS03LTEtMS0w_e60d69a8-c5a8-454e-9e65-828a5962a7f6">17,591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i985faa780d224792b8352dc1688c2523_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtMS0xLTEtMA_6f70e7f0-5e39-4f3b-b047-8f949b9a3cc3">99,913</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i985faa780d224792b8352dc1688c2523_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtMy0xLTEtMA_cde877e4-f9b6-483f-86fc-d664c320c7f2">239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i985faa780d224792b8352dc1688c2523_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtNS0xLTEtMA_ad09b79a-4c5c-474f-be00-fa9f31b5475b">100</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i985faa780d224792b8352dc1688c2523_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtNy0xLTEtMA_7b62b2c3-7a8b-4d00-9862-d3eba26ae5d2">100,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItMS0xLTEtNDE3_109db86b-1b93-4f5f-88c5-5055ea1e31ee">152,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItMy0xLTEtNDE3_0796451a-bedd-4ecb-8558-b975dd4c54e4">256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItNS0xLTEtNDE3_9dfb23bd-f02e-48a2-a2d6-e7e91eb27279">123</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItNy0xLTEtNDE3_06d06a86-da5e-4dbb-b6c7-74cd6c5ef24b">152,929</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtMS0xLTEtMA_6a8004c0-1695-4037-9f9c-22eaab98d014">636,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtMy0xLTEtMA_b943977f-d267-4d92-bb40-1af35ee915d2">470</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtNS0xLTEtMA_291a685b-985b-4d5f-8f47-1dc4af32d0e7">268</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtNy0xLTEtMA_45f849c6-97fd-485f-bdf2-59ebf4584b5d">636,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020 and December&#160;31, 2019, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i617ac4fd033044e09b8ee7f3e7c1a199">As of March&#160;31, 2020 and December&#160;31, 2019, we held <ix:nonFraction unitRef="security" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTE4Ng_e06709df-16ca-4448-b3ef-e2f7dc694967">92</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTE5Mw_e41d6ef1-aee0-455d-b3f5-596d8a27f82a">113</ix:nonFraction> debt securities, respectively, that were in an unrealized loss position for less than one year. We did <ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMzI5ODUzNDg4ODI4Mg_b552168f-7c27-4c0a-b93b-b12d1e0c823d"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMzI5ODUzNDg4ODI4Mg_d4e53e83-e285-4730-97fa-af2d8e629ff4">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses as of March&#160;31, 2020 and December&#160;31, 2019 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2020 and December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTM4NA_a09b8dd2-61ea-4fa8-84ca-9ae8fceb8e8e">224.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTM5MQ_6883d7a7-a3fc-4abc-8941-7e18ff697cf6">345.7</ix:nonFraction> million, respectively. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2020 and December&#160;31, 2019. Given our intent and ability to hold such securities until recovery, and the lack of significant change in the credit risk of these investments, we do not consider these marketable securities to be impaired as of March&#160;31, 2020 and December&#160;31, 2019.</ix:continuation></span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_46"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RleHRyZWdpb246NWExYTRhOTA3Zjk2NGI0M2JmNzUxNmJjYmEwMjA0YmVfMTM1_e76639e6-1f7b-4d15-ac01-daef09c87bcf" continuedAt="i7208b2ee2d124726a185da094691d4a8" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i7208b2ee2d124726a185da094691d4a8"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RleHRyZWdpb246NWExYTRhOTA3Zjk2NGI0M2JmNzUxNmJjYmEwMjA0YmVfMTM2_d98e4fff-902e-47f5-95a8-3971cbf86e4e" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory, which consists of commercial supply of TIBSOVO&#174;, consists of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.697%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMS0xLTEtMS0w_89b6024f-d045-4d4a-b700-f4e96a4ef140">180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMS0zLTEtMS0w_bceedcf9-98d6-49af-880e-1d24ba10d242">180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMi0xLTEtMS0w_c20a9073-8bc1-43cf-93fc-be025b785744">8,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMi0zLTEtMS0w_bdb58a9d-2ac8-4aec-8e9b-d77f9e5fa87e">6,808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMy0xLTEtMS0w_c030c654-3854-4264-b18e-64ec159cb77f">1,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMy0zLTEtMS0w_148da32f-67ea-45ce-8ccc-dea4ebec4e6b">343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfNC0xLTEtMS0w_35c80f33-d9e3-4448-b5e6-11f7e95a82de">9,778</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfNC0zLTEtMS0w_649ba84f-d722-44c9-80d2-93141b09f69f">7,331</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_49"></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjY2Mw_670c670c-e193-4dfd-8d25-1c0ed7339c41" continuedAt="ide2a3c887e524b6d98bbe27146c30589" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ide2a3c887e524b6d98bbe27146c30589" continuedAt="i48da346af93c42cbb5503026487a467d"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" format="ixt-sec:durwordsen" name="agio:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMTM4Mw_369127c7-2623-40f5-b9ad-1e54e69941f6">eight years</ix:nonNumeric> and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal option is not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. Operating lease costs for the three months ended March 31, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMTczMw_25fe6934-75ba-462e-b2da-38b5f96e301a">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfNDM5ODA0NjUxNTQyNA_6f1f679c-5e46-429a-ad65-0fc08127b434">3.1</ix:nonFraction>&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMTg1OQ_e49a7743-bd28-4166-bff9-7a887c605e0f">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfNDM5ODA0NjUxNTQzOA_5202a1aa-bd3d-4202-a3af-1a492a731bfd">3.1</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not entered into any material short-term leases or financing leases as of March&#160;31, 2020.</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMzI5ODUzNDg4NzU3NA_5533b289-5d58-4a8b-9ff3-4bd5fc5e7e98" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:85.317%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.683%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMC0xLTEtMS0w_dd92a5a5-d502-4b17-be06-10d5cd17851b">9,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMS0xLTEtMS0w_fbe1ac83-73e8-4f23-99ab-e130a3a3c587">14,380</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMi0xLTEtMS0w_2deee499-4dc5-458d-b972-5ef2e3d10be9">16,773</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMy0xLTEtMS0w_2ad14f7e-51f1-4bd3-bd97-569ff2d3c4e9">18,126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNC0xLTEtMS0w_ebbf73a4-3f1a-4811-bc4a-36c5d13eb27b">18,660</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:LesseeOperatingLeaseLiabilityPaymentsDueYearSix" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNS0xLTEtMS0w_9a08440b-35c2-4385-8842-56bcf6b2aef2">19,507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNi0xLTEtMS0w_6dca8f61-ca28-4b98-ab9e-4aab1f674411">44,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Undiscounted minimum rental commitments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNy0xLTEtMS0w_cb74dadf-6313-4af9-98ab-6cc4c3aace3a">141,226</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfOS0xLTEtMS00NDc_0b8bcbcd-e14f-4663-bbf5-547770c2e7b2">30,750</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMTAtMS0xLTEtNDQ3_f4368644-7073-4caf-be1f-bbdf78c61f8c">110,476</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i48da346af93c42cbb5503026487a467d">In arriving at the operating lease liabilities as of March&#160;31, 2020 and December&#160;31, 2019, we applied the weighted-average incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjI1NQ_1e2f251c-e01f-4738-9704-de93eb573b82"><ix:nonFraction unitRef="number" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjI1NQ_b1e6f403-7f09-4087-9f91-9b01fa282ba3">5.7</ix:nonFraction></ix:nonFraction>% for both periods over a weighted-average remaining lease term of <ix:nonNumeric contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjMwNg_522ea7e9-0b2e-44cc-9350-cedff6d96fe9">7.9</ix:nonNumeric> years and <ix:nonNumeric contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfNDM5ODA0NjUxNTQ4Mw_7c0d631b-6736-459d-bbbe-fe234727a674">8.2</ix:nonNumeric> years, respectively.</ix:continuation></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%;"> </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_52"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RleHRyZWdpb246NmRjMGIyNzAxMGFhNDkxZWE5MmUyYWM0YTY3ZDY5YTdfODQ_a6f5a987-5b9f-4b7e-a520-fe58acc4e38f" continuedAt="i9c72fbdc3eb348d7905500855832d056" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i9c72fbdc3eb348d7905500855832d056"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RleHRyZWdpb246NmRjMGIyNzAxMGFhNDkxZWE5MmUyYWM0YTY3ZDY5YTdfODc_88ea273e-b4fe-419b-84e0-8cf6a833a358" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.830%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMS0xLTEtMS0w_73a38568-f7e6-4f36-a5ab-98bac53cf466">7,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMS0zLTEtMS0w_582c58d1-f882-4194-8772-df33426d16e5">18,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMi0xLTEtMS0w_1e0805d6-3344-4591-9810-641b767c38d1">18,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMi0zLTEtMS0w_6cbb47ea-1988-4700-bd6f-10dbac8d4f33">21,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMy0xLTEtMS0w_86732bbb-47ed-4d51-a469-9b3e244786be">9,238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMy0zLTEtMS0w_009a1986-d0cb-4a4c-be78-2c39c8ac2b14">8,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNC0xLTEtMS0w_8fa3cde2-f598-43f8-b131-5fd04901e5bf">4,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNC0zLTEtMS0w_f7519c1e-5905-4290-9df9-3b01dded9172">4,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNS0xLTEtMS0w_9301c1a6-1505-4f19-97b6-1c5f3897737d">39,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNS0zLTEtMS0w_40781783-d5d8-4e30-aaad-8ad8c68dccb3">53,142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_55"></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3MA_7d8da548-e5bf-45b3-bb32-a38f97efea52" continuedAt="i75af276691344c00b1cbdce87fc748f1" escape="true">Product Revenue</ix:nonNumeric></span></div><ix:continuation id="i75af276691344c00b1cbdce87fc748f1" continuedAt="i285f330d5af24f3a923e5cdfa3f98b81"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzI5ODUzNDg5MjA4NQ_e8add603-cd1c-43ce-86f7-1fb61f267d5e" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We sell TIBSOVO&#174;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers in the U.S., or collectively, the Customers. The Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The performance obligation related to the sale of TIBSOVO&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:6pt;margin-bottom:9pt;"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzI5ODUzNDg5MjMxOQ_a9d6266b-2c96-4a37-b4e3-6ce1544cb19d" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.830%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35fda49bee8b485999b812e174739a48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQ0NmIxOWU3N2Y2MDQwYTA5OWM2NzA0MTdiZGYwN2VlL3RhYmxlcmFuZ2U6NDQ2YjE5ZTc3ZjYwNDBhMDk5YzY3MDQxN2JkZjA3ZWVfMi0xLTEtMS01NjQ_e76ea54d-49c3-4221-8fd1-2116f8e5df71">22,674</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68cad50d747b48a7b8ceb77216e8aa02_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQ0NmIxOWU3N2Y2MDQwYTA5OWM2NzA0MTdiZGYwN2VlL3RhYmxlcmFuZ2U6NDQ2YjE5ZTc3ZjYwNDBhMDk5YzY3MDQxN2JkZjA3ZWVfMi0zLTEtMS01NjQ_771cb60d-38b7-48a7-9e8f-a5a074c1a4cf">9,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reserves for Variable Consideration</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contractual Adjustments</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Rebates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government rebates consist of Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Returns</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><ix:continuation id="i285f330d5af24f3a923e5cdfa3f98b81" continuedAt="iac56f3f0d4414f5abc84509e78769758"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3Nw_5655f450-d35e-4fd3-9ebd-faca6f6daf51" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government Rebates</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS0xLTEtMS0w_565d5b5d-5c78-4995-9b39-701e0b345805">874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS0zLTEtMS0w_0e99affc-23e2-4945-afad-fb65b4e4c50b">1,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS01LTEtMS0w_da73ec52-3292-4c3d-b38b-1a485ba25cc7">1,798</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS03LTEtMS0w_8b7858f6-3617-43c0-bb29-520bfa16f0d1">3,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current provisions relating to sales in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:CurrentYearProvisionForContractualAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi0xLTEtMS0w_606d5d47-5066-4ff4-b295-bddcc5bcc373">3,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:CurrentYearProvisionsForRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi0zLTEtMS0w_a78d4192-915e-4317-80a1-01badaf3615b">1,338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="agio:ProvisionForRightToRecoverProductInCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi01LTEtMS0w_1998cbf2-3763-46b9-9c0e-43b8de547df4">537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerCurrentYearReserveProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi03LTEtMS0w_4c27d376-dad0-4012-84a8-c52b5727ea7c">4,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments relating to prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" sign="-" name="agio:PriorYearProvisionForContractualAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy0xLTEtMS0w_33ddf8be-235a-4db4-bc85-620b734c192b">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="agio:PriorYearProvisionsForRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy0zLTEtMS0w_ffe99a33-4aac-4b60-8ee6-a34694bfcc1b">76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="agio:ProvisionForRightToRecoverProductInPriorYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy01LTEtMS0w_f485006f-4aef-4218-a66e-d76a87e905cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="agio:ContractWithCustomerPriorYearsReserveProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy03LTEtMS0w_6fc820f3-f32f-4de2-9558-988f59318812">73</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC0xLTEtMS0w_e20428c2-4687-4de7-ac95-13e925e2c182">2,072</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC0zLTEtMS0w_2ebb7da3-f3ee-4120-86d9-7fdb5c6553d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC01LTEtMS0w_d31cc8cb-bbaf-4699-aea1-449279b32455">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerCurrentYearReserveRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC03LTEtMS0w_afb44d16-ac55-42b7-95b2-2954bc940cfa">2,072</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS0xLTEtMS0w_38f68be0-cfe6-4905-92ff-2a55d39e1680">653</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS0zLTEtMS0w_65e99be4-4c9a-4bfa-9a25-e19aac737c0d">677</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS01LTEtMS0w_eb03fa4f-92e1-4385-a20c-6bd88e487119">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerPriorYearsReserveRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS03LTEtMS0w_5b1b6990-fd2d-42a2-80e8-0cd6997f42d2">1,330</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi0xLTEtMS0w_b7a87a68-a06e-4f67-b9c3-e28d891ab574">1,146</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi0zLTEtMS0w_439ff12b-6835-4082-85a5-f9cc82490935">1,861</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi01LTEtMS0w_13087572-3810-4f0e-897f-c4a59ba4dc25">2,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi03LTEtMS0w_53bd9da9-2264-4f7b-87b3-b285718f822c">5,342</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3Mg_f9c36564-88b3-4cd9-ad94-eb404eb2fb6d" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.976%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMS0xLTEtMS0w_aa5b4d82-14e0-4396-b5f5-6558756c84dd">707</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMS0zLTEtMS0w_23323756-fb6d-4628-ae3f-ea4ad7adbeb7">540</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Component of accrued expenses </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAllowanceAndReservesLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMi0xLTEtMS0w_45ae59de-3ac2-4fd1-84da-d141799dedfd">4,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAllowanceAndReservesLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMi0zLTEtMS0w_c3c460a2-bc82-4f00-b6ed-6c7f65544cdb">3,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue-related reserves</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMy0xLTEtMS0w_ef3ef620-abe5-464d-af57-8863dbceb0dc">5,342</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMy0zLTEtMS0w_46f6c9bb-97d0-4f9a-b842-c7b1ce7641e9">3,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3Mw_deb6e75a-f775-4504-a748-8c5098255b68" continuedAt="ied2332935a0d42638836defc58071dac" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets during the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contract assets</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi0xLTEtMS0w_ca25bb8a-20cb-4996-9927-65750f62a0f5">8,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractwithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi0zLTEtMS0w_af1bb924-eccc-4f65-bd8f-397e68240f35">27,624</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi01LTEtMS0w_a03936de-dfce-4dfc-8a10-45d05bf9c7b2">24,763</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi03LTEtMS0w_3845b5a1-6512-4ed4-bd62-cc8b6792169b">11,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:continuation id="iac56f3f0d4414f5abc84509e78769758"><ix:continuation id="ied2332935a0d42638836defc58071dac">(1)  Additions to contract assets relate to amounts billed to Customers for product sales and.deductions to contract assets primarily relate to collection of receivables during the reporting period.</ix:continuation></ix:continuation> </span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_58"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxOTA_95948be6-48e3-4810-a1fe-3ae170fc99d2" continuedAt="i100b6072dd1044a6b6a9b6e0e34678a3" escape="true">Collaboration and License Agreements </ix:nonNumeric></span></div><ix:continuation id="i100b6072dd1044a6b6a9b6e0e34678a3" continuedAt="ibb7076e3d08142a886f8e193824cc77f"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accounting analysis and revenue recognition</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaboration and license agreements typically involve us granting licenses of our intellectual property and performing research and development services in exchange of upfront fees, milestone payments and royalty payments. Since December 31, 2019, there have been no material changes to the key terms of our collaboration or license agreements. For further information on the terms and conditions of our existing collaboration and license agreements, please see the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For arrangements that include sales-based royalties and sales-based milestones and in which the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Milestone revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At each reporting period we evaluate whether milestones are considered probable of being reached and, to the extent that a significant reversal would not occur in future periods, estimate the amount to be included in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are considered constrained and are excluded from the transaction price until those approvals are received.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><ix:continuation id="ibb7076e3d08142a886f8e193824cc77f" continuedAt="ibecbd6deb75943a992c5d728ca65a0a0"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Celgene Corporation</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into the following collaboration agreements, or collectively, the Collaboration Agreements, with Celgene, a wholly-owned subsidiary of Bristol-Myers Squibb Company, or BMS, which is a related party through ownership of our common stock: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In April 2010, we entered into a discovery and development collaboration and license agreement focused on cancer metabolism, or the 2010 Agreement, which was amended in October 2011 and July 2014. The discovery phase of the 2010 Agreement expired in April 2016. On August 15, 2016, we terminated the 2010 Agreement as to the program directed to the isocitrate dehydrogenase 1, or IDH1, target, for which ivosidenib was the lead development candidate. Accordingly, the sole program remaining under the 2010 Agreement is IDHIFA&#174; (enasidenib), a co-commercialized licensed program for which Celgene leads and funds global development and commercialization activities. Under the remaining terms of the 2010 Agreement, we are eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="agio:RevenueRecognitionMilestoneMethodEligibleReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzM3Mg_2093716c-c878-4bd0-a361-b1004acab565">80.0</ix:nonFraction>&#160;million in potential milestone payments for the enasidenib program. The potential milestone payments are comprised of: (i) up to $<ix:nonFraction unitRef="usd" contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="agio:PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzQ5Ng_b9ba858f-1ea5-4d89-a898-6468123b4c5a">55.0</ix:nonFraction> million in milestone payments upon achievement of specified ex-U.S. regulatory milestone events, and (ii) a $<ix:nonFraction unitRef="usd" contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="agio:PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzU5OQ_59d3a993-6dd5-4ad9-9b2e-eb98ca155b34">25.0</ix:nonFraction> million milestone payment upon achievement of a specified ex-U.S. commercial milestone event, as well as royalties at tiered, low-double digit to mid-teen percentage rates on net sales of IDHIFA&#174;.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In April&#160;2015, we entered into a joint worldwide development and profit share collaboration and license agreement with Celgene, and our wholly owned subsidiary, Agios International Sarl, entered into a collaboration and license agreement with Celgene International II Sarl, or collectively, the AG-881 Agreements, to establish a worldwide collaboration focused on the development and commercialization of vorasidenib products. Under the AG-881 Agreements, we and Celgene split all worldwide development costs for vorasidenib, subject to specified exceptions. The AG-881 Agreements were terminated effective September 4, 2018, upon which we received sole global rights to vorasidenib. In connection with the termination of the AG-881 Agreements, Celgene will be eligible to receive royalties from us at a low single-digit percentage rate on worldwide net sales of products containing vorasidenib.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">In May&#160;2016, we entered into a master research and collaboration agreement with Celgene, or the 2016 Agreement, focused on metabolic immuno-oncology, or MIO. The initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzI5ODUzNDkxMzg3MA_e91388f5-9090-44e2-9f63-c9d6bd473913">four</span>-year research term of the 2016 Agreement ends May 2020. On March 25, 2020 Celgene declined the option to extend the research agreement for up to <ix:nonFraction unitRef="extension" contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQzOA_b6a7d8c7-adb6-47f1-b5a5-906e2d0d8223">two</ix:nonFraction>, or in specified cases, up to <ix:nonFraction unitRef="extension" contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQ3MQ_f494155b-f722-4f4f-90ae-efbe6c1485f6">four</ix:nonFraction> additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQ4NQ_1f9fa6ea-bf2b-47b0-80ab-ef3b836dafa9">one</span>-year terms which would have required the payment of a $<ix:nonFraction unitRef="usd" contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531" decimals="INF" format="ixt:numdotdecimal" name="agio:UpfrontPaymentAgreementExtensionFeeReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDcwNw_ad68be27-2c7b-4e5a-a911-9204b4eaad1e">40.0</ix:nonFraction>&#160;million extension fee. Further, on April 10, 2020 Celgene notified us that they will be declining to elect any program as a continuation program under the 2016 agreement. Celgene had designated AG-270, our inhibitor of  methionine adenosyltransferase 2a,  or MAT2A, as a development candidate under the 2016 Agreement. On March 25, 2020, Celgene notified us of their decision to decline their option to enter into a Development &amp; Commercialization Agreement with respect to the MAT2A program under the 2016 Agreement which would have required the payment of a $<ix:nonFraction unitRef="usd" contextRef="icf8e4931186847f7af3d6555eddb2ef4_I20160517" decimals="INF" format="ixt:numdotdecimal" name="agio:OptionExerciseFeeReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NTAxNA_3b044564-15a6-43cb-96ea-8b20a2e9a393">30.0</ix:nonFraction>&#160;million fee. As a result of the decisions, the research services will be fully satisfied as of May 17, 2020, no additional performance obligations remain under the 2016 Agreement and we are no longer eligible for any milestone payments for the 2016 agreement.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration revenue</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="agio:RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODQ_1dc97677-7d4a-49db-ba63-9688f35f22c3" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.830%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Licenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d39d16372b54ef7b70c6ceb2f6802c9_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfMy0xLTEtMS0w_430cfc76-8f1d-473d-93b9-9c28021e2f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic8cc725b4829480fa6c29d3f371c5ae3_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfMy0zLTEtMS0w_32a5a377-fe8b-4351-97c5-ff6d792e525a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">On-going research and development services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d50ef5ca59c4f6d94a83843d5742328_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfNC0xLTEtMS0w_68bfc607-426c-43a7-a2c0-abff45e3b93b">59,220</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91175df5ecdd49638bd57d0783c41bdc_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfNC0zLTEtMS0w_0470c8c5-7ac5-4e9d-bc18-bc70b80ad1f8">17,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were not considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercialization activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i108d62e896fc49d1b83a96231e5bc13e_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOC0xLTEtMS0w_4966991f-dc09-43fb-a90d-6c374cfb8718">877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3447e34e86e4a2ea996f1ad6af3f411_D20190101-20190331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOC0zLTEtMS0w_fbdcad45-a7d9-40c7-836c-19ebcc9b8258">854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue - related party</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e999092fe5a47b995df7486ab8722ad_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOS0xLTEtMS0w_344adac4-2ca3-49c8-bab9-c382888bbd39">60,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02db62d3a5c6475eb891c555c988387c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOS0zLTEtMS0w_24db0331-e78d-493b-ac51-0bbd6ebaf847">17,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><ix:continuation id="ibecbd6deb75943a992c5d728ca65a0a0" continuedAt="iaf6df4a631814dfda5f001d5a96e32fb"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODI_6a71e26a-87dc-4161-8bf3-5c265e809a84" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets and liabilities during the three months ended March 31, 2020:</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.929%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.724%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Collaboration receivable &#8211; related party </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc256153a0dc460d8411bbd9eb5fbb40_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi0xLTEtMS0w_be30e61d-2bfc-436f-a52e-f3da530c9b68">1,539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa2a9618801f42c48cc8313f6b4cd731_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractwithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi0zLTEtMS0w_926ce05e-e27a-4e68-8571-bf4accc7e1da">3,332</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaa2a9618801f42c48cc8313f6b4cd731_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi01LTEtMS0w_9a0b2d50-325a-442e-9d77-8d53c8d7336b">2,294</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53c90550dda24d7eb8b02c2f2c2f719e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi03LTEtMS0w_0a55254e-d1e4-40cc-a71a-137a148767e0">2,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Royalty receivable &#8211; related party </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d243dbfb39c481597c75558a4b5ffa9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy0xLTEtMS0w_56e41d67-4c13-4634-9035-0cd32c2e3858">2,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d106c4df9564a3caf0ba3be633967df_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractwithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy0zLTEtMS0w_4a5b678e-bdd7-4e40-b00a-8433bedb29a7">3,334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2d106c4df9564a3caf0ba3be633967df_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy01LTEtMS0w_72b81c0d-762e-447e-9397-d2acdaaef4f9">2,934</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i811057ddd1de4d0eb6492cfeadecbf6a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy03LTEtMS0w_e9c82770-ccbc-41f9-929d-7f8136d6e480">3,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue &#8211; related party, current and net of current portions </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i096066d9ee4641e1b8faebda2ab34627_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS0xLTEtMS0w_7afd03c4-52a3-4309-9cdb-c82274a9bce3">61,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if84fd2a101824c788fae2a197d74ffa9_D20200101-20200331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS0zLTEtMS0w_fd1e0039-de9c-40ab-aa13-30db9f8dc6cd">579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if84fd2a101824c788fae2a197d74ffa9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS01LTEtMS0w_b874c8f8-ce30-4a17-8ef6-39b611e02e0b">57,344</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id04eae8cb5824809b789766bea430fe0_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS03LTEtMS0w_d2878363-dee8-4f3c-837e-5d8f2d5bc0ec">4,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period and unbilled amounts related to future reimbursable costs. Deductions to receivables relate to collection of receivables during the reporting period.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. </span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(3)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in collaboration revenue from on-going research and development services during the three months ended March 31, 2020 is primarily due to the fact that subsequent to Celgene&#8217;s decision to decline extending the research term, the Company updated its estimate of the future costs that will be incurred to complete one of its performance obligations under the 2016 collaboration Agreement that is recognized overtime using an input method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.561%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.429%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMi0xLTEtMS0w_56f36364-a7a6-4bca-b9de-21f90732e639">59,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMi0zLTEtMS0w_882caabc-6c46-4dc6-bcfb-cc3925e99e0b">16,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance obligations satisfied in previous periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMy0xLTEtMS0w_8974963d-4519-4dd0-b23f-6c667df07b23">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMy0zLTEtMS0w_6bd12df7-dca5-4aca-94ab-a0c14bf4147d">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNjY5OQ_fb721016-b7e2-4323-b625-77e3bcd5253f">10.5</ix:nonFraction> million. This amount is expected to be recognized as performance obligations are satisfied through September 2023. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the underlying performance obligation, or delivery of the enasidenib license, had been satisfied as of June 2014, royalty revenue is recognized as the related sales occur. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="agio:RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODc_9fd4559c-e1c4-4371-a36c-90b5735fd479" continuedAt="ibe37ad5037da430e9e8e20c10b5fade5" escape="true">During the three months ended March 31, 2020 and 2019, we recognized the following as royalty revenue:</ix:nonNumeric></span></div><div style="margin-top:6pt;margin-bottom:9pt;"><ix:continuation id="ibe37ad5037da430e9e8e20c10b5fade5"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.076%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.598%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty revenue &#8211; related party</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic82eaa651b994a398eb65997f0b11e71_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmQxZmIzNzJhMGY3ZTRlNGZhYjY1ODU5NTJhZDdkMWNmL3RhYmxlcmFuZ2U6ZDFmYjM3MmEwZjdlNGU0ZmFiNjU4NTk1MmFkN2QxY2ZfMi0xLTEtMS0w_1763d017-c0f7-467c-9341-c4014160072a">3,334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if879b8d640fd4528a046bfb43e105676_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmQxZmIzNzJhMGY3ZTRlNGZhYjY1ODU5NTJhZDdkMWNmL3RhYmxlcmFuZ2U6ZDFmYjM3MmEwZjdlNGU0ZmFiNjU4NTk1MmFkN2QxY2ZfMi0zLTEtMS0w_8ad11453-c7ec-4567-b356-7ca760f9b2fb">2,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Milestone revenue</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_455247b0-9c63-4498-a4ed-ca455c5a0bab"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_89f9cea3-12ef-4965-802d-c83ed7c135a7"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_c8c8fa33-4b2f-4f5a-bdea-27e38d3da9c5"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_fb7726c3-6d23-4808-95dc-960aa612fe79">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> milestones were achieved during the three months ended March 31, 2020 or 2019. The next potential milestone expected to be achieved under our Collaboration Agreements is the first regulatory approval of enasidenib in any of China, Japan or a major European country, which would result in a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331" decimals="INF" format="ixt:numdotdecimal" name="agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzc2Ng_9c7566ff-4657-4e2a-8175-2fae29a63e34">35.0</ix:nonFraction> million under the 2010 Agreement.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CStone Pharmaceuticals </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, we and CStone Pharmaceuticals, or CStone, entered into an exclusive license agreement, or the CStone Agreement, to grant CStone specified intellectual property licenses to enable CStone to develop and commercialize certain products containing ivosidenib in mainland China, Hong Kong, Macau and Taiwan, or the CStone Territory. We retain development and commercialization rights for the rest of the world. On March 2, 2020, we amended the CStone Agreement to include Singapore as part of the CStone Territory. Pursuant to the CStone Agreement, CStone will initially be responsible for the development and commercialization of ivosidenib in acute myeloid leukemia, or AML, cholangiocarcinoma, and, at our discretion, brain cancer indications. CStone is responsible for all costs it incurs in developing, obtaining regulatory approval of, and commercializing ivosidenib in the CStone Territory, as well as certain costs incurred by us. Pursuant to the CStone Agreement, we received an initial upfront payment in the amount of $<ix:nonFraction unitRef="usd" contextRef="if6726df3a7204f6b9e2e0d1efc7914f1_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODcyNQ_14b8807f-8318-40f5-b855-a8dbca76f7ce">12.0</ix:nonFraction> million and are entitled to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i3da6969fb0f94cae987375f25efa45d4_I20200331" decimals="-3" format="ixt:numdotdecimal" name="agio:ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODc3Ng_b5077ee2-5085-402f-90f2-ba1853c9eb55">407.0</ix:nonFraction> million in milestone payments upon the achievement of certain development, regulatory and sales milestone events. We </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><ix:continuation id="iaf6df4a631814dfda5f001d5a96e32fb"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">will also be entitled to receive tiered royalties, ranging from <ix:nonFraction unitRef="number" contextRef="i9b95111b950c47f2a99d64f7549560da_D20180601-20180630" decimals="INF" name="agio:RoyaltyPercentageRemitted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODk1Mg_3d2d898f-4a6d-46dd-a310-162fe157d87a">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if9319d12250d4cd4816f3f7f9a1a58ec_D20180601-20180630" decimals="INF" name="agio:RoyaltyPercentageRemitted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODk1OA_88f755eb-98b5-4ef6-a872-18a52d4f73aa">19</ix:nonFraction>% percent, on annual net sales, if any, of ivosidenib in the CStone Territory.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration revenue</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODE_bd9a983e-e95d-4ea9-87ee-4b084ddea319" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue -other:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.976%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License and other services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib54283dcee9d43cf9fb07a1481b6d9dc_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfMy0xLTEtMS0w_eba2a649-6e20-4694-8c62-9c0d7589fd7f">192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieda041072edb42d2a45ab6f7a35301cf_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfMy0zLTEtMS0w_a9ccbb9d-7478-49b6-95d1-879bd042253f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were not considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c9f069f49404c26883dc94c9bf8bf4b_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNS0xLTEtMS0w_1d172814-670c-450f-b005-163110c92655">801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id57699cbaff4472d9cf3ea62c0cbb2fb_D20190101-20190331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNS0zLTEtMS0w_4fccab86-0c9e-4f42-87e3-7e353bbc1b79">970</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue - other</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id861975ff87f4dbc8890a79d84ea157e_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNy0xLTEtMS0w_d9518e77-d57f-4ee9-83a1-e214af3ec1bc">993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie310e674843d43f68873f2b9cc63f547_D20190101-20190331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNy0zLTEtMS0w_21214cac-9bc6-40db-8701-bdf8918227ec">970</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxOTI_c5135c1a-9eae-487e-96e1-bd43454c6013" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets during the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.929%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.724%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets (1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration receivable - other</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57f90389d1054ec5a3f958cb88835d5a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi0xLTEtMS0w_f5abff5f-5a9e-478f-afc8-2d80c8b29a72">1,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i280f176668304207a8331664a7bf1e74_D20200101-20200331" decimals="-3" name="agio:ContractWithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi0zLTEtMS0w_5d766226-c13b-45e9-a0c6-86a21ad98e3c">993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i280f176668304207a8331664a7bf1e74_D20200101-20200331" decimals="-3" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi01LTEtMS0w_6b0e7621-46aa-49b6-be38-c6a812a8f09f">888</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae5252cae278436a972c726382d0b31e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi03LTEtMS0w_892bfb84-4a17-496f-9ee9-57060a06d167">2,033</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)     Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="i269bc734bdc446a984c9d2c5b91a592c_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfOTU1Mg_de925a42-7883-4f6f-af92-3aaa23d90a1e">0.5</ix:nonFraction> million.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The license was determined to be the predominant item to which sales-based royalties and sales-based milestones relate. As the license was delivered in June 2018, we will recognize royalty revenue when the related sales occur. To date, <ix:nonFraction unitRef="usd" contextRef="ic38711366192418d8c09c3d6abfa8e66_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfOTgwOA_d4694334-56fc-4a33-b76c-1c8b91ac8722">no</ix:nonFraction> royalties have been received under the CStone Agreement.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Milestone revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="usd" contextRef="i93e49459503f4101adaa3ac89788c0cc_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfOTg4Ng_6fd3563b-df93-4d48-b312-811a6843477e">No</ix:nonFraction> milestones were earned during the three months ended March 31, 2020 and 2019. The next potential milestone expected to be achieved under the CStone Agreement is the dosing of the first patient in a local study in a solid tumor indication in mainland China. Achievement of this event will result in a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i269bc734bdc446a984c9d2c5b91a592c_I20200331" decimals="-5" format="ixt:numdotdecimal" name="agio:ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxNzk_6569f526-2898-452a-bf96-5fe30d0626cd">5.0</ix:nonFraction> million.</span></div></ix:continuation><div id="i7c71c9a7a53d48458a969df1a7cd05a7_61"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5NA_4a5e11b2-cfbe-41b5-ab4e-35a91d17b67a" continuedAt="i5ad97f91f3894e55b290f3688bcf77bb" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="i5ad97f91f3894e55b290f3688bcf77bb" continuedAt="i0f46250a96c3477e8563678f0c69d78b"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2013 Stock Incentive Plan</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based stock units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of March&#160;31, 2020, the total number of shares reserved under the 2007 Plan and the 2013 Plan was <ix:nonFraction unitRef="shares" contextRef="i39e8393880f542d281e86b6aff922c87_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfNzQ1_a2a23d35-18ca-408f-971c-d4271e3d5a94">11,030,628</ix:nonFraction>, and we had <ix:nonFraction unitRef="shares" contextRef="ida454044d7e04cf78a0d3ed1df7dd45d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfNzYw_e56e3cee-0cf0-4d57-b79e-2de1b1664233">2,708,920</ix:nonFraction> shares available for future issuance under the 2013 Plan.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><ix:continuation id="i0f46250a96c3477e8563678f0c69d78b" continuedAt="i3806e1d1342c40abaf61d771ecb5f5ac"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock options</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5Nw_8a55dc06-9e02-4ec7-903e-cd63091f8ccb" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents stock option activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.590%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.061%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exercise Price</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMS0xLTEtMS0w_84588446-d7c7-4be0-a74c-1f83e47f000d">6,201,485</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMS0zLTEtMS0w_70aa8203-c851-4386-aa38-31f37e9333f8">58.61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMi0xLTEtMS0w_d27fc860-5376-4769-9226-e8dbbbedd4ad">792,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMi0zLTEtMS0w_dec39b47-aab5-448c-a259-c5a25d8ef22c">51.09</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMy0xLTEtMS0w_910114c9-ab08-45f2-b944-e40801b0f562">133,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMy0zLTEtMS0w_b5e9dcd8-17ce-4767-82c7-0bab56b7289d">25.84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited/Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNC0xLTEtMS0w_8d9e465d-20aa-41e7-8d02-a29cd1012d66">110,904</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNC0zLTEtMS0w_75ed00a7-b1d4-4840-b683-5e9d94c3e663">69.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNS0xLTEtMS0w_93215256-8435-4f30-b6d8-22d10192ee40">6,749,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNS0zLTEtMS0w_5b1ef647-d9e3-41fa-be4e-9b3d31098619">58.20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNi0xLTEtMS0w_8eab27e0-2bb8-4bd6-994b-d3b616056a52">3,874,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNi0zLTEtMS0w_f0e37852-cf53-4daa-8581-b5577363991e">59.71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNy0xLTEtMS0w_e0dd6936-fd96-401b-aac5-8144df57457c">6,749,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNy0zLTEtMS0w_af9784e8-f364-43ba-a2da-dbd3dd570d61">58.20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ida454044d7e04cf78a0d3ed1df7dd45d_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfOTMx_c269ada4-c584-4179-9027-36e5736cde31">104.0</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i04dd698bbbf04386be79177cadfcb551_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTA5NQ_6fc929f4-af3a-458e-b9ff-83b2db3e3a03">2.7</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted stock units</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5OQ_265a33af-9d77-4ae6-889c-097bfcdc31f1" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents RSU activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia72433a7819146b3a0daa5c98f8ffa28_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMS0xLTEtMS0w_02eda3ab-c408-458e-ac63-5a12b46003fb">766,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia72433a7819146b3a0daa5c98f8ffa28_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMS0zLTEtMS0w_027429a7-0dd7-48ce-91fa-3f2a4e58f1f1">63.44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMi0xLTEtMS0w_7e08e8f0-ce2a-4d39-b9fb-93d8216389f7">744,447</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMi0zLTEtMS0w_143ace7b-1ffe-4419-a344-2de86efb560b">51.38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMy0xLTEtMS0w_7556ed26-0f60-4a60-812e-c2756f40b9a8">192,870</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMy0zLTEtMS0w_97fb3c6d-d8ce-42ea-aa6a-8be68ce9d5c9">70.54</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNC0xLTEtMS0w_c65638a8-61c9-465a-ac81-2f5ee674ea93">27,655</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNC0zLTEtMS0w_46fdcb68-0c8d-451e-909d-f0aa9483cce9">66.70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNS0xLTEtMS0w_e481cbd2-9f71-4b14-afaf-58962e3a1273">1,290,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNS0zLTEtMS0w_b7b06cc2-c3e2-4fab-9b33-e092fc4dae08">55.36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTIzOQ_989c83d2-1bc6-49a7-93d5-5ee1f6038308">58.3</ix:nonFraction> million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTM3OQ_3dc4418f-c0f5-4ae8-80fd-1842c8ccf7ac">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance-based stock units </span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzUwMg_60fbae04-6b31-4816-bd00-5cab3943a3d2" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents PSU activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.736%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.768%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc7485735e584ad183fa3ab8df167007_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMS0xLTEtMS0w_2e947c41-3ec4-42b0-9abc-890fb18795bc">218,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc7485735e584ad183fa3ab8df167007_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMS0zLTEtMS0w_d3b49498-db8a-418a-a04a-6eab49af64c1">55.64</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMi0xLTEtMS0w_aa1e41b1-420b-4f63-9e17-787093792a91">20,622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMi0zLTEtMS0w_07cd9dbf-4c46-48e6-a0cf-d896b739a89d">48.49</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMy0xLTEtMS0w_1f8bed30-6d72-4d91-88dd-e5a12c7e3a90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMy0zLTEtMS0w_afe1bd3e-868a-4c8d-8299-09ad86c04b65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idfe0ad5afa984d16ba94c0190f3a7bb7_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfNS0xLTEtMS0w_f332c0ac-e464-41f5-8a3e-88a5cd821d2a">238,765</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idfe0ad5afa984d16ba94c0190f3a7bb7_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfNS0zLTEtMS0w_49ee1917-8b06-43f2-ac60-4c18aaaff081">55.03</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ibc517a1325e3471bb6ee91315080f545_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTczMA_5b9b01ad-62b6-4d89-b93b-36daa7cc6020">0.5</ix:nonFraction>&#160;million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, which we expect to recognize over a weighted-average period of <ix:nonNumeric contextRef="i13ac445102f7441f9e4b8ba54ae46f21_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTk0MA_371f2534-0add-438a-bcaf-ba71cb080198">0.1</ix:nonNumeric> years, and $<ix:nonFraction unitRef="usd" contextRef="i1d0177361b9c4b0b90dc4288e2d48078_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTk0OA_91f318c2-9f97-4532-a51d-af6d2df88b12">11.3</ix:nonFraction> million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><ix:continuation id="i3806e1d1342c40abaf61d771ecb5f5ac"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Market-based stock units</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="agio:ScheduleOfMarketBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzUwMw_f82b98e0-a044-4696-a98d-a30606ad7554" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:67.838%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.787%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.385%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i256d78b2b36e45f28bd9b75429058398_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMS0xLTEtMS0w_843eef46-f8e2-4f6a-9e54-4fe07e8c7298">42,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i256d78b2b36e45f28bd9b75429058398_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMS0zLTEtMS0w_de3935c9-829b-465a-91ca-5cc0292bf35c">41.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMi0xLTEtMS0w_4e8c1b82-768d-430f-9286-4b7ccb33c968">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMi0zLTEtMS0w_8662c291-8dd0-4bc0-b4ff-5f2c73ff4d0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i899a9e83495b4f28b410853e4bd3e1a9_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfNS0xLTEtMS0w_59dd50e3-383c-4120-a7fb-f42220ab17d5">42,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i899a9e83495b4f28b410853e4bd3e1a9_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfNS0zLTEtMS0w_8aecc0ef-b832-4cb5-bd7e-78eff02f1e73">41.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of March&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i899a9e83495b4f28b410853e4bd3e1a9_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjUxMA_11e83fd4-96e7-40cb-a75a-560dfee778e7">0.5</ix:nonFraction> million of total unrecognized compensation expense related to MSUs, which we expect to recognize over the remaining derived service period of <ix:nonNumeric contextRef="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjY0Nw_5d5fa787-9f52-4be6-a0b7-d0e3430b9834">0.5</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2013 Employee Stock Purchase Plan</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued <ix:nonFraction unitRef="shares" contextRef="i28d21d465e804cd7be91d92333466787_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjg0Mg_0d7ed0a4-ac83-4ff9-b9ff-a42d83edce89">62,694</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic8dacf8900174e15a3112799baf17da0_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjg0OQ_f84d3e5c-9893-4bd8-a75a-506ba5ca33a5">32,410</ix:nonFraction> shares of common stock during the three months ended March 31, 2020 and 2019, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i28d21d465e804cd7be91d92333466787_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzAzNA_48ecac9c-6a90-4104-b573-5b214e37f458">836,363</ix:nonFraction> shares of our common stock. As of March&#160;31, 2020, we had <ix:nonFraction unitRef="shares" contextRef="i3e96f9d80bf045189e770a60c9426d0f_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzA4Mg_abf001da-f9b4-4d5d-bd1b-f8e93c3043e4">528,952</ix:nonFraction> shares of common stock available for future issuance under the 2013 ESPP.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based compensation expense</span></div><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5NQ_204a286e-f1c9-4b1b-801a-f809d64134ce" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.877%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.698%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id544e772704d4df68d5aafeb2c9bb919_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMi0xLTEtMS0w_043a1a0f-3ac7-4319-b711-e1eea5cc120c">11,603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00295454cded4864b99639e493192cdc_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMi0zLTEtMS0w_fffd50d4-0a5d-4ee8-acc4-2075a71a8203">13,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMy0xLTEtMS0w_0fa14b50-7e11-4459-967e-18ba3e9b521c">6,132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida2a85e29bc44bb4b78adcee2aa8a238_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMy0zLTEtMS0w_80b03a3d-3f5e-4355-9f7a-90d53fbc46d9">4,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance-based stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0xLTEtMS0xNzU3_7c25b58a-7994-48e5-b1a7-3d5a4c1a43ba">1,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b778fd9cd91494abee392de786ad04e_D20190101-20190331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0zLTEtMS0xNzU3_274dffd8-4e5e-4d03-8619-da1d8682a565">186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3964e595953c4f299314ea4efb11d354_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0xLTEtMS0w_4c8644f4-5756-415d-a94c-6424e9bf7314">297</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b1c325e2dd54b6aa424bba94309ad67_D20190101-20190331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0zLTEtMS0w_6c88c562-924d-4f41-b769-14b4585ef969">328</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02d3013b6a4c4bdbae10be0d1e36aeec_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNS0xLTEtMS0w_54b10d6c-e07d-4eb0-817b-635d46167ee1">270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4533663f1404a6c94d173dbdd0d8fe6_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNS0zLTEtMS0w_89a1a4ab-9818-4d61-b4e6-3ab153767956">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNi0xLTEtMS0w_34037a9f-24c6-4637-a618-37cc72e4ed75">19,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNi0zLTEtMS0w_9d0b7654-d060-4fd1-a6dc-d9c2e04d346d">18,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzUwNA_15322ca2-1088-48e3-aeee-5efc1f9f67c6" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.707%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.280%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.283%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc2e58225fba4370abf79603604d587c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMi0xLTEtMS0w_a63e32e6-446a-43f9-8662-1d0e329c9b80">9,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85f2e56eb9624864a6a945bcd372afda_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMi0zLTEtMS0w_abfb35df-7430-4dd7-840d-df32542bfee6">10,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic09bbe0bec9644d0bdb9f127f396b6ee_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMy0xLTEtMS0w_08329712-a71c-434e-af64-9786072a7e2b">10,126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2c6cd3484924f04bded7e03913923fb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMy0zLTEtMS0w_f676ebd7-e071-4f53-ac36-6f7747a8dad9">8,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfNC0xLTEtMS0w_c287f6d1-efe2-457f-8c78-9b6028c8ce02">19,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfNC0zLTEtMS0w_5cbb40a6-ec59-482a-b5a9-7dec47417a27">18,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_64"></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11. <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RleHRyZWdpb246MjljM2RjYWYxNDNjNDAzODlmZjMzY2Y0MDNiNDZlMDBfMTI2NQ_6c218006-38a0-4a9a-b105-d8df0094f48d" continuedAt="ia5eabe10e0624b53aa4b9da1c5a34cf8" escape="true">Loss per Share</ix:nonNumeric></span></div><ix:continuation id="ia5eabe10e0624b53aa4b9da1c5a34cf8" continuedAt="i64c6f77e193e4154a873d457953f3126"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of <ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RleHRyZWdpb246MjljM2RjYWYxNDNjNDAzODlmZjMzY2Y0MDNiNDZlMDBfMTI2Ng_756451b7-7a4c-44be-a21a-ef971dcdcf0a" escape="true">March&#160;31, 2020 are not considered to be common stock equivalents.</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since we had a net loss for all periods presented, the effect of all potentially dilutive securities is anti-dilutive. Accordingly, basic and diluted net loss per share was the same for all periods presented.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><ix:continuation id="i64c6f77e193e4154a873d457953f3126"><ix:nonNumeric contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RleHRyZWdpb246MjljM2RjYWYxNDNjNDAzODlmZjMzY2Y0MDNiNDZlMDBfMTI2OA_0996eb76-5298-4855-8a87-827859333a9f" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:70.834%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.215%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.217%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i63d93efc8a284556ab8f020edd3dc6e0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0xLTEtMS0w_821fe710-4750-481e-8899-c0fe40168c64"><ix:nonFraction unitRef="shares" contextRef="i63d93efc8a284556ab8f020edd3dc6e0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0xLTEtMS0w_969e42c3-2bdf-4f0c-b610-ff61d4856024">6,749,373</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0a127ee084474fe89e94f05cb952f47b_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0zLTEtMS0w_c6e8dcb6-a85f-4068-88c7-0d021d27f662"><ix:nonFraction unitRef="shares" contextRef="i0a127ee084474fe89e94f05cb952f47b_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0zLTEtMS0w_cb63dd71-d57c-44af-9d83-5ea5874ca1ee">6,482,873</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i091c1b621ade4bb9a85dbc64bfb48525_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0xLTEtMS0w_36bd97bf-3ccc-4248-a313-8f4b990b6372"><ix:nonFraction unitRef="shares" contextRef="i091c1b621ade4bb9a85dbc64bfb48525_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0xLTEtMS0w_438eb214-2c20-413d-bbfd-fb1c4f24d1f6">1,290,875</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7729db14fc3848fe915720a14a4de566_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0zLTEtMS0w_08b66426-1d37-4980-b63b-e45a726be979"><ix:nonFraction unitRef="shares" contextRef="i7729db14fc3848fe915720a14a4de566_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0zLTEtMS0w_58c611d0-57d0-4b4f-956f-d8b50b6641fc">709,162</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance-based stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a6e57a772564177acc7f7a661b71d0f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0xLTEtMS0w_cc2114b1-b7f6-4540-a22e-ff68a336d5e3"><ix:nonFraction unitRef="shares" contextRef="i8a6e57a772564177acc7f7a661b71d0f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0xLTEtMS0w_eb3b1973-5441-47f2-8478-f5849a21f979">78,920</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic07875a2aa9f4507b1f46ea8b5fed18d_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0zLTEtMS0w_7823d8e7-37ad-465b-89d4-2d7a5b074bc7"><ix:nonFraction unitRef="shares" contextRef="ic07875a2aa9f4507b1f46ea8b5fed18d_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0zLTEtMS0w_ce9daf8f-ffb2-4d4a-b122-fa259f29cc58">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2c7313c325334ec4b2e51b1fbd9a8afb_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0xLTEtMS0w_56f7031e-03b2-4871-9315-0f0748409904"><ix:nonFraction unitRef="shares" contextRef="i2c7313c325334ec4b2e51b1fbd9a8afb_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0xLTEtMS0w_d24cd8bf-ad1d-41a1-82e3-1f98654259a9">13,430</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i429a7cb2f66d4ba1976785a1a8199946_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0zLTEtMS0w_1a02028c-9ca4-48af-a3a4-8a6f7105edc3"><ix:nonFraction unitRef="shares" contextRef="i429a7cb2f66d4ba1976785a1a8199946_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0zLTEtMS0w_54337ea6-d076-43d5-b70f-2d8aef74d4d9">6,778</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0xLTEtMS0w_1974ece4-d5d6-44c7-8e8d-c513494b150e"><ix:nonFraction unitRef="shares" contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0xLTEtMS0w_958a914e-11a4-459b-9da2-63a8d5167b9c">8,132,598</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0zLTEtMS0w_4629ce3e-8097-4643-ac73-1ec4f54c091e"><ix:nonFraction unitRef="shares" contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0zLTEtMS0w_6000a024-9656-4e08-8664-b03c7380c0c3">7,198,813</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_67"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Forward-looking Information</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following discussion of our financial condition and results of operations should be read with our unaudited condensed consolidated financial statements as of March&#160;31, 2020 and for the three months ended March 31, 2020 and 2019, and related notes included in Part I., Item&#160;1. of this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC on February&#160;19, 2020. This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates, forecasts and projections, and the beliefs and assumptions of our management, and include, without limitation, statements with respect to our expectations regarding our research, development and commercialization plans and prospects, results of operations, selling, general and administrative expenses, research and development expenses, the sufficiency of our cash for future operations and business activity disruption due to the COVID-19 pandemic. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; "vision" and similar statements or variation of these terms or the negative of those terms and similar expressions are intended to identify these forward-looking statements. Readers are cautioned that these forward-looking statements are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by our forward-looking statements are those discussed under the heading &#8220;Risk Factors&#8221; in Part II, Item&#160;1A. and elsewhere in this report, and in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. We undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_70"></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company committed to the fundamental transformation of patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hematologic Malignancies and Solid Tumors</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing ivosidenib for the treatment of IDH1 mutant-positive cancers. Ivosidenib is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it a highly targeted therapy for the treatment of patients with cancers that harbor IDH1 mutations, including those with acute myeloid leukemia, or AML, myelodysplastic syndromes, or MDS, and cholangiocarcinoma. We hold worldwide development and commercial rights to ivosidenib and have licensed certain development and commercialization rights to ivosidenib to CStone in mainland China, Hong Kong, Macau, Taiwan, and Singapore. We will fund the future development and commercialization costs related to this program with the exception of development and commercialization activities of CStone under the CStone Agreement. In July 2018, the FDA approved TIBSOVO&#174; for the treatment of adult patients with R/R AML and a susceptible IDH1 mutation. The FDA's approval of TIBSOVO&#174; in R/R AML was based on clinical data from a phase 1 open-label, single-arm, multicenter dose-escalation and expansion trial of adult patients with advanced R/R AML and an IDH1 mutation. In December 2018, we submitted an marketing authorization application, or MAA to the European Medicines Agency, or EMA for TIBSOVO&#174; for the treatment of adult patients with R/R AML. In May 2019, the FDA approved our sNDA to update the U.S. Prescribing Information for TIBSOVO&#174; to include patients with newly diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. The FDA granted orphan drug designation for ivosidenib for the treatment of cholangiocarcinoma, granted Breakthrough Therapy designation for ivosidenib in combination with azacitidine for the treatment of newly diagnosed AML with an IDH1 mutation in adult patients who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy, and granted Breakthrough Therapy designation for ivosidenib for the treatment of adult patients with relapsed or refractory MDS with a susceptible IDH1 mutation as detected by an FDA-approved test.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Celgene, in collaboration with us, is developing enasidenib for the treatment of IDH2 mutant-positive hematologic malignancies. Enasidenib is an orally available, selective, potent inhibitor of the mutated IDH2 protein, making it a highly targeted therapeutic candidate for the treatment of patients with cancers that harbor IDH2 mutations, including those with AML, who have a historically poor prognosis. In August 2017, the FDA granted Celgene approval of IDHIFA&#174; for the treatment of </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">adult patients with R/R AML and an IDH2 mutation. In June 2018, Celgene submitted an MAA to the EMA for IDHIFA&#174; for IDH2 mutant-positive AML, which it subsequently withdrew in December 2019. Celgene has worldwide development and commercialization rights for IDHIFA&#174;, and we are eligible to receive royalties at tiered low-double digit to mid-teen percentage rates on any net sales of IDHIFA&#174; and have exercised our rights to provide up to one-third of the field-based commercialization efforts in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our pre-commercial clinical cancer product candidates are vorasidenib, AG-270, and AG-636.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing vorasidenib for the treatment of IDH mutant-positive low grade glioma. Vorasidenib is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing AG-270 for the treatment of cancers carrying a methylthioadenosine phosphorylase, or MTAP, deletion, which is present in approximately 15 percent of all cancers. AG-270 is an orally available selective potent inhibitor of MAT2A. On March 25, 2020, Celgene declined to exercise its right to opt into co-development and co-commercialization for the for AG-270, our MAT2A inhibitor development program, under the 2016 Agreement.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the first quarter of 2020, we made the decision to cease the internal development of AG-636 for the treatment of hematologic malignancies, including lymphoma due to limited enrollment in our phase 1 study in lymphoma. AG-636 is an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase, or DHODH, licensed by us from Aurigene Discovery Technologies Limited, or Aurigene. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">RGDs</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lead product candidate in our RGD portfolio, mitapivat, targets pyruvate kinase-R, or PKR, for the treatment of pyruvate kinase, or PK, deficiency and other hemolytic anemias. PK deficiency is a rare genetic disorder that often results in severe hemolytic anemia, jaundice and lifelong conditions associated with chronic anemia and secondary complications due to inherited mutations in the pyruvate kinase enzyme within red blood cells. Mitapivat is an orally available small molecule and a potent activator of the wild-type (normal) and mutated PKR enzymes, which has resulted in restoration of adenosine triphosphate levels and a decrease in 2,3-diphosphoglycerate levels in blood sampled from patients with PK deficiency and treated ex-vivo with mitapivat. We are also developing mitapivat for the treatment of patients with thalassemia and sickle cell disease. We have worldwide development and commercial rights to mitapivat and expect to fund the future development and commercialization costs related to this program. We are also developing AG-946, our next -generation PKR activator, and plan to initiate a phase 1 study in healthy volunteers in mid-2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the aforementioned development programs, we are seeking to advance a number of early-stage discovery programs in the areas of hematological malignancies and solid tumors, RGDs and MIO, a developing field which aims to modulate the activity of relevant immune cells by targeting critical metabolic nodes, thereby enhancing the immune mediated anti-tumor response.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration and license agreements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 9, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration and License Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, of the notes to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a description of the key terms of our arrangements with Celgene and CStone.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_73"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We have determined that our most critical accounting policies are those relating to revenue recognition, accrued research and development expenses, and stock-based compensation. Except those that have been disclosed in Note 2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Summary of Significant Accounting Policies, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">of the notes to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no significant changes to our existing critical accounting policies discussed in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_76"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Operations Overview</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impact of COVID-19 on our Business</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The spread of SARS-CoV-2 and the resulting disease COVID-19 during the first quarter of 2020 has caused an economic downturn on a global scale, as well as significant volatility in the financial markets. In March 2020 the World Health Organization declared COVID-19 a pandemic. As of April 30, 2020, we have not experienced a significant financial or supply chain impact directly related to the pandemic but has experienced some disruptions to clinical operations, including patient enrollment in our clinical trials. In this time of uncertainty as a result of the COVID-19 pandemic, we are continuing to serve our customers while taking precautions to provide a safe work environment for our employees and customers. We have established and implemented a work from home policy for our employees. We have also made internal resource allocation </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">decisions in order to deliver on key business objectives and to increase our financial flexibility, including, for example, by pausing the development of certain preclinical research programs, delaying the start of certain longer-term clinical studies, limiting staff hiring and reducing the number of contract workers, and delaying or limiting information technology and facilities infrastructure projects. We may have to take further actions that we determine are in the best interests of our employees or as required by federal, state, or local authorities.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the pandemic continues to unfold, the extent of the pandemic&#8217;s effect on our operational and financial performance will depend in large part on future developments, which cannot be predicted with confidence at this time. Future developments include changes in the duration, scope and severity of the pandemic, the actions taken to contain or mitigate its impact, the impact on governmental programs and budgets, the development of treatments or vaccines, and the resumption of widespread economic activity. Any prolonged material disruption of the Company&#8217;s employees, suppliers, manufacturing, or customers could negatively impact its consolidated financial position, consolidated results of operations and consolidated cash flows.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, our operations have primarily focused on organizing and staffing our company, business planning, raising capital, assembling our core capabilities in cellular metabolism, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials and marketing our approved products. To date, we have financed our operations primarily through funding received from our various collaboration agreements discussed above, private placements of our preferred stock, our initial public offering of our common stock and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, since inception, we have incurred significant operating losses. Our net losses were $40.3 million and $93.1 million for the three months ended March 31, 2020 and 2019, respectively. As of March&#160;31, 2020, we had an accumulated deficit of $1.6 billion. We expect to continue to incur significant expenses and net losses until such time we are able to report profitable results. Our net losses may fluctuate significantly from year to year. We expect that we will continue to incur significant expenses as we continue to advance and expand clinical development activities for our lead programs: ivosidenib, enasidenib, vorasidenib, mitapivat, and AG-270; continue to discover and validate novel targets and drug product candidates; expand and protect our intellectual property portfolio; and hire additional commercial, development and scientific personnel.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our wholly owned product, TIBSOVO&#174;, received approval from the FDA on July 20, 2018 for the treatment of adult patients with R/R AML with susceptible IDH1 mutation. Upon FDA approval of TIBSOVO&#174; in the U.S., we began generating product revenue from sales of TIBSOVO&#174;. We sell TIBSOVO&#174; to a limited number of specialty distributors and specialty pharmacy providers in the U.S., or collectively, the Customers. These Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also recognize collaboration revenue from our agreements with Celgene and CStone, and royalty revenue from Celgene on sales of IDHIFA&#174;.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the future, we expect to continue to generate revenue from a combination of product sales, royalties on product sales, cost reimbursements, milestone payments, and upfront payments to the extent we enter into future collaborations or licensing agreements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of sales consists primarily of manufacturing costs for sales of TIBSOVO&#174;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of TIBSOVO&#174; recorded during the three months ended March 31, 2020 and three months ended March 31, 2019, respectively, were expensed prior to July 20, 2018 and, therefore, are not included in costs of sales during the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three months ended March 31, 2020 and three months ended March 31, 2019, respectively.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and development expenses</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as our product candidate development programs progress. However, the successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development and commercialize these product candidates. We are also unable to positively predict when future net cash inflows will commence from TIBSOVO&#174; </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ivosidenib), IDHIFA&#174; (enasidenib), vorasidenib, mitapivat, AG-270 or any of our other product candidates. This is due to the numerous risks and uncertainties associated with developing medicines, including the uncertainty of:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">establishing an appropriate safety profile with an investigational new drug application, or IND, and/or new drug application, or NDA, enabling toxicology and clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the successful enrollment in, and completion of, clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">establishing compliant commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">maintaining an acceptable safety profile of the products following approval.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">employee-related expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct research and development and both preclinical and clinical activities on our behalf, and the cost of consultants;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the cost of lab supplies and acquiring, developing and manufacturing preclinical and clinical study materials; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and the maintenance of facilities, insurance and other operating costs.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes the clinical development activities related to our most advanced programs:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ivosidenib (mutant IDH1 inhibitor)</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1b, multicenter, international, open-label clinical trial, to evaluate safety and clinical activity of ivosidenib or enasidenib in combination with induction and consolidation therapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation who are eligible for intensive chemotherapy. This trial has completed enrollment.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1/2 frontline combination clinical trial, conducted by Celgene, of either ivosidenib or enasidenib in combination with VIDAZA&#174; (azacitidine) in newly diagnosed AML patients not eligible for intensive chemotherapy. The trial has completed enrollment.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">AGILE, a global, registration-enabling phase 3 clinical trial, combining ivosidenib and VIDAZA&#174; (azacitidine) in newly diagnosed AML patients with an IDH1 mutation who are ineligible for intensive chemotherapy. The trial is enrolling patients and, due to disruptions related to the COVID-19 pandemic, we now expect to complete enrollment in 2021.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">HOVON150/AMLSG29, an intergroup sponsored, global, registration-enabling phase 3 trial, supported in collaboration with Celgene, combining ivosidenib or enasidenib with standard induction and consolidation chemotherapy in frontline AML patients with an IDH1 or IDH2 mutation. The trial is currently enrolling patients, and enrollment has slowed due to disruptions related to the COVID-19 pandemic.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1 multicenter, open-label, dose-escalation and expansion clinical trial, designed to assess its safety, clinical activity and tolerability as a single agent in patients with advanced hematologic malignancies with an IDH1 mutation. The trial recently reopened enrollment of its relapsed or refractory MDS arm, and due to disruptions related to the COVID-19 pandemic, we now expect to complete enrollment in 2021.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1 multicenter, open-label, dose-escalation and expansion clinical trial, designed to assess its safety, clinical activity and tolerability as a single agent in patients with advanced solid tumors with an IDH1 mutation, including glioma, cholangiocarcinoma, and chondrosarcoma. The trial has completed enrollment.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">ClarIDHy, a registration-enabling phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial of ivosidenib in previously-treated patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation. The primary endpoint of the trial was met and, due to disruptions related to the COVID-19 pandemic, we now expect to file an sNDA with the FDA for TIBSOVO&#174; in cholangiocarcinoma between the end of 2020 and mid-2021.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1 multi-center, open-label clinical trial of ivosidenib in patients with advanced IDH1 mutant-positive solid tumors, including glioma. The trial has completed enrollment.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A perioperative study with ivosidenib and vorasidenib in low grade glioma to further investigate their effects on brain tumor tissue. The trial has completed enrollment.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vorasidenib</span></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1 multi-center, open-label clinical trial of vorasidenib in patients with advanced IDH1 or IDH2 mutant-positive solid tumors, including glioma. The trial has completed enrollment.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">The above mentioned perioperative study with ivosidenib and vorasidenib in low grade glioma to further investigate their effects on brain tumor tissue. The trial has completed enrollment.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">INDIGO, a registration-enabling phase 3 clinical trial of vorasidenib in low-grade (grade 2) glioma with an IDH1 or IDH 2 mutation. The trial is enrolling patients, and the Company expects site start-up and enrollment delays due to disruptions related to the COVID-19 pandemic.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Mitapivat: PK Activator</span></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">DRIVE PK, a global phase 2, first-in-patient, open-label safety and efficacy clinical trial of mitapivat in adult, transfusion-independent patients with PK deficiency. This trial has completed enrollment. </span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">ACTIVATE-T, a single arm, global, pivotal trial of mitapivat in regularly-transfused patients with PK deficiency. The trial has completed enrollment. Due to anticipated challenges in accessing clinical sites following completion of dosing as a result of the COVID-19 pandemic, we expect to report topline data from the trial between the end of 2020 and mid-2021.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">ACTIVATE, a 1:1 randomized, placebo-controlled, global, pivotal trial of mitapivat in patients with PK deficiency who do not receive regular transfusions. The trial has closed enrollment. Due to anticipated challenges in accessing clinical sites following completion of dosing as a result of the COVID-19 pandemic, we expect to report topline data from the trial between the end of 2020 and mid-2021.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 2, open-label safety and efficacy clinical trial of mitapivat in adult patients with non-transfusion-dependent thalassemia. The trial has completed enrollment. </span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">In collaboration with the National Institutes of Health, or NIH, we are evaluating mitapivat in a phase 2 trial in patients with sickle cell disease pursuant to a cooperative research and development agreement. New enrollment has been paused during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">AG-270: Targeting MAT2A for the treatment of MTAP-deleted cancers</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1 trial in multiple tumor types carrying an MTAP deletion. The first part of the trial, which is complete, is a single agent dose-escalation phase in which cohorts of patients received ascending doses of AG-270 to determine the pharmacokinetics, pharmacodynamics and optimal dose, and schedule. The next phase of development, which was initiated in September 2019, is evaluating AG-270 in combination with taxanes in two areas of high unmet needs. One arm of the study will test AG-270 in combination with docetaxel in MTAP-deleted non-small cell lung cancer and the other arm will test AG-270 in combination with nab-paclitaxel and gemcitabine in MTAP-deleted pancreatic ductal adenocarcinoma. Both combination arms have initiated and are enrolling patients.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">AG-636: Targeting DHODH for the treatment of hematologic malignancies</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A phase 1 dose-escalation trial of AG-636 in subjects with advanced lymphoma. In the first quarter of 2020, we made the decision to halt internal development of AG-636, due to limited enrollment in this study, and will wind down the study during 2020. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">AG-946: Next-generation PKR Activator</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">We plan to initiate a phase 1 study of AG-946 in healthy volunteers in mid-2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other research and platform programs</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other research and platform programs include activities related to exploratory efforts, target validation and lead optimization for our discovery and follow-on programs, and our proprietary metabolomics platform.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, general and administrative expenses</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, business development, commercial, legal and human resources functions. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other significant costs include facility related costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate that our selling, general and administrative expenses will increase in the future to support continued research and development, and commercialization activities, including the potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_79"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain prior-year amounts have been reclassified to conform with current presentation. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the three months ended March 31, 2020 and 2019</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Total Revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.699%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue &#8211; related party</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue &#8211; other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">970&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty revenue &#8211; related party</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Total Revenue - First Quarter of 2020 vs. First Quarter of 2019 - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in total revenue of $56.9&#160;million for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 was primarily due to an increase in collaboration revenue - related party of $42.2 million and an increase in product revenue of $13.5 million. The increase in collaboration revenue - related party for the three months ended March 31, 2020 is primarily due to the fact that subsequent to Celgene&#8217;s decision to decline extending the research term, we updated our estimate of the future costs that will be incurred from on-going research and development services to complete one of our performance obligations under the 2016 collaboration agreement that is recognized overtime using an input method. The increase in product revenue is primarily the result of increased sales volume of TIBSOVO&#174;. </span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Total Operating Expenses</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.699%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,791&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Operating Expenses</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Total Operating Expenses - First Quarter of 2020 vs. First Quarter of 2019 - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating expenses for the three months ended March 31, 2020 were relatively consistent with total operating expenses for the three months ended March 31, 2019. The increase in selling, general and administrative expense of $6.7 million during the three months ended March 31, 2020 was primarily due to higher personnel costs, including stock-based compensation expense, related to our workforce. The decrease in research and development expenses during the three months ended March 31, 2020 is described below under Research and Development Expenses. We expect cost of sales to increase moderately in 2020 as we have depleted our finished goods inventory that was expensed prior to receiving FDA approval of TIBSOVO&#174;.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development expenses, by major program, are outlined in the table below: </span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"></td><td style="width:72.888%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.394%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.887%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.889%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Enasidenib (IDH2 inhibitor)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">358&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ivosidenib (IDH1 inhibitor)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vorasidenib (AG-881) (Pan IDH inhibitor)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,317&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mitapivat (PKR activator)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,462&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AG-270 (MAT2A inhibitor)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AG-636 (DHODH inhibitor) discontinued</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AG-946 (Next-Gen PKR activator)</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,406&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other research and platform programs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total direct research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation and related expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,024&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities and IT related expenses &amp; other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total indirect research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Total Research and development Expenses - First Quarter of 2020 vs. First Quarter of 2019 - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The decrease in total research and development expenses of $4.3 million for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 was primarily due to a $6.2 million decrease in our direct expenses. The decrease in direct expenses was primarily due to a decrease in ivosidenib costs for the three months ended March 31, 2020 primarily as a result of decreased clinical costs due to $3.2 million in milestones achieved during the three months ended March 31, 2019 for the initiation of the HO150/AMLSG29 trial, and decreased activity on trial activities for ClarIDHy and the Phase 1 hematological malignancies trial. The increase in indirect expenses of $1.9 million was primarily due to a $1.6 million increase in employee related expenses driven by additional hiring during the three months ended March 31, 2020 to support increased clinical program activity.</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Income</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.699%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,405&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest Income - First Quarter of 2020 vs. First Quarter of 2019 -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The change in interest income is primarily attributable to the decrease in our outstanding marketable securities and changes in interest rates earned on our marketable securities. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loss from Operations and Net Loss</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.699%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,192)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97,483)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,256)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(93,078)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Loss from Operations and Net Loss &#8211; First Quarter of 2020 vs. First Quarter of 2019 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8211; The decrease in loss from operations and net loss</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 was primarily driven by higher total revenue as described above in Total Revenue. </span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_82"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sources of liquidity</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, and through March&#160;31, 2020, we have funded our operations through commercial sales of TIBSOVO&#174;, upfront, milestone, extension, cost reimbursement and royalty payments related to our collaboration agreements, product sales, proceeds received from our issuance of preferred stock, our initial public offering and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to our existing cash, cash equivalents and marketable securities, we are eligible to earn milestone payments, cost reimbursements, and royalty payments under our collaboration agreements with Celgene and CStone. Our ability to earn the milestone payments, cost reimbursements and royalty payments, and the timing of earning these amounts are dependent upon the timing and outcome of our development, regulatory and commercial activities, and is uncertain at this time. Our right to payments under our collaboration agreements with Celgene and CStone are our only committed potential external source of funds.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash flows</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides information regarding our cash flows for the three months ended March 31, 2020 and 2019:</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105,358)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103,271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,162&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net cash used in operating activities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. During the three months ended March 31, 2020, we received $22.1 million from sales of TIBSOVO&#174;, $5.2 million in cost reimbursements and royalty payments related to our Collaboration Agreements with Celgene, $2.9 million in interest received, and $0.9 million in cost reimbursement related to our Collaboration agreement with CStone. These amounts were offset by increased operating expenses that relate to increased staffing needs due to our expanding operations and expanded facilities and IT related costs.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2019, we received $10.8 million from sales of TIBSOVO&#174; and $4.9 million in cost reimbursements and royalty payments under our Collaboration Agreements with Celgene. These amounts were offset by increased operating expenses which relate to increases in clinical study costs due to advancements in our most advanced product candidates, commercialization efforts, expanded facilities and increased staffing needs due to our expanding operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net cash provided by investing activities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Cash provided by investing activities for the three months ended March 31, 2020 was primarily the result of higher proceeds from maturities and sales of marketable securities than purchases of marketable securities, offset by $4.5 million in purchases of property and equipment. Cash provided by investing activities for the three months ended March 31, 2019 was primarily the result of higher proceeds from maturities and sales of marketable securities than purchases of marketable securities, offset by $2.0 million in purchases of property and equipment.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net cash provided by financing activities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Cash provided by financing activities for the three months ended March 31, 2020 was primarily the result of the $5.5 million of proceeds received from stock option exercises and purchases made pursuant to our 2013 ESPP. Cash provided by financing activities for the three months ended March 31, 2019 was primarily the result of the $4.9 million of proceeds received from stock option exercises and purchases made pursuant to our 2013 ESPP.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding requirements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to commercialize TIBSOVO&#174;, and continue the research, development and clinical trials of, and seek additional marketing approvals for, our product candidates. If we obtain additional marketing approval for any of our other product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of Celgene, CStone or other partners. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that our existing cash, cash equivalents and marketable securities as of&#160;March&#160;31, 2020, together with anticipated product and royalty revenue, anticipated interest income and anticipated expense reimbursements under our collaboration agreements, but excluding any additional collaboration-related payments, will enable us to fund our operating expenses and capital expenditure requirements through the end of June 2022. Our future capital requirements will depend on many factors, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the success of our collaborations;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the extent to which we acquire or in-license other medicines and technologies;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the costs associated with preparation for the potential commercial launch of one or more of our product candidates;</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the levels of sales of TIBSOVO&#174; or royalties on sales of IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">operational delays due to the ongoing COVID-19 pandemic; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to establish and maintain additional collaborations on favorable terms, if at all. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed potential external source of funds other than our collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_85"></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-balance Sheet Arrangements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules. </span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into agreements in the normal course of business with CROs for clinical trials and CMOs for supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes. These contractual obligations are cancelable at any time by us, generally upon prior written notice to the vendor.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, except for the minimum rental commitments disclosed in Note 6, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q, there were no significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_88"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3.&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk related to changes in interest rates. As of March&#160;31, 2020 and December&#160;31, 2019, we had cash, cash equivalents and marketable securities of $613.1 million and $717.8 million, respectively, consisting primarily of investments in U.S. Treasuries, government securities and corporate debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are primarily in short-term marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we do not believe an immediate and uniform 100 basis point change in interest rates would have a material effect on the fair market value of our investment portfolio.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also exposed to market risk related to changes in foreign currency exchange rates. We have contracts with CROs located in Asia and Europe that are denominated in foreign currencies, and we are subject to fluctuations in foreign currency rates in connection with these agreements. We do not currently hedge our foreign currency exchange rate risk. As of March&#160;31, 2020 and December&#160;31, 2019, liabilities denominated in foreign currencies were immaterial.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_91"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4.&#160;Controls and Procedures</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of March&#160;31, 2020, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, occurred during the fiscal quarter ended March&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_94"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_97"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A. Risk Factors</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained herein, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of our management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; "vision" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The risks described are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These risk factors restate and supersede the risk factors set forth under the heading &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have incurred significant operating losses. Our net losses were $411.5 million, $346.0 million and $314.7 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively, and $40.3 million for the three months ended March 31, 2020. As of March&#160;31, 2020, we had an accumulated deficit of $1.6 billion. To date, we have generated only modest revenue from sales of TIBSOVO&#174; and royalties on sales of IDHIFA&#174;. Other than the FDA approvals of TIBSOVO&#174; (for the treatment of IDH1 mutant-positive adult patients with R/R AML or newly diagnosed AML who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy) and IDHIFA&#174; (for the treatment of IDH2 mutant-positive adult patients with R/R AML), we have not obtained marketing approval for any of our product candidates, which are in preclinical or clinical development stages. We have financed our operations primarily through public offerings of our common stock and our collaboration agreements with Celgene and have devoted substantially all of our efforts to research and development. We expect to continue to incur significant expenses and net losses until such time as we are able to report profitable results. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that we will incur significant expenses if and as we:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">initiate and continue clinical trials for our products and product candidates, including: ivosidenib, enasidenib, vorasidenib, mitapivat, and AG-270;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">continue our research and preclinical development of our product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">seek to identify additional product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">seek marketing approvals for our product candidates that successfully complete clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">establish and maintain a sales, marketing and distribution infrastructure to commercialize any medicines for which we have or may obtain marketing approval;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">maintain, expand and protect our intellectual property portfolio;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">hire additional clinical, quality control and scientific personnel;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">add additional personnel to support our product development and planned future commercialization efforts and our operations;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">add equipment and physical infrastructure to support our research and development; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">acquire or in-license other medicines and technologies.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To become and remain profitable, we must develop and eventually commercialize one or more medicines with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those medicines for which we may obtain marketing approval and satisfying any post-marketing requirements. Notwithstanding the extent to which we may succeed in these activities, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect to incur significant expenses as we continue to advance our ongoing activities, particularly as we continue the research and development of, initiate and continue clinical trials of, seek marketing approvals for, and potentially commercialize our product candidates, to the extent that such expenses are not the responsibility of Celgene or other collaborators. For example, we have incurred and expect to continue to incur expenses related to the commercialization of TIBSOVO&#174;, and expect to continue to incur expenses in connection with the buildout of a limited commercial infrastructure in the EU. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that our existing cash, cash equivalents and marketable securities as of&#160;March&#160;31, 2020, together with anticipated product and royalty revenue, anticipated interest income and anticipated expense reimbursements under our collaboration agreements, but excluding any additional collaboration-related payments, will enable us to fund our operating expenses and capital expenditure requirements through the end of June 2022. Our estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the success of, and developments regarding, our collaborations;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">commercialization expenses relating to approved medicines such as TIBSOVO&#174; and IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">levels of product revenue from sales of TIBSOVO&#174; and royalties on sales IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the cost associated with preparation for the potential commercial launch of one or more of our product candidates, including the build-out of a limited commercial infrastructure in the EU;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our ability to establish and maintain additional collaborations on favorable terms, if at all; </span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">operational delays due to the COVID-19 pandemic; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the extent to which we acquire or in-license other medicines and technologies.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain additional marketing approvals and achieve product sales. In addition, TIBSOVO&#174;, IDHIFA&#174;, or other product candidates, if approved, may not achieve or maintain commercial success. Even if we succeed in developing and commercializing one or more of our product candidates, we may never achieve sufficient sales revenue to achieve or maintain profitability. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Until such time as we can generate positive cash flow, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">external source of funds, other than agreements with our collaborators, which are limited in scope and duration. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may require us to enter into agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We commenced operations in late 2008. Our operations to date have been primarily limited to organizing and staffing our company, business planning, raising capital, acquiring and developing our technology, identifying potential product candidates, undertaking preclinical and clinical studies of our product candidates, and establishing a commercial infrastructure. All of our product candidates are still in preclinical and clinical development, with the exception of TIBSOVO&#174; and IDHIFA&#174;. Typically, it takes about 10 to 15 years to develop one new medicine from the time it is discovered to when it is available for treating patients, assuming that it successfully completes all stages of research and development and achieves marketing approval, all of which is highly uncertain. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may adversely affect our ability to successfully commercialize our products and product candidates. We are in the process of transitioning from a company with solely a research focus to a company capable of supporting commercial activities and we have not yet demonstrated our ability to conduct large-scale sales and marketing activities. We may not be successful in such a transition.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial condition and operating results to may continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recent changes in tax law may adversely affect our business or financial condition.  On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act, or the Tax Act, which significantly reformed the U.S. Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, contained significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income and elimination of net operating loss carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), the imposition of a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of Congress&#8217; response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, and the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was enacted on March 27, 2020. Both contain numerous tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of the 80%-of-income limitation on the use of net operating losses, which was enacted as part of the Tax Act. It also provides that net operating losses arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible to be carried back up to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30 to 50% of adjusted taxable income.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Regulatory guidance under the Tax Act, the FFCR Act and the CARES Act is and continues to be forthcoming, and such guidance could ultimately increase or lessen impact of these laws on our business and financial condition. It is also likely that Congress will enact additional legislation in connection with the COVID-19 pandemic, some of which could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the FFCR Act or the CARES Act.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to the Discovery, Development, and Commercialization of our Product Candidates</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not successfully commercialize TIBSOVO&#174; in current and any additional indications for which it may be approved our prospects may be substantially harmed.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2018, the FDA approved TIBSOVO&#174; for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation, and in May 2019, the FDA approved TIBSOVO&#174; for the treatment of adult patients with newly diagnosed AML with a susceptible IDH1 mutation who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. In December 2019, the FDA granted Breakthrough Therapy designation for ivosidenib for the treatment of adult patients with relapsed or refractory MDS with a susceptible IDH1 mutation as detected by an FDA-approved test, and we recently reopened enrollment in the MDS arm of our Phase 1 clinical trial of ivosidenib with the goal of generating sufficient data to pursue a regulatory filing in this indication. We are also evaluating ivosidenib in other clinical trials for the treatment of IDH1 mutant-positive cancers. Our ability to generate product revenue from TIBSOVO&#174; will depend heavily on our successful development and commercialization of the product.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The development and commercialization of TIBSOVO&#174; (ivosidenib) could be unsuccessful if:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">TIBSOVO&#174; becomes no longer accepted as safe, efficacious, and cost-effective for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation in the medical community and by third-party payors;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we fail to maintain the necessary financial resources and expertise to manufacture, market and sell TIBSOVO&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we fail to continue to develop and implement effective marketing, sales and distribution strategies and operations for the development and commercialization of TIBSOVO&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we fail to continue to develop, validate and maintain a commercially viable manufacturing process for TIBSOVO&#174; that is compliant with current good manufacturing practices;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we fail to successfully obtain third party reimbursement and generate commercial demand that results in sales of TIBSOVO&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our efforts to commercialize TIBSOVO&#174; are impeded by the effects of the COVID-19 pandemic;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we encounter any third-party patent interference, derivation, inter partes review, post-grant review, reexamination or patent infringement claims with respect to ivosidenib;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we fail to comply with regulatory and legal requirements applicable to the sale of TIBSOVO&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">competing drug products are approved for the same indications as TIBSOVO&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">new significant safety risks are identified;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">ivosidenib does not demonstrate acceptable safety and efficacy in current or future clinical trials, or otherwise does not meet applicable regulatory standards for approval in indications other than for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation and the treatment of adult patients with newly diagnosed AML with a susceptible IDH1 mutation who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we experience significant delays or an inability to successfully develop and commercialize TIBSOVO&#174; (ivosidenib), our business would be materially harmed.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in our efforts to identify or discover potential product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A key element of our strategy is to identify and test compounds that target cellular metabolism and adjacent areas of biology in a variety of different types of hematologic malignancies, solid tumors and RGDs, as well as in immune cells for the treatment of cancer. A significant portion of the research that we are conducting involves new compounds and drug discovery methods, including our proprietary technology. The drug discovery that we are conducting using our proprietary technology may not be successful in identifying compounds that are useful in treating cancer or RGDs. In addition, our efforts in the emerging field of metabolic immuno-oncology may not be as successful as our efforts to date in cancer metabolism and RGDs. Furthermore, our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the research methodology used may not be successful in identifying appropriate biomarkers or potential product candidates; or</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to generate incremental product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The COVID-19 pandemic, which began in late 2019 and has spread worldwide, may affect our ability to initiate or continue our planned, ongoing and future clinical trials, disrupt regulatory activities, disrupt our ability to maintain a commercial infrastructure for our products or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business and operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The COVID-19 pandemic, which began in December 2019, has spread worldwide, causing many governments to implement measures to slow the spread of the outbreak through quarantines, strict travel restrictions, heightened border scrutiny, and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future progression of the pandemic and its effects on our business and operations are uncertain. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event of a continuation of shelter-in-place orders and/or other mandated local travel restrictions, our employees conducting research and development activities may not be able to access our research space, and our core activities may be significant limited or curtailed, possibly for an extended period of time. In light of the pandemic, we may choose to pause certain research programs, delay the start of certain longer-term clinical studies and limit hiring. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have enrolled, and seek to enroll, patients in our clinical trials at sites located both in the United States and internationally. We face difficulties recruiting or retaining patients in our ongoing clinical trials because of the pandemic. Patients enrolled in our clinical trials may be unable or unwilling to visit clinical trial sites which may impact the collection of important clinical trial data. In addition limitations in the ability to visit sites has affected, and may continue to adversely affect, our enrollment timelines for our clinical trials, and may adversely affect the timing of completion of our clinical trials or our ability to complete clinical trials in a fully compliant manner. For example, due to disruptions related to the COVID-19 pandemic, we have delayed our expectations for completion of enrollment of our phase 3 AGILE clinical trial and the MDS arm of our phase 1 clinical trial of ivosidenib until 2021. Additionally, the potential suspension of clinical trial activity at clinical trial sites may have an adverse impact on our clinical trial plans and timelines.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may face disruptions in our ability to prepare and submit applications to regulatory authorities for drug approvals and to build and maintain a commercial infrastructure for our products and product candidates. For example, we now expect to submit to the FDA an sNDA for TIBSOVO&#174; for previously treated IDH1 mutant-positive cholangiocarcinoma in the first half of 2021, instead of by the end of 2020. We may face disruptions that may affect our ability to initiate and complete clinical trials including disruptions in procuring items that are essential for our research and development activities, including, for example, raw materials used in the manufacturing of our product candidates and laboratory supplies for planned and ongoing clinical trials, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. We may face manufacturing disruptions or disruptions related to the ability to obtain necessary institutional review board, or IRB, or other necessary site approvals, as well as other delays at clinical trial sites.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The response to the COVID-19 pandemic may redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The COVID-19 pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds through public offerings and may also impact the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not know whether we will be able to develop any additional medicines of commercial value, based on our approach to the discovery and development of product candidates that target cellular metabolism.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our scientific approach focuses on using our proprietary technology to identify key metabolic enzymes in diseased cells in the laboratory and then using these key enzymes to screen for and identify product candidates targeting cellular metabolism and adjacent areas of biology. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our focus on using our proprietary technology to screen for and identify product candidates targeting cellular metabolism and adjacent areas of biology may not result in the discovery and development of commercially viable medicines to treat patients with hematologic malignancies, solid tumors or RGDs. Any medicines that we develop may not effectively correct metabolic pathways or alter the metabolic state of immune cells. If we are able to develop a product candidate that targets cellular metabolism and adjacent areas of biology in preclinical studies, we may not succeed in demonstrating safety and efficacy of the product candidate in human clinical trials. In addition, even if we obtain marketing approval for one of our product candidates, we can provide no assurance that commercialization of such product candidate will be successful.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend heavily on the success of our clinical product candidates. Clinical trials of our product candidates may not be successful. If we or our collaborators are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Other than TIBSOVO&#174;, IDHIFA&#174;, vorasidenib, mitapivat, AG-270 and AG-636, we have not commenced clinical trials for any of our other product candidates. Our ability to generate product revenue will depend heavily on the successful development and eventual commercialization of our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of ivosidenib, mitapivat and our other product candidates will depend on many factors, including the following:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">successful enrollment in, and completion of, clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">safety, tolerability and efficacy profiles that are satisfactory to the FDA, the EMA or any comparable foreign regulatory authority for marketing approval;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">timely receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">establishing both clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the performance of any collaborators;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our medicines;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">launching commercial sales of the medicines, if and when approved, whether alone or in collaboration with others;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">acceptance of the medicines, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">effectively competing with other therapies;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">continuing acceptable safety profile for the medicines following approval;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">enforcing and defending intellectual property rights and claims; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">achieving desirable medicinal properties for the intended indications.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any collaborator. If we or any collaborators do not achieve one or more of these factors in a timely manner or at all, we or such collaborators could experience significant delays or an inability to successfully commercialize our most advanced product candidates, which would materially harm our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If clinical trials of products or product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We, and any collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. In June 2018 Celgene submitted an MAA to the EMA for IDHIFA&#174; for IDH2 mutant-positive AML, which it subsequently withdrew in December 2019. In December 2018, we submitted an MAA to the EMA for TIBSOVO&#174; for the treatment of adult patients with IDH1 mutant-positive R/R AML and we plan to submit an sNDA for TIBSOVO&#174; for previously treated IDH1 mutant-positive cholangiocarcinoma to the FDA in the first half of 2021. However, we can provide no assurance that we will successfully submit such sNDA, or any NDA for any of our other product candidates, or that any MAA, NDA or sNDA submitted by us or Celgene will receive regulatory approval on the timeframe we expect, or at all. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. For instance, in December 2016, we withdrew our IND for AG-519, our second PKR activator, following verbal notification of a clinical hold from the FDA relating to a previously disclosed case of drug-induced cholestatic hepatitis which occurred in our phase 1 clinical trial of AG-519 in healthy volunteers. Although these decisions and this hepatic adverse event finding do not affect our ongoing clinical trials for mitapivat, our first PKR activator, we cannot provide any assurances that there will not be similar or other treatment-related severe adverse events in our other clinical trials of mitapivat, that our other trials will not be placed on clinical hold in the future, or that patient recruitment for our other trials will not be adversely impacted.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of, or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well-tolerated when that is not in fact the case.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us, or any collaborators, and impair our ability to generate revenue from product sales, regulatory and commercialization milestones and royalties. Moreover, if we or our collaborators are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we or our collaborators may:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">not obtain marketing approval at all;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">be subject to additional post-marketing testing requirements; or</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">have the medicine removed from the market after obtaining marketing approval.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our failure to successfully complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we, or any collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of our product candidates, potential clinical development, marketing approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulators or institutional review boards may not authorize us, our collaborators or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we or our collaborators may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">clinical trials of our product candidates may produce negative or inconclusive results, and we or our collaborators may decide, or regulators may require us, to conduct additional clinical trials, including testing in more subjects, or abandon product development programs;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate; enrollment in these clinical trials, which may be particularly challenging for some of the orphan diseases we target in our RGD programs, may be slower than we anticipate; or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">third-party contractors used by us or our collaborators may fail to comply with regulatory requirements or meet their contractual obligations in a timely manner, or at all;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we or our collaborators might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulators, institutional review boards, or the data safety monitoring board for such trials may require that we, our collaborators or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the cost of clinical trials of our product candidates may be greater than anticipated;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us, our collaborators or our investigators, regulators or institutional review boards to suspend or terminate the trials.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Should the COVID-19 pandemic persist and/or spread, our clinical development plans could be affected. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. Some participants and clinical investigators may not be able to comply with clinical trial protocols, for example if quarantines or other travel limitations continue to impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our clinical trials. For example, due to disruptions related to the COVID-19 pandemic, we have delayed our expectations for completion of enrollment of our phase 3 AGILE clinical trial and the MDS arm of our phase 1 clinical trial of ivosidenib until 2021. Furthermore, site initiations and patient enrollment may be delayed or suspended by local health authorities considering the COVID-19 outbreak.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product development costs for us, or any collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we, or any collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any collaborators, to bring products to market before we, or any collaborators, do and impair our ability, or the ability of any collaborators, to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of marketing approval of any of our product candidates.</span></div><div style="text-align:justify;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our collaborators may not be able to initiate or continue clinical trials for our product candidates if we or they are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States. For example, in the first quarter of 2020, we made the decision to halt internal development of AG-636 for the treatment of hematologic malignancies, including lymphoma due to limited enrollment in our phase 1 study in lymphoma. Furthermore, enrollment has been and may continue to be particularly challenging in light of the ongoing COVID-19 pandemic and even more so for some of the orphan diseases we target in our RGD programs. For example, due to disruptions related to the COVID-19 pandemic, we have delayed our expectations for completion of enrollment of our phase 3 AGILE clinical trial and the MDS arm of our phase 1 clinical trial of ivosidenib until 2021. In addition, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates.</span></div><div style="text-align:justify;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient enrollment is also affected by other factors including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">severity of the disease under investigation;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">availability and efficacy of approved medications for the disease under investigation;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">eligibility criteria for the study in question;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">perceived risks and benefits of the product candidate under study;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">patient referral practices of physicians;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the ability to monitor patients adequately during and after treatment; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Utilizing our precision medicine approach, we generally focus our development activities on genetically or biomarker defined patients most likely to respond to our therapies. As a result, the potential patient populations for our clinical trials are narrowed, and we may experience difficulties in identifying and enrolling a sufficient number of patients in our clinical trials. In particular, the successful completion of our clinical development program for mitapivat for the treatment of PK deficiency is dependent upon our ability to enroll a sufficient number of patients with PK deficiency. PK deficiency is a rare disease with a small patient population. Further, there are only a limited number of specialist physicians that regularly treat patients with PK </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">deficiency and major clinical centers that support PK deficiency are concentrated in a few geographic regions. The small population of patients, the nature of the disease and limited trial sites may make it difficult for us to enroll enough patients to complete our clinical trials for mitapivat for PK deficiency in a timely and cost-effective manner.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, other companies are conducting clinical trials, or may in the future conduct clinical trials, which may have similar eligibility criteria as our current or future clinical trials. For example, Daiichi Sankyo Company, Ltd., with DS-1001b, Bayer AG, or Bayer, with BAY1436032, and Forma Therapeutics Holdings, LLC, or Forma, with FT-2102, are conducting clinical trials that are targeted specifically towards patients with IDH1 mutant positive-cancers and/or include IDH mutant positive populations; Rocket Pharma LTD is in the preclinical stages of development for a gene therapy targeting PK deficiency; Forma is developing a PKR activator for the treatment of hemolytic anemias; and IDEAYA Biosciences, Inc., or IDEAYA, is developing a MAT2A inhibitor for the treatment of MTAP-deleted cancers. As these companies and others initiate and conduct clinical trials, they may compete for eligible patients with our clinical trials of our product candidates. Competition for these patients may make it particularly difficult for us to enroll enough patients to complete our clinical trials for our product candidates in a timely and cost-effective manner.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. Our or our collaborators&#8217; inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If serious adverse side effects or unexpected characteristics are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With the exception of TIBSOVO&#174; and IDHIFA&#174;, all of our most advanced product candidates are still in clinical stage development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could cause us or any collaborators, an institutional review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in a more restrictive label, or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. If adverse effects were to arise in patients being treated with any of our product candidates, it could require us to halt, delay or interrupt clinical trials of such product candidate or adversely affect our ability to obtain requisite approvals to advance the development and commercialization of such product candidate. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we, or any collaborators, may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in earlier stage testing for treating cancer, RGDs or other diseases have later been found to cause side effects that prevented further development of the compound. For instance, in December 2016, we withdrew our IND for AG-519, our second PKR activator, following verbal notification of a clinical hold from the FDA relating to a previously disclosed case of drug-induced cholestatic hepatitis which occurred in our phase 1 clinical trial of AG-519 in healthy volunteers. Although these decisions and this hepatic adverse event finding do not affect our ongoing clinical trials for mitapivat, we cannot provide any assurances that there will not be similar or other treatment-related severe adverse events in our other clinical trials for mitapivat, that our other trials will not be placed on clinical hold in the future, or that patient recruitment for our other trials will not be adversely impacted.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to successfully develop companion diagnostics for our product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our therapeutics.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because we are focused on precision medicine, in which predictive biomarkers will be used to identify the right patients for our drug candidates, we believe that our success will depend, in part, on our ability to develop companion diagnostics, which are assays or tests to identify an appropriate patient population for these drug candidates. There has been limited success to date industry-wide in developing these types of companion diagnostics. To be successful, we need to address a number of scientific, technical and logistical challenges. We have little experience in the development of diagnostics and may not be successful in developing appropriate diagnostics to pair with any of our therapeutic product candidates that receive marketing approval. Companion diagnostics are subject to regulation by the FDA and similar regulatory authorities outside the United States as medical devices and require separate regulatory approval prior to commercialization. Given our limited experience in developing diagnostics, we rely and expect to continue to rely in part or in whole on third parties for their design and manufacture. We also depend on Celgene and Abbott Laboratories for the development of the FDA approved companion diagnostics for IDHIFA&#174; and TIBSOVO&#174;, respectively, and may in the future depend on other third parties for the development of other companion diagnostics for our cancer therapeutic product candidates. If any parties, including without limitation Celgene or us, or any third parties engaged by Celgene or us are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience delays in doing so:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the development of our therapeutic product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our therapeutic product candidates may not receive marketing approval if safe and effective use of a therapeutic product candidate depends on an in vitro diagnostic; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may not realize the full commercial potential of any therapeutics that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our medicines.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of any of these events, our business would be harmed, possibly materially.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to obtain, or may be delayed in obtaining, marketing approval for our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is possible that the FDA or EMA may refuse to accept for substantive review any NDA, sNDA or MAA that we and/or Celgene submit for our product candidates, or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA or EMA does not accept or approve our applications for any of our product candidates, it may require that we conduct additional clinical trials, preclinical studies or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA- or EMA-required trials or studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional trials or studies, if performed and completed, may not be considered sufficient by the FDA or EMA to approve our applications. For example, Celgene withdrew its MAA with the EMA for IDHIFA&#174; for IDH2 mutant-positive AML in December 2019. Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us or Celgene from commercializing our product candidates, generating revenue and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Infections and deaths related to the COVID-19 pandemic may disrupt U.S. or international healthcare and regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay review and/or decision making with respect </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to marketing approvals for our product candidates. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if any of our product candidates receives marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of any collaborators, to market the product.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any collaborators, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we, or any collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, including, for example, the black box warning for differentiation syndrome on the labels for IDHIFA&#174; and TIBSOVO&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we, or any collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we, or any collaborators, could be sued and held liable for harm caused to patients;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the product may become less competitive; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our reputation may suffer.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">TIBSOVO&#174; and IDHIFA&#174;, or any of our product candidates that receive marketing approval in the future, may fail to gain and/or maintain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">efficacy and potential advantages compared to alternative treatments;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the approval, availability, market acceptance and reimbursement for the companion diagnostic;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the ability to offer our medicines for sale at competitive prices;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">convenience and ease of administration compared to alternative treatments;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">ensuring uninterrupted product supply;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the strength of marketing and distribution support;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">sufficient third-party coverage or reimbursement; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the prevalence and severity of any side effects.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to establish and maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have limited experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for approved medicines for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. Although we have established sales and marketing capabilities to support our co-promotion efforts for IDHIFA&#174; and our sales of TIBSOVO&#174;, we will need to further build our sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, our other product candidates if and when they are approved, including, for example, to support the potential approval of one or more product candidates in the EU.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Factors that may inhibit our efforts to commercialize our medicines on our own include:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of product revenue to us are likely to be lower than if we were to market and sell any medicines that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current products and product candidates, and we and our collaborators will face competition with respect to any product candidates that we or they may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates, such as AML and high risk myelodysplasia. For example, Jazz Pharmaceuticals plc, AbbVie Inc. (in collaboration with Roche Holdings Inc.), Novartis International AG, Pfizer, Inc. and Astellas Pharma Inc. are each marketing therapies to treat AML, Acceleron Pharma Inc. and bluebird bio, Inc. are each marketing therapies to treat beta thalassemia, and a number of other biotechnology companies have product candidates in clinical development in similar indications as ours. Some competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches, for example, in the area of RGDs. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing most of our initial product candidates for the treatment of cancer. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy, and cancer drugs are frequently prescribed off-label by healthcare professionals. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that our product candidates, if approved, will be priced at a significant premium over competitive generic products, as is the case with TIBSOVO&#174; and IDHIFA&#174;. This may make it difficult for us to achieve our business strategy of using our product candidates in combination with existing therapies or replacing existing therapies with our product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also pursuing product candidates to treat patients with RGDs. There are a variety of treatment options available, including a number of marketed enzyme replacement therapies, for treating patients with RGDs. In addition to currently marketed therapies, there are also a number of products that are either enzyme replacement therapies or gene therapies in various stages of clinical development to treat RGDs. These products in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are also a number of product candidates in preclinical or clinical development by third parties to treat hematologic malignancies, solid tumors and RGDs by targeting similar mechanisms of action as our product candidates. These companies </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">include large pharmaceutical companies, such as AstraZeneca plc, Bayer, Daiichi Sankyo, Eli Lilly and Company, Roche and its subsidiary Genentech, Inc., GlaxoSmithKline plc, Merck, and Pfizer, as well as biotechnology companies of various sizes, such as Forma, IDEAYA and Rocket Pharma. In addition, there are several companies developing immunotherapies, including metabolic immunotherapies, targeting cancer, including AstraZeneca; BeiGene, Ltd.; Bristol-Myers Squibb Company; GlaxoSmithKline; Genentech; and Merck. Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. In addition, our competitors may discover biomarkers that more efficiently measure metabolic pathways than our methods, which may give them a competitive advantage in developing potential products. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other clinical stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the FDA does not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be adversely affected. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With FDA approval of an NDA, the product covered by the application is specified as a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any reference-listed drug may be typically lost to the generic product. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed drug. The FDCA also provides a period of three years of new clinical investigation data exclusivity in connection with the approval of a supplemental indication for the product for which a clinical trial is essential for approval.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event that a generic manufacturer is somehow able to obtain FDA approval without adherence to these periods of data exclusivity, the competition that our approved products may face from generic versions could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we or any collaborators are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by third-party payors, including government health administration authorities and private health coverage insurers. If coverage and reimbursement is not available, or reimbursement is available only to limited levels, we, or any collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or the ability of any collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any collaborators, to commercialize any of our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of any collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or any collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenue. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we, or any collaborator, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we, or any collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product liability lawsuits against us or our collaborators could cause us or our collaborators to incur substantial liabilities and could limit commercialization of any medicines that we or they may develop.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our collaborators face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk as we or they commercially sell any medicines that we or they may develop. If we or our collaborators cannot successfully defend ourselves or themselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">decreased demand for any product candidates or medicines that we may develop;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">injury to our reputation and significant negative media attention;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">significant costs to defend the related litigation;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">substantial monetary awards to trial participants or patients;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">loss of revenue;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">reduced resources of our management to pursue our business strategy; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the inability to commercialize any medicines that we may develop.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we advance or expand our clinical trials and if we successfully commercialize any medicine. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. In addition, if one of our collaboration partners were to become subject to product liability claims or were unable to successfully defend themselves against such claims, any such collaboration partner could be more likely to terminate such relationship with us and therefore substantially limit the commercial potential of our products.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our internal computer systems, or those of any third parties with which we contract, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from computer viruses, worms and other destructive or disruptive software, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber attacks by malicious third parties. Cyber incidents are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber incidents could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber incidents also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company, including personal information of our employees.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">System failures, accidents, cyber attacks or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical and commercialization activities and business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions, in addition to possibly requiring substantial expenditures of resources to remedy. For example, the loss of clinical trial data from completed or future trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and our product research, development and commercialization efforts could be delayed. In addition, we may not have adequate insurance coverage to provide compensation for any losses associated with such events.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If a material breach of our security or that of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed, we could lose business and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to: processing health and other sensitive data; obtaining consent of individuals to whom the personal health data relates; providing information to individuals regarding data processing activities; implementing safeguards to protect the security and confidentiality of personal data; providing notification of data breaches; and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of GDPR. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR&#8217;s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the EU. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security of personal information could expose us to fines and penalties under such laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by GDPR, though the California Consumer Privacy Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with current and any future federal and state laws regarding privacy and security of personal information could expose us to fines and penalties. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Dependence on Third Parties</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are reliant on Celgene for the successful development and commercialization of IDHIFA&#174;. If Celgene does not successfully commercialize IDHIFA&#174; for the treatment of adult patients with R/R AML and an IDH2 mutation, our future prospects may be substantially harmed.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2017, the FDA approved IDHIFA&#174; for the treatment of adult patients with R/R AML and an IDH2 mutation, on the basis of an NDA submitted by Celgene. Although IDHIFA&#174; has received FDA approval in R/R AML with an IDH2 mutation, we and Celgene are still evaluating enasidenib in other clinical trials. Celgene maintains worldwide development and commercial rights to IDHIFA&#174; and will fund the development and commercialization costs related to this program, although we have certain co-commercialization and co-promotion rights to IDHIFA&#174;. Under the 2010 Agreement, Celgene is responsible for all development costs for enasidenib, and we are eligible to receive up to $80.0 million in milestone payments and a tiered royalty on any net sales of products containing IDHIFA&#174;. Thus, our ability to generate revenue from IDHIFA&#174; will depend heavily on Celgene&#8217;s successful development and eventual commercialization of the product.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The development and continued commercialization of IDHIFA&#174; (enasidenib) could be unsuccessful if:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">IDHIFA&#174; becomes no longer accepted as safe, efficacious, and cost-effective for the treatment of adult patients with R/R AML and an IDH2 mutation in the medical community and by third-party payors;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Celgene fails to continue to apply the necessary financial resources and expertise to manufacturing, marketing and selling IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Celgene does not continue to develop and implement effective marketing, sales and distribution strategies and operations for development and commercialization of IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Celgene does not continue to develop, validate and maintain a commercially viable manufacturing process for IDHIFA&#174; that is compliant with current good manufacturing practices;</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Celgene does not successfully obtain third party reimbursement and generate commercial demand that results in sales of IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Celgene fails to provide us with timely and accurate information regarding development, sales and marketing activities;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we or Celgene encounter any third party patent interference, derivation, inter partes review, post-grant review, reexamination or patent infringement claims with respect to enasidenib;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Celgene does not comply with regulatory and legal requirements applicable to the sale of IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">competing drug products are approved for the same indications as IDHIFA&#174;;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">new safety risks are identified;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">enasidenib does not demonstrate acceptable safety and efficacy in current or future clinical trials, or otherwise does not meet applicable regulatory standards for approval in indications other than for the treatment of adult patients with R/R AML and an IDH2 mutation; or</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Celgene does not maintain or defend intellectual property rights associated with enasidenib.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also face the risk that Celgene could determine to reprioritize its commercial or development programs and reduce or terminate its efforts on the development or commercialization of IDHIFA&#174;. For example, Bristol-Myers Squibb, or BMS, acquired Celgene in November 2019. BMS may not retain and motivate key personnel who are important to the continued development of the programs under our agreements with Celgene. In addition, BMS could determine to reprioritize Celgene&#8217;s development programs such that it ceases to diligently pursue the development of our programs, and/or cause the agreements between Celgene and us to terminate.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or Celgene experience significant delays or an inability to successfully develop and continue to commercialize IDHIFA&#174; (enasidenib), our business would be materially harmed.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The failure to maintain the CStone Agreement or the failure of CStone to perform its obligations under the CStone Agreement, could negatively impact our business prospects in the CStone Territory.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, we entered into the CStone Agreement, for the development and commercialization of ivosidenib, either as monotherapy or in combination with other therapies, in the CStone Territory. Pursuant to the CStone Agreement, CStone will be responsible for the development and commercialization of ivosidenib in the CStone Territory. Our ability to generate royalty and milestone revenue under the CStone Agreement is dependent on CStone&#8217;s performance of its obligations under the agreement. We cannot control the amount and timing of resources that CStone will dedicate to these efforts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to a number of other risks associated with our dependence on the CStone Agreement with respect to ivosidenib in the CStone Territory, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">CStone may fail to comply with applicable regulatory guidelines with respect to developing, manufacturing or commercializing ivosidenib, which could adversely impact future development or potential sales of ivosidenib in the CStone Territory or elsewhere;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">We and CStone could disagree as to future development plans and CStone may delay, fail to commence or stop future clinical trials or other development;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">There may be disputes between CStone and us, including disagreements regarding the CStone Agreement, that may result in the delay of or failure to achieve developmental, regulatory and sales objectives that would result in milestone or royalty payments, the delay or termination of any future development or commercialization of ivosidenib in the CStone Territory, and/or costly litigation or arbitration that diverts our management&#8217;s attention and resources;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">CStone may fail to provide us with timely and accurate information regarding development, sales and marketing activities or supply forecasts, which could adversely impact our ability to comply with our obligations to CStone, as well as our ability to generate accurate financial forecasts; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Business combinations, significant changes in CStone&#8217;s business strategy, or the impact of public health epidemics, such as the COVID-19 pandemic, may adversely affect CStone&#8217;s ability or resources available to perform its obligations under the CStone Agreement.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The CStone Agreement is also subject to early termination, including through CStone&#8217;s right under certain circumstances to terminate upon advance notice to us. If the CStone Agreement is terminated early, we may not be able to find another collaborator for the further development and commercialization of ivosidenib in the CStone Territory on acceptable terms, or at all, and we may be unable to pursue continued development and commercialization of ivosidenib in the CStone Territory on our own.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely and expect to continue to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not independently conduct clinical trials of any of our product candidates. We rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. In addition, we currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third-parties or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays may occur in our product development activities. Although we seek to carefully manage our relationships with our CROs, we could encounter similar challenges or delays in the future and these challenges or delays could have a material adverse impact on our business, financial condition and prospects.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our reliance on third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our responsibility to comply with any such standards. We and these third parties are required to comply with current good clinical practices, or cGCP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with cGCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing practices, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. As a result, our results of operations and the commercial prospects for our medicines would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also rely and expect to continue to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for late-stage clinical trials and for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or medicines or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of any of these product candidates for which we or our collaborators obtain marketing approval. To date, we have obtained materials for our product candidates for our ongoing preclinical and clinical testing from third-party manufacturers. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we have long-term supply agreements in place for commercial supply of TIBSOVO&#174; with third-party manufacturers, we may be unable to establish any further long-term supply agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the possible breach of the manufacturing agreement by the third party;</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">reliance on the third party for regulatory compliance, quality assurance, environmental and safety and pharmacovigilance reporting.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements on a global basis. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If either we or any third parties on which we rely are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and research and development operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply for bulk drug substance or drug product. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on our collaborations and may depend on collaborations with additional third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are party to several collaboration agreements, including the 2010 Agreement with Celgene and the CStone Agreement. These collaborations involve complex allocations of rights, provide for milestone payments to us based on the achievement of specified clinical development, regulatory and commercial milestones, provide us with royalty-based revenue if certain product candidates are successfully commercialized and provide for cost reimbursements of certain development activities. We cannot predict the success of these collaborations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek other third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Collaborations involving our product candidates, including our collaborations with Celgene and CStone, pose the following risks to us:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations. Under the 2010 Agreement, programs under a co-development and co-commercialization agreement pursuant to the 2016 Agreement and the CStone Agreement, development and commercialization plans and strategies for licensed programs, such as enasidenib, or in the CStone Territory, ivosidenib, will be conducted in accordance with a plan and budget approved by a joint committee comprised of equal numbers of representatives from each of us and Celgene or CStone, as to which Celgene or CStone, as applicable, may have final decision-making authority.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities. For example, in March 2020, Celgene notified us of its decision to decline its option to enter into a development and commercialization agreement with respect to MAT2A and provided notice of its decision to decline its right to extend the research term of the 2016 Agreement. Further, in April 2020 Celgene notified us that BMS will be declining to elect any program for continued development and opt-in rights under the 2016 Agreement.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing, which may result in a need for additional capital to pursue further development or commercialization of the applicable product candidate. For example, under the 2010 Agreement, it is possible for Celgene to terminate the agreement, upon 90 days prior written notice, with respect to any product candidate at any point in the research, development and clinical trial process, without triggering a termination of the remainder of the collaboration arrangement.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our medicines or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaborators with marketing and distribution rights to one or more medicines may not commit sufficient resources to the marketing and distribution of such medicine or medicines.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. For example, under specified circumstances Celgene has the first right to maintain or defend our intellectual property rights with respect to enasidenib under the 2010 Agreement and, although we may have the right to assume the maintenance and defense of our intellectual property rights if Celgene does not, our ability to do so may be compromised by Celgene&#8217;s actions.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our medicines or product candidates or that result in costly litigation or arbitration that diverts management attention and resources.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">We may lose certain valuable rights under circumstances identified in our collaborations, including, in the case of our agreements with Celgene, if we undergo a change of control.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. For example, in September 2018, we and Celgene agreed to terminate the AG-881 Agreements effective as of September 4, 2018, as a result of which we will be responsible for future development costs of vorasidenib, other than certain agreed-up costs which we and Celgene had split until December 31, 2018. Celgene can terminate its remaining agreements with us, in their entirety or with respect to enasidenib under the 2010 Agreement or any program under the 2016 Agreement, upon 90 days&#8217; notice and can terminate each entire agreement with us in connection with a material breach of the agreement by us that remains uncured for a period ranging from 60 to 90 days. CStone has the right, under certain circumstances, to terminate the CStone Agreement upon advance notice to us, and may, subject to specified cure periods, terminate the CStone Agreement in the event of our uncured material breach or under specified circumstances relating to our insolvency.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all.</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">If present or future collaborators of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated. For example, BMS may not retain and motivate key personnel who are important to the continued development of the programs under our agreements with Celgene. In addition, BMS could determine to reprioritize Celgene&#8217;s development programs such that it ceases to diligently pursue the development of our programs, and/or cause the agreements between Celgene and us to terminate.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. For example, during the discovery phase of the 2016 Agreement, we may not directly or indirectly develop, manufacture or commercialize, except pursuant to the agreement, any medicine or product candidate with specified activity against certain metabolic targets except in connection with certain third-party collaborations or with respect to certain targets the rights to which have reverted back to us pursuant to the terms of the 2016 Agreement. Following the discovery phase until termination or expiration of the 2010 Agreement, either in its entirety or with respect to the relevant program, we may not directly or indirectly develop, manufacture or commercialize, outside of the collaboration, any medicine or product candidate with specified activity against any collaboration target that is within a licensed program or against any former collaboration target against which Celgene is conducting an independent program under the agreement. Following the discovery phase of the 2016 Agreement until termination or expiration of the applicable co-development and co-commercialization agreement or license agreement under the 2016 Agreement, we may not directly or indirectly develop, manufacture or commercialize, outside of the collaboration, any medicine or product candidate with specified activity against the collaboration target that is the subject of such co-development and co-commercialization agreement or license agreement, except in connection with certain third-party collaborations or with respect to certain targets the rights to which have reverted back to us pursuant to the terms of the 2016 Agreement. During the term of the CStone Agreement, we are prohibited from developing or commercializing, in the CStone Territory and in specified indications, other compounds or products that inhibit IDH1 mutations at specified levels of binding.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Intellectual Property</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to obtain and maintain patent or trade secret protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary medicines and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and medicines that are important to our business. We do not yet have issued patents for all our most advanced product candidates in all markets in which we intend to commercialize but we continue to actively pursue patent protection for our assets around the world.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent prosecution process is costly and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify and/or file patent applications on every aspect of our research and development output that is or may be eligible for patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who may have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. There is also the possibility that loss or theft of data or records may jeopardize the ability to seek patent protection or impede the progress or drafting of patent applications.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have licensed patent rights, and in the future may license additional patent rights, from third parties. Such licenses may be accompanied by milestone and/or royalty payment obligations. These licensed patent rights may be valuable to our business, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or medicines underlying such licenses. We cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. If any such licensors fail to </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties also apply to patent rights we own.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or medicines or that effectively prevent others from commercializing competitive technologies and medicines. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore we cannot be certain that we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assuming the other requirements for patentability are met, prior to March 2013, in the United States, the first to make the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. Beginning in March 2013, the United States transitioned to a first inventor to file system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize medicines without infringing third-party patent rights.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of the patent or in one or more patent claims being narrowed or invalidated, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and medicines. Given the significant amount of time required for the discovery, development, preclinical and clinical testing and regulatory review and approval of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In such circumstances we would be relying primarily on regulatory or marketing exclusivity to exclude others from commercializing a generic version of our products. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitors may infringe our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third parties may initiate legal proceedings alleging that we or our collaborators are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We have in the past and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our medicines and technology, </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">including opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings before the USPTO or other patent offices around the world. For example, in 2011, The Leonard and Madlyn Abramson Family Cancer Research Institute at the Abramson Cancer Center of the University of Pennsylvania initiated a lawsuit against us, one of our founders, Craig B. Thompson, M.D., and Celgene, alleging misappropriation of intellectual property and, in 2012, the Trustees of the University of Pennsylvania initiated a similar lawsuit against us and Dr.&#160;Thompson. Each of these lawsuits was settled in 2012. We are not aware of any other legal proceedings having been filed against us to date. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we or one of our collaborators are found to infringe a third party&#8217;s intellectual property rights, we or they could be required to obtain a license from such third party to continue developing and marketing our medicines and technology. However, we or our collaborators may not be able to obtain any required license on commercially reasonable terms or at all. Even if we or our collaborators were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We or our collaborators could be forced, including by court order, to cease developing and commercializing the infringing technology or medicine. In addition, we or our collaborators could be found liable for monetary damages. A finding of infringement could prevent us or our collaborators from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we or our collaborators have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our employees, consultants or advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our organization.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our confidential information related to our proprietary platforms and technology, our business and competitive position could be harmed.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to seeking patents for some of our technology and medicines, we also rely on maintaining the confidentiality of unpatented know-how, technology and other proprietary information, to maintain our competitive position. For example, we consider the confidential information and know-how related to our cellular metabolism technology platform to be our primary intellectual property assets in this space. Unpatented proprietary technical information and know-how can be difficult to protect. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We seek to protect this proprietary technical information and know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our proprietary technical information and know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Moreover, we anticipate that with respect to this platform, at least some of this technical information and know-how will, over time, be disseminated </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we complete necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and comparable regulatory authorities in other countries. With the exception of the FDA approvals of IDHIFA&#174; and TIBSOVO&#174;, we and our collaborators have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. For example, &#160;Celgene submitted an MAA to the EMA for IDHIFA&#174; for IDH2 mutant-positive AML which it subsequently withdrew in December 2019. Although we have an MAA under review by the EMA for TIBSOVO&#174; for the treatment of adult patients with IDH1 mutant-positive R/R AML failure to obtain marketing approval for TIBSOVO&#174; or any other product candidate will prevent us from commercializing the product candidate. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in this process.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application we submit, or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we or our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved medicine not commercially viable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accordingly, if we or our collaborators experience delays in obtaining approval or if we or they fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to market and sell our medicines in the EU and many other jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, a product must be approved for reimbursement before the product can be approved for sale in that country. We or our collaborators may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Celgene submitted an MAA to the EMA for IDHIFA&#174; for IDH2 mutant-positive AML, which it subsequently withdrew in December 2019 and we have an MAA under review by the EMA for TIBSOVO&#174; for the treatment of adult patients with IDH1 mutant-positive R/R AML. Celgene or we may not be successful in obtaining EMA approval of IDHIFA&#174; or TIBSOVO&#174;, respectively, on a timely basis, or ever. Moreover, approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any market.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, on June&#160;23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the EU on January 31, 2020. Under the withdrawal agreement, there is a transitional period until December 31, 2020 (extendable up to two years). Discussions between the United Kingdom and the EU have so far mainly focused on finalizing withdrawal issues and transition agreements but have been extremely difficult to date. To date, only an outline of a trade agreement has been reached. Much remains open but the Prime Minister has indicated that the United Kingdom will not seek to extend the transitional period beyond the end of 2020. If no trade agreement has been reached before the end of the transitional period, there may be significant market and economic disruption. The Prime Minister has also indicated that the United Kingdom will not accept high regulatory alignment with the EU.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of our product candidates in the United Kingdom. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EU for our product candidates, which could significantly and materially harm our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, other European countries may seek to conduct referenda with respect to continuing membership with the EU. We do not know to what extent Brexit or other comparable initiatives, or any resulting changes, would affect our ability to conduct clinical trials or obtain marketing approval in these jurisdictions, and each could materially impact our ability to conduct clinical trials or obtain marketing approval on a timely basis, or at all. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">A fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process, nor does it assure approval of the product candidate by FDA.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, enasidenib and ivosidenib received fast track designation for treatment of patients with AML that harbor an IDH2 and IDH1 mutation, respectively. If a drug is intended for the treatment of a serious or life-threatening disease or condition and the drug demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible for such designation, the FDA may decide not to grant it. Even if our product candidates receive fast track designation, we may not experience a faster development process, review or approval, if at all, compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We, or any collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Moreover, even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 3, 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any product or product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any product or product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and record keeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our medicines for uses other than their respective approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws, which violations may result in the imposition of significant administrative, civil and criminal penalties.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, later discovery of previously unknown adverse events or other problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">restrictions on such medicine, manufacturers or manufacturing processes;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">restrictions on the labeling or marketing of a medicine;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">restrictions on distribution or use of a medicine;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">warning letters or other notice of violation letters;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">withdrawal of the medicine from the market;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">recall of medicines;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">damage to relationships with any potential collaborators;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">unfavorable press coverage and damage to our reputation;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">fines, restitution or disgorgement of profits or revenue;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">suspension or withdrawal of marketing approvals;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">refusal to permit the import or export of our medicines;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">product seizure;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">injunctions or the imposition of civil or criminal penalties; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">litigation involving patients using our medicines.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which, in the event of a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with healthcare providers, physicians and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">constrain the business or financial arrangements and relationships through which we market, sell and distribute any medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and transparency statutes, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Under the Trump Administration&#8217;s regulatory reform initiatives, the FDA&#8217;s policies, regulations and guidance may be revised or revoked and that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump Administration may impact our business and industry. Namely, the Trump Administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. An under-staffed FDA could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, on January 30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, which required that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two-for-one&#8221; provisions. This Executive Order includes a budget neutrality provision that required the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB on February 2, 2017, the administration indicates that the &#8220;two-for-one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February 24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a &#8220;Regulatory Reform Officer&#8221; and establish a &#8220;Regulatory Reform Task Force&#8221; to implement the two-for-one provisions and other previously issued executive orders relating to the review of federal regulations, however it is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our drug candidates and affect the prices we, or they, may obtain.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell any drugs for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved drugs.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Among the provisions of the Patient Protection and Affordable Care Act, or ACA, of potential importance to our business and our drug candidates are the following:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">expansion of eligibility criteria for Medicaid programs;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">new requirements to report certain financial arrangements with physicians and teaching hospitals;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year that started in 2013 and will stay in effect through 2024 unless additional Congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One Executive Order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. The loss of the cost share reduction payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Further, on June 14, 2018, U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12 billion in ACA risk corridor payments to third-party payors who argued were owed to them. The effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and potentially our business, are not yet known. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Centers for Medicare &amp; Medicaid Services, or CMS, has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. On November 30, 2018, CMS announced a proposed rule that would amend the Medicare Advantage and Medicare Part D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the proposed rule changes would allow Medicare Advantage plans to use pre authorization (PA) and step therapy (ST) for six protected classes of drugs, with certain exceptions, permit plans to implement PA and ST in Medicare Part B drugs; and change the definition of &#8220;negotiated prices&#8221; while a definition of &#8220;price concession&#8221; in the regulations. It is unclear whether these proposed changes we be accepted, and if so, what effect such changes will have on our business. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. We continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA. For example, with enactment of the Tax Cuts and Jobs Act of 2017 or TCJA, which was signed by the President on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The Trump Administration and CMS have both stated that the ruling will have no immediate effect, and on December 30, 2018 the same judge issued an order staying the judgment pending appeal. The Trump Administration thereafter represented to the Court of Appeals considering this judgment that it does not oppose the lower court's ruling. On July 10, 2019, the Court of Appeals for the Fifth Circuit heard oral argument in this case. In those arguments, the Trump Administration argued in support of upholding the lower court decision. On December 18, 2019, that court affirmed the lower court&#8217;s ruling that the individual mandate portion of the ACA is unconstitutional and remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. On January 21, 2020, the U.S. Supreme Court declined to review this decision on an expedited basis. On March 3, 2020, that court agreed to hear this case. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business. It is possible that repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future legislation to repeal and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">repealed along with ACA coverage expansion provisions. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States, and members of Congress and the Administration have stated that they will address such costs through new legislative and administrative measures. The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Specifically, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example, on May 11, 2018, the current administration issued a plan to lower drug prices. Under this blueprint for action, the current administration indicated that the Department of Health and Human Services, or HHS, will take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies, advance biosimilars and generics to boost price competition, evaluate the inclusion of prices in drug makers&#8217; ads to enhance price competition, speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug makers, avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and Medicaid, work to give Medicare Part D plan sponsors more negotiation power with drug makers, examine which Medicare Part B drug prices could be negotiated by Medicare Part D plans, improve the design of the Medicare Part B Competitive Acquisition Program, update Medicare&#8217;s drug-pricing dashboard to increase transparency, prohibit Medicare Part D contracts that include &#8220;gag rules&#8221; that prevent pharmacists from informing patients when they could pay less out-of-pocket by not using insurance, and require that Medicare Part D plan members be provided with an annual statement of plan payments, out-of-pocket spending, and drug price increases. In addition, on December 23, 2019, the Trump Administration published a proposed rulemaking that, if finalized, would allow states or certain other non-federal government entities to submit importation program proposals to the FDA for review and approval. Applicants would be required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers. At the same time, the FDA issued draft guidance that would allow manufacturers to import their own FDA-approved drugs that are authorized for sale in other countries (multi-market approved products). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any collaborators to more stringent drug labeling and post-marketing testing and other requirements.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that we will be subject to additional risks in commercializing our product candidates outside the United States, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">different regulatory requirements for approval of drugs in foreign countries; </span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">reduced protection for intellectual property rights; </span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, fires and the impact of public health epidemics, such as the ongoing COVID-19 pandemic.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Employee Matters and Managing Growth</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our future success depends on our ability to retain our key executives and scientific leadership and to attract, retain and motivate qualified personnel.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are highly dependent on the principal members of our management and scientific teams, each of whom is employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. Although we have managed recent executive transitions, including of our chief executive officer and chief scientific officer, we cannot predict the likelihood, timing or effect of future departures among our executive leadership. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, including our scientific co-founders, may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In response to the COVID-19 pandemic, we have been required to close our facilities except for a limited number of essential facilities and laboratory staff. In the event of a continuation of shelter-in-place orders and other mandated local travel restrictions, our employees conducting research and development activities may not be able to access our research space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, disclose unauthorized activities to us, or comply with securities laws. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, including for illegal insider trading activities, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect to expand our development, regulatory and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to experience growth in the number of our employees and the scope of our operations, including in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the future, we may enter into transactions to acquire other businesses, products or technologies. Because we have not made any acquisitions to date, our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Common Stock and Other Matters</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">limit the manner in which stockholders can remove directors from the board;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">limit who may call stockholder meetings;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities analysts do not publish research or reports about our business or if they publish negative, or inaccurate, evaluations of our stock, the price of our stock and trading volume could decline.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">An active trading market for our common stock may not be sustained.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although our common stock is listed on the Nasdaq Global Select Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or to sell their shares at all. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The price of our common stock is likely to be volatile, which could result in substantial losses for purchasers of our common stock.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading price of our common stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. For example, since January&#160;1, 2015 the price of our common stock on the Nasdaq Global Select Market has ranged from $27.77 per share to $138.85 per share. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The COVID-19 pandemic, which has had a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material effect on our business. While the full extent of the economic impact and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the COVID-19 pandemic could materially and adversely affect our business and the value of our common stock.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The market price for our common stock may be influenced by many factors, including:</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the timing and results of clinical trials of product candidates;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">commencement or termination of collaborations for our development programs;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">failure or discontinuation of any of our development programs;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">results of clinical trials of product candidates of our competitors;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulatory or legal developments in the United States and other countries;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the recruitment or departure of key personnel;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the results of our efforts to develop additional product candidates or products;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">actual or anticipated changes in estimates as to financial results or development timelines;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">announcement or expectation of additional financing efforts;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">sales of our common stock by us, our insiders or other stockholders;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">variations in our financial results, including fluctuations in levels of sales of TIBSOVO&#174; or royalties on sales of IDHIFA&#174;, or results of companies that are perceived to be similar to us;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">changes in the structure of healthcare payment systems;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the societal and economic impact of public health epidemics, such as the ongoing COVID-19 pandemic;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">general economic, industry and market conditions; and</span></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of the forgoing matters were to occur, or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, following periods of volatility in the market price of a company's securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management's attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain stockholders hold a substantial number of shares of our common stock. If such stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our stock incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act, and, in any event, we have filed a registration statement permitting shares of common stock issued on exercise of options or upon vesting of restricted stock units, performance-based stock units or market-based stock units to be freely sold in the public market. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain holders of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates. Any sales of securities by these stockholders who have exercised registration rights could have a material adverse effect on the trading price of our common stock.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our executive officers, directors and a small group of stockholders, in the aggregate, beneficially owned shares representing a significant percentage of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and affairs. For example, these persons, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under Section&#160;382 of the Code and corresponding provisions of state law, if a company undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income may be limited. Our prior equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change. We completed a review of our changes in ownership through December&#160;31, 2019, and determined that we did not have a qualified ownership change since our last review as of December 31, 2018. Future ownership changes under Section 382 may limit the amount of net operating loss and tax credit carryforwards that we could potentially utilize to reduce future tax liabilities.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. As described above in &#8220;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#8221; the Tax Act, as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons we may be unable to use a material portion of our net operating losses and other tax attributes.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including as a result of changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred and will continue to incur significant legal, accounting and other expenses as a public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations. Our management and other personnel devote, and will need to continue to devote, a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div id="i7c71c9a7a53d48458a969df1a7cd05a7_475"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;5.&#160;Other Information</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 30, 2020, we entered into a Sales Agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, under which we may issue and sell shares of common stock, from time to time, having an aggregate offering price of up to $250.0 million. Sales of common stock through Cowen may be made by any method that is deemed an &#8220;at the market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Cowen has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell our shares of common stock based upon our instructions. We are not obligated to make any sales of our common stock under the Sales Agreement. Any sales under the Sales Agreement will be made pursuant to a prospectus relating to such offering to be filed with the Securities and Exchange Commission.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_100"></div><div style="height:45pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6.&#160;Exhibits</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:6.579%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:40.899%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.621%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.355%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.313%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.248%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.687%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.403%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Incorporated by Reference</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Description of Exhibit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Form</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">File&#160;Number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Date of Filing</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Filed</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Herewith</span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex31.htm">Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">001-36014</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 30, 2013</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex32.htm">Amended and Restated By-Laws</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">001-36014</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 30, 2013</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-letteragree.htm">Letter Agreement, dated as of October 7, between the Registrant and Bruce Car</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">10.2&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit102-agiosamendm.htm">Amendment to Master Research and Collaboration Agreement, dated as of February 5, 2020, by and among the Registrant, Celgene Corporation and Celgene RIVOT Ltd</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">10.3&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-agioscstone.htm">Amendment I to License Agreement, dated as of March 2, 2020, by and between the Registrant and CStone Pharmaceuticals</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">10.4&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit104-agioscstone.htm">Amendment II to License Agreement, dated as of March 2, 2020, by and between the Registrant and CStone Pharmaceuticals</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-1x03x31x20.htm">Certification of principal executive officer pursuant to Rule&#160;13a 14(a)/15d 14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-2x03x31x20.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-1x03x31x20.htm">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-2x03x31x20.htm">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.INS</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.SCH</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.CAL</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Calculation Linkbase Document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.DEF</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.LAB</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Label Linkbase Document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.PRE</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Presentation Linkbase Document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"># Indicates management contract or compensatory plan or arrangement</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8224; Confidential treatment has been granted as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">* This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing</span></div></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div id="i7c71c9a7a53d48458a969df1a7cd05a7_103"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i7c71c9a7a53d48458a969df1a7cd05a7_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:49.395%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.258%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.149%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.998%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AGIOS PHARMACEUTICALS, INC.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Jacqualyn A. Fouse</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Jacqualyn A. Fouse, Ph.D.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(principal executive officer)</span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Andrew Hirsch</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Andrew Hirsch<br/>Chief Financial Officer and Head of Corporate Development<br/>(principal financial officer)</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-letteragree.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i973e3a6332f843c08b43872bfdd6089c_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div><img alt="image01.jpg" src="image01.jpg" style="height:55px;width:209px;"></div><div><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">October 7, 2019</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Bruce Car</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dear Bruce,</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">I am pleased to extend to you a contingent offer for the position of Chief Scientific Officer at Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;), reporting to me with a start date of January 6, 2020.  You will receive a semi-monthly salary of $20,833.34 which is equivalent to $500,000.16 annually. Agios will provide relocation assistance for your move to the Boston area covering reasonable relocation costs.  If you leave the company within 18 months you will be required to repay the full amount covered for relocation assistance.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You will be eligible for our annual Bonus and Equity Programs.&#160; If the company meets or exceeds its annual goals, a pool will be established for employees, which will be subject to approval by the Board of Directors. &#160;This pool will be allocated according to level and your individual performance.&#160; Your bonus payment and equity grant will be pro-rated based on the amount of time you worked at Agios in the prior calendar year and you must be employed by Agios at the time of payment&#47;grant in order to receive them. Your target bonus is 45% of your base compensation.  You will be eligible to participate in the 2020 plan year, which begins on January 1, 2020.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to approval by the Board of Directors or its designated representative, on your start date (the &#8220;Grant Date&#8221;), you will be granted&#58; (i) stock options to purchase shares of the company&#8217;s Common stock (the &#8220;Options&#8221;) with a Black-Scholes value of $1.5 million, based on the closing price of the Company&#8217;s common stock on the Grant Date (the &#8220;Closing Price&#8221;)&#59; (ii) a number of restricted stock units (the &#8220;RSUs), which the number shall be determined by dividing $500,000 by the Closing Price&#59; and (iii) a number of performance share units (the &#8220;PSUs&#8221;), which number shall be determined by dividing $1.0 million by the Closing Price.  The Options will have an exercise price per share equal to the Closing Price and will become exercisable as to 25% of the underlying shares on the first anniversary of the Grant Date and the remaining shares will vest and become exercisable monthly thereafter until the fourth anniversary of the Grant Date.  Each RSU shall entitle you to receive one share of the Company&#8217;s common stock for each RSU that vests.   One-third of the RSUs shall vest on each of the first, second and third anniversaries of the Grant Date.  The PSUs give you the opportunity to earn full value shares of Agios stock upon achievement against any or all of the performance goals outlined, with each PSU entitling you to receive one share of the Company&#8217;s common stock for each PSU that vests.  Achievement against each goal will be evaluated independently by the Compensation Committee of the Board of Directors.   Upon confirmed achievement, you will receive 100% of the target share units corresponding to the specific goal as outlined.  The opportunity to achieve all of these milestones runs through the end of 2022, at which time, any unearned shares will be forfeited.  The specific performance milestones for the PSUs will be the same as those contained in 2019 PSU grants to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88 Sidney Street &#9679;   Cambridge, MA 02139</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Main&#58;  617-649-8600 </font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">&#9679;</font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Fax</font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58; 617-649-8618</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">www. agios.com</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div><div><img alt="image01.jpg" src="image01.jpg" style="height:55px;width:209px;"></div><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Company&#8217;s executive officers.  The Option, RSUs, and PSUs will be subject to the terms and conditions of the Company&#8217;s 2013 Stock Incentive Plan (the &#8220;Plan&#8221;) and the applicable award agreement.  </font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You will be eligible to participate in all of the company&#8217;s benefits plans, which include Medical and Dental Insurance Programs, Flexible Spending Program for medical and daycare expenses, Life Insurance, AD&#38;D, and Short and Long Term Disability Plans, and 401(k). The Company provides a discretionary time off policy and 11 paid holidays annually in accordance with the company holiday schedule.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You are also eligible to receive severance benefits under our Severance Benefits Plan, effective April 22, 2016 (the &#8220;Severance Benefits Plan&#8221;) for a Covered Termination as defined in the Severance Benefits Plan.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the initial recruitment process you were advised that your acceptance of this position is with the understanding that the offer of employment is contingent upon successful completion of a background investigation.  We will contact you as soon as the background check process has been completed.  At that time, assuming successful completion of this process, we can determine the date when your employment will begin.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The offer of employment is also contingent upon your signing the company&#8217;s standard  Forms of Agreement Regarding Inventions, Confidentiality and Non-Competition (Copy attached) and I-9 Employment Verification Form.  You will be required to submit documentation that establishes identity and employment eligibility in accordance with the US Immigration and Naturalization requirements.  If there are any other agreements of any type that you are aware of which may impact or limit your ability to perform your job at Agios Pharmaceuticals, please let us know as soon as possible.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This offer letter is not intended to create or constitute an employment agreement or contract between you and Agios Pharmaceuticals.  It is also important for you to understand that Massachusetts is an &#8220;at will&#8221; employment state.  This means that you will have the right to terminate your employment relationship with Agios Pharmaceuticals at any time for any reason.  Similarly, Agios Pharmaceuticals will have the right to terminate its employment relationship with you at any time for any reason, except as prohibited by law. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88 Sidney Street &#9679;   Cambridge, MA 02139</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Main&#58;  617-649-8600 </font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">&#9679;</font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Fax</font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58; 617-649-8618</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">www. agios.com</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div><div><img alt="image01.jpg" src="image01.jpg" style="height:55px;width:209px;"></div><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">I am very excited about having you join our team and I anticipate that you will make many important contributions to our Company and strategic mission.  Please acknowledge your acceptance of this offer by returning a signed copy of this letter no later than October 14, 2019. </font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Best regards, </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#47;s&#47; Jacqualyn Fouse</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-right:-18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Jacqualyn Fouse, Ph.D. Chief Executive Officer</font></div><div style="text-indent:18pt;padding-right:-18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agios Pharmaceuticals, Inc</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> I accept this contingent offer of employment with Agios Pharmaceuticals Inc., subject to successful completion of my background investigation.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Signature&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#47;s&#47; Bruce D. Car&#160;&#160;&#160;&#160;&#160;October 11, 2019&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88 Sidney Street &#9679;   Cambridge, MA 02139</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Main&#58;  617-649-8600 </font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">&#9679;</font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Fax</font><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58; 617-649-8618</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#365f91;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">www. agios.com</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-agiosamendm.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3026b5bd47914725bd6d622e52ca090f_1"></div><div style="height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Double asterisks denote omissions.</font></div><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT TO</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MASTER RESEARCH AND COLLABORATION AGREEMENT</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment to Master Research and Collaboration Agreement (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is entered into as of February 5, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), by and among Agios Pharmaceuticals, Inc., a Delaware corporation (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agios</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), on the one hand, and Celgene Corporation, a Delaware corporation (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Celgene Corp.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), with respect to all rights and obligations under the Master Collaboration Agreement (as defined below) in the United States, and Celgene RIVOT Ltd., a Bermuda entity (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Celgene RIVOT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), with respect to all rights and obligations under the Master Collaboration Agreement outside of the United States (Celgene RIVOT and Celgene Corp. together, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Celgene</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), on the other hand.  Capitalized terms used herein and not defined herein shall have the meanings ascribed to them in the Master Collaboration Agreement.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties entered into that certain Master Research and Collaboration Agreement, dated as of May 17, 2016 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Master Collaboration Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), pursuant to which Celgene obtained exclusive options to obtain certain rights to participate in the development and commercialization of Compounds and Products arising out of activities conducted pursuant to certain research and development programs under the Master Collaboration Agreement and to share profits and losses arising from the development and commercialization of such Compounds and Products on a worldwide basis&#59; and</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties previously entered into a certain Appendix Substitution Agreement dated as of January 29, 2019, relating to the Master Collaboration Agreement&#59;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties are entering into this Amendment to provide for (i) a modification to the notice period for extensions of the Research Term and (ii) an extension of the Option Exercise Window solely with respect to the &#91;**&#93;, in each case as set forth below.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment Relating to Research Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.1.2(a) of the Master Collaboration Agreement is hereby deleted and replaced in its entirety with the following&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;2.1.2(a) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Initial Extension Right</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Celgene may, at its election, extend the Research Term for up to two (2) one (1) year extension periods (each to run consecutively after the end of the then-current Research Term) by giving notice to Agios of its election (i) in the case of the first one (1) year extension period, by no later than &#91;**&#93; and (ii) in the case of the second one (1) year extension period, at least &#91;**&#93; prior to the expiration of the then-current Research Term, and (in each case (i) and (ii)) by paying the Research Term Extension Fee as set forth in Section 6.3.&#8221;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment Relating to the Option Exercise Window with respect to the &#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Prior to the Amendment Date, Agios provided to Celgene an Option Data Package for the &#91;**&#93;.  Celgene acknowledges receipt of such Option Data Package.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;The Option Exercise Window applicable to the &#91;**&#93; is hereby amended to continue through &#91;**&#93; and to expire at the end of such day.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Continued Effectiveness of Master Collaboration Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As amended hereby, the Master Collaboration Agreement remains in full force and effect.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;Signature Pages Follow&#93;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and intending to be legally bound hereby, the Parties have caused this Amendment to be executed by their respective duly authorized officers as of the date first written above.</font></div><div style="padding-left:216pt;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">CELGENE CORPORATION</font></div><div style="text-indent:-18pt;padding-left:234pt;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Susana Parathath&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Susana ParathathTitle&#58; Dir Global Alliances</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;Signature Page to Amendment to Master Research and Collaboration Agreement&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and intending to be legally bound hereby, the Parties have caused this Amendment to be executed by their respective duly authorized officers as of the date first written above.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Solely with respect to the rights and obligations under the Master Collaboration Agreement outside of the United States (subject to Section 12.13 of the Master Collaboration Agreement)&#58;</font></div><div style="padding-left:216pt;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">CELGENE RIVOT LTD.</font></div><div style="text-indent:-18pt;padding-left:234pt;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Kevin Mello</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Kevin MelloTitle&#58; Director </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;Signature Page to Amendment to Master Research and Collaboration Agreement&#93;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and intending to be legally bound hereby, the Parties have caused this Amendment to be executed by their respective duly authorized officers as of the date first written above.</font></div><div style="padding-left:216pt;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</font></div><div style="text-indent:-18pt;padding-left:234pt;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Andrew Hirsch&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Andrew HirschTitle&#58; Chief Financial Officer</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> &#91;Signature Page to Amendment to Master Research and Collaboration Agreement&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103-agioscstone.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i377fa8ae8de04bc0a927fde35561450b_1"></div><div style="height:45pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Double asterisks denote omissions.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Execution Copy</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT I</font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TO</font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LICENSE AGREEMENT</font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Amendment I to License Agreement (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), dated as of February 6, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), by and between Agios Pharmaceuticals, Inc. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agios</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and CStone Pharmaceuticals (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Each of Agios and Licensee may be referred to herein as a &#8220;Party&#8221; and Agios and Licensee may be referred to herein collectively as the &#8220;Parties.&#8221;</font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Agios and Licensee entered into a License Agreement as of June 25, 2018 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Parties have determined that it is desirable for Agios and Licensee to co-sponsor certain Local Studies&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Parties desire to amend and clarify certain provisions of the Agreement relating to Local Studies as set forth in this Amendment.</font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the Parties, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Amendments to Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties hereby amend the Agreement as follows&#58;  </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27.68pt;">Co-Sponsorship of Local Studies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The following new Section 4.01(h) is hereby inserted into the Agreement immediately following Section 4.01(g) thereof&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;(h)&#160;With respect to each Local Study, after consultation with and approval by the JDC (subject to the decision-making provisions of Article III) for such Local Study, Agios shall sponsor such Local Study, with CStone acting as co-sponsor to the extent permitted by the applicable laws and regulations of &#91;**&#93; (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Co-Sponsored Local Study</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Subject to the oversight of the JSC and JDC, Licensee shall have responsibility for the conduct of Local Studies, including Co-Sponsored Local Studies, at its own cost and expense, provided that, (i) as to Co-Sponsored Local Studies, Licensee shall not designate any contract research </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">organization (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">CRO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) without first obtaining Agios&#8217; written consent, which written consent may not be unreasonably withheld or delayed, provided that, if Agios withholds its  consent, it shall provide Licensee with valid reason(s) or concern(s) underlying such withholding of consent, and Agios shall grant its consent if such concerns are addressed by the Licensee and confirmed by Agios&#59; (ii) as to Co-Sponsored Local Studies, Licensee shall, as between the Parties, be and remain solely responsible for engaging and overseeing such designated CRO, (iii) notwithstanding Section 5.01(c), Licensee shall not make any Regulatory Filing regarding a Co-Sponsored Local Study unless and until Agios has first reviewed and approved such Regulatory Filing, which approval may not be unreasonably withheld or delayed, provided that, if Agios withholds its approval, it will provide Licensee with valid reason(s) or concern(s) underlying such withholding of approval, and Agios shall grant its approval after Licensee has considered and incorporated the reasonable comments of Agios and has addressed Agios&#8217;s concerns and such resolution is confirmed by Agios, (iv) Licensee shall not adopt any protocol or modify any previously adopted protocol for any Co-Sponsored Local Study without Agios&#8217; prior written consent, which written consent may not be unreasonably withheld or delayed, provided that, if Agios withholds its  consent, it shall provide Licensee with valid reason(s) or concern(s) underlying such withholding of consent (v) Licensee shall, as between the Parties, be and remain solely responsible and bear sole liability for all data generated in any Local Study or included in any Regulatory Filing in relation thereto, (vi) Licensee shall, as between the Parties, be and remain solely responsible and shall bear sole liability and costs for all aspects of the conduct of each Local Study, except that, in the event the Parties have agreed that Agios will provide clinical supply for such Local Study, Agios shall be liable for Losses to the extent arising from the failure of the clinical supply of Ivosidenib Materials to meet the applicable specifications as of the delivery thereof to Licensee or the applicable CRO for such Local Study in accordance with Article VII and the Clinical Supply Agreement, and (vii) Licensee shall file the INDs required for the conduct of the Co-Sponsor Local Studies.&#8221;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Additional Provisions Relating to Co-Sponsored Local Studies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The following new Sections 4.01(i)-(k) are hereby inserted into the Agreement immediately following Section 4.01(h) thereof&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;(i)&#160;Upon reasonable notification by Agios to Licensee and based upon an audit scope to be reasonably agreed by the Parties, Agios or its designated representative(s) may conduct an audit of any Licensee Entity and all clinical trial sites engaged by any Licensee Entity in connection with any Co-Sponsored Local Study to review the compliance of such Licensee Entity and clinical trial sites with the applicable Development Plan, GCP, and Applicable Law.  If Agios requests to conduct such an audit prior to commencement of the first Co-Sponsored Local Study, such Co-Sponsored Local Study shall not commence and Licensee shall not permit any CRO or other third party vendor to conduct such Co-Sponsored Local Study until the satisfactory completion of such audit and the Parties have agreed to a plan to resolve the issues arising from such audit, unless </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">otherwise agreed by the Parties.  Licensee will have the right to be present at any such audit conducted by Agios or its designated representatives.  Starting from after the completion of the initial audit, Agios may conduct audit of Licensee &#91;**&#93; during the Term with respect to Licensee&#8217;s conduct of Co-Sponsored Local Studies, which Agios shall request by providing &#91;**&#93; prior written notice to Licensee, and to be conducted during regular business hours.</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;Licensee will provide Agios with copies of all quality oversight and audit reports prepared in connection with any inspection or audit of any Licensee Entity, Subcontractor or Clinical Trial site that any Licensee Entity has engaged or is evaluating to potentially engage in connection with a Co-Sponsored Local Study, in each case no later than &#91;**&#93; after receiving or preparing such report&#59; provided that such report may be redacted to remove information unrelated to Licensed Products or studies conducted with Licensed Products.</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)&#160;Licensee shall immediately notify Agios of any serious or material deviation from the applicable protocol or from GCP.  Licensee shall notify Agios of any safety issue and fulfil pharmacovigilance obligations with respect to drug safety of any Co-Sponsored Local Study in accordance with the Safety Data Exchange Agreement dated June 20, 2019 entered into by and between the Parties.&#8221;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27.68pt;">Governance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Section 3.10(a) of the Agreement is hereby amended by adding the following new clause (v) at the end of such Section (immediately prior to period at the end of such Section) and striking the word &#8220;and&#8221; immediately preceding clause (iv) thereof&#58; &#8220;&#59; and (v) &#91;**&#93;.&#8221; </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Indemnification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Sections 13.01 and 13.02 of the Agreement are hereby amended and restated in their entireties to read as follows&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 13.01&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Indemnification by Agios</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Agios shall indemnify, hold harmless and defend Licensee and its Affiliates, and their respective directors, officers, consultants, agents, contractors and employees (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Licensee Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) from and against any and all Third Party suits, claims, actions, demands, liabilities, expenses, costs, damages, deficiencies, obligations or losses (including reasonable attorneys&#8217; fees, court costs, witness fees, damages, judgments, fines and amounts paid in settlement) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Losses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to the extent that such Losses arise out of (a) any breach of this Agreement by Agios, (b) the Development, Manufacture or Commercialization of the Licensed Compound or any Licensed Product by or on behalf of any Agios Entity, including the Losses specifically set forth as Agios&#8217;s liability in Section 4.01(h)(vi), but excluding the Losses arising out of any Local Study or Co-Sponsored Local Study for which Licensee is obligated to indemnify, hold harmless and defend Agios pursuant to Section 13.02, or (c) the gross negligence or willful misconduct of any Agios Indemnitee.  Notwithstanding the foregoing, Agios shall not have any obligation to indemnify the Licensee Indemnitees to the extent that the applicable Losses </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">arise out of the negligence or willful misconduct of any Licensee Indemnitee or any breach of this Agreement by Licensee.</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 13.02&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Indemnification by Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Licensee shall indemnify, hold harmless and defend Agios and its Affiliates, and their respective directors, officers, consultants, agents, contractors and employees (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Agios Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) from and against any and all Losses, to the extent that such Losses arise out of (a) any breach of this Agreement by Licensee, or any act or failure to act by any Licensee Entity that causes a breach of any In-License Agreement, (b) the Development, Manufacture or Commercialization of the Licensed Compound or any Licensed Product by or on behalf of any Licensee Entity, including all Losses arising out of any Local Study or Co-Sponsored Local Study but excluding the Losses specifically set forth as Agios&#8217;s liability in Section 4.01(h)(vi), or (c) the gross negligence or willful misconduct of any Licensee Indemnitee.  Notwithstanding the foregoing, Licensee shall not have any obligation to indemnify the Agios Indemnitees to the extent that the applicable Losses arise out of the negligence or willful misconduct of any Agios Indemnitee or any breach of this Agreement by Agios.&#8221;</font></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties hereby confirm and agree that, as amended hereby, the provisions of the Agreement remain in full force and effect and the Agreement remains a binding obligation of the Parties.  In the event of a conflict between the Agreement and this Amendment, the provisions of this Amendment shall prevail.  This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Facsimile signatures and signatures transmitted via .pdf shall be treated as original signatures.  Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting the Agreement.  </font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div id="i377fa8ae8de04bc0a927fde35561450b_4"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the Parties have caused this Amendment I to be executed by their duly authorized representatives.</font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font><br></font></div><div style="padding-right:-58.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">CSTONE PHARMACEUTICALS</font></div><div><font><br></font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;">&#47;s&#47; Andrew Hirsch</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">_____________&#160;By&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;">&#47;s&#47; Bing Yuan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">_______________</font></div><div style="margin-top:6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">Name&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;"> Andrew Hirsch</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;"> __________&#160;Name&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;">Bing Yuan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">______________</font></div><div style="padding-right:-28.7pt;margin-top:6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Chief Financial Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">______&#160;Title&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Chief Strategy and Business Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">____</font></div><div style="padding-right:-28.7pt;margin-top:6pt;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;Signature Page to Amendment I to License Agreement&#93;</font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>exhibit104-agioscstone.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i000d78fee2ee45c7a765e9418831b174_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Double asterisks denote omissions.</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Execution Copy</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT II</font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TO </font></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LICENSE AGREEMENT</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Amendment II to License Agreement (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), dated as of March 2, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), is made and entered into by and between Agios Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware with a principal place of business at 88 Sidney Street, Cambridge, MA 02139 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agios</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and CStone Pharmaceuticals, a corporation organized and existing under the laws of the Cayman Islands, with a registered address at P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Each of Agios and Licensee may be referred to herein as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and Agios and Licensee may be referred to herein collectively as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;</font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Agios and Licensee entered into a License Agreement as of June 25, 2018 (as amended, supplemented or otherwise modified through, but not including, the date hereof, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Parties wish to amend the Agreement to include Singapore as part of the Territory as herein provided&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the Parties, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement. </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Amendments to Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;">The following definition shall be added as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of the Agreement as of the Amendment Effective Date, and the section number of the defined terms thereafter shall be adjusted accordingly&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Agios Singapore Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">all Patent Rights that (a) are Controlled as of the Amendment Effective Date or during the Term by Agios in Singapore, and (b) cover any Licensed Product, or its Development, Manufacture or Commercialization in the Field in Singapore&#59; but excluding Joint Combination </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Therapy Patent Rights.  Agios Singapore Patent Rights as of the Amendment Effective Date include those listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A-1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> attached hereto.&#8221;  </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;">The definition &#8220;Jurisdiction&#8221; of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1.61</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is hereby amended and restated to read in its entirety as follows as of the Amendment Effective Date&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Jurisdiction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means each of the following&#58; (i) Mainland China, (ii) Taiwan, (iii) Hong Kong, (iv) Macau, and (v) Singapore. </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Section 4.01(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is hereby amended and restated to read in its entirety as follows as of the Amendment Effective Date&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;Licensee shall use Commercially Reasonable Efforts to obtain, or cause to be obtained, Regulatory Approval and, if applicable, Reimbursement Approval, for a Licensed Product in each Initial Indication and Additional Indication in each of (i) Mainland China, (ii) Taiwan, (iii) Hong Kong and Macau (with it being agreed that, if Regulatory Approval is obtained in Hong Kong, Licensee shall not also be required to separately obtain Regulatory Approval in Macau), and (iv) Singapore, including by providing all necessary resourcing required to seek and maintain Regulatory Approval and, if applicable, Reimbursement Approval for a Licensed Product.&#8221; </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Section 6.04 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(Commercialization Efforts) is hereby amended and restated to read in its entirety as follows as of the Amendment Effective Date&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;Licensee shall use Commercially Reasonable Efforts to Commercialize Licensed Products in each of (i) Mainland China, (ii) Taiwan, (iii) Hong Kong and Macau (it being understood that, if Licensee Commercializes Licensed Products in Hong Kong, it may be commercially Reasonable to not separately also Commercialize Licensed Products in Macau given the small number of Patents in Macau), and (iv) Singapore.&#8221; </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;">The second sentence of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.03(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is hereby amended and restated to read in its entirety as follows as of the Amendment Effective Date&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;For purposes of this Section, &#8220;Exception&#8221; shall mean, (i) with respect to a given Global Study, that SDA will not accept such Global Study (with or without any bridging study(ies) as sufficient to support an application for Regulatory Approval for the applicable Licensed Product in Mainland China and, instead, requires Licensee to conduct one or more alternative studies (other than any bridging study(ies)) to support the filing of an application for Regulatory Approval for such Licensed Product in Mainland China or (ii) solely with respect to Hong Kong, Macau, Taiwan and Singapore, that Agios shall provide to Licensee the U.S. NDA dossier at no cost for use in Licensee&#8217;s applications for Regulatory Approval in Hong Kong, Macau, Taiwan and Singapore.&#8221; </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.03pt;">Section </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.04(d) is hereby amended and restated to read in its entirety as follows as of the Amendment Effective Date&#58; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;In the event that Licensee achieves a milestone set forth in rows (iii) through (ix) in a Jurisdiction other than &#91;**&#93; or &#91;**&#93;, Licensee shall pay to Agios &#91;**&#93; percent (&#91;**&#93;%) multiplied by the applicable milestone payment upon such achievement, with the remaining &#91;**&#93; percent (&#91;**&#93;%) due upon achievement of the applicable milestone in &#91;**&#93;.   For the avoidance of doubt, no development or regulatory milestone(s) shall be payable by Licensee for the achievement of the milestones set forth in Section 8.04(a) in &#91;**&#93;.&#8221;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt;">Agios hereby makes the same representations and warranties set forth under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 11.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(Additional Agios Warranties) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of the Agreement with respect to the Agios Singapore Patent Rights listed in Exhibit A-1 as of the Amendment Effective Date, in each case, substituting &#34;Agios Singapore Patent Rights&#34; for &#34;Agios Patent Rights&#34;, &#8220;Singapore&#8221; for &#8220;Territory&#8221;, and &#8220;Exhibit A-1&#8221; for &#8220;Exhibit A&#8221; with respect to each representation and warranty, and otherwise mutatis mutandis.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;">Licensee hereby makes the same representations and warranties set forth under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 11.04 (Additional Licensee Warranties and Covenants) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of the Agreement with respect to Singapore as of the Amendment Effective Date, mutatis mutandis.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">Section 17.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Entire Agreement) is hereby amended and restated to read in its entirety as follows as of the Amendment Effective Date&#58; </font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;This Agreement, the first amendment dated March 2, 2020, and second amendment dated March 2, 2020 together with the exhibits and schedules attached hereto and any other amendments hereto, constitute the entire agreement between Agios or any of its Affiliates, on the one hand, and Licensee or any of its Affiliates, on the other hand, with respect to the subject matter hereof, supersedes all prior understandings and writings between Agios or any of its Affiliates, on the one hand, and Licensee or any of its Affiliates, on the other hand relating to such subject matter, including the Confidentiality Agreement, and, subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.01 (Development in the Field in the Territory)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, shall not be modified, amended or (subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE XIV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(Term and Termination)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) terminated, except by another agreement in writing executed by the Parties. </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Mutual Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The representations and warranties made by each of Licensee and Agios under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 11.01 (Mutual Representations and Warranties)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of the Agreement shall apply to this Amendment as if the same were set out herein in full, mutatis mutandis, except that the representations and warranties made hereunder shall be made as of the Amendment Effective Date.  </font></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;padding-left:27pt;">Miscellaneous</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;">The Parties hereby confirm and agree that, as amended hereby, the provisions of the Agreement remain in full force and effect and the Agreement remains a binding obligation of the Parties.  In the event of a conflict between the Agreement and this Amendment, the provisions of this Amendment shall prevail.  </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;">This Amendment and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of the State of New York, exclusive of its conflicts of laws principles.  </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;">This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Facsimile signatures and signatures transmitted via .pdf shall be treated as original signatures.  Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting the Agreement.  </font></div><div style="padding-left:36pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">*    *    *</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized representatives on the Amendment Effective Date.</font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font><br></font></div><div style="padding-right:-58.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">AGIOS PHARMACEUTICALS, INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">CSTONE PHARMACEUTICALS</font></div><div><font><br></font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;">&#47;s&#47; Andrew Hirsch</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">_____________&#160;By&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;">&#47;s&#47; Bing Yuan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">_______________</font></div><div style="margin-top:6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">Name&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;"> Andrew Hirsch</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;"> __________&#160;Name&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration: underline;">Bing Yuan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;">______________</font></div><div style="padding-right:-28.7pt;margin-top:6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; __</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Chief Financial Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">______&#160;Title&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Chief Strategy and Business Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">____</font></div><div style="padding-right:-28.7pt;margin-top:6pt;margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit31-1x03x31x20.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia66351e9a9574789b2dcf9d44f463774_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Jacqualyn A. Fouse, certify that&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; April&#160;30, 2020 </font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:57.824%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.176%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit31-2x03x31x20.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2f8ef309c3be4861b7bb6b439da286f9_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Andrew Hirsch, certify that&#58;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; April&#160;30, 2020</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:47.266%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.734%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; Andrew Hirsch</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Andrew Hirsch</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Head of Corporate Development</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit32-1x03x31x20.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i5ba72009562b4923b8d0d1a01e2b01c7_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Jacqualyn A. Fouse, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; April&#160;30, 2020</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:57.824%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.176%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exhibit32-2x03x31x20.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia494ff208a264cd58c86fb0f5f25432d_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Andrew Hirsch, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to his knowledge on the date hereof&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-27pt;padding-left:45pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:-27pt;padding-left:45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; April&#160;30, 2020</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.586%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.414%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; Andrew Hirsch</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Andrew Hirsch</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Head of Corporate Development</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>agio-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a02d1e66-dea3-48df-83b5-cb17f8e40104,g:f4811f45-5f64-498d-9bc7-c730ea92ab47-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:agio="http://agios.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://agios.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://agios.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OverviewandBasisofPresentation" roleURI="http://agios.com/role/OverviewandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Overview and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OverviewandBasisofPresentationAdditionalInformationDetails" roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Overview and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsPolicies" roleURI="http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies">
        <link:definition>2203201 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2104102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2205202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://agios.com/role/FairValueMeasurements">
        <link:definition>2106103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://agios.com/role/FairValueMeasurementsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2408402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2409403 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://agios.com/role/MarketableSecurities">
        <link:definition>2110104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://agios.com/role/MarketableSecuritiesTables">
        <link:definition>2311302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetails" roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails">
        <link:definition>2412404 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofMarketableSecuritiesDetails" roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails">
        <link:definition>2413405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://agios.com/role/Inventory">
        <link:definition>2114105 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://agios.com/role/InventoryTables">
        <link:definition>2315303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryDetails" roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails">
        <link:definition>2416406 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://agios.com/role/Leases">
        <link:definition>2117106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://agios.com/role/LeasesTables">
        <link:definition>2318304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://agios.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2419407 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails">
        <link:definition>2420408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1">
        <link:definition>2420408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://agios.com/role/AccruedExpenses">
        <link:definition>2121107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://agios.com/role/AccruedExpensesTables">
        <link:definition>2322305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesSummaryofAccruedExpensesDetails" roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails">
        <link:definition>2423409 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenue" roleURI="http://agios.com/role/ProductRevenue">
        <link:definition>2124108 - Disclosure - Product Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueTables" roleURI="http://agios.com/role/ProductRevenueTables">
        <link:definition>2325306 - Disclosure - Product Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails">
        <link:definition>2426410 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails">
        <link:definition>2427411 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofRevenueRelatedReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails">
        <link:definition>2428412 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails">
        <link:definition>2429413 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://agios.com/role/CollaborationandLicenseAgreements">
        <link:definition>2130109 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>2331307 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails">
        <link:definition>2432414 - Disclosure - Collaboration and License Agreements - Celegene Purchase Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsCollaborationRevenueDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails">
        <link:definition>2433415 - Disclosure - Collaboration and License Agreements - Collaboration Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails">
        <link:definition>2434416 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails">
        <link:definition>2435417 - Disclosure - Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>2436418 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails">
        <link:definition>2437419 - Disclosure - Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails">
        <link:definition>2438420 - Disclosure - Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails">
        <link:definition>2439421 - Disclosure - Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://agios.com/role/ShareBasedPayments">
        <link:definition>2140110 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://agios.com/role/ShareBasedPaymentsTables">
        <link:definition>2341308 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAdditionalInformationDetails" roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>2442422 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofStockOptionActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails">
        <link:definition>2443423 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails">
        <link:definition>2444424 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails">
        <link:definition>2445425 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails">
        <link:definition>2446426 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails">
        <link:definition>2447427 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShare" roleURI="http://agios.com/role/LossperShare">
        <link:definition>2148111 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareTables" roleURI="http://agios.com/role/LossperShareTables">
        <link:definition>2349309 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>2450428 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="agio_ContractWithCustomerContractualAdjustmentReserve" abstract="false" name="ContractWithCustomerContractualAdjustmentReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveProvisions" abstract="false" name="ContractWithCustomerCurrentYearReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CollaborationReceivableOtherCurrent" abstract="false" name="CollaborationReceivableOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" abstract="false" name="ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_EmployeeStockPurchasePlan2013Member" abstract="true" name="EmployeeStockPurchasePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_MarketBasedStockUnitsMember" abstract="true" name="MarketBasedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" abstract="false" name="ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAllowanceAndReservesLiability" abstract="false" name="ContractWithCustomerAllowanceAndReservesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PerformanceStockUnitMember" abstract="true" name="PerformanceStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_EmployeePurchasePlanMember" abstract="true" name="EmployeePurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent" abstract="false" name="IncreaseDecreaseinCollaborationReceivableOtherCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CollaborationRevenueOtherMember" abstract="true" name="CollaborationRevenueOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RoyaltyPercentageRemitted" abstract="false" name="RoyaltyPercentageRemitted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInPriorYears" abstract="false" name="ProvisionForRightToRecoverProductInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_UpfrontPaymentAgreementExtensionFeeReceivable" abstract="false" name="UpfrontPaymentAgreementExtensionFeeReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CollaborationRevenueRelatedPartyMember" abstract="true" name="CollaborationRevenueRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_OptionExerciseFeeReceivable" abstract="false" name="OptionExerciseFeeReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveRecoveries" abstract="false" name="ContractWithCustomerPriorYearsReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" abstract="false" name="ContractWithCustomerAssetProceedsFromCollectionOfReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductPriorYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityLineItems" abstract="true" name="ContractWithCustomerAssetAndLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CStoneAgreementMember" abstract="true" name="CStoneAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_Agreement2010Member" abstract="true" name="Agreement2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" abstract="true" name="PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_PerformanceBasedStockUnitMember" abstract="true" name="PerformanceBasedStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" abstract="false" name="ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractualAdjustmentsRollForward" abstract="true" name="ContractualAdjustmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_PriorYearProvisionsForRebateReserve" abstract="false" name="PriorYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveRecoveries" abstract="false" name="ContractWithCustomerCurrentYearReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductReserve" abstract="false" name="ContractWithCustomerRightToRecoverProductReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseRemainingLeaseTerm" abstract="false" name="LesseeOperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" abstract="false" name="RevenueFromContractsWithCustomersMilestoneRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetRevenueRecognized" abstract="false" name="ContractWithCustomerAssetRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_PriorYearProvisionForContractualAdjustments" abstract="false" name="PriorYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityTable" abstract="true" name="ContractWithCustomerAssetAndLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" abstract="false" name="IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CurrentYearProvisionForContractualAdjustments" abstract="false" name="CurrentYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CStonePharmaceuticalsMember" abstract="true" name="CStonePharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CommercializationActivityMember" abstract="true" name="CommercializationActivityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CurrentYearProvisionsForRebateReserve" abstract="false" name="CurrentYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" abstract="false" name="IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" abstract="true" name="CollaborationReceivableDueFromRelatedPartiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_TwoThousandAndThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_OtherStockAwardsMember" abstract="true" name="OtherStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_CurrentAssetMember" abstract="true" name="CurrentAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" abstract="false" name="ContractWithCustomerLiabilityIncreaseFromCashReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" abstract="false" name="PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" abstract="false" name="ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_CollaborationReceivableDuefromRelatedPartiesCurrent" abstract="false" name="CollaborationReceivableDuefromRelatedPartiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveProvisions" abstract="false" name="ContractWithCustomerPriorYearsReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfMarketBasedUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" abstract="true" name="RoyaltyReceivableDuefromRelatedPartiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" abstract="true" name="CollaborationReceivableDuefromRelatedPartiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" abstract="false" name="RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerTotalAllowancesAndReserves" abstract="false" name="ContractWithCustomerTotalAllowancesAndReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" abstract="false" name="RoyaltyReceivableDuefromRelatedPartiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ProductReturnsRollForward" abstract="true" name="ProductReturnsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_DeferredRevenueCurrentMember" abstract="true" name="DeferredRevenueCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ChangeInContractWithCustomerAssetRollForward" abstract="true" name="ChangeInContractWithCustomerAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_MasterResearchAndCollaborationAgreementMember" abstract="true" name="MasterResearchAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_GovernmentRebatesRollForward" abstract="true" name="GovernmentRebatesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserve" abstract="false" name="ContractWithCustomerRebateReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" abstract="false" name="PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" abstract="false" name="PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMilestoneMethodEligibleReceivable" abstract="false" name="RevenueRecognitionMilestoneMethodEligibleReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" abstract="false" name="IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInCurrentYear" abstract="false" name="ProvisionForRightToRecoverProductInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CelgeneMember" abstract="true" name="CelgeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" abstract="true" name="PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets" abstract="false" name="ProceedsFromStockOptionsExercisedInOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractwithCustomerAssetRevenueRecognized" abstract="false" name="ContractwithCustomerAssetRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_OperatingLeaseRightOfUseAssetAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>agio-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a02d1e66-dea3-48df-83b5-cb17f8e40104,g:f4811f45-5f64-498d-9bc7-c730ea92ab47-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20200331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd6a2ef-dd30-462c-b32a-cc9159feb272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_80aeb204-a18a-44ae-8a9b-740d2cd94cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd6a2ef-dd30-462c-b32a-cc9159feb272" xlink:to="loc_us-gaap_LiabilitiesCurrent_80aeb204-a18a-44ae-8a9b-740d2cd94cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_71e920c9-8831-4a3b-84aa-49dedf086c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd6a2ef-dd30-462c-b32a-cc9159feb272" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_71e920c9-8831-4a3b-84aa-49dedf086c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c58f1229-15e9-4a07-a0f9-a4fbe4dd1299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd6a2ef-dd30-462c-b32a-cc9159feb272" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c58f1229-15e9-4a07-a0f9-a4fbe4dd1299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_02b7628b-f1b7-40bb-929f-db9a90f0d5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd6a2ef-dd30-462c-b32a-cc9159feb272" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_02b7628b-f1b7-40bb-929f-db9a90f0d5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6386506c-48e3-4f52-baad-8494e885824a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd6a2ef-dd30-462c-b32a-cc9159feb272" xlink:to="loc_us-gaap_StockholdersEquity_6386506c-48e3-4f52-baad-8494e885824a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6dc786d2-b083-4cc8-b035-34266e62cdac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_44222e0e-51de-4908-8652-d4b91dce1994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc786d2-b083-4cc8-b035-34266e62cdac" xlink:to="loc_us-gaap_PreferredStockValue_44222e0e-51de-4908-8652-d4b91dce1994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a44916ed-22b5-4c37-8a2a-3af6d6b10a05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc786d2-b083-4cc8-b035-34266e62cdac" xlink:to="loc_us-gaap_CommonStockValue_a44916ed-22b5-4c37-8a2a-3af6d6b10a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6e8b29d0-5bb7-496b-ae31-51e7ad60963d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc786d2-b083-4cc8-b035-34266e62cdac" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6e8b29d0-5bb7-496b-ae31-51e7ad60963d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d00b9f44-1b10-406b-95b2-494c0ff829c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc786d2-b083-4cc8-b035-34266e62cdac" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d00b9f44-1b10-406b-95b2-494c0ff829c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7694d6e4-1863-4cfb-b639-63e4991867db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc786d2-b083-4cc8-b035-34266e62cdac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7694d6e4-1863-4cfb-b639-63e4991867db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_98ce4f34-3a9b-4cfc-af99-2fba5dfb9404" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_e18d6e21-b195-4ddd-bfec-4f0e82a1b9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_98ce4f34-3a9b-4cfc-af99-2fba5dfb9404" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_e18d6e21-b195-4ddd-bfec-4f0e82a1b9c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_700ba364-4d66-40fa-83b3-7bbe6e9ec787" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_98ce4f34-3a9b-4cfc-af99-2fba5dfb9404" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_700ba364-4d66-40fa-83b3-7bbe6e9ec787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2d1f4397-046f-42f9-a864-54e13228feda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_98ce4f34-3a9b-4cfc-af99-2fba5dfb9404" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2d1f4397-046f-42f9-a864-54e13228feda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c4c90ad-de40-4a0a-ba86-f6ce2d146aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_98ce4f34-3a9b-4cfc-af99-2fba5dfb9404" xlink:to="loc_us-gaap_LiabilitiesCurrent_2c4c90ad-de40-4a0a-ba86-f6ce2d146aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44ee7899-e270-4a59-8103-b86e8811f53a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_48040e79-2e8f-4730-a14c-f0068d083ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44ee7899-e270-4a59-8103-b86e8811f53a" xlink:to="loc_us-gaap_AccountsPayableCurrent_48040e79-2e8f-4730-a14c-f0068d083ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_76b5c11c-e37f-48dc-822c-815eeca96c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44ee7899-e270-4a59-8103-b86e8811f53a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_76b5c11c-e37f-48dc-822c-815eeca96c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_119ada0a-9243-40d1-b034-3db229bd86df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44ee7899-e270-4a59-8103-b86e8811f53a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_119ada0a-9243-40d1-b034-3db229bd86df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_455492dd-ccaf-47f1-a1ff-b7984bcef8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44ee7899-e270-4a59-8103-b86e8811f53a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_455492dd-ccaf-47f1-a1ff-b7984bcef8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_556c38d9-ec7d-44e2-9bc6-7ec9c516c3de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44ee7899-e270-4a59-8103-b86e8811f53a" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_556c38d9-ec7d-44e2-9bc6-7ec9c516c3de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d90a458b-b548-4364-95ed-9c9ad38472ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5067e6d4-3bc3-438f-b1e6-6ae93d91a3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d90a458b-b548-4364-95ed-9c9ad38472ff" xlink:to="loc_us-gaap_AssetsCurrent_5067e6d4-3bc3-438f-b1e6-6ae93d91a3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3de1e3b1-1333-42b9-9153-12f8f1d65241" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d90a458b-b548-4364-95ed-9c9ad38472ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3de1e3b1-1333-42b9-9153-12f8f1d65241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d42b8b9c-d32c-4cf8-b415-74745153d60d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d90a458b-b548-4364-95ed-9c9ad38472ff" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d42b8b9c-d32c-4cf8-b415-74745153d60d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_566df012-6536-4e9f-a174-8fd14b7a48a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d90a458b-b548-4364-95ed-9c9ad38472ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_566df012-6536-4e9f-a174-8fd14b7a48a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_7e1d2b47-67ca-4011-ae6d-5adae6f3ebfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d90a458b-b548-4364-95ed-9c9ad38472ff" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_7e1d2b47-67ca-4011-ae6d-5adae6f3ebfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4cf64183-b5d8-47fe-b7ec-a929da72096d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d90a458b-b548-4364-95ed-9c9ad38472ff" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4cf64183-b5d8-47fe-b7ec-a929da72096d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ee56743-9194-420c-b15c-5e42336fbd57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ee56743-9194-420c-b15c-5e42336fbd57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0c0c4471-66d4-4ef7-b4d7-b79574a94714" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0c0c4471-66d4-4ef7-b4d7-b79574a94714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_2b3eb0f1-78b8-452b-b3d8-daec3b68edba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_2b3eb0f1-78b8-452b-b3d8-daec3b68edba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrent_205f841b-cca9-4c7f-a837-93a5512d1a47" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrent_205f841b-cca9-4c7f-a837-93a5512d1a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableOtherCurrent_24fd9dce-8c56-4b26-a985-1dd19cd31328" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableOtherCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_agio_CollaborationReceivableOtherCurrent_24fd9dce-8c56-4b26-a985-1dd19cd31328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_e50748c5-6834-414d-a745-93719dc73594" xlink:href="agio-20200331.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_e50748c5-6834-414d-a745-93719dc73594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_80710671-00d6-48e8-a654-a7b396347a03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_us-gaap_InventoryNet_80710671-00d6-48e8-a654-a7b396347a03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554eb1c0-e548-4b46-b33b-52a3c85b8824" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29376a08-e5e7-404f-9c69-9e0461edcdd5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554eb1c0-e548-4b46-b33b-52a3c85b8824" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b79d8632-e052-4ff6-8386-ad7f4cf0679a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5778c26-ed78-449c-863f-6577c8333b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b79d8632-e052-4ff6-8386-ad7f4cf0679a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5778c26-ed78-449c-863f-6577c8333b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b5f189f6-ea2f-4ac9-8309-0c5ee2153e22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b79d8632-e052-4ff6-8386-ad7f4cf0679a" xlink:to="loc_us-gaap_CostsAndExpenses_b5f189f6-ea2f-4ac9-8309-0c5ee2153e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_220f551b-8fb5-4581-ab4f-d0dc82a02eec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5a250773-bc9b-4d1a-928f-7e721adf476b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_220f551b-8fb5-4581-ab4f-d0dc82a02eec" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5a250773-bc9b-4d1a-928f-7e721adf476b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6623f514-d9f5-44eb-8760-bdb0b2e6fad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_220f551b-8fb5-4581-ab4f-d0dc82a02eec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6623f514-d9f5-44eb-8760-bdb0b2e6fad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d689d5eb-404b-47f9-a8a5-6fb5ffb11f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_220f551b-8fb5-4581-ab4f-d0dc82a02eec" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d689d5eb-404b-47f9-a8a5-6fb5ffb11f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93353b18-99f4-483b-ad94-477703c2a365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1293a719-bfd2-48e9-aa07-0c1666a416db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_93353b18-99f4-483b-ad94-477703c2a365" xlink:to="loc_us-gaap_OperatingIncomeLoss_1293a719-bfd2-48e9-aa07-0c1666a416db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_aabc3e0c-d059-47b8-bdee-9179dfe231e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_93353b18-99f4-483b-ad94-477703c2a365" xlink:to="loc_us-gaap_InvestmentIncomeInterest_aabc3e0c-d059-47b8-bdee-9179dfe231e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_15abea94-ae7b-4da4-9733-da043be45e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ccec0b15-f44f-40e7-961f-befca0c1db8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_15abea94-ae7b-4da4-9733-da043be45e28" xlink:to="loc_us-gaap_NetIncomeLoss_ccec0b15-f44f-40e7-961f-befca0c1db8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1903a19d-06f5-4a37-a943-583efb41dd39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_15abea94-ae7b-4da4-9733-da043be45e28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1903a19d-06f5-4a37-a943-583efb41dd39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3733c77-cb01-4736-ac00-5484fdeada41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_488b14b8-43b2-4e79-930a-8bb804e953e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3733c77-cb01-4736-ac00-5484fdeada41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_488b14b8-43b2-4e79-930a-8bb804e953e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ff843f-a143-412c-8919-1b0336c9582b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3733c77-cb01-4736-ac00-5484fdeada41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ff843f-a143-412c-8919-1b0336c9582b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_11e9da05-c99f-426c-aad2-ffbda6708976" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3733c77-cb01-4736-ac00-5484fdeada41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_11e9da05-c99f-426c-aad2-ffbda6708976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6491588-d808-41d5-ad55-f086564be7f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_972fad75-df6f-49b6-8581-3320f4c4d226" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6491588-d808-41d5-ad55-f086564be7f2" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_972fad75-df6f-49b6-8581-3320f4c4d226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b561f6f6-320d-418c-a73b-64570d09e192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6491588-d808-41d5-ad55-f086564be7f2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b561f6f6-320d-418c-a73b-64570d09e192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_622e0ee4-9e31-42d2-ac8f-8a3e39d264cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ae43e7fc-14a1-489b-9677-cbc2b33ff526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_622e0ee4-9e31-42d2-ac8f-8a3e39d264cf" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ae43e7fc-14a1-489b-9677-cbc2b33ff526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c12f1236-b79a-480f-bd6c-f34e31daf787" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_622e0ee4-9e31-42d2-ac8f-8a3e39d264cf" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c12f1236-b79a-480f-bd6c-f34e31daf787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5425d89f-dc4c-4ddf-9215-6e8158ddc140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_622e0ee4-9e31-42d2-ac8f-8a3e39d264cf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5425d89f-dc4c-4ddf-9215-6e8158ddc140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5440fe9a-aea6-4d3e-97d8-1512335ce076" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_NetIncomeLoss_5440fe9a-aea6-4d3e-97d8-1512335ce076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_02c75564-1cad-45a2-a020-09ea40d0a0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_Depreciation_02c75564-1cad-45a2-a020-09ea40d0a0bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_daedb0df-581f-4297-b0e2-276720149129" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_ShareBasedCompensation_daedb0df-581f-4297-b0e2-276720149129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_07fa4ecb-2d1d-4f12-8d4b-a149cd218905" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_07fa4ecb-2d1d-4f12-8d4b-a149cd218905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OperatingLeaseRightOfUseAssetAmortization_217aca73-e1d6-4237-8728-277e815cd90b" xlink:href="agio-20200331.xsd#agio_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_agio_OperatingLeaseRightOfUseAssetAmortization_217aca73-e1d6-4237-8728-277e815cd90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_167e8d31-926c-456f-b617-878452641338" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_167e8d31-926c-456f-b617-878452641338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent_46069528-cb93-4cd1-85f8-f6d92ed665cf" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent_46069528-cb93-4cd1-85f8-f6d92ed665cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent_eae7cf3c-2606-4c59-a072-89b2198d64f0" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent_eae7cf3c-2606-4c59-a072-89b2198d64f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_c00fbc8e-af20-45d1-8fd1-94b303182dda" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_c00fbc8e-af20-45d1-8fd1-94b303182dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_914cd0f6-b2c2-410d-bcf1-0d48ccf0b6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_914cd0f6-b2c2-410d-bcf1-0d48ccf0b6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4450397-ab76-4201-961d-646f946c425e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4450397-ab76-4201-961d-646f946c425e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff2af97f-57ea-43c0-ab39-b83740a65845" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff2af97f-57ea-43c0-ab39-b83740a65845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f1a26152-195d-4a40-b52c-ca8039c2aa6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f1a26152-195d-4a40-b52c-ca8039c2aa6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_6b44a626-fac6-4695-bb8a-0aa88caf6e05" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_6b44a626-fac6-4695-bb8a-0aa88caf6e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_59081728-fd8d-48c4-9dfe-75a4ad693516" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4633370-2662-488b-aae6-7b11599a97c7" xlink:to="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_59081728-fd8d-48c4-9dfe-75a4ad693516" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="simple" xlink:href="agio-20200331.xsd#OverviewandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#OverviewandBasisofPresentationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:calculationLink xlink:role="http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_400a09ca-17fe-400b-a686-65967f17372c" xlink:href="agio-20200331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_926b4044-73c0-4764-a333-f9540d1d7dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_400a09ca-17fe-400b-a686-65967f17372c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_926b4044-73c0-4764-a333-f9540d1d7dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_18653de0-4479-4ab3-9dcc-9b3c17b9f226" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_400a09ca-17fe-400b-a686-65967f17372c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_18653de0-4479-4ab3-9dcc-9b3c17b9f226" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a68acee0-76a8-4dad-b71c-9d7b70a052d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11e154e2-e3c9-4643-b993-3e1793cb934a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a68acee0-76a8-4dad-b71c-9d7b70a052d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11e154e2-e3c9-4643-b993-3e1793cb934a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de4c8120-c063-4ab6-9076-e711e8ba54ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a68acee0-76a8-4dad-b71c-9d7b70a052d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de4c8120-c063-4ab6-9076-e711e8ba54ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_47ed2e5f-1253-4f6c-832c-7f2d0b1bd9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a68acee0-76a8-4dad-b71c-9d7b70a052d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_47ed2e5f-1253-4f6c-832c-7f2d0b1bd9fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20200331.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20200331.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#InventoryScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_35a912c0-ddfd-443c-b145-a482e87b080f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c7474b67-9049-4bd9-a25f-c8ff8edafce8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_35a912c0-ddfd-443c-b145-a482e87b080f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c7474b67-9049-4bd9-a25f-c8ff8edafce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0753af1e-dfbb-4f59-8712-9af8e968394a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_35a912c0-ddfd-443c-b145-a482e87b080f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0753af1e-dfbb-4f59-8712-9af8e968394a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_66f7304c-74ec-46fe-907d-0a8e77f426f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_35a912c0-ddfd-443c-b145-a482e87b080f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_66f7304c-74ec-46fe-907d-0a8e77f426f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20200331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://agios.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ed70c18b-c46e-4c27-9f8f-003cdb0e5182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ed70c18b-c46e-4c27-9f8f-003cdb0e5182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_219ad0b1-e7d2-4fa9-9589-42868db74dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_219ad0b1-e7d2-4fa9-9589-42868db74dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5510d00a-5722-4449-a62f-2b1e66717805" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5510d00a-5722-4449-a62f-2b1e66717805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47df288f-5ec1-4832-8155-a54d215476a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47df288f-5ec1-4832-8155-a54d215476a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b455c72b-50cd-4c2e-aff8-0ed0836929a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b455c72b-50cd-4c2e-aff8-0ed0836929a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_40ae545d-14af-45a9-b807-753f36e54b1f" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:to="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_40ae545d-14af-45a9-b807-753f36e54b1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_4312737e-a1a7-4c5c-85a6-166ebfbd6e53" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1bfecf0-41f7-4fc7-87e7-b1e3d0330ad6" xlink:to="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_4312737e-a1a7-4c5c-85a6-166ebfbd6e53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c42e43a0-bb42-49e2-9af0-b44a4c35b70f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46f4488e-8c47-4b17-9895-c0227954ade3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c42e43a0-bb42-49e2-9af0-b44a4c35b70f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46f4488e-8c47-4b17-9895-c0227954ade3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a398b055-8152-4a8c-a01c-be178aa4098b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c42e43a0-bb42-49e2-9af0-b44a4c35b70f" xlink:to="loc_us-gaap_OperatingLeaseLiability_a398b055-8152-4a8c-a01c-be178aa4098b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpenses"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_97d572fd-ddc1-4b3d-9f38-f0d694ac20f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_81881215-e4e0-4202-bb0a-702537533025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_97d572fd-ddc1-4b3d-9f38-f0d694ac20f7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_81881215-e4e0-4202-bb0a-702537533025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_63205adf-d5f0-455d-9801-1db2070f6a7b" xlink:href="agio-20200331.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_97d572fd-ddc1-4b3d-9f38-f0d694ac20f7" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_63205adf-d5f0-455d-9801-1db2070f6a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_68391c44-b019-4072-9dd6-7557f65c105e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_97d572fd-ddc1-4b3d-9f38-f0d694ac20f7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_68391c44-b019-4072-9dd6-7557f65c105e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6b0202cf-6527-4f0f-8652-3b62a95bf4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_97d572fd-ddc1-4b3d-9f38-f0d694ac20f7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6b0202cf-6527-4f0f-8652-3b62a95bf4c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenue"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_2e5277f8-87f8-4b87-82af-416aca523800" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_32fadbb1-b269-4e28-a424-891aa7e8b309" xlink:href="agio-20200331.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_2e5277f8-87f8-4b87-82af-416aca523800" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_32fadbb1-b269-4e28-a424-891aa7e8b309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_4c7449b9-019f-4b41-aa00-3764487c7671" xlink:href="agio-20200331.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_2e5277f8-87f8-4b87-82af-416aca523800" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_4c7449b9-019f-4b41-aa00-3764487c7671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_9af40f9e-4864-4f38-afdf-4e91bb2f2d6a" xlink:href="agio-20200331.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_2e5277f8-87f8-4b87-82af-416aca523800" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_9af40f9e-4864-4f38-afdf-4e91bb2f2d6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_065c0383-ed61-4d5e-b384-a8da24f7baf8" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_f507efdc-9bb0-482f-bab6-04f24eb48182" xlink:href="agio-20200331.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_065c0383-ed61-4d5e-b384-a8da24f7baf8" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_f507efdc-9bb0-482f-bab6-04f24eb48182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_9e1e3f0a-4340-4be6-bec7-b0ecf70a288e" xlink:href="agio-20200331.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_065c0383-ed61-4d5e-b384-a8da24f7baf8" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_9e1e3f0a-4340-4be6-bec7-b0ecf70a288e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_8b73614f-b03e-4e31-bbf2-eedcaba6a00f" xlink:href="agio-20200331.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_065c0383-ed61-4d5e-b384-a8da24f7baf8" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_8b73614f-b03e-4e31-bbf2-eedcaba6a00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_4fb8536a-345f-48e1-9ded-883424074df7" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_e6fd6649-1ae3-4ac5-820c-ed224a4061a9" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_4fb8536a-345f-48e1-9ded-883424074df7" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_e6fd6649-1ae3-4ac5-820c-ed224a4061a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_9566a964-1236-401e-a625-fa76d03574be" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_4fb8536a-345f-48e1-9ded-883424074df7" xlink:to="loc_agio_ContractWithCustomerRebateReserve_9566a964-1236-401e-a625-fa76d03574be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_53bada64-4ecb-47c6-86e7-c3280b284b34" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_4fb8536a-345f-48e1-9ded-883424074df7" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_53bada64-4ecb-47c6-86e7-c3280b284b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_36674d5a-7cdf-4ebe-aec1-b5efe69b4803" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_4e706395-e137-47d2-b755-1828d9de304f" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_36674d5a-7cdf-4ebe-aec1-b5efe69b4803" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_4e706395-e137-47d2-b755-1828d9de304f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_90b849f7-b064-42ba-9f3f-67c34724b162" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_36674d5a-7cdf-4ebe-aec1-b5efe69b4803" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_90b849f7-b064-42ba-9f3f-67c34724b162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_06b925b6-33c0-433b-a6b9-7c8517189d65" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_36674d5a-7cdf-4ebe-aec1-b5efe69b4803" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_06b925b6-33c0-433b-a6b9-7c8517189d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_6656e3c8-4d22-42a5-9c0f-94978ba2bb59" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_63ed083b-08ba-4a13-a227-9c9be99ea8ad" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_6656e3c8-4d22-42a5-9c0f-94978ba2bb59" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_63ed083b-08ba-4a13-a227-9c9be99ea8ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_2a9aac8b-973c-4902-8d3b-298caacee88e" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_6656e3c8-4d22-42a5-9c0f-94978ba2bb59" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_2a9aac8b-973c-4902-8d3b-298caacee88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_6c86dee2-0b1c-46fc-9940-c1f329805fa5" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_6656e3c8-4d22-42a5-9c0f-94978ba2bb59" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_6c86dee2-0b1c-46fc-9940-c1f329805fa5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_746b8c71-3e49-432a-9e69-ee63d09c2712" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_950e19c9-f89e-49b5-b5ac-1dd54865734c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_746b8c71-3e49-432a-9e69-ee63d09c2712" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_950e19c9-f89e-49b5-b5ac-1dd54865734c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_7ac8b169-0152-49eb-b9c6-3c0f06bab11e" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_746b8c71-3e49-432a-9e69-ee63d09c2712" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_7ac8b169-0152-49eb-b9c6-3c0f06bab11e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCollaborationRevenueDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPayments"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShare" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShare"/>
  <link:calculationLink xlink:role="http://agios.com/role/LossperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareTables" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShareTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/LossperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>agio-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a02d1e66-dea3-48df-83b5-cb17f8e40104,g:f4811f45-5f64-498d-9bc7-c730ea92ab47-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20200331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended" id="ic815deb1a7134fa5ae4dbdbbf2f49464_CoverPage"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i00573f35ca6942b799ce07e7cc856b3f_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i0cf6550aa6e74f41a132969e4596fed7_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i6370a28fb10841938b83c180aebc2568_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e7605332-c75f-4166-a4fa-f8fc5b732b68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_RevenuesAbstract_e7605332-c75f-4166-a4fa-f8fc5b732b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16dbf652-86f9-44cf-8bbd-0a9173b44553" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e7605332-c75f-4166-a4fa-f8fc5b732b68" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16dbf652-86f9-44cf-8bbd-0a9173b44553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6a14d76b-6d84-4fe4-886c-3869440e83a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6a14d76b-6d84-4fe4-886c-3869440e83a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d5a94687-0c61-46ed-be1b-e245f7e604d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d5a94687-0c61-46ed-be1b-e245f7e604d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_55c270dc-5a7d-412f-899b-265411480ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_55c270dc-5a7d-412f-899b-265411480ab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6c1eb345-24a6-48bd-831a-5d28b0d91836" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_CostsAndExpenses_6c1eb345-24a6-48bd-831a-5d28b0d91836" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bdaaa257-85e0-4423-9c25-ca96f341855e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_OperatingIncomeLoss_bdaaa257-85e0-4423-9c25-ca96f341855e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_bee17954-9cf5-446d-8aae-6fbcd858e2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_bee17954-9cf5-446d-8aae-6fbcd858e2f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d19f32e6-5dab-4f3a-9573-4c1dd116d109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_NetIncomeLoss_d19f32e6-5dab-4f3a-9573-4c1dd116d109" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_55b11f1a-38f6-4fd5-860b-164b74d543fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_55b11f1a-38f6-4fd5-860b-164b74d543fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c022932f-99c1-4f71-b6bf-26a12dcc5b48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c022932f-99c1-4f71-b6bf-26a12dcc5b48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fa93dc5c-43cc-4d64-8202-5303248f8fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_StatementTable_fa93dc5c-43cc-4d64-8202-5303248f8fbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0639252b-ec4b-4fe5-aad8-8dc8069051ea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fa93dc5c-43cc-4d64-8202-5303248f8fbb" xlink:to="loc_srt_ProductOrServiceAxis_0639252b-ec4b-4fe5-aad8-8dc8069051ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0639252b-ec4b-4fe5-aad8-8dc8069051ea_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0639252b-ec4b-4fe5-aad8-8dc8069051ea" xlink:to="loc_srt_ProductsAndServicesDomain_0639252b-ec4b-4fe5-aad8-8dc8069051ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0639252b-ec4b-4fe5-aad8-8dc8069051ea" xlink:to="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e86e297e-9916-4bf0-bdf7-59ae9a0c2fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_us-gaap_ProductMember_e86e297e-9916-4bf0-bdf7-59ae9a0c2fbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_fc9e3c3a-e626-4055-bd5a-50f791e3e7b7" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_fc9e3c3a-e626-4055-bd5a-50f791e3e7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_f23981f1-2f3d-4a5a-b510-76231db9c2ac" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_agio_CollaborationRevenueOtherMember_f23981f1-2f3d-4a5a-b510-76231db9c2ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_0ae161f1-0ae6-4516-9902-45e94292fc9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_us-gaap_RoyaltyMember_0ae161f1-0ae6-4516-9902-45e94292fc9f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="iff7dc0f586c2453fa0bb61f26abbb496_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2f92fa4225a7419cb19c7d0ba83a14e7_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7c3dd1bc-d6b8-40a3-adc2-b268b078f0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_SharesOutstanding_7c3dd1bc-d6b8-40a3-adc2-b268b078f0e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_457654c2-e3cf-4be6-80d4-13c099aeefb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StockholdersEquity_457654c2-e3cf-4be6-80d4-13c099aeefb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ee25da63-655f-412a-adb4-4c4e077b6838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ee25da63-655f-412a-adb4-4c4e077b6838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3fb3d081-ee6e-405b-8080-63dff7b0c7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3fb3d081-ee6e-405b-8080-63dff7b0c7bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee8b1333-31a4-48d3-bd90-0e3000d2c8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee8b1333-31a4-48d3-bd90-0e3000d2c8e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80f56e93-8c23-4cef-9618-67f6d534370a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80f56e93-8c23-4cef-9618-67f6d534370a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d44deae-33f3-4d20-b244-a6e0afecf74f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_NetIncomeLoss_8d44deae-33f3-4d20-b244-a6e0afecf74f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5ea0a1af-946f-462a-8952-69f44498bef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4ef3ebc0-9ac0-4c5a-8056-59d0d902cda7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c61ad7da-526e-496e-8d9b-adeeeb3b4866" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StatementTable_c61ad7da-526e-496e-8d9b-adeeeb3b4866" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d2769f29-6732-402e-b796-a1c8f771b358" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c61ad7da-526e-496e-8d9b-adeeeb3b4866" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d2769f29-6732-402e-b796-a1c8f771b358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d2769f29-6732-402e-b796-a1c8f771b358_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d2769f29-6732-402e-b796-a1c8f771b358" xlink:to="loc_us-gaap_EquityComponentDomain_d2769f29-6732-402e-b796-a1c8f771b358_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d2769f29-6732-402e-b796-a1c8f771b358" xlink:to="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e29bcd0-e3e3-4308-bd5c-4732fdfb9ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_CommonStockMember_8e29bcd0-e3e3-4308-bd5c-4732fdfb9ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cab02b03-51db-45d8-b402-a8db613bbb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cab02b03-51db-45d8-b402-a8db613bbb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb908999-97de-4be4-9542-a1f73082bfb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb908999-97de-4be4-9542-a1f73082bfb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_aae145ce-4e70-46b9-8a52-a14bf47e8bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_RetainedEarningsMember_aae145ce-4e70-46b9-8a52-a14bf47e8bad" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i48921ab683a14b1383f723d1da7d1b81_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="simple" xlink:href="agio-20200331.xsd#OverviewandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="extended" id="ib0a2f41393d944d191fb0a0aee452df9_OverviewandBasisofPresentation"/>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#OverviewandBasisofPresentationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="extended" id="i5056c2d2889f449abeb649bafa9cb9a8_OverviewandBasisofPresentationAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:definitionLink xlink:role="http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended" id="ie6830de4af6d4376af8b999811817236_OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i04617f9910734501ab4fa9d37e6bd131_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i5133eb421d9e43a6971efb0cd88f99d5_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended" id="i1903e42752a14925a3ebaad401917efc_FairValueMeasurements"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended" id="if306324fbde14447bca1d971431525c8_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i6e0713162e3b4221acb8585f6a5293b0_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b00f1a0e-f600-47cd-a34b-4fdc32471333" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b00f1a0e-f600-47cd-a34b-4fdc32471333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8cf6313d-bfdc-41be-b474-b0b7c111dd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8cf6313d-bfdc-41be-b474-b0b7c111dd1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_329da68e-41e3-46c0-b0b8-a300f2e397c3" xlink:href="agio-20200331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_329da68e-41e3-46c0-b0b8-a300f2e397c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d83bf1b0-11ec-4b78-b4b7-6645d766bf92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d83bf1b0-11ec-4b78-b4b7-6645d766bf92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d83bf1b0-11ec-4b78-b4b7-6645d766bf92_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d83bf1b0-11ec-4b78-b4b7-6645d766bf92" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d83bf1b0-11ec-4b78-b4b7-6645d766bf92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c68fdb09-10b5-477a-a004-507d575b2424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d83bf1b0-11ec-4b78-b4b7-6645d766bf92" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c68fdb09-10b5-477a-a004-507d575b2424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cf69886e-65a3-4c84-a6a1-5b12f6ee2b01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c68fdb09-10b5-477a-a004-507d575b2424" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cf69886e-65a3-4c84-a6a1-5b12f6ee2b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94b58ec-8fad-498f-9afc-e0f16c41bf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94b58ec-8fad-498f-9afc-e0f16c41bf8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c94b58ec-8fad-498f-9afc-e0f16c41bf8f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94b58ec-8fad-498f-9afc-e0f16c41bf8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c94b58ec-8fad-498f-9afc-e0f16c41bf8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94b58ec-8fad-498f-9afc-e0f16c41bf8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d4bebf2-a15a-41e3-9ac3-625e85acce31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d4bebf2-a15a-41e3-9ac3-625e85acce31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ca5a023c-f836-4269-9848-3cc15a670f39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ca5a023c-f836-4269-9848-3cc15a670f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a505496d-1f9e-4496-b7c1-8722e9f05feb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a505496d-1f9e-4496-b7c1-8722e9f05feb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_921c4884-9cce-472c-acbc-1a3f27b5eccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:to="loc_us-gaap_InvestmentTypeAxis_921c4884-9cce-472c-acbc-1a3f27b5eccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_921c4884-9cce-472c-acbc-1a3f27b5eccb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_921c4884-9cce-472c-acbc-1a3f27b5eccb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_921c4884-9cce-472c-acbc-1a3f27b5eccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_921c4884-9cce-472c-acbc-1a3f27b5eccb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_df474a4b-d125-48a7-b171-cbed3f36555c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_CashEquivalentsMember_df474a4b-d125-48a7-b171-cbed3f36555c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_27655bd2-4fe0-4828-a694-900a1f71421b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_27655bd2-4fe0-4828-a694-900a1f71421b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6cf7160-7473-4c14-9158-2512ee8057ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6cf7160-7473-4c14-9158-2512ee8057ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7c6a0928-9975-46d5-a9a7-f806b0f390f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7c6a0928-9975-46d5-a9a7-f806b0f390f5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="ic13922aa25f34120a012a081311d4ed2_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee375281-48b7-410e-b55a-26741ccfddbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_882899f8-e6d0-42bd-8501-df62a8284b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee375281-48b7-410e-b55a-26741ccfddbb" xlink:to="loc_us-gaap_FairValueNetAssetLiability_882899f8-e6d0-42bd-8501-df62a8284b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee375281-48b7-410e-b55a-26741ccfddbb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_34d23ca8-5863-4a03-9f8f-dba1bd719a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_34d23ca8-5863-4a03-9f8f-dba1bd719a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f124bb21-161c-48ae-94c0-fa052ff3d4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_34d23ca8-5863-4a03-9f8f-dba1bd719a8a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f124bb21-161c-48ae-94c0-fa052ff3d4ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83e14faf-6ba7-4cdd-a2b6-4d3b75434fba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83e14faf-6ba7-4cdd-a2b6-4d3b75434fba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3c9de7fa-a792-4838-9274-34a13c3daf81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83e14faf-6ba7-4cdd-a2b6-4d3b75434fba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3c9de7fa-a792-4838-9274-34a13c3daf81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended" id="i625db5cb236045eabb70ef9a40c8cea8_MarketableSecurities"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended" id="ifeca23f1864145f5b0d961c7d4a34283_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended" id="ib4deefaca24248239ecd974a9b406df4_MarketableSecuritiesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended" id="i90a1e271e6e64a929c81b26e2f5f22bc_MarketableSecuritiesSummaryofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37b88705-22d2-4290-885d-45ae97fe5859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37b88705-22d2-4290-885d-45ae97fe5859" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e80f4e54-c86c-4a96-b4ee-47d94d5cc36e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e80f4e54-c86c-4a96-b4ee-47d94d5cc36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c4caaf8-ed92-44f1-8ee3-1f77676568cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c4caaf8-ed92-44f1-8ee3-1f77676568cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e1b2ec3b-21b3-48d6-a485-93e48881ad59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e1b2ec3b-21b3-48d6-a485-93e48881ad59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7bbd310f-81e3-41e4-9a98-4b84df574874" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7bbd310f-81e3-41e4-9a98-4b84df574874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7bbd310f-81e3-41e4-9a98-4b84df574874_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7bbd310f-81e3-41e4-9a98-4b84df574874" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7bbd310f-81e3-41e4-9a98-4b84df574874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7bbd310f-81e3-41e4-9a98-4b84df574874" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_50a07aca-a3c9-4dc9-b353-e93e88ebe14c" xlink:href="agio-20200331.xsd#agio_CurrentAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:to="loc_agio_CurrentAssetMember_50a07aca-a3c9-4dc9-b353-e93e88ebe14c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_84669b9d-4cc1-4e92-88d2-0ba80bdf8385" xlink:href="agio-20200331.xsd#agio_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:to="loc_agio_NonCurrentAssetsMember_84669b9d-4cc1-4e92-88d2-0ba80bdf8385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e67e0b24-7409-4797-8f90-a11fee0566cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:to="loc_us-gaap_InvestmentTypeAxis_e67e0b24-7409-4797-8f90-a11fee0566cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e67e0b24-7409-4797-8f90-a11fee0566cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_e67e0b24-7409-4797-8f90-a11fee0566cf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e67e0b24-7409-4797-8f90-a11fee0566cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_e67e0b24-7409-4797-8f90-a11fee0566cf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_44b8d936-e120-431d-a9a2-a863dfcc87d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_44b8d936-e120-431d-a9a2-a863dfcc87d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e54ba790-d70d-4aea-8e29-763f18eef0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e54ba790-d70d-4aea-8e29-763f18eef0bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_43b1dc02-5085-4633-acac-8339c9b9f8f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_43b1dc02-5085-4633-acac-8339c9b9f8f8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20200331.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended" id="i1db14168327a427588f4c89d86b2397c_Inventory"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20200331.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended" id="i7e38e36fbcb546b9ab499814d288ab96_InventoryTables"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#InventoryScheduleofInventoryDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended" id="i222ff471376443568f0acf1452673b4e_InventoryScheduleofInventoryDetails"/>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20200331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://agios.com/role/Leases" xlink:type="extended" id="icd1bb2ae847e490e8d9e604d2fbba553_Leases"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended" id="i1821a2f81bc948e9804d09efb7f5cc9c_LeasesTables"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i4f07d345535f44da9f3b453b8b6a8934_LeasesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="extended" id="i4719ed0011ac4c69b07d9ba397bb7706_LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpenses"/>
  <link:definitionLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended" id="id1010bb257084cfaae81f4e1d7f7ccd8_AccruedExpenses"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended" id="i1b464a09b0984c398c3eff8833c27e90_AccruedExpensesTables"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended" id="i6b44d9ca222c4a3796caf2554667e4ba_AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenue"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended" id="i5e5e9f48eb814cd8baeabb6997db4a5b_ProductRevenue"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended" id="i770a306d11b14d7c9e46f4d325ddf5b9_ProductRevenueTables"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended" id="i5dac5c80199d46cdac3bed142d101ccf_ProductRevenueScheduleofProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e1cd66ac-c45a-43af-8286-1c6d2ee68cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f52d284f-ae29-42ae-8660-c12e10f11570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e1cd66ac-c45a-43af-8286-1c6d2ee68cab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f52d284f-ae29-42ae-8660-c12e10f11570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8113e3e7-4762-4086-9a11-bd3e35adb430" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e1cd66ac-c45a-43af-8286-1c6d2ee68cab" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8113e3e7-4762-4086-9a11-bd3e35adb430" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea79f477-e60c-4629-9ebd-d61f04d566da" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8113e3e7-4762-4086-9a11-bd3e35adb430" xlink:to="loc_srt_ProductOrServiceAxis_ea79f477-e60c-4629-9ebd-d61f04d566da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea79f477-e60c-4629-9ebd-d61f04d566da_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ea79f477-e60c-4629-9ebd-d61f04d566da" xlink:to="loc_srt_ProductsAndServicesDomain_ea79f477-e60c-4629-9ebd-d61f04d566da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10ec0b90-0502-4e66-b717-0f7f53ca82e6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ea79f477-e60c-4629-9ebd-d61f04d566da" xlink:to="loc_srt_ProductsAndServicesDomain_10ec0b90-0502-4e66-b717-0f7f53ca82e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c93036fa-3c94-470e-9824-9cc8e23d06c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10ec0b90-0502-4e66-b717-0f7f53ca82e6" xlink:to="loc_us-gaap_ProductMember_c93036fa-3c94-470e-9824-9cc8e23d06c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended" id="iabd2bb82f82a4cee9451f2d10d70bca2_ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended" id="i366c32bef516462c8e28b23f6649f7ee_ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="extended" id="i3c5084980bcf41e3ab2d3e326920d46d_ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="extended" id="id4403fc392594ce5a44ff6ab2a8ad61b_CollaborationandLicenseAgreements"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended" id="ice8c2e4e588148a6a843fcd7fa2b88be_CollaborationandLicenseAgreementsTables"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails" xlink:type="extended" id="id4cba700270046b6909cc9058861cbf7_CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_0a690807-5d80-497c-a781-0c5d730db7b8" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_0a690807-5d80-497c-a781-0c5d730db7b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram_14aa0d3b-7d75-4341-bc1d-94c6753026a8" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram_14aa0d3b-7d75-4341-bc1d-94c6753026a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram_8209f560-9612-473c-8bce-6fa448608fdf" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram_8209f560-9612-473c-8bce-6fa448608fdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement_f19eab56-47a5-4639-a449-fde0eafaadb9" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement_f19eab56-47a5-4639-a449-fde0eafaadb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions_ff009787-26fc-4e86-b24f-8125c629549b" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions_ff009787-26fc-4e86-b24f-8125c629549b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions_79034d12-6464-4560-9354-1625e8393356" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions_79034d12-6464-4560-9354-1625e8393356" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm_18fa6d5c-7515-47a1-82b8-a75f95ef58b7" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm_18fa6d5c-7515-47a1-82b8-a75f95ef58b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_fc49fb07-2e5c-4868-848b-871a5718f098" xlink:href="agio-20200331.xsd#agio_UpfrontPaymentAgreementExtensionFeeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_fc49fb07-2e5c-4868-848b-871a5718f098" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OptionExerciseFeeReceivable_755025b0-ef74-41f7-9a36-40cf7a1df572" xlink:href="agio-20200331.xsd#agio_OptionExerciseFeeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_OptionExerciseFeeReceivable_755025b0-ef74-41f7-9a36-40cf7a1df572" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_d0083830-bcb2-4154-a793-bed171ddbdac" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_98939435-b1af-489b-aa67-4a0050a14139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:to="loc_us-gaap_TypeOfArrangementAxis_98939435-b1af-489b-aa67-4a0050a14139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98939435-b1af-489b-aa67-4a0050a14139_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_98939435-b1af-489b-aa67-4a0050a14139" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98939435-b1af-489b-aa67-4a0050a14139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_98939435-b1af-489b-aa67-4a0050a14139" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_d72fe1c2-8aae-4617-b09e-26f767aa203a" xlink:href="agio-20200331.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:to="loc_agio_Agreement2010Member_d72fe1c2-8aae-4617-b09e-26f767aa203a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MasterResearchAndCollaborationAgreementMember_3f1c1443-21ed-449b-b46f-b3cf53314bd7" xlink:href="agio-20200331.xsd#agio_MasterResearchAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:to="loc_agio_MasterResearchAndCollaborationAgreementMember_3f1c1443-21ed-449b-b46f-b3cf53314bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b988291f-083c-46f0-af72-a7b31e4fafeb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:to="loc_srt_CounterpartyNameAxis_b988291f-083c-46f0-af72-a7b31e4fafeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b988291f-083c-46f0-af72-a7b31e4fafeb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b988291f-083c-46f0-af72-a7b31e4fafeb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b988291f-083c-46f0-af72-a7b31e4fafeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb7974c3-c7f2-41d2-81c1-c260861c9ef3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b988291f-083c-46f0-af72-a7b31e4fafeb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb7974c3-c7f2-41d2-81c1-c260861c9ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_8179ab9d-4d4a-4188-b6da-d02ffe511f20" xlink:href="agio-20200331.xsd#agio_CelgeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb7974c3-c7f2-41d2-81c1-c260861c9ef3" xlink:to="loc_agio_CelgeneMember_8179ab9d-4d4a-4188-b6da-d02ffe511f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b6ed6ae-522d-4805-b249-79f168137991" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:to="loc_srt_RangeAxis_7b6ed6ae-522d-4805-b249-79f168137991" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b6ed6ae-522d-4805-b249-79f168137991_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b6ed6ae-522d-4805-b249-79f168137991" xlink:to="loc_srt_RangeMember_7b6ed6ae-522d-4805-b249-79f168137991_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f98278fd-00a4-422b-be34-373aba5e6514" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b6ed6ae-522d-4805-b249-79f168137991" xlink:to="loc_srt_RangeMember_f98278fd-00a4-422b-be34-373aba5e6514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_90e7cd89-d15e-48b6-89ca-f6b19f0ec88d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f98278fd-00a4-422b-be34-373aba5e6514" xlink:to="loc_srt_MaximumMember_90e7cd89-d15e-48b6-89ca-f6b19f0ec88d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCollaborationRevenueDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="extended" id="ia664461a2ebd4838af347b2ccaf408ae_CollaborationandLicenseAgreementsCollaborationRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5294c129-134d-479e-b040-59d7bfc217c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54b6b2c8-7e91-4dd0-a8fe-0ade37661f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5294c129-134d-479e-b040-59d7bfc217c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54b6b2c8-7e91-4dd0-a8fe-0ade37661f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c6a48a49-daa2-4baf-a6c8-db10fbc78a77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5294c129-134d-479e-b040-59d7bfc217c6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c6a48a49-daa2-4baf-a6c8-db10fbc78a77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c6a48a49-daa2-4baf-a6c8-db10fbc78a77" xlink:to="loc_srt_ProductOrServiceAxis_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83" xlink:to="loc_srt_ProductsAndServicesDomain_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83" xlink:to="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_611e0944-76bc-41d4-968b-83947e6d1e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_us-gaap_LicenseAndServiceMember_611e0944-76bc-41d4-968b-83947e6d1e26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchServicesMember_83147404-15b9-4095-a622-e5a4be67e76a" xlink:href="agio-20200331.xsd#agio_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_agio_ResearchServicesMember_83147404-15b9-4095-a622-e5a4be67e76a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CommercializationActivityMember_060b3ac1-716c-46ce-b773-ecaa5f5d702d" xlink:href="agio-20200331.xsd#agio_CommercializationActivityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_agio_CommercializationActivityMember_060b3ac1-716c-46ce-b773-ecaa5f5d702d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_7a0c5cb1-3c20-491d-a0e0-bad39fe7b3c5" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_7a0c5cb1-3c20-491d-a0e0-bad39fe7b3c5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i318f1a2bd235470483df906c3f89b22a_CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_46e0f30e-8971-4e65-823e-ccbfcfd56f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_46e0f30e-8971-4e65-823e-ccbfcfd56f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractwithCustomerAssetRevenueRecognized_07917041-61ad-40ea-9e52-aa5230f54496" xlink:href="agio-20200331.xsd#agio_ContractwithCustomerAssetRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:to="loc_agio_ContractwithCustomerAssetRevenueRecognized_07917041-61ad-40ea-9e52-aa5230f54496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_4dc57256-9c10-4249-aa34-bbc55a052a76" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_4dc57256-9c10-4249-aa34-bbc55a052a76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_59211b32-1c6d-4b83-b890-059ada914bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:to="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_02170498-024e-4b7c-a140-bef2fce2f309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:to="loc_us-gaap_ContractWithCustomerLiability_02170498-024e-4b7c-a140-bef2fce2f309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fe0f49c5-314c-47f4-8a1d-a0389e05b949" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fe0f49c5-314c-47f4-8a1d-a0389e05b949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_0394f537-d60d-4231-8347-1f83f6f14f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_0394f537-d60d-4231-8347-1f83f6f14f6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a1585877-2114-40d7-9292-af6d463058d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityTable_65125af6-2a6c-4db6-a529-ccb685dd3f1f" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityTable_65125af6-2a6c-4db6-a529-ccb685dd3f1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a6737603-33de-4892-855c-ce63fb1eb37d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable_65125af6-2a6c-4db6-a529-ccb685dd3f1f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a6737603-33de-4892-855c-ce63fb1eb37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a6737603-33de-4892-855c-ce63fb1eb37d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a6737603-33de-4892-855c-ce63fb1eb37d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a6737603-33de-4892-855c-ce63fb1eb37d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a6737603-33de-4892-855c-ce63fb1eb37d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_f12c5224-22b2-4dd3-a050-ba6496ef1d06" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:to="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_f12c5224-22b2-4dd3-a050-ba6496ef1d06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_d95ba119-1844-4964-ab87-9d74700a8f78" xlink:href="agio-20200331.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_d95ba119-1844-4964-ab87-9d74700a8f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredRevenueCurrentMember_b031050e-7f06-43bb-aa75-fe9e7184a230" xlink:href="agio-20200331.xsd#agio_DeferredRevenueCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:to="loc_agio_DeferredRevenueCurrentMember_b031050e-7f06-43bb-aa75-fe9e7184a230" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="extended" id="i462684e0129248cba76e9f51d569a1d5_CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="i3ab681bcd3f347e5bd0bbaa88d24c6ba_CollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ef706513-42d6-41c3-bbd2-e3375e83e717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ef706513-42d6-41c3-bbd2-e3375e83e717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_7ccfe1b4-2cc6-4d26-99c7-a65c9b445556" xlink:href="agio-20200331.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_7ccfe1b4-2cc6-4d26-99c7-a65c9b445556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_32c46594-f7dc-4c1d-92a0-9ea34ab0cd9b" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_32c46594-f7dc-4c1d-92a0-9ea34ab0cd9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dab12926-0a3a-4987-b04a-414832786d57" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:to="loc_srt_ProductOrServiceAxis_dab12926-0a3a-4987-b04a-414832786d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dab12926-0a3a-4987-b04a-414832786d57_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dab12926-0a3a-4987-b04a-414832786d57" xlink:to="loc_srt_ProductsAndServicesDomain_dab12926-0a3a-4987-b04a-414832786d57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dab12926-0a3a-4987-b04a-414832786d57" xlink:to="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_18b575fd-5d21-46a0-9b63-3db65e4b3e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:to="loc_us-gaap_RoyaltyMember_18b575fd-5d21-46a0-9b63-3db65e4b3e09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_6c23a82c-aa41-415a-82ab-4ff3a96d0a8e" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_6c23a82c-aa41-415a-82ab-4ff3a96d0a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5a2dc791-468b-4c37-baff-ab4fe6f204e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5a2dc791-468b-4c37-baff-ab4fe6f204e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a2dc791-468b-4c37-baff-ab4fe6f204e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5a2dc791-468b-4c37-baff-ab4fe6f204e2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a2dc791-468b-4c37-baff-ab4fe6f204e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5047658b-e292-49cc-9522-312a1127b609" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5a2dc791-468b-4c37-baff-ab4fe6f204e2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5047658b-e292-49cc-9522-312a1127b609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_d96eccc4-a239-4d62-a47e-a8ebc0e33839" xlink:href="agio-20200331.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5047658b-e292-49cc-9522-312a1127b609" xlink:to="loc_agio_Agreement2010Member_d96eccc4-a239-4d62-a47e-a8ebc0e33839" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="extended" id="id79a007054d64215aa87d866220a33ef_CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_535bc5a9-2f17-4576-bf1d-4ac81a175427" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_535bc5a9-2f17-4576-bf1d-4ac81a175427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_47a0f938-6a17-4524-8aef-6deafd4dbd83" xlink:href="agio-20200331.xsd#agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_47a0f938-6a17-4524-8aef-6deafd4dbd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyPercentageRemitted_2504dc5d-8b83-41e9-ae1e-38899e13e3e1" xlink:href="agio-20200331.xsd#agio_RoyaltyPercentageRemitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_RoyaltyPercentageRemitted_2504dc5d-8b83-41e9-ae1e-38899e13e3e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_dd691756-a9c3-4f37-b252-69151f3dea23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_dd691756-a9c3-4f37-b252-69151f3dea23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cb8436f-f722-4954-abae-82f0b7cb034e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cb8436f-f722-4954-abae-82f0b7cb034e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_9830dac5-f9c9-4d8f-b97a-b78596509de5" xlink:href="agio-20200331.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_9830dac5-f9c9-4d8f-b97a-b78596509de5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_9a4d7d64-4ae6-4841-91c9-3db57bc9c16d" xlink:href="agio-20200331.xsd#agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_21a5b7fc-a0ac-49df-93b8-667e1ab30878" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_srt_CounterpartyNameAxis_21a5b7fc-a0ac-49df-93b8-667e1ab30878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a5b7fc-a0ac-49df-93b8-667e1ab30878_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_21a5b7fc-a0ac-49df-93b8-667e1ab30878" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21a5b7fc-a0ac-49df-93b8-667e1ab30878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37fd76ea-4f7a-4c9a-8aa1-117b670cbdca" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_21a5b7fc-a0ac-49df-93b8-667e1ab30878" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37fd76ea-4f7a-4c9a-8aa1-117b670cbdca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStonePharmaceuticalsMember_7ea71e79-56f3-4e8d-924f-2447e93ff94d" xlink:href="agio-20200331.xsd#agio_CStonePharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37fd76ea-4f7a-4c9a-8aa1-117b670cbdca" xlink:to="loc_agio_CStonePharmaceuticalsMember_7ea71e79-56f3-4e8d-924f-2447e93ff94d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7b54d2-f31b-47c8-8630-e8f41a8b93e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7b54d2-f31b-47c8-8630-e8f41a8b93e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_267af13d-b277-47e2-847a-7d32339d602f" xlink:href="agio-20200331.xsd#agio_CStoneAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7b54d2-f31b-47c8-8630-e8f41a8b93e5" xlink:to="loc_agio_CStoneAgreementMember_267af13d-b277-47e2-847a-7d32339d602f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a8de7513-ac89-4f2c-b13c-fcc736073a08" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_srt_ProductOrServiceAxis_a8de7513-ac89-4f2c-b13c-fcc736073a08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8de7513-ac89-4f2c-b13c-fcc736073a08_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a8de7513-ac89-4f2c-b13c-fcc736073a08" xlink:to="loc_srt_ProductsAndServicesDomain_a8de7513-ac89-4f2c-b13c-fcc736073a08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a8de7513-ac89-4f2c-b13c-fcc736073a08" xlink:to="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_dfba0782-6481-4f50-ad72-d6fe15473d5c" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_dfba0782-6481-4f50-ad72-d6fe15473d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_1da1c4dd-59ad-4222-9514-f7c8594be5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:to="loc_us-gaap_RoyaltyMember_1da1c4dd-59ad-4222-9514-f7c8594be5a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2847cd6-0b48-4217-a82c-b217707b83db" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_srt_RangeAxis_e2847cd6-0b48-4217-a82c-b217707b83db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2847cd6-0b48-4217-a82c-b217707b83db_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e2847cd6-0b48-4217-a82c-b217707b83db" xlink:to="loc_srt_RangeMember_e2847cd6-0b48-4217-a82c-b217707b83db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e2847cd6-0b48-4217-a82c-b217707b83db" xlink:to="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_777aa1e3-19a2-494c-ba83-aea74507472a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:to="loc_srt_MinimumMember_777aa1e3-19a2-494c-ba83-aea74507472a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7047e866-c83a-48b9-8f62-f75642de3d4d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:to="loc_srt_MaximumMember_7047e866-c83a-48b9-8f62-f75642de3d4d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="extended" id="ibae18123528e46b5a8302d9b3a16b724_CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5820401c-97c5-46d1-bdb0-dbf02c786ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9558bfaf-18a3-4211-b799-d321166819b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5820401c-97c5-46d1-bdb0-dbf02c786ac7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9558bfaf-18a3-4211-b799-d321166819b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5820401c-97c5-46d1-bdb0-dbf02c786ac7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:to="loc_srt_ProductOrServiceAxis_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e" xlink:to="loc_srt_ProductsAndServicesDomain_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e" xlink:to="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_5a60f026-0eda-4cb0-8b6d-08d351c74db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:to="loc_us-gaap_LicenseAndServiceMember_5a60f026-0eda-4cb0-8b6d-08d351c74db5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_7c8d2d6a-08a3-4f17-af52-f20a6ece6550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:to="loc_us-gaap_ServiceOtherMember_7c8d2d6a-08a3-4f17-af52-f20a6ece6550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_10c30a59-1ac8-4b1c-863c-fcd80feb53f8" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:to="loc_agio_CollaborationRevenueOtherMember_10c30a59-1ac8-4b1c-863c-fcd80feb53f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_84a62826-c46c-4ec2-92f1-16eed67c9469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:to="loc_us-gaap_TypeOfArrangementAxis_84a62826-c46c-4ec2-92f1-16eed67c9469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84a62826-c46c-4ec2-92f1-16eed67c9469_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84a62826-c46c-4ec2-92f1-16eed67c9469" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84a62826-c46c-4ec2-92f1-16eed67c9469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7572aa62-ea14-492e-af83-62238635d1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84a62826-c46c-4ec2-92f1-16eed67c9469" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7572aa62-ea14-492e-af83-62238635d1f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_f2cdd600-f83b-4b0e-aa37-ea6d503b7b4b" xlink:href="agio-20200331.xsd#agio_CStoneAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7572aa62-ea14-492e-af83-62238635d1f0" xlink:to="loc_agio_CStoneAgreementMember_f2cdd600-f83b-4b0e-aa37-ea6d503b7b4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="extended" id="i06434ea84d4446bd8978c8d250506042_CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7e68584-1499-4fb2-aa47-a189595eebf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7e68584-1499-4fb2-aa47-a189595eebf0" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_fdd517a1-5d87-4a27-b075-a9d53df182c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_fdd517a1-5d87-4a27-b075-a9d53df182c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_0b4d3229-c904-4666-aea8-d5bfcea8c5f5" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_0b4d3229-c904-4666-aea8-d5bfcea8c5f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_fb64dee3-e290-4c3e-acb4-8122e8216ccb" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_fb64dee3-e290-4c3e-acb4-8122e8216ccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_4bbc8042-d1a1-46cf-a91e-785d5b4fd857" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7e68584-1499-4fb2-aa47-a189595eebf0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9af26a2b-9e86-4c36-8f8e-c15098d69844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9af26a2b-9e86-4c36-8f8e-c15098d69844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9af26a2b-9e86-4c36-8f8e-c15098d69844_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9af26a2b-9e86-4c36-8f8e-c15098d69844" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9af26a2b-9e86-4c36-8f8e-c15098d69844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7ef7654b-6d00-4fab-a993-341a146a341a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9af26a2b-9e86-4c36-8f8e-c15098d69844" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7ef7654b-6d00-4fab-a993-341a146a341a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_f11018b3-4177-4836-98a6-c93fce03311d" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7ef7654b-6d00-4fab-a993-341a146a341a" xlink:to="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_f11018b3-4177-4836-98a6-c93fce03311d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e7211ff-1406-493f-93d7-07d3ebf0569e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e7211ff-1406-493f-93d7-07d3ebf0569e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e7211ff-1406-493f-93d7-07d3ebf0569e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e7211ff-1406-493f-93d7-07d3ebf0569e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e7211ff-1406-493f-93d7-07d3ebf0569e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb5dfe7-ab58-4310-b9ad-fc1633dc5e69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e7211ff-1406-493f-93d7-07d3ebf0569e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb5dfe7-ab58-4310-b9ad-fc1633dc5e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_842343a5-fe5e-4a97-8c12-a1b456f23ac3" xlink:href="agio-20200331.xsd#agio_CStoneAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb5dfe7-ab58-4310-b9ad-fc1633dc5e69" xlink:to="loc_agio_CStoneAgreementMember_842343a5-fe5e-4a97-8c12-a1b456f23ac3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPayments"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended" id="icf6aeb12f2e546578186acd96aca9cbc_ShareBasedPayments"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended" id="i18d401734e05484dbf7b4fa2764eadc3_ShareBasedPaymentsTables"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended" id="ib30075bd4f6a4533a6074b81be7c9607_ShareBasedPaymentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a9635c52-bfb8-4ea2-af83-5ad5c5484a22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a9635c52-bfb8-4ea2-af83-5ad5c5484a22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_837fdce8-4afd-4400-aa5b-5446f375a4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_837fdce8-4afd-4400-aa5b-5446f375a4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0450fab8-9ad4-4f70-8837-1e31a9dddfbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0450fab8-9ad4-4f70-8837-1e31a9dddfbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1646e41-7211-4027-8366-936b9a046096" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1646e41-7211-4027-8366-936b9a046096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5cb1e903-b2c5-4a6e-9013-ba83830fddc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5cb1e903-b2c5-4a6e-9013-ba83830fddc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_71828391-b9b2-4b4b-9454-24e433038c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_71828391-b9b2-4b4b-9454-24e433038c9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_dbc3a8ab-4fae-4fb2-a192-ef9e679d8036" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_dbc3a8ab-4fae-4fb2-a192-ef9e679d8036" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fde287dc-843c-4838-9ad9-762199a771ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:to="loc_us-gaap_PlanNameAxis_fde287dc-843c-4838-9ad9-762199a771ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fde287dc-843c-4838-9ad9-762199a771ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fde287dc-843c-4838-9ad9-762199a771ba" xlink:to="loc_us-gaap_PlanNameDomain_fde287dc-843c-4838-9ad9-762199a771ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fde287dc-843c-4838-9ad9-762199a771ba" xlink:to="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_ccb3c504-9489-4a75-839d-5cffde9a9511" xlink:href="agio-20200331.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_ccb3c504-9489-4a75-839d-5cffde9a9511" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_2f60c83d-d277-4050-ae4d-1fb0f712191d" xlink:href="agio-20200331.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_2f60c83d-d277-4050-ae4d-1fb0f712191d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_18f286ef-a52f-4cee-93f3-8c5f93b245d8" xlink:href="agio-20200331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_18f286ef-a52f-4cee-93f3-8c5f93b245d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc76c103-163d-4e6e-a314-d83421e3497d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:to="loc_us-gaap_AwardTypeAxis_cc76c103-163d-4e6e-a314-d83421e3497d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc76c103-163d-4e6e-a314-d83421e3497d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc76c103-163d-4e6e-a314-d83421e3497d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc76c103-163d-4e6e-a314-d83421e3497d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc76c103-163d-4e6e-a314-d83421e3497d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d758d9f6-bfad-4640-b595-ef4b0a1bdd3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d758d9f6-bfad-4640-b595-ef4b0a1bdd3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember_855dc571-b817-40f8-89ae-dd0253e3e752" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember_855dc571-b817-40f8-89ae-dd0253e3e752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_b0a41cd1-9d3c-4930-891b-bdbf41fcec80" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_b0a41cd1-9d3c-4930-891b-bdbf41fcec80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_6321b52d-1f67-4ecf-89be-fb03d80d247d" xlink:href="agio-20200331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_agio_MarketBasedStockUnitsMember_6321b52d-1f67-4ecf-89be-fb03d80d247d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="extended" id="i44c2933a137646e69698b322a6e10e73_ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended" id="i3fe02d091bd84183aed6c33b79083077_ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f40a1c4a-67c0-4693-9d6f-b21a8e137ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f40a1c4a-67c0-4693-9d6f-b21a8e137ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06a4f7f8-e04a-4534-9fee-bca32e7f9a14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06a4f7f8-e04a-4534-9fee-bca32e7f9a14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6c72c39-820b-4af8-81f9-3984fc6c4263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6c72c39-820b-4af8-81f9-3984fc6c4263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5b3ce53a-4c31-46ea-bcc0-2b12be96187e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5b3ce53a-4c31-46ea-bcc0-2b12be96187e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0057a35c-d335-4115-bcfc-99eec5aeff56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3539cdc-39b5-479f-8865-eacacab58f25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3539cdc-39b5-479f-8865-eacacab58f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8009c5a9-5a25-4495-9e0e-c1a002217c11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8009c5a9-5a25-4495-9e0e-c1a002217c11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2c58b3de-6517-409e-8256-7a199b0b3725" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2c58b3de-6517-409e-8256-7a199b0b3725" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0606933c-cc6a-40db-811a-4f6b23172686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0606933c-cc6a-40db-811a-4f6b23172686" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_54852c55-d2ae-4870-939f-9af32a09f274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bee5043c-8ea2-4f9b-9e03-d5c86c8f18f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bee5043c-8ea2-4f9b-9e03-d5c86c8f18f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bc20bbb1-251c-4586-8b79-5ebdb20e9896" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bee5043c-8ea2-4f9b-9e03-d5c86c8f18f5" xlink:to="loc_us-gaap_AwardTypeAxis_bc20bbb1-251c-4586-8b79-5ebdb20e9896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc20bbb1-251c-4586-8b79-5ebdb20e9896_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bc20bbb1-251c-4586-8b79-5ebdb20e9896" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc20bbb1-251c-4586-8b79-5ebdb20e9896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec0ab0dc-fe9f-4d02-b82b-8b43d0c10dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bc20bbb1-251c-4586-8b79-5ebdb20e9896" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec0ab0dc-fe9f-4d02-b82b-8b43d0c10dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_45c86c96-6473-4681-8d0f-c689b014d5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec0ab0dc-fe9f-4d02-b82b-8b43d0c10dc7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_45c86c96-6473-4681-8d0f-c689b014d5f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended" id="iaa812f7ebe2d4fa583622c8c67fef650_ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c35f9c09-9f36-49fe-93fb-0811a39ed033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c35f9c09-9f36-49fe-93fb-0811a39ed033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c19e8a0d-4e7b-46b6-8a08-4f543238dd90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c19e8a0d-4e7b-46b6-8a08-4f543238dd90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2ca1919-35f1-46a9-9df0-74a589269a03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2ca1919-35f1-46a9-9df0-74a589269a03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee5a3aa8-009b-4816-8994-e71dc1db4ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_470664fc-fa6c-4b79-a295-e4df589546b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_470664fc-fa6c-4b79-a295-e4df589546b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cb3b10d1-ddc1-456a-a2d8-d4f3a82e5b65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cb3b10d1-ddc1-456a-a2d8-d4f3a82e5b65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be3b94c6-8f0d-4cdb-86cb-a75c0f163377" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be3b94c6-8f0d-4cdb-86cb-a75c0f163377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_359e5dc0-79b1-4972-9b4c-dd342759469e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14d097ca-cc40-4fb2-be91-46f4e6df4112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14d097ca-cc40-4fb2-be91-46f4e6df4112" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfdb4004-5f25-45e4-a8ad-b15544578eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14d097ca-cc40-4fb2-be91-46f4e6df4112" xlink:to="loc_us-gaap_AwardTypeAxis_bfdb4004-5f25-45e4-a8ad-b15544578eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfdb4004-5f25-45e4-a8ad-b15544578eb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bfdb4004-5f25-45e4-a8ad-b15544578eb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfdb4004-5f25-45e4-a8ad-b15544578eb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bfdb4004-5f25-45e4-a8ad-b15544578eb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_452191af-d087-4a14-b1f2-7f064e62ccdb" xlink:href="agio-20200331.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:to="loc_agio_PerformanceBasedStockUnitMember_452191af-d087-4a14-b1f2-7f064e62ccdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_923a189b-cb15-467b-a162-ad5348bba4be" xlink:href="agio-20200331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:to="loc_agio_MarketBasedStockUnitsMember_923a189b-cb15-467b-a162-ad5348bba4be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended" id="i1b264a72f14449ca9443d3738785d422_ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccb00860-6aa2-4837-a0e3-4901038d94d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3115b-22cc-4b22-a5ae-6ec784a1bdb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccb00860-6aa2-4837-a0e3-4901038d94d9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3115b-22cc-4b22-a5ae-6ec784a1bdb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e97087-f639-48af-8620-8d0abc537d05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccb00860-6aa2-4837-a0e3-4901038d94d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e97087-f639-48af-8620-8d0abc537d05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e97087-f639-48af-8620-8d0abc537d05" xlink:to="loc_us-gaap_AwardTypeAxis_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5b7b3d47-8490-496b-95d4-5edffea3e533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5b7b3d47-8490-496b-95d4-5edffea3e533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b566ef5a-4958-4ff4-8f11-614519b0a596" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b566ef5a-4958-4ff4-8f11-614519b0a596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_809e21b9-bdff-48be-a99e-ba24c1f17a91" xlink:href="agio-20200331.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_agio_PerformanceBasedStockUnitMember_809e21b9-bdff-48be-a99e-ba24c1f17a91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_574daae5-36a7-41a2-9f1a-11814d614ad0" xlink:href="agio-20200331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_574daae5-36a7-41a2-9f1a-11814d614ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember_774bea0f-339a-47f2-a6d8-df38109c6d1a" xlink:href="agio-20200331.xsd#agio_OtherStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_agio_OtherStockAwardsMember_774bea0f-339a-47f2-a6d8-df38109c6d1a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended" id="i010c63955a6c47cba6b19f10a7f68128_ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ff8b8-f3b0-4c26-a630-f0204562a3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa9622c5-7f79-4b75-a093-808f5ef017d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ff8b8-f3b0-4c26-a630-f0204562a3a0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa9622c5-7f79-4b75-a093-808f5ef017d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62d31ed3-ab1b-4813-ad84-7e3ac066b78e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ff8b8-f3b0-4c26-a630-f0204562a3a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62d31ed3-ab1b-4813-ad84-7e3ac066b78e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2381896-14d0-48c1-a637-f7f1b2fe8216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62d31ed3-ab1b-4813-ad84-7e3ac066b78e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2381896-14d0-48c1-a637-f7f1b2fe8216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2381896-14d0-48c1-a637-f7f1b2fe8216_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2381896-14d0-48c1-a637-f7f1b2fe8216" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2381896-14d0-48c1-a637-f7f1b2fe8216_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2381896-14d0-48c1-a637-f7f1b2fe8216" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bf7f2d4c-a84c-4c5d-89ee-b2e47a0db6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bf7f2d4c-a84c-4c5d-89ee-b2e47a0db6ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a070d564-028d-4cc2-b2f6-e9261a6e5b08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a070d564-028d-4cc2-b2f6-e9261a6e5b08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShare" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShare"/>
  <link:definitionLink xlink:role="http://agios.com/role/LossperShare" xlink:type="extended" id="i8d5db82be2c749868411b48ec5daf72b_LossperShare"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareTables" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShareTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/LossperShareTables" xlink:type="extended" id="if65830c5c1a1498a8b502b3d5ac0f1d6_LossperShareTables"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i8997ddb3daea4526a60d5fe3520e7cb7_LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2397fe9a-31c4-48a6-bc87-9297bc77a298" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1125f626-e920-4e0a-b31a-287a7317a40f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2397fe9a-31c4-48a6-bc87-9297bc77a298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1125f626-e920-4e0a-b31a-287a7317a40f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52423c35-1cbc-4eed-bcc0-957ed395c2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2397fe9a-31c4-48a6-bc87-9297bc77a298" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52423c35-1cbc-4eed-bcc0-957ed395c2c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02296a16-2f98-40b2-817e-a2656f5f9362" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52423c35-1cbc-4eed-bcc0-957ed395c2c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02296a16-2f98-40b2-817e-a2656f5f9362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02296a16-2f98-40b2-817e-a2656f5f9362_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02296a16-2f98-40b2-817e-a2656f5f9362" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02296a16-2f98-40b2-817e-a2656f5f9362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02296a16-2f98-40b2-817e-a2656f5f9362" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b4ef12b-cf14-48ef-8c58-2da86d8b3f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b4ef12b-cf14-48ef-8c58-2da86d8b3f1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4b8b9d39-5ea1-4972-9008-36bfbc5266ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4b8b9d39-5ea1-4972-9008-36bfbc5266ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_4515764e-75f5-4717-8593-376bafb8112d" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_agio_PerformanceStockUnitMember_4515764e-75f5-4717-8593-376bafb8112d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_3a440c98-63d0-4d69-9630-c3b8f65c72bb" xlink:href="agio-20200331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_agio_EmployeePurchasePlanMember_3a440c98-63d0-4d69-9630-c3b8f65c72bb" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>agio-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a02d1e66-dea3-48df-83b5-cb17f8e40104,g:f4811f45-5f64-498d-9bc7-c730ea92ab47-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_c9d0581a-eeba-41bb-bebf-00581c2ff5d0_terseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue &#8211; related party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_label_en-US" xlink:label="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability, Related Party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_documentation_en-US" xlink:label="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:to="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram_6a4bc45d-d827-48c4-ab6d-d4db025491b0_terseLabel_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment upon achievement of a specified commercial milestone event</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram_label_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" xlink:to="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f3645c5b-5697-4610-bc8d-edb1f0513443_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1141804-9d34-4137-b3c1-8d4952f52382_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c43f372-b422-40ec-a58c-6ac7a0385551_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_17bcbf61-eb07-4d5d-b854-d3e5243e6eed_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts included in the contract liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9067f023-b422-4b2e-9f69-f7ac5f2dd5c3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_1e67a10c-b933-4096-ad66-11f87921d89e_terseLabel_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable &#8211; related party</link:label>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_label_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoyaltyReceivableDuefromRelatedPartiesCurrentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:href="agio-20200331.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:to="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d955a10f-ec4d-42ee-8a34-64f6c00d1baa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386da332-9407-4303-8862-b97bc3102908_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fe2e1335-909f-45e0-b28f-abed455e5c63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3c209dab-90ea-4d9b-80c8-5eaccca838bb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant and Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_b77276c8-9e45-47a7-8b84-fd129082e989_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_13a184a0-b9ad-4e4d-9808-2a00a3828f95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fc08ef50-dd91-4774-ba95-9870e9eae689_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent_a9fcb5e9-588b-47ad-859e-f2b3d9b8f2f3_negatedTerseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; other</link:label>
    <link:label id="lab_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent_label_en-US" xlink:label="lab_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseinCollaborationReceivableOtherCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent" xlink:to="lab_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_24021e09-8454-44d0-8123-00f221898b79_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_94e58800-9f95-4cdd-b87e-4902f44678de_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c444568d-76d3-4406-b214-a616cf9ab1ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9fe0a266-8deb-45b6-a3f9-d87284de7386_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_96bc39ce-660b-4cad-9600-540e584395bc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_Agreement2010Member_e84896a1-3f13-4ef5-916c-08202140d56f_terseLabel_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Agreement</link:label>
    <link:label id="lab_agio_Agreement2010Member_label_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement2010Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member" xlink:href="agio-20200331.xsd#agio_Agreement2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_Agreement2010Member" xlink:to="lab_agio_Agreement2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_b82132a9-141e-4f5e-b887-99a65ea83872_terseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; related party</link:label>
    <link:label id="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_label_en-US" xlink:label="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborationReceivableDuefromRelatedPartiesCurrentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:to="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ade013f0-cbb1-4b53-9f95-e45d228482d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_0c7f4d92-2497-4aa4-bac6-18145d24defd_terseLabel_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Plan and 2013 Plan</link:label>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:href="agio-20200331.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32fde7e5-91f3-4ff8-bc64-511df99a848e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4e8919cb-2591-451e-b3ec-3d6c5b722051_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_828c8f66-dbd1-4128-9dad-16598a4f21bf_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_4ecfd38b-3d05-4e42-b3e4-17783f6976bb_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70cadb46-5b64-4023-8d1c-1d80f77f99cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b2caa8ce-bd3f-4888-a0ac-21c19d9efff8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d498b334-e306-4ea0-9df3-5367cf90b987_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_85d7e145-1906-4d5e-b0ed-6579851f1d80_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cbf6adf7-1cc5-4bbf-80b8-3a9ac4500c9a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_15889775-a264-4326-80bb-b78201872ada_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_OtherStockAwardsMember_dc62f532-7847-4142-900c-dd319033a75e_terseLabel_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Awards</link:label>
    <link:label id="lab_agio_OtherStockAwardsMember_label_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Awards [Member]</link:label>
    <link:label id="lab_agio_OtherStockAwardsMember_documentation_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember" xlink:href="agio-20200331.xsd#agio_OtherStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_OtherStockAwardsMember" xlink:to="lab_agio_OtherStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c81067b7-6bb5-4c70-8a4d-697983e1c995_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_72929686-3739-4b1f-adaa-f69b953126ce_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_08415c2c-c198-4efe-b05d-706c1ce9f4a8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining operating lease assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_05374db4-801c-4b22-96b8-c1a8effe52bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CStoneAgreementMember_fa44dad1-74d3-4f2a-9bf9-09bbfd93ae68_terseLabel_en-US" xlink:label="lab_agio_CStoneAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStone Agreement</link:label>
    <link:label id="lab_agio_CStoneAgreementMember_label_en-US" xlink:label="lab_agio_CStoneAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStoneAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember" xlink:href="agio-20200331.xsd#agio_CStoneAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CStoneAgreementMember" xlink:to="lab_agio_CStoneAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7562e0f9-b9aa-4978-bc21-47d6eae87334_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unsatisfied performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_8f705f44-32d5-496c-b268-34c1b9b8e468_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue-related reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_label_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Total Allowances And Reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:to="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_675f9486-c390-4e61-b2ba-44da45c8b0e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DeferredRevenueCurrentMember_d25267c0-4b1d-4c4d-853c-de1ed61bd3a0_terseLabel_en-US" xlink:label="lab_agio_DeferredRevenueCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue &#8211; related party, current and net of current portions</link:label>
    <link:label id="lab_agio_DeferredRevenueCurrentMember_label_en-US" xlink:label="lab_agio_DeferredRevenueCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DeferredRevenueCurrentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredRevenueCurrentMember" xlink:href="agio-20200331.xsd#agio_DeferredRevenueCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DeferredRevenueCurrentMember" xlink:to="lab_agio_DeferredRevenueCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ef64ffb5-a62a-4847-8cc5-3f0acd0a39b2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_015d6835-27ec-4180-9c7e-4c646dcdeec5_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing transactions</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_94500021-e1d3-4fa6-8bbd-e15522f480aa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion &#8211; related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdf502a3-0df8-4189-8eda-948f80fb4f10_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da0a9763-b709-42c8-b59a-95fbffa11f0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1717b124-f900-4b0e-b1e4-22ee780fb987_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a787dc24-9563-4dde-a44a-7e818ea8a7fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_07e01c36-ac82-4e3b-84de-f2d4fa1907ae_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities arising from obtaining financing lease assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions_313da76f-d8e5-4f68-88bb-5586cfd1df67_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of allowable special case extensions</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:to="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_7eee9518-352e-44c7-97af-8dcdcfa8e6bf_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Current Year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:href="agio-20200331.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:to="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f3f22c78-c3eb-46a1-ae55-656909f4383f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems_5b852073-362a-4156-9cd0-687c58fdf83c_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability [Line Items]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions_ef9641fe-7268-49aa-bbce-d79f0ba58bb5_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" xlink:to="lab_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304eff96-439f-48f7-83c3-5a8f913fd3ce_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8ada8e55-7af7-4206-8ae3-320abfa8a38e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_81e699ad-2495-4414-b450-65f1d7a41d6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance-Based Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cd5b3dd3-7d9e-4559-ade1-800ed8532c36_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dd98b760-8c1f-4d65-ad1c-6c1520e255ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_640c384c-64e4-4f6d-ac68-74a2a70e6356_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseInOperatingLeaseLiability_ef1299cc-2f6c-4416-ae7c-f347e05c2ea2_terseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_47db9150-32c9-440d-9a57-582bd1c67f01_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_GovernmentRebatesRollForward_1f36ea66-6ed3-4bf9-8bc6-e8754ed2b18b_terseLabel_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates [Roll Forward]</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_label_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates [Roll Forward]</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_documentation_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward" xlink:href="agio-20200331.xsd#agio_GovernmentRebatesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_GovernmentRebatesRollForward" xlink:to="lab_agio_GovernmentRebatesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b956bec0-8d8c-49a9-bde6-920ab366b1bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6e3e4f97-5a0b-470f-82b9-dcd9b7de501d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33441444-98a9-4a14-a51f-de04908787da_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d540f98-8cbe-4eaf-8af7-1ff764bc618f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_078367ab-e172-4e28-8f3d-ad60e1c55620_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_714efd22-ddfe-4a82-b4c5-f515c5c66deb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1a25f81a-4707-4e9c-9dca-22caaf8094a4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bec33568-49e5-4ef2-8682-b902ac609c65_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7446aed2-0a86-4886-bc8a-7fe377094e97_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_99ade1a6-55bc-4293-9cf2-c9481b6e02e8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_925d70fe-f526-4182-841c-d016e97f61bb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_001463dd-1e00-4f14-aa57-4b099e20d65d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52c7b527-19a6-4319-978c-ba50f3924904_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_0b588a90-e94f-4e40-816d-8b0495d7b3e5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_464c5566-09a6-495f-aa02-b3eb9b72ad6f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5c08b1ea-0e46-49fb-9e2f-a93f3ae5c365_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b6840650-1bb6-4576-9c04-04e1d14cb698_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_OperatingLeaseRightOfUseAssetAmortization_82326ea2-bea1-4d79-95b3-2d4562c12da4_terseLabel_en-US" xlink:label="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_agio_OperatingLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:label id="lab_agio_OperatingLeaseRightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:href="agio-20200331.xsd#agio_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm_d26a2f42-0b64-4006-9c1c-f572b91f9a77_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special case extension term</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" xlink:to="lab_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eff15dc9-8bea-4c5b-89a7-4149ca90993b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3919e57b-b457-45ad-96c1-352fe138b6cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ead2804b-61e4-47bc-acfe-d014a60e1c8b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_848937f9-11ad-46a4-89c5-f78c3f11609f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_364e863e-2a57-4ce8-ac52-3ee163cab127_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_19b03abe-2163-4246-926b-31965d498258_terseLabel_en-US" xlink:label="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones achieved</link:label>
    <link:label id="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_label_en-US" xlink:label="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Revenue Recognized</link:label>
    <link:label id="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_documentation_en-US" xlink:label="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:href="agio-20200331.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:to="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_36a62cbe-d991-4d42-a665-185aaf1f34cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_95404be6-f267-4249-ba89-399c4ec3a2f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense for options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_bdc2f479-125b-4bf4-8a06-84c29685d3a1_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractWithCustomerAssetProceedsFromCollectionOfReceivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:to="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_cb382217-091a-4019-87c2-fb8684223596_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CStonePharmaceuticalsMember_a46475e4-b400-4848-86e6-e3851ac15433_terseLabel_en-US" xlink:label="lab_agio_CStonePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStone Pharmaceuticals</link:label>
    <link:label id="lab_agio_CStonePharmaceuticalsMember_label_en-US" xlink:label="lab_agio_CStonePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStonePharmaceuticalsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStonePharmaceuticalsMember" xlink:href="agio-20200331.xsd#agio_CStonePharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CStonePharmaceuticalsMember" xlink:to="lab_agio_CStonePharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_31729acb-b27c-4af7-811f-614504702c15_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5d53a9a1-5229-4719-a827-0d1815eb6d9c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_2e15786f-a0db-4818-bc62-e170c65f8518_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b7460cbc-1cb7-45b3-bf85-a45dd9182bb1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_3fe38709-8f47-42e2-a815-2ad20dcaf065_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_label_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Allowance And Reserves, Liability</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:to="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_725616be-2b92-4cb0-8c50-6ee299249c37_terseLabel_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_label_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:href="agio-20200331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:to="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7781417b-34f5-436e-a0de-259f710ca01b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted minimum rental commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2900d7e5-a716-4292-bd2a-4df35edd3369_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_40c8c375-27b5-4a44-a016-afb41fa7dc09_terseLabel_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable &#8211; related party</link:label>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoyaltyReceivableDuefromRelatedPartiesCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:href="agio-20200331.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:to="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_644d7014-ba00-4826-bb8a-160e541fc661_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8d4eb1b4-2585-478e-9f1b-58e763426c5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f99b606c-4d81-40aa-85ac-45e6527b454f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_20228748-746c-414c-9c6c-a36340594735_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone-based receivable payments, eligible to be received</link:label>
    <link:label id="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_label_en-US" xlink:label="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueRecognitionMilestoneMethodEligibleReceivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:to="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_3b752c7e-cd9e-41de-9c31-fed0a5bede85_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Revenue Recognized</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:to="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e1dd35e1-4d0b-4ff8-94c3-b4c19ea37d4f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92bd9914-085c-4ff8-868d-a3f4fa07a486_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f378bcde-43be-487a-aa75-57138fe3c6b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_439085cf-88f7-4452-9e47-58ba1e232960_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8b1e502a-60b3-4b45-8fa6-ec0e16f8083f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6e01497f-dd3f-4301-8373-fdd8afac33c8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_9da73b7b-9697-4dcc-8e78-76bb80c07fe6_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a981668f-0d83-4b19-8fff-82b9eba6b0a3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3cc0e270-ca75-4dbc-a99e-9fee080ddbbd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_be011a07-d64f-48f1-b182-811e947ba5f6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7d71d778-b4b0-479b-90a0-ead845d4dfdc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractwithCustomerAssetRevenueRecognized_a9c593ad-2e74-41d0-9095-b44bdc950c64_terseLabel_en-US" xlink:label="lab_agio_ContractwithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_agio_ContractwithCustomerAssetRevenueRecognized_label_en-US" xlink:label="lab_agio_ContractwithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractwithCustomerAssetRevenueRecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractwithCustomerAssetRevenueRecognized" xlink:href="agio-20200331.xsd#agio_ContractwithCustomerAssetRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractwithCustomerAssetRevenueRecognized" xlink:to="lab_agio_ContractwithCustomerAssetRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_53a25e8d-7ce7-4850-971d-02594f850784_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_089223ae-1406-46a8-9cb3-3dd8a9c11f0b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_2c583e6c-bff3-4f21-864f-fe36bface8ce_terseLabel_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_label_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:to="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_a9c5e31b-3eaa-45ca-a7b4-c23b3078197d_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CelgeneMember_cf8b269c-0e35-406f-8e63-acd20151aff4_terseLabel_en-US" xlink:label="lab_agio_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene</link:label>
    <link:label id="lab_agio_CelgeneMember_label_en-US" xlink:label="lab_agio_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CelgeneMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember" xlink:href="agio-20200331.xsd#agio_CelgeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CelgeneMember" xlink:to="lab_agio_CelgeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_750efb0a-b715-4975-80a7-896ce9ce8564_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9f2edcb7-9dfd-4d46-93ca-dcec0345ca1b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_be86da21-b691-4542-a994-98a9b8e9d440_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_dad3d50e-3390-4268-9f64-e922e8547b0c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_245e3cd4-bc11-42fb-aff2-4976667bcde3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_bb3ac02c-7dbe-42e9-8401-c1f2f42591d0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1ac92f77-cda7-413a-9bb5-580caab3152f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7323f0c3-de1e-426e-b930-c405dcb0ebfa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b3950a0f-7eae-4858-bbfc-a023da1003b0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_bc887435-e3eb-47ec-af3a-332d494df827_terseLabel_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs</link:label>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AccruedResearchAndDevelopmentCostsCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="agio-20200331.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_39bc4319-6e31-4882-b952-06d33c05204a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_7a0a78c1-017e-4e1d-881e-2bc39919ee41_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_29ea8041-9ba2-482c-9d9d-07fdf6c3a7d6_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Right To Recover Product, Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1bd073b0-d19c-4f61-9391-f8fab51f9ea5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_110af43f-0e0f-4627-904b-ab6de5a76641_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_6c218fe8-43f2-4f0c-ba5f-ae2b6c204a79_terseLabel_en-US" xlink:label="lab_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_label_en-US" xlink:label="lab_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" xlink:href="agio-20200331.xsd#agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" xlink:to="lab_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ResearchServicesMember_ab4e68d0-10bd-4421-9d27-20056793abf1_terseLabel_en-US" xlink:label="lab_agio_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On-going research and development services</link:label>
    <link:label id="lab_agio_ResearchServicesMember_label_en-US" xlink:label="lab_agio_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ResearchServicesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchServicesMember" xlink:href="agio-20200331.xsd#agio_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ResearchServicesMember" xlink:to="lab_agio_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_33c51475-614a-4285-8d0b-09b8777f25cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7b14d5f3-7939-45c9-8abc-dd0ca0d1ac2d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_26dd5d79-3e5a-40e3-a1fa-9459a5cc7a71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_105f73ec-d132-4f47-9444-a7fb3037af51_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceStockUnitMember_a1a0e6c5-1a88-438e-905a-436daf4e67b5_verboseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock units</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_label_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PerformanceStockUnitMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceStockUnitMember" xlink:to="lab_agio_PerformanceStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_fa652c38-08c5-4325-880a-5a3917cdbb1f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e2ddf25d-8774-4767-b3e6-6906d5e09069_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_48525998-0d15-414c-bbf9-f012143bed7e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_69048f11-c70e-427d-ba38-a1727bee12de_terseLabel_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Stock Incentive Plan</link:label>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandAndThirteenStockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:href="agio-20200331.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_99a31a30-abd1-4402-8e3c-af039f8066ee_terseLabel_en-US" xlink:label="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Revenue</link:label>
    <link:label id="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_label_en-US" xlink:label="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From External Customers, Royalty Revenue [Table Text Block]</link:label>
    <link:label id="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_documentation_en-US" xlink:label="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:href="agio-20200331.xsd#agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:to="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_74559b3d-18c1-4c4e-ab73-d1f95cab20e1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_263f70f1-f766-4480-818a-760b5bac7525_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ced83e64-f9ad-4688-b5b1-86b989ec6e65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_c20a83f3-277f-40f2-ae5b-b34a41b3f5a4_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a767a7c8-17ab-4b6d-9407-ad5725a05756_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b044f008-7141-4c13-aae8-3d178bb741d4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_61e26c9d-dbb8-4ea0-9c83-526dd5da7373_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Excluded from Calculation of Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_713e02a9-604e-4dd0-a925-456e781bba4d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_56660e46-77ae-4deb-a2e0-f0980c6005d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_84b4e0dd-6ee1-4a43-b1a9-653de62cd58a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_13438b5e-bd6a-42ba-853b-c47b85a9488e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d65c4fb4-924e-4b09-ad1d-a0e71d62c255_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c7a15ffa-2a5f-4916-a769-992f88736926_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9eeb6d4b-98d9-4426-b5b9-3ad67682aaf9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8edcb92c-6574-479d-8229-99a6c605a7af_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c64f3103-320b-447b-b6c0-5cc3a7767f09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_981a2987-1302-4c49-b84e-45a50144491d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9fbb2331-2fdf-4192-a159-1b87248185df_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_dfe4eb45-4a7d-4e0a-93b8-afaa9f39f0f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_cbd48f86-f2ac-4e86-ad2e-4951d2add9c3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ae56eafc-6a70-4c26-bf72-d5ce5bad7b52_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_d5635df1-3858-4e7a-95af-8d909ebbab3d_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial payment received</link:label>
    <link:label id="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_label_en-US" xlink:label="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase From Cash Receipts</link:label>
    <link:label id="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:to="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_827f0366-b5b1-47a4-9b4f-cf215b3b7597_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2361b3c9-f6c3-49fd-b4bf-def85407fee8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a56117e0-7dad-4002-a701-73136a28a748_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_26c16cff-2d3d-476c-be1c-2ce6031ae8ff_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets and Liabilities, Product Revenue</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_baf24b19-e535-4be3-9011-c35026327bb4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1520cdd0-1239-4202-a2ea-7c68b9d5ff6f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9da3add5-0be2-4a16-bdc4-f2b9297d929f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_48d16890-c633-4198-95e1-c92af2dbed0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue Allowance and Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_0fbe144b-428a-4ee5-95ba-75404852214c_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4399bce1-4fb3-4888-ade2-c8071b9efcf7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911c269e-e26a-4839-9abf-0973b8c8a187_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8bdf26fa-1b79-4d22-94b0-1befc8dc77dd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_d18ae23e-2632-4316-b1a9-dff2066ec565_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_7f453e2c-f7e3-4973-b2f2-60d897759493_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other services</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cdb858c7-2964-4de7-9232-7f30d548103f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_a06db1b5-1376-4452-894b-0ea2003e3320_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Six</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_65e0aef4-7f5c-4e67-846d-a28a15edf813_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cf6a0b4b-f687-4b33-b546-042c7fcffa7c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_2f3c5b22-2d98-40e5-9f7b-85461f14a61c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_34615dbc-547e-45dd-98e0-558b68ef6f63_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_29ee829f-e38b-4786-8468-d791cfef3269_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_9c844261-6a84-4a7b-b1e7-72e8ff24cc21_terseLabel_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_label_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units [Member]</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_documentation_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember" xlink:href="agio-20200331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_MarketBasedStockUnitsMember" xlink:to="lab_agio_MarketBasedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_295ff3dd-247d-41c2-b9be-f9af88593826_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a4d44ea2-608d-4577-abca-5ff65420e153_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_91216ca5-b552-4a98-9320-3663ec01a69d_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract adjustments, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_a34194e9-d5b4-40b7-91a5-a2a17dcf44d4_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract adjustments, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contractual Adjustment Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:to="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_517fecae-8690-4096-b764-99f9691e8ce9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ba6ec133-a003-4c4b-89ea-e5f43ba7a564_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7419ce83-0df8-4691-9643-9e60ff2d4492_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_fbca4a9d-669b-463c-a4e8-7ee35b97ca6e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5eccac3-eeca-49c4-b82b-078b5c34e0fd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_264af9a8-de77-45ea-9c19-8e19198ff83d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_108dc0c8-6b6a-4c16-8823-392ad7322091_terseLabel_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Roll Forward]</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_label_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Roll Forward]</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_documentation_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward" xlink:href="agio-20200331.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractualAdjustmentsRollForward" xlink:to="lab_agio_ContractualAdjustmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_124e6474-93b8-49aa-abf3-dcb1a4f90d42_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b7052d94-2cd2-4fb2-bd40-1a86b1e94d0d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_05a83a0d-2bc8-4624-9e0c-9d64a36b0e41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5a617b0f-47a8-43c0-a632-e3486d9cf287_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under 2013 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_56beb833-f3d0-4b88-8ad5-ee668dd59fbb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4817e8e0-c84e-4a26-acfd-6c23507dfe55_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_af2c553c-c36f-4688-b023-a2e5d28ea170_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember_5eefe2aa-1fac-4dd6-a27c-6c0c9277974c_terseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Probable of Meeting Vesting Criteria</link:label>
    <link:label id="lab_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember_label_en-US" xlink:label="lab_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Probable Of Meeting Vesting Criteria [Member]</link:label>
    <link:label id="lab_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember_documentation_en-US" xlink:label="lab_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Probable Of Meeting Vesting Criteria</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" xlink:to="lab_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b47bac8f-957f-4a2d-b40a-9a55dba15cae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Minimum Rental Commitments Under Uncancelable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcf95695-82df-4f56-8540-80510270eaab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e8cdbfee-e5c1-4a8f-ac12-d9d31a2abadd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4040d31b-9f42-4a99-9590-b4b5f1e8da85_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_29896fae-da1a-42af-beec-8fb6b06e5fbb_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, adjustments relating to prior year</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:href="agio-20200331.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:to="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_9651d9b1-7e90-45ce-af32-9acd77e606c0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e660b2fb-efa4-4c58-bf88-15fd72bba263_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d6139c13-d59a-4928-8425-be5b8808bbca_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3c2b32ab-8dcb-4d89-b9a3-979744311848_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f8d4bb87-d914-4b7f-ae04-98772d703614_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_4963e6e9-6ba3-4ece-9c35-b80d05cf900d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_3280aa97-3f1f-4eb7-939e-5d73f8628f49_terseLabel_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue &#8211; other</link:label>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_label_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, Other [Member]</link:label>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_documentation_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationRevenueOtherMember" xlink:to="lab_agio_CollaborationRevenueOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_9ae79476-e2da-4f5c-a3e9-d9237659fb0e_totalLabel_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CashEquivalentsAndAvailableForSaleSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="agio-20200331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6a6070b5-d6f9-40ff-9079-91746e1139cb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3b841e6a-ae70-4e61-824c-20d6380763fc_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9e6dd82f-5b49-4199-a80e-eeaf1218d336_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_0eadf134-48ed-4231-8556-1021426dc904_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b26afbb8-f2f4-4815-a79d-6c8c1eeea158_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_05457cfa-0d97-4c00-b789-41a8179593ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_418469c9-cb79-4211-9ac3-11acba5365f5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dac87f00-416c-4cb9-be44-98d459864345_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_5a1f2309-766a-44d4-9191-a71228709955_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_efb47725-fd98-4415-8237-66913b76798c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cc15020a-2036-445b-af96-334321ba90dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18c11caa-5f6b-4dff-840d-f66205f97c9c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_47d410a4-6310-444e-9368-afd545cabb88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9520c033-9cf7-4061-9a51-ecc3f15c3b44_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6f08a2fb-2817-4a08-adb6-6d8a7f13c9ca_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CommercializationActivityMember_b53e7770-5fc3-4e32-a134-6541484054dd_terseLabel_en-US" xlink:label="lab_agio_CommercializationActivityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization activities</link:label>
    <link:label id="lab_agio_CommercializationActivityMember_label_en-US" xlink:label="lab_agio_CommercializationActivityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Activity [Member]</link:label>
    <link:label id="lab_agio_CommercializationActivityMember_documentation_en-US" xlink:label="lab_agio_CommercializationActivityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CommercializationActivityMember" xlink:href="agio-20200331.xsd#agio_CommercializationActivityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CommercializationActivityMember" xlink:to="lab_agio_CommercializationActivityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4e90f72b-f112-449e-9e04-7a17dc71c476_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_24a5cde6-3cd2-4c2a-b3a1-8a78282d0a85_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8310ad25-419a-491f-b902-68499bda25ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a89aff10-33fd-417f-a329-6e4d8a956b43_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_7a6d94fb-25e8-4ab1-b89b-47b7442c6902_terseLabel_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue &#8211; related party</link:label>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_label_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, Related Party [Member]</link:label>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_documentation_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationRevenueRelatedPartyMember" xlink:to="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_61cc6f4f-d2d9-4ffd-b912-df2ca5413c10_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5ae7c4b7-b614-4cb3-8c61-86d1a4341344_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_701538ae-2161-42e3-ac79-eb71c5184aab_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0a341bb1-cc1a-42b6-b334-50a35546a001_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_41bd9701-6229-4890-bd7c-2cbea059fb05_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_019328db-c323-4eaa-9ae6-018357d1518c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_90b999fc-f69e-4955-913a-f51b786a8f3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_e65e8c33-82fe-454d-b09d-2649cfa806af_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:href="agio-20200331.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:to="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_MasterResearchAndCollaborationAgreementMember_83a9e24d-685d-4c84-ae46-769279d17e0f_terseLabel_en-US" xlink:label="lab_agio_MasterResearchAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Agreement</link:label>
    <link:label id="lab_agio_MasterResearchAndCollaborationAgreementMember_label_en-US" xlink:label="lab_agio_MasterResearchAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MasterResearchAndCollaborationAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MasterResearchAndCollaborationAgreementMember" xlink:href="agio-20200331.xsd#agio_MasterResearchAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_MasterResearchAndCollaborationAgreementMember" xlink:to="lab_agio_MasterResearchAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_865ff437-73e4-4ee4-bc1c-e77603510cf2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_6927bb55-0e93-4458-958b-b1d701ec2a69_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve" xlink:href="agio-20200331.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionsForRebateReserve" xlink:to="lab_agio_PriorYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_d7d69a4b-c431-43dd-ad93-3bbf5289ad10_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_7944036b-75dd-4072-8f52-dc48d14e10ab_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7c99a589-b522-4db9-b45f-80b5d5e4b78c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1237c6be-f042-4702-a017-a5730a407955_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_f16d9629-89a9-477c-959b-0959d2603372_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_031e9b4c-476d-4745-9777-03d091ad450d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_17a9c8d2-13a8-4c82-9590-588a972e52f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_dc094ba0-6dc8-4166-9ab0-08d56af76b62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_10cc4c01-908c-48f7-8a8f-0f067802238d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_8b3b3412-81a6-4db2-a64f-8f22507d7a95_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Six</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:to="lab_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceOtherMember_40b69505-b0ca-470d-b3bb-d867cf759283_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other services</link:label>
    <link:label id="lab_us-gaap_ServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceOtherMember" xlink:to="lab_us-gaap_ServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ChangeInContractWithCustomerLiabilityRollForward_467418a5-289c-4e9e-93a7-6ae5d5245235_terseLabel_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c4e91a8d-3c8d-4030-b366-82980572d721_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_161998a1-cf30-49e0-87e2-4f505918b03f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b9e1bde-a4df-4178-a257-2d3008b524e4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_ab47566b-2744-4f7b-9130-84447e2a2259_negatedTerseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable &#8211; related party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:to="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_2086aa4d-3b89-446c-b4fc-824f4f9f922b_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaboration Revenue Under CStone Agreement</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement [Table Text Block]</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_documentation_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:to="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f16e54b8-ecc8-4adb-9d24-93f36e68bc3f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_184fd0b5-c9c5-4d38-adf3-ddf321a5dbf1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram_8b99032d-ca81-4529-9042-50c8b6970271_terseLabel_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of specified regulatory milestone events</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram_label_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" xlink:to="lab_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable_5a40656e-d101-4649-b88d-6d98d71c16ee_terseLabel_en-US" xlink:label="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment agreement extension fee receivable</link:label>
    <link:label id="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable_label_en-US" xlink:label="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UpfrontPaymentAgreementExtensionFeeReceivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:href="agio-20200331.xsd#agio_UpfrontPaymentAgreementExtensionFeeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:to="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_99b2b48e-2c4e-4e18-bdcf-3455d728a775_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaboration Revenue</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:to="lab_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ffcc3fd6-1830-43f6-a3c3-684673caa941_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize compensation expense (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_25347bf9-584f-44e2-beb5-76e7d2badb7a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_d6b96f28-0e27-4d8d-9e14-14f01ca391f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8eedba1c-554f-47b5-8ad4-652b93cb0c1f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_dd7b36e4-b073-485b-9e5c-9aff0ea415a0_terseLabel_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_label_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset [Roll Forward]</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_documentation_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward" xlink:to="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_2a172a22-75de-430e-902e-1801c921a568_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Related Reserves</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_label_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_documentation_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:href="agio-20200331.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:to="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7401dc4d-061b-4254-8891-f93ccaa8a9de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c912dc2d-de6f-4c2e-8347-c25507437d34_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7487ac01-0296-485d-be76-551f5b79c56c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a902c24c-e7f2-444b-94bb-2b671d4720b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_673ee685-b721-4471-ab22-b9f8176ed880_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_50212c28-eeb2-4fde-816b-8649e62184a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bf1a8f87-72ab-4a5c-8085-f1ab9083d77f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_26504e87-0bd3-44d9-a66a-89979adc9f10_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_05880a29-09cd-4c4f-b08d-77dd76572e0f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9de879f6-6f78-43e3-b479-3b8b12e376eb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_fd43a179-b2e6-43bc-b168-3b422d36a6d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of debt securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1ce90bcc-4088-4729-8c09-7c8e41ed95e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_31124e2e-8012-4d48-95ba-4210f1c49831_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceBasedStockUnitMember_584bdf96-30b7-4082-b0d0-2b1cb2591088_terseLabel_en-US" xlink:label="lab_agio_PerformanceBasedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Stock Units</link:label>
    <link:label id="lab_agio_PerformanceBasedStockUnitMember_label_en-US" xlink:label="lab_agio_PerformanceBasedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Stock Unit [Member]</link:label>
    <link:label id="lab_agio_PerformanceBasedStockUnitMember_documentation_en-US" xlink:label="lab_agio_PerformanceBasedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Stock Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember" xlink:href="agio-20200331.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceBasedStockUnitMember" xlink:to="lab_agio_PerformanceBasedStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3928675a-49b7-48b7-96b7-499c75d6b850_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_92292225-7841-411e-919c-afbeac6bd4a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fa8a84f5-f806-4208-86b6-eacb1a1176c5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0f1a7ccd-9673-49c0-bcb2-bd3e45cf63f7_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_17c824f5-74b6-4624-b326-f1eb303ea7bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acb1c9c0-13e5-458a-a2cc-12aa7f08b374_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7d3fda28-0e81-41b6-bc91-4b7b1db02347_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55050919-1a0f-49bd-bdd6-f2a9aeef8b00_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Unvested shares end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_ffba2577-2fd2-41c6-9389-0ef6680aef76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opportunity to purchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_8ae508da-e591-4af9-a7a3-56e36a63eaa4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_79f8569b-6436-4000-9266-baa85ac6054a_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_218f8f28-8a82-4afe-b662-74746f4ceb19_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_fc5e8eec-a730-49cc-9b36-5fb40aee91ad_verboseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable - other</link:label>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_label_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Receivable, Due From Related Parties, Current [Member]</link:label>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_documentation_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:to="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a5008d7c-943d-4d6a-b049-c0670d2fadbd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_85931cdd-e462-445f-8ebe-dbae2f97e67b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_feab4741-e97f-46b3-a70c-67707f6feb3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_3b825169-b642-4d90-af3f-1775fe1fc9ea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b0bd3ae-b3aa-463f-aa54-a0fb20e8942f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f3811a5-ddf8-4356-92c7-97c36bfc6f18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_3c672464-2f5b-46df-af27-3a3024f1884b_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Prior Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_4b3dd960-9979-4de1-9d12-4b29cf851c05_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Prior Years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentAssetMember_56129240-15ee-4252-a75d-85fbdd9792d3_terseLabel_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_agio_CurrentAssetMember_label_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CurrentAssetMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember" xlink:href="agio-20200331.xsd#agio_CurrentAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentAssetMember" xlink:to="lab_agio_CurrentAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent_a84eb834-f1bb-4be4-b6ed-755366514ee0_negatedLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; related party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" xlink:to="lab_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_235dd905-1450-48a8-b81d-9ab3fda23054_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_OptionExerciseFeeReceivable_f0d18a15-4769-42ad-a94b-6d0ce228596a_terseLabel_en-US" xlink:label="lab_agio_OptionExerciseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee receivable</link:label>
    <link:label id="lab_agio_OptionExerciseFeeReceivable_label_en-US" xlink:label="lab_agio_OptionExerciseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionExerciseFeeReceivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OptionExerciseFeeReceivable" xlink:href="agio-20200331.xsd#agio_OptionExerciseFeeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_OptionExerciseFeeReceivable" xlink:to="lab_agio_OptionExerciseFeeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_317fdba4-aa1e-4460-97b7-deaf9b24eadb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1d7c86c6-cd09-4440-9518-10c509939bc3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_66a76365-6da6-4c00-b7b0-4f910fad4711_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d060306-4e4a-43f2-96e9-75f6f0fd04b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a055105c-c01e-4fae-8bd5-fcd34c2b64af_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6651d222-c58f-4393-8dac-f3ec73b327e2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b9352c5e-aa19-4784-8670-0300b5c701b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized; 68,789,925 and 68,401,105 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_1b6609ef-dec3-4220-9baf-1a87e8693468_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Market-Based Units Activity</link:label>
    <link:label id="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Market-Based Units Activity [Table Text Block]</link:label>
    <link:label id="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_documentation_en-US" xlink:label="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Market-Based Units Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:href="agio-20200331.xsd#agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:to="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7359e6ad-6774-44df-89a0-a4f7355b795b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fc4d0d7f-c1eb-4568-ba29-a922da411f25_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableOtherCurrent_fba73fc9-6d4c-4608-8e29-66b732b57883_terseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; other</link:label>
    <link:label id="lab_agio_CollaborationReceivableOtherCurrent_label_en-US" xlink:label="lab_agio_CollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborationReceivableOtherCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableOtherCurrent" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableOtherCurrent" xlink:to="lab_agio_CollaborationReceivableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrent_bb6fdcce-1e75-4b25-8942-686bdce3417b_terseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; related party</link:label>
    <link:label id="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborationReceivableDuefromRelatedPartiesCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrent" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrent" xlink:to="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1e3dbe6c-94bb-4add-98e9-340b37b4f452_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1283f48c-59eb-4b72-9a89-2c4fa4d313fc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseRemainingLeaseTerm_ae74554e-0918-4c87-905b-e90a652fa948_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_agio_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3d26d594-d438-4e21-b94e-a2424cc5e023_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement_1a96dce8-99b7-4e45-b1bd-eae7540a9871_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreements</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" xlink:to="lab_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f6657b4-217a-4d71-885e-051c392f993b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_f9e808f7-79e5-4487-ae66-7a7ac7c922e9_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue &#8211; related party</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e5acc1bf-0228-4da4-9ddb-612c376437d2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e1da9172-0e48-4fcf-882e-00d3a30cbbf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e820497e-2acc-4288-9d2c-1d03fd6c3bae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43f452e3-b1f8-46c9-be98-06178bed82c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f7bad17b-4432-43a7-982e-c0fa0ba6f965_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7b6caf9c-a5fa-4f8c-b24e-c666b5ffdd11_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_18276a08-0fda-4b3e-9966-bc1cd07943ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_2e8a11fb-f74f-432b-b263-86445cb67a4e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RoyaltyPercentageRemitted_c3e4fcb9-fc8a-4e0b-836a-30eeddfd2ec8_terseLabel_en-US" xlink:label="lab_agio_RoyaltyPercentageRemitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage</link:label>
    <link:label id="lab_agio_RoyaltyPercentageRemitted_label_en-US" xlink:label="lab_agio_RoyaltyPercentageRemitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage Remitted</link:label>
    <link:label id="lab_agio_RoyaltyPercentageRemitted_documentation_en-US" xlink:label="lab_agio_RoyaltyPercentageRemitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyPercentageRemitted" xlink:href="agio-20200331.xsd#agio_RoyaltyPercentageRemitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RoyaltyPercentageRemitted" xlink:to="lab_agio_RoyaltyPercentageRemitted" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeePurchasePlanMember_ecfba544-15a0-4921-869d-c7f2579e5113_terseLabel_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan shares</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_label_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeePurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember" xlink:href="agio-20200331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeePurchasePlanMember" xlink:to="lab_agio_EmployeePurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock_926834fd-bfeb-4935-a0a5-7b6820b9d650_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets and Liabilities, CStone Agreement</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_26185659-c970-45bc-8c41-ff00e221baeb_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_05b11dd0-16e8-4ae8-8b37-946b5baa5737_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue &#8211; related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_66c2697a-8b8b-43ea-8811-d14be8cae0d8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net accretion of premium and discounts on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_730213a2-f9fb-4e05-8d02-8b188bbdf0bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityTable_e2dc8e5d-9dbb-4abb-85cf-d2d9e94fa7ed_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityTable_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability [Table]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityTable_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_47c49108-e29a-43da-9418-fc58c176a942_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ec3e1679-0834-48da-b774-e25a31591c27_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_d8e5731a-6708-42a1-bf9f-eb96490d439a_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the prior year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Prior Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_9d379294-d359-4643-9e7a-d58478bd09b4_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_2c7aa98a-ba2a-45e7-a497-77c32fcdde9b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_99ac738d-d8c3-4ec0-834d-68d0a5e2f775_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March 31, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_281932b8-f755-4401-bb66-f4898c3d7a5e_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_abc8575c-770e-473a-bb26-e1794f173bc0_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebate Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserve" xlink:to="lab_agio_ContractWithCustomerRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_60a9271d-fe96-4c2c-8a2f-dc59e4ea7d56_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5e5ab5a7-5b45-4854-9878-5aa9e6e3b8b3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1262744e-9b08-416a-b42d-42a05a2f3316_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock equivalents excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f70fefcf-b2a2-4579-913f-31b250504b80_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_e4156b91-e626-45d6-8e00-99ab949c1cba_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dff152f9-e38f-45af-882d-b2cd031a9ade_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3956baf5-422b-4f93-bac5-91745cfeb552_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_92f7cbdb-1638-4826-b61a-8a220aade8b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_fa9bb229-497a-4568-a548-d9a453761b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6a020b7e-62ae-45ef-9807-253fd8656322_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_d1c688e4-82a7-4b98-8f9f-f357b4ff9000_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Prior Years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:href="agio-20200331.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:to="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_44204a35-e0f1-487e-be62-07d2d56e4252_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b2640de0-40b8-428d-9225-d817e3b13b26_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_832cefed-68a6-4551-a16a-d0c66496e4a0_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Current Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_feecd249-1cef-47cc-b0d3-a63d2bcbfbb5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_3ef962cd-15bf-436a-b727-aa233dfdd45b_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProductReturnsRollForward_5934ef6b-0f36-4be3-9cd0-6e5f3dcea162_terseLabel_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns [Roll Forward]</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_label_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns [Roll Forward]</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_documentation_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward" xlink:href="agio-20200331.xsd#agio_ProductReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProductReturnsRollForward" xlink:to="lab_agio_ProductReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e8a3a710-39b7-4476-89b8-1f1f8ab095c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_b4b26c3f-3950-4eb2-98c2-9e591a89b07d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts Receivable [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_c2a31fde-2867-42ba-9e5e-0d412158517b_terseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Not Probable of Meeting Vesting Criteria</link:label>
    <link:label id="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_label_en-US" xlink:label="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Not Probable Of Meeting Vesting Criteria [Member]</link:label>
    <link:label id="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_documentation_en-US" xlink:label="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Not Probable Of Meeting Vesting Criteria</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:to="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cd31d30-4c38-46d5-b9d3-d68c498c3179_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_0e6a8c46-a6b3-41ba-ba8a-a935e9e6cdae_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:href="agio-20200331.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:to="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_NonCurrentAssetsMember_a5d7de65-7cbb-4ca2-adec-534223681b3e_terseLabel_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_agio_NonCurrentAssetsMember_label_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonCurrentAssetsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember" xlink:href="agio-20200331.xsd#agio_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_NonCurrentAssetsMember" xlink:to="lab_agio_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_28ee1a5b-949c-4b9a-972a-ee22f6d9bf98_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets_8c0f45fd-5e74-4d9a-94aa-d0d978640680_terseLabel_en-US" xlink:label="lab_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises in other current assets</link:label>
    <link:label id="lab_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets_label_en-US" xlink:label="lab_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsFromStockOptionsExercisedInOtherCurrentAssets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets" xlink:href="agio-20200331.xsd#agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets" xlink:to="lab_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>agio-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a02d1e66-dea3-48df-83b5-cb17f8e40104,g:f4811f45-5f64-498d-9bc7-c730ea92ab47-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20200331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_deb7f69f-3505-4b49-96e3-72353f52c3b1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_DocumentType_deb7f69f-3505-4b49-96e3-72353f52c3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c34748f3-898a-4711-8f47-aa280506c362" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_DocumentQuarterlyReport_c34748f3-898a-4711-8f47-aa280506c362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e36e862b-c669-4b55-b0ae-718c1b7197da" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_DocumentPeriodEndDate_e36e862b-c669-4b55-b0ae-718c1b7197da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3a445cd2-c3ec-4764-83d5-0c15f5d7943e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_DocumentTransitionReport_3a445cd2-c3ec-4764-83d5-0c15f5d7943e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e562e8d7-07bb-4ebe-8eaf-a4ef41aabfe8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityFileNumber_e562e8d7-07bb-4ebe-8eaf-a4ef41aabfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_486e4ed0-ced0-4c7a-8416-c4d08bce7a75" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityRegistrantName_486e4ed0-ced0-4c7a-8416-c4d08bce7a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cea69498-95d2-475f-b03b-26961a488571" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cea69498-95d2-475f-b03b-26961a488571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_577a16ac-94e9-400d-bf6d-89125ef22f51" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityTaxIdentificationNumber_577a16ac-94e9-400d-bf6d-89125ef22f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_615ffebd-b53a-406d-b453-e21a8b774e54" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityAddressAddressLine1_615ffebd-b53a-406d-b453-e21a8b774e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_66999be8-39d8-4dd8-b95a-825343c86b80" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityAddressCityOrTown_66999be8-39d8-4dd8-b95a-825343c86b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_47f20743-5465-4c0c-af50-b7e77a14a465" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityAddressStateOrProvince_47f20743-5465-4c0c-af50-b7e77a14a465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_83a2fa3f-4c71-4c31-8b28-8ee74b260dee" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityAddressPostalZipCode_83a2fa3f-4c71-4c31-8b28-8ee74b260dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d8e95243-a5ec-478a-a272-31de3e97b414" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_CityAreaCode_d8e95243-a5ec-478a-a272-31de3e97b414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f19ba4a2-511d-4d31-ade9-9b763c05c5ea" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_LocalPhoneNumber_f19ba4a2-511d-4d31-ade9-9b763c05c5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8180eab7-8c36-45e5-9f6a-f9ff75e91021" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_Security12bTitle_8180eab7-8c36-45e5-9f6a-f9ff75e91021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_220b527f-30c0-49e1-9905-0e407b6a8af5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_TradingSymbol_220b527f-30c0-49e1-9905-0e407b6a8af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_059cf6a1-b4f1-4fad-b946-d533491992ad" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_SecurityExchangeName_059cf6a1-b4f1-4fad-b946-d533491992ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_11e015fd-0d33-41ff-b5fc-632806f145d7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityCurrentReportingStatus_11e015fd-0d33-41ff-b5fc-632806f145d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_085d5f29-d8ae-4b3f-acb4-7517a11aed43" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityInteractiveDataCurrent_085d5f29-d8ae-4b3f-acb4-7517a11aed43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9f5aa921-a906-43f5-926f-d0e4d7cd2e1c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityFilerCategory_9f5aa921-a906-43f5-926f-d0e4d7cd2e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7d0417fa-5918-48e5-b285-1b17c32706f7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntitySmallBusiness_7d0417fa-5918-48e5-b285-1b17c32706f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_55730666-072c-4c8b-ba2a-9d43ac035b43" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityEmergingGrowthCompany_55730666-072c-4c8b-ba2a-9d43ac035b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7cf78a9f-ef70-46d6-9398-c6b484970042" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityShellCompany_7cf78a9f-ef70-46d6-9398-c6b484970042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f18ae95b-021b-4571-8def-24d8e2a93939" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f18ae95b-021b-4571-8def-24d8e2a93939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_15bb539c-da17-4f31-aa5b-201eca4d6fba" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_DocumentFiscalYearFocus_15bb539c-da17-4f31-aa5b-201eca4d6fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a64a46e4-f3f2-497f-a6ba-2ed160fe4b79" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a64a46e4-f3f2-497f-a6ba-2ed160fe4b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4775779d-3703-494b-8c48-3dd05ae62071" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_AmendmentFlag_4775779d-3703-494b-8c48-3dd05ae62071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9d6038a3-8dba-4454-92a8-bc61d7fa5996" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_EntityCentralIndexKey_9d6038a3-8dba-4454-92a8-bc61d7fa5996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d1bc82e1-68f1-427f-ad55-5c1b46f8b31d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f5120fdf-04b3-46df-8c38-528dfec52d5a" xlink:to="loc_dei_CurrentFiscalYearEndDate_d1bc82e1-68f1-427f-ad55-5c1b46f8b31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1b265c89-fe57-4d17-b573-777c7a9dbb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1b265c89-fe57-4d17-b573-777c7a9dbb5a" xlink:to="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:to="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_047fb1d7-2fc3-4092-8e2c-3a2317b35a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_047fb1d7-2fc3-4092-8e2c-3a2317b35a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b8f10174-468f-4d78-b0f4-585ad44e324b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b8f10174-468f-4d78-b0f4-585ad44e324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_18509981-e4e3-49fe-bcf5-3acba82d37a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_18509981-e4e3-49fe-bcf5-3acba82d37a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrent_9ad1e97a-54ce-4d6f-a7e1-a8cba900f34f" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrent_9ad1e97a-54ce-4d6f-a7e1-a8cba900f34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableOtherCurrent_eab9b46b-ab37-48ed-9740-4a19f4566757" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableOtherCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_agio_CollaborationReceivableOtherCurrent_eab9b46b-ab37-48ed-9740-4a19f4566757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_485d4908-c6f9-44e3-8ab0-d0fa8e7090e4" xlink:href="agio-20200331.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_485d4908-c6f9-44e3-8ab0-d0fa8e7090e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_abe37dfc-d24d-4026-815e-cfa69c176986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_us-gaap_InventoryNet_abe37dfc-d24d-4026-815e-cfa69c176986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_502880eb-c4bc-4c5b-92e1-87d6a1806c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_502880eb-c4bc-4c5b-92e1-87d6a1806c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bd48fac2-27dc-4651-b799-1b539f761f23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73e567a2-6080-4354-97ea-d577afa9dca9" xlink:to="loc_us-gaap_AssetsCurrent_bd48fac2-27dc-4651-b799-1b539f761f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9fbaf994-b9ec-4c29-b0cf-2f6787174ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9fbaf994-b9ec-4c29-b0cf-2f6787174ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4b7cc5d5-e265-4cbe-992d-56fa6f44c2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4b7cc5d5-e265-4cbe-992d-56fa6f44c2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fab5dff8-044e-4aab-b190-87053d3c1830" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fab5dff8-044e-4aab-b190-87053d3c1830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_b79c0d69-750a-49d2-8154-47ea424a8e20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_b79c0d69-750a-49d2-8154-47ea424a8e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2781a405-174d-43c1-941f-7ae8352956e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2781a405-174d-43c1-941f-7ae8352956e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_673c6c5c-7935-42d8-a90c-332f7ead7550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1ca289a-7226-4fde-8c12-0b449c649835" xlink:to="loc_us-gaap_Assets_673c6c5c-7935-42d8-a90c-332f7ead7550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1b265c89-fe57-4d17-b573-777c7a9dbb5a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_882d54dd-ae7f-4e16-9e52-c061d0fbdcea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:to="loc_us-gaap_AccountsPayableCurrent_882d54dd-ae7f-4e16-9e52-c061d0fbdcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f589578f-921c-4ca7-b7fd-fa568b82da83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f589578f-921c-4ca7-b7fd-fa568b82da83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c99fc2ba-21e1-4a72-98ad-10c3fb14c09a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c99fc2ba-21e1-4a72-98ad-10c3fb14c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4964c0dd-c3a6-460f-a43e-bfdd23871ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4964c0dd-c3a6-460f-a43e-bfdd23871ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_c3c6b0aa-42b9-4803-aa34-6d73aa59c934" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_c3c6b0aa-42b9-4803-aa34-6d73aa59c934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_49ab1e98-15fe-4990-890a-e3e0c57eef9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c15699ef-3de9-4437-9ab1-e7d8b3e7f82d" xlink:to="loc_us-gaap_LiabilitiesCurrent_49ab1e98-15fe-4990-890a-e3e0c57eef9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0898ffe5-46de-4d17-98a8-e6d02f9c19b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0898ffe5-46de-4d17-98a8-e6d02f9c19b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07b6475f-b1a2-49b8-922e-f7d3fd88a9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07b6475f-b1a2-49b8-922e-f7d3fd88a9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_a12d2d88-8584-4590-a1ff-b7f3ab230830" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_a12d2d88-8584-4590-a1ff-b7f3ab230830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f8935f6b-f694-41a1-bdaa-88b65cb6862e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:to="loc_us-gaap_Liabilities_f8935f6b-f694-41a1-bdaa-88b65cb6862e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_963666c6-c2f2-4f3b-9b13-bca1ff5a1fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:to="loc_us-gaap_PreferredStockValue_963666c6-c2f2-4f3b-9b13-bca1ff5a1fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f0208a06-a94a-4f0c-9dee-cf966b05ba5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:to="loc_us-gaap_CommonStockValue_f0208a06-a94a-4f0c-9dee-cf966b05ba5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_222f4195-e188-42ce-8afa-503beb660f89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_222f4195-e188-42ce-8afa-503beb660f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fb78a5c4-9a92-49fe-b657-b5312a588139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fb78a5c4-9a92-49fe-b657-b5312a588139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7038186-5543-407b-bb35-f3cc9da56557" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7038186-5543-407b-bb35-f3cc9da56557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35c3e425-01ce-45d0-ba87-29196af7f3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a3937d6-a80d-45bb-92a4-7b59d6c956ab" xlink:to="loc_us-gaap_StockholdersEquity_35c3e425-01ce-45d0-ba87-29196af7f3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6cb66b55-89bf-409d-8c30-43849cdc217a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da127638-a46b-4b0f-800b-016784e99ebe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6cb66b55-89bf-409d-8c30-43849cdc217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1675c7ad-20e7-4d87-9e96-6a0d517eb32d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1675c7ad-20e7-4d87-9e96-6a0d517eb32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_795719ca-3757-47cc-a3ee-3104f0830b55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_795719ca-3757-47cc-a3ee-3104f0830b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8eae3772-dabf-4b10-864f-c7f25efec8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8eae3772-dabf-4b10-864f-c7f25efec8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d405b871-8429-4249-ae60-b4bfece76f54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d405b871-8429-4249-ae60-b4bfece76f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7abf5fd7-6fd8-45cf-af46-beb2a608623e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7abf5fd7-6fd8-45cf-af46-beb2a608623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5e0a1ed6-99a5-4c1d-b48f-f8c93256b17f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5e0a1ed6-99a5-4c1d-b48f-f8c93256b17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_deea161e-0e2d-44c9-8c6c-82bb7e39c889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_CommonStockSharesIssued_deea161e-0e2d-44c9-8c6c-82bb7e39c889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87d68291-5bc6-4f83-8eab-b5f7a1de48c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc7c778-4952-4a04-9612-6d06489c0973" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_87d68291-5bc6-4f83-8eab-b5f7a1de48c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4e7cb020-79b6-4211-bc98-808308ee503e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fa93dc5c-43cc-4d64-8202-5303248f8fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e7cb020-79b6-4211-bc98-808308ee503e" xlink:to="loc_us-gaap_StatementTable_fa93dc5c-43cc-4d64-8202-5303248f8fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0639252b-ec4b-4fe5-aad8-8dc8069051ea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fa93dc5c-43cc-4d64-8202-5303248f8fbb" xlink:to="loc_srt_ProductOrServiceAxis_0639252b-ec4b-4fe5-aad8-8dc8069051ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0639252b-ec4b-4fe5-aad8-8dc8069051ea" xlink:to="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e86e297e-9916-4bf0-bdf7-59ae9a0c2fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_us-gaap_ProductMember_e86e297e-9916-4bf0-bdf7-59ae9a0c2fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_fc9e3c3a-e626-4055-bd5a-50f791e3e7b7" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_fc9e3c3a-e626-4055-bd5a-50f791e3e7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_f23981f1-2f3d-4a5a-b510-76231db9c2ac" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_agio_CollaborationRevenueOtherMember_f23981f1-2f3d-4a5a-b510-76231db9c2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_0ae161f1-0ae6-4516-9902-45e94292fc9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_512056bb-5028-465d-beb5-7cf4402ba880" xlink:to="loc_us-gaap_RoyaltyMember_0ae161f1-0ae6-4516-9902-45e94292fc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fa93dc5c-43cc-4d64-8202-5303248f8fbb" xlink:to="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e7605332-c75f-4166-a4fa-f8fc5b732b68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_RevenuesAbstract_e7605332-c75f-4166-a4fa-f8fc5b732b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16dbf652-86f9-44cf-8bbd-0a9173b44553" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e7605332-c75f-4166-a4fa-f8fc5b732b68" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16dbf652-86f9-44cf-8bbd-0a9173b44553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6a14d76b-6d84-4fe4-886c-3869440e83a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6a14d76b-6d84-4fe4-886c-3869440e83a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d5a94687-0c61-46ed-be1b-e245f7e604d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d5a94687-0c61-46ed-be1b-e245f7e604d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_55c270dc-5a7d-412f-899b-265411480ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_55c270dc-5a7d-412f-899b-265411480ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6c1eb345-24a6-48bd-831a-5d28b0d91836" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_303783de-08e0-4d61-9479-29b171ede50d" xlink:to="loc_us-gaap_CostsAndExpenses_6c1eb345-24a6-48bd-831a-5d28b0d91836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bdaaa257-85e0-4423-9c25-ca96f341855e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_OperatingIncomeLoss_bdaaa257-85e0-4423-9c25-ca96f341855e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_bee17954-9cf5-446d-8aae-6fbcd858e2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_bee17954-9cf5-446d-8aae-6fbcd858e2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d19f32e6-5dab-4f3a-9573-4c1dd116d109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_NetIncomeLoss_d19f32e6-5dab-4f3a-9573-4c1dd116d109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_55b11f1a-38f6-4fd5-860b-164b74d543fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_55b11f1a-38f6-4fd5-860b-164b74d543fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c022932f-99c1-4f71-b6bf-26a12dcc5b48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54d97ea0-ca2b-4b6e-8325-1b14ccec280e" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c022932f-99c1-4f71-b6bf-26a12dcc5b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac26a430-93ab-49a9-bdff-b69229b77d43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c80ec72-66d9-47af-abfb-2d7ff0c38c04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac26a430-93ab-49a9-bdff-b69229b77d43" xlink:to="loc_us-gaap_NetIncomeLoss_5c80ec72-66d9-47af-abfb-2d7ff0c38c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f04f2fbe-dbf5-4ac8-a921-cf802f8bf000" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac26a430-93ab-49a9-bdff-b69229b77d43" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f04f2fbe-dbf5-4ac8-a921-cf802f8bf000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_855643c7-e48f-4399-92e7-55bd28d9e483" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f04f2fbe-dbf5-4ac8-a921-cf802f8bf000" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_855643c7-e48f-4399-92e7-55bd28d9e483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_05d9d931-424c-4389-9d0e-8e6b9413e0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac26a430-93ab-49a9-bdff-b69229b77d43" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_05d9d931-424c-4389-9d0e-8e6b9413e0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_efaf4e07-242a-4a4c-95d5-640776718825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c61ad7da-526e-496e-8d9b-adeeeb3b4866" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_efaf4e07-242a-4a4c-95d5-640776718825" xlink:to="loc_us-gaap_StatementTable_c61ad7da-526e-496e-8d9b-adeeeb3b4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d2769f29-6732-402e-b796-a1c8f771b358" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c61ad7da-526e-496e-8d9b-adeeeb3b4866" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d2769f29-6732-402e-b796-a1c8f771b358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d2769f29-6732-402e-b796-a1c8f771b358" xlink:to="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e29bcd0-e3e3-4308-bd5c-4732fdfb9ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_CommonStockMember_8e29bcd0-e3e3-4308-bd5c-4732fdfb9ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cab02b03-51db-45d8-b402-a8db613bbb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cab02b03-51db-45d8-b402-a8db613bbb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb908999-97de-4be4-9542-a1f73082bfb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb908999-97de-4be4-9542-a1f73082bfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_aae145ce-4e70-46b9-8a52-a14bf47e8bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_087c9c47-c029-4b3f-b28d-9aff70cbcc7d" xlink:to="loc_us-gaap_RetainedEarningsMember_aae145ce-4e70-46b9-8a52-a14bf47e8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c61ad7da-526e-496e-8d9b-adeeeb3b4866" xlink:to="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7c3dd1bc-d6b8-40a3-adc2-b268b078f0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_SharesOutstanding_7c3dd1bc-d6b8-40a3-adc2-b268b078f0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_457654c2-e3cf-4be6-80d4-13c099aeefb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StockholdersEquity_457654c2-e3cf-4be6-80d4-13c099aeefb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ee25da63-655f-412a-adb4-4c4e077b6838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ee25da63-655f-412a-adb4-4c4e077b6838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3fb3d081-ee6e-405b-8080-63dff7b0c7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3fb3d081-ee6e-405b-8080-63dff7b0c7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee8b1333-31a4-48d3-bd90-0e3000d2c8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee8b1333-31a4-48d3-bd90-0e3000d2c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80f56e93-8c23-4cef-9618-67f6d534370a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80f56e93-8c23-4cef-9618-67f6d534370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d44deae-33f3-4d20-b244-a6e0afecf74f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_NetIncomeLoss_8d44deae-33f3-4d20-b244-a6e0afecf74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5ea0a1af-946f-462a-8952-69f44498bef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_SharesOutstanding_5ea0a1af-946f-462a-8952-69f44498bef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4ef3ebc0-9ac0-4c5a-8056-59d0d902cda7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3da60ee4-0560-4f82-b9bb-a11129da39e5" xlink:to="loc_us-gaap_StockholdersEquity_4ef3ebc0-9ac0-4c5a-8056-59d0d902cda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9d426bd-0a1c-4ae9-a6a0-3ba047c783ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9d426bd-0a1c-4ae9-a6a0-3ba047c783ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38fde487-8216-416e-8ee3-e3af88b1002e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9d426bd-0a1c-4ae9-a6a0-3ba047c783ff" xlink:to="loc_us-gaap_NetIncomeLoss_38fde487-8216-416e-8ee3-e3af88b1002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_668ee298-14b7-4601-b6b7-1de08fd0c084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9d426bd-0a1c-4ae9-a6a0-3ba047c783ff" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_668ee298-14b7-4601-b6b7-1de08fd0c084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_fa5b29a4-ff44-47a4-a4fb-8cc93590365c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_668ee298-14b7-4601-b6b7-1de08fd0c084" xlink:to="loc_us-gaap_Depreciation_fa5b29a4-ff44-47a4-a4fb-8cc93590365c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ee2f523-60d2-48bd-b7b5-0e9d8ee9ddc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_668ee298-14b7-4601-b6b7-1de08fd0c084" xlink:to="loc_us-gaap_ShareBasedCompensation_7ee2f523-60d2-48bd-b7b5-0e9d8ee9ddc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_265f96ba-11c2-447f-89f0-57382e057bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_668ee298-14b7-4601-b6b7-1de08fd0c084" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_265f96ba-11c2-447f-89f0-57382e057bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OperatingLeaseRightOfUseAssetAmortization_00d11149-b93d-4450-b415-507863064875" xlink:href="agio-20200331.xsd#agio_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_668ee298-14b7-4601-b6b7-1de08fd0c084" xlink:to="loc_agio_OperatingLeaseRightOfUseAssetAmortization_00d11149-b93d-4450-b415-507863064875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_668ee298-14b7-4601-b6b7-1de08fd0c084" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_62f7e193-c2f0-4a41-bf8f-8e9d038685a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_62f7e193-c2f0-4a41-bf8f-8e9d038685a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent_0a3d44d3-31f6-4e1a-a106-2f5de625f2ab" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent_0a3d44d3-31f6-4e1a-a106-2f5de625f2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent_b832926d-27ea-47f6-a149-c6f30eeda7da" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent_b832926d-27ea-47f6-a149-c6f30eeda7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_a7c0d979-3ea9-48a0-96e1-9b793ee29574" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_a7c0d979-3ea9-48a0-96e1-9b793ee29574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d14fe603-64d4-4df1-a505-de2e24d02820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d14fe603-64d4-4df1-a505-de2e24d02820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e617597e-9abc-41ad-8ccb-769946e3a9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e617597e-9abc-41ad-8ccb-769946e3a9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bf94506e-ba8f-4121-9f60-d797ba0c6963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bf94506e-ba8f-4121-9f60-d797ba0c6963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_91f85b64-f11f-4b10-b326-039acd5e818f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_91f85b64-f11f-4b10-b326-039acd5e818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_e6b70684-857c-4d4c-a5a2-9197797b39f5" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_e6b70684-857c-4d4c-a5a2-9197797b39f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_fd035bf3-fc6f-43b5-926c-bc6e4f19121a" xlink:href="agio-20200331.xsd#agio_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_187418c2-27a7-4439-80ab-f3828be349b4" xlink:to="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_fd035bf3-fc6f-43b5-926c-bc6e4f19121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3d51c0b-9adc-4d9c-8a2a-638160463280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_f9d426bd-0a1c-4ae9-a6a0-3ba047c783ff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3d51c0b-9adc-4d9c-8a2a-638160463280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_72e1f724-dede-4f8c-8499-22043f272b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_72e1f724-dede-4f8c-8499-22043f272b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee773420-fde3-4bc6-8c1f-f008dff98af0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_72e1f724-dede-4f8c-8499-22043f272b9e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee773420-fde3-4bc6-8c1f-f008dff98af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_25a9cba0-9c43-4c8e-9500-69a179ac2905" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_72e1f724-dede-4f8c-8499-22043f272b9e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_25a9cba0-9c43-4c8e-9500-69a179ac2905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fec243ad-8640-4457-b977-7ce2cdb1d75e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_72e1f724-dede-4f8c-8499-22043f272b9e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fec243ad-8640-4457-b977-7ce2cdb1d75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ab87598-1202-45b5-a2ad-2378cbfc3f02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_72e1f724-dede-4f8c-8499-22043f272b9e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ab87598-1202-45b5-a2ad-2378cbfc3f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_03414880-3648-46b6-8619-072ef8b0de0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_03414880-3648-46b6-8619-072ef8b0de0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_3b8b4550-1c4c-4611-bce1-8095f152ffcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_03414880-3648-46b6-8619-072ef8b0de0c" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_3b8b4550-1c4c-4611-bce1-8095f152ffcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_cbccbc3d-b34d-41c2-b4a0-df572a10df55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_03414880-3648-46b6-8619-072ef8b0de0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_cbccbc3d-b34d-41c2-b4a0-df572a10df55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d12ef4bc-f029-4eaa-8862-2e4d341bc5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_03414880-3648-46b6-8619-072ef8b0de0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d12ef4bc-f029-4eaa-8862-2e4d341bc5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9446b9d9-84ea-4583-b333-d193347828ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9446b9d9-84ea-4583-b333-d193347828ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fac219ed-8a91-4565-9913-4be8a2cc5563" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fac219ed-8a91-4565-9913-4be8a2cc5563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e83d586b-b166-4ccc-845f-fa915bd718c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e83d586b-b166-4ccc-845f-fa915bd718c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_45c035c4-76d7-46b4-894d-397b54db3c85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f09db81c-6105-4fe2-92f7-9e42b9c8a474" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_45c035c4-76d7-46b4-894d-397b54db3c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cb3bc68e-0781-47ec-ad29-0401e8f37ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_45c035c4-76d7-46b4-894d-397b54db3c85" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cb3bc68e-0781-47ec-ad29-0401e8f37ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets_6daf2b6c-f1de-4629-b260-24b00b249deb" xlink:href="agio-20200331.xsd#agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_45c035c4-76d7-46b4-894d-397b54db3c85" xlink:to="loc_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets_6daf2b6c-f1de-4629-b260-24b00b249deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c05e4aac-9747-49ef-8fa1-bfbc2207a507" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_45c035c4-76d7-46b4-894d-397b54db3c85" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c05e4aac-9747-49ef-8fa1-bfbc2207a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ed0f0d36-3471-4e87-9f9b-4fc1bfa96027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_45c035c4-76d7-46b4-894d-397b54db3c85" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ed0f0d36-3471-4e87-9f9b-4fc1bfa96027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="simple" xlink:href="agio-20200331.xsd#OverviewandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b85f8b15-db15-4e8c-ae7e-a2d6d3169b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_37f59743-c9af-4c72-a165-a966219ea012" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b85f8b15-db15-4e8c-ae7e-a2d6d3169b19" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_37f59743-c9af-4c72-a165-a966219ea012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#OverviewandBasisofPresentationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4608943-17b0-4a91-a82e-3bb1bf28ecbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ae310c15-0103-42ef-81a9-d33bba17c54f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4608943-17b0-4a91-a82e-3bb1bf28ecbe" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ae310c15-0103-42ef-81a9-d33bba17c54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_764bf0c5-36ee-407a-935d-90555ba47784" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4a385dab-988a-477e-a95f-9c250ded6537" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_764bf0c5-36ee-407a-935d-90555ba47784" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4a385dab-988a-477e-a95f-9c250ded6537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_567dce00-4d05-4892-aae3-d152d79df55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_764bf0c5-36ee-407a-935d-90555ba47784" xlink:to="loc_us-gaap_UseOfEstimates_567dce00-4d05-4892-aae3-d152d79df55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4b30ce44-3ff3-4c17-9389-4fb5396bf895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e49809bd-0e1a-465d-af0e-33251caa09d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b30ce44-3ff3-4c17-9389-4fb5396bf895" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e49809bd-0e1a-465d-af0e-33251caa09d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_181b8795-7718-44d4-9730-10746ffb818e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_54d41eab-ec86-4906-8bf9-c986906bcfec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_181b8795-7718-44d4-9730-10746ffb818e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_54d41eab-ec86-4906-8bf9-c986906bcfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e9cb528f-7580-48b7-a287-df1fca66d39b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_181b8795-7718-44d4-9730-10746ffb818e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e9cb528f-7580-48b7-a287-df1fca66d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_da097980-b6cf-488c-92ad-38fc82f9575c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_181b8795-7718-44d4-9730-10746ffb818e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_da097980-b6cf-488c-92ad-38fc82f9575c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_d955c5f8-0de1-470d-b97a-9d54ef992318" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_181b8795-7718-44d4-9730-10746ffb818e" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_d955c5f8-0de1-470d-b97a-9d54ef992318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4e061b8d-7edb-49eb-933c-59e8965c5810" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_181b8795-7718-44d4-9730-10746ffb818e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4e061b8d-7edb-49eb-933c-59e8965c5810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_89b08e8e-933e-408e-87b2-fff12c71af93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_181b8795-7718-44d4-9730-10746ffb818e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_89b08e8e-933e-408e-87b2-fff12c71af93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a81169b9-446c-41ae-b81e-a6cce202f1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_58f9699c-1e9f-4598-80ef-c9a7d2e94ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a81169b9-446c-41ae-b81e-a6cce202f1fd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_58f9699c-1e9f-4598-80ef-c9a7d2e94ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f5f7aa0d-9394-4613-b935-391403d690b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a93e704b-2d9b-4e8a-8a91-1461621058ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f5f7aa0d-9394-4613-b935-391403d690b6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a93e704b-2d9b-4e8a-8a91-1461621058ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_051df454-39bc-42de-abd4-88344e5c93bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_051df454-39bc-42de-abd4-88344e5c93bf" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d83bf1b0-11ec-4b78-b4b7-6645d766bf92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d83bf1b0-11ec-4b78-b4b7-6645d766bf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c68fdb09-10b5-477a-a004-507d575b2424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d83bf1b0-11ec-4b78-b4b7-6645d766bf92" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c68fdb09-10b5-477a-a004-507d575b2424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cf69886e-65a3-4c84-a6a1-5b12f6ee2b01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c68fdb09-10b5-477a-a004-507d575b2424" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cf69886e-65a3-4c84-a6a1-5b12f6ee2b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94b58ec-8fad-498f-9afc-e0f16c41bf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94b58ec-8fad-498f-9afc-e0f16c41bf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94b58ec-8fad-498f-9afc-e0f16c41bf8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d4bebf2-a15a-41e3-9ac3-625e85acce31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d4bebf2-a15a-41e3-9ac3-625e85acce31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ca5a023c-f836-4269-9848-3cc15a670f39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ca5a023c-f836-4269-9848-3cc15a670f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a505496d-1f9e-4496-b7c1-8722e9f05feb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a32271ec-1352-4582-a315-f98c4df0538a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a505496d-1f9e-4496-b7c1-8722e9f05feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_921c4884-9cce-472c-acbc-1a3f27b5eccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:to="loc_us-gaap_InvestmentTypeAxis_921c4884-9cce-472c-acbc-1a3f27b5eccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_921c4884-9cce-472c-acbc-1a3f27b5eccb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_df474a4b-d125-48a7-b171-cbed3f36555c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_CashEquivalentsMember_df474a4b-d125-48a7-b171-cbed3f36555c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_27655bd2-4fe0-4828-a694-900a1f71421b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_27655bd2-4fe0-4828-a694-900a1f71421b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6cf7160-7473-4c14-9158-2512ee8057ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f6cf7160-7473-4c14-9158-2512ee8057ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7c6a0928-9975-46d5-a9a7-f806b0f390f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ec0440d1-5688-4dd8-b358-6d08aa0c25c8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7c6a0928-9975-46d5-a9a7-f806b0f390f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f70511d8-576b-4a3f-90e6-22cc30349f64" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b00f1a0e-f600-47cd-a34b-4fdc32471333" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b00f1a0e-f600-47cd-a34b-4fdc32471333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8cf6313d-bfdc-41be-b474-b0b7c111dd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8cf6313d-bfdc-41be-b474-b0b7c111dd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_329da68e-41e3-46c0-b0b8-a300f2e397c3" xlink:href="agio-20200331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_51e65f10-a7f1-41b7-b95a-48a1d5e43a21" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_329da68e-41e3-46c0-b0b8-a300f2e397c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6b9a64f1-5645-40a1-a107-f2d40dccb116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6b9a64f1-5645-40a1-a107-f2d40dccb116" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_34d23ca8-5863-4a03-9f8f-dba1bd719a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efb8fa8-9fcd-4f16-9e99-d38bf988a5b7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_34d23ca8-5863-4a03-9f8f-dba1bd719a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f124bb21-161c-48ae-94c0-fa052ff3d4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_34d23ca8-5863-4a03-9f8f-dba1bd719a8a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f124bb21-161c-48ae-94c0-fa052ff3d4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83e14faf-6ba7-4cdd-a2b6-4d3b75434fba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23fe57ae-f289-4e56-aeeb-1f8554b4b9f9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83e14faf-6ba7-4cdd-a2b6-4d3b75434fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3c9de7fa-a792-4838-9274-34a13c3daf81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83e14faf-6ba7-4cdd-a2b6-4d3b75434fba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3c9de7fa-a792-4838-9274-34a13c3daf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee375281-48b7-410e-b55a-26741ccfddbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a4adf3-be1c-4553-9635-71e1a8ba616a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee375281-48b7-410e-b55a-26741ccfddbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_882899f8-e6d0-42bd-8501-df62a8284b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee375281-48b7-410e-b55a-26741ccfddbb" xlink:to="loc_us-gaap_FairValueNetAssetLiability_882899f8-e6d0-42bd-8501-df62a8284b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_28195b68-f451-4d9b-9b33-a2ab13e5d2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e3729d41-8e42-439d-aa6b-9991afe5f46e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_28195b68-f451-4d9b-9b33-a2ab13e5d2bf" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e3729d41-8e42-439d-aa6b-9991afe5f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3d747306-5e40-490e-880b-b2f5ffef8494" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_540ef618-40f0-4086-8d7e-98690f2e2179" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3d747306-5e40-490e-880b-b2f5ffef8494" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_540ef618-40f0-4086-8d7e-98690f2e2179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_594d4c39-9676-4654-973f-a899609963f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_d6339b74-d61e-4c47-936d-a7872df7d0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_594d4c39-9676-4654-973f-a899609963f8" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_d6339b74-d61e-4c47-936d-a7872df7d0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_5f90292f-1d0b-42f2-8288-7e37daef1573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_594d4c39-9676-4654-973f-a899609963f8" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_5f90292f-1d0b-42f2-8288-7e37daef1573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_3567d853-1c87-4fc4-9130-ff0168a192fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_594d4c39-9676-4654-973f-a899609963f8" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_3567d853-1c87-4fc4-9130-ff0168a192fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_c9eeceb8-2973-4292-9a6c-500c147fed51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_594d4c39-9676-4654-973f-a899609963f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_c9eeceb8-2973-4292-9a6c-500c147fed51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ded3d527-4912-4cfd-92df-e2ab9961d540" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ded3d527-4912-4cfd-92df-e2ab9961d540" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7bbd310f-81e3-41e4-9a98-4b84df574874" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7bbd310f-81e3-41e4-9a98-4b84df574874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7bbd310f-81e3-41e4-9a98-4b84df574874" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_50a07aca-a3c9-4dc9-b353-e93e88ebe14c" xlink:href="agio-20200331.xsd#agio_CurrentAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:to="loc_agio_CurrentAssetMember_50a07aca-a3c9-4dc9-b353-e93e88ebe14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_84669b9d-4cc1-4e92-88d2-0ba80bdf8385" xlink:href="agio-20200331.xsd#agio_NonCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e02ee438-58de-4f0d-9360-d2e08e2a6d78" xlink:to="loc_agio_NonCurrentAssetsMember_84669b9d-4cc1-4e92-88d2-0ba80bdf8385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e67e0b24-7409-4797-8f90-a11fee0566cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:to="loc_us-gaap_InvestmentTypeAxis_e67e0b24-7409-4797-8f90-a11fee0566cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_e67e0b24-7409-4797-8f90-a11fee0566cf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_44b8d936-e120-431d-a9a2-a863dfcc87d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_44b8d936-e120-431d-a9a2-a863dfcc87d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e54ba790-d70d-4aea-8e29-763f18eef0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e54ba790-d70d-4aea-8e29-763f18eef0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_43b1dc02-5085-4633-acac-8339c9b9f8f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4b42f85-5828-47fb-8616-ec91068d4a06" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_43b1dc02-5085-4633-acac-8339c9b9f8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07394abf-a392-4d33-9b8c-bda788be397f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37b88705-22d2-4290-885d-45ae97fe5859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37b88705-22d2-4290-885d-45ae97fe5859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e80f4e54-c86c-4a96-b4ee-47d94d5cc36e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e80f4e54-c86c-4a96-b4ee-47d94d5cc36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c4caaf8-ed92-44f1-8ee3-1f77676568cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c4caaf8-ed92-44f1-8ee3-1f77676568cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e1b2ec3b-21b3-48d6-a485-93e48881ad59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da5ef322-8270-49e7-8ed7-3219bc42a8ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e1b2ec3b-21b3-48d6-a485-93e48881ad59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20200331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1391d366-8ffa-4615-aa9b-e1b2943be4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_e9331f4c-4468-4ef0-a20e-3341983859fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1391d366-8ffa-4615-aa9b-e1b2943be4a2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_e9331f4c-4468-4ef0-a20e-3341983859fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20200331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f73dd9e7-87ae-47a6-a492-bbe8c76b64fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e03ea71b-00e8-488f-967e-9df05d302d05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f73dd9e7-87ae-47a6-a492-bbe8c76b64fb" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e03ea71b-00e8-488f-967e-9df05d302d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#InventoryScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ac5c2872-6df3-41e5-8b0e-8b455a213bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2b9498f8-f4fe-4975-8de7-82d3a5f4c496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ac5c2872-6df3-41e5-8b0e-8b455a213bcb" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2b9498f8-f4fe-4975-8de7-82d3a5f4c496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_546a33a7-4a2d-43a0-88b1-26500da958d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ac5c2872-6df3-41e5-8b0e-8b455a213bcb" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_546a33a7-4a2d-43a0-88b1-26500da958d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_015d0f01-dd34-4ef1-bfd6-4629e310903d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ac5c2872-6df3-41e5-8b0e-8b455a213bcb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_015d0f01-dd34-4ef1-bfd6-4629e310903d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b87d74c0-c995-421e-b7ce-2d70e228c970" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ac5c2872-6df3-41e5-8b0e-8b455a213bcb" xlink:to="loc_us-gaap_InventoryNet_b87d74c0-c995-421e-b7ce-2d70e228c970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20200331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://agios.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9e524b53-411b-42fe-8270-c3f14436e7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ae53feb7-a471-4ec7-a450-d19c9400abff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e524b53-411b-42fe-8270-c3f14436e7a3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ae53feb7-a471-4ec7-a450-d19c9400abff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6695736a-8174-4efb-a890-3dec20498833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_32e0e19f-118b-4921-b3b2-6c1c5a815ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6695736a-8174-4efb-a890-3dec20498833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_32e0e19f-118b-4921-b3b2-6c1c5a815ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ed6da2d3-db90-4f42-a6a4-75bc9a40b130" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseRemainingLeaseTerm_96161408-b9fd-4e5f-8ca7-168379f8346e" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ed6da2d3-db90-4f42-a6a4-75bc9a40b130" xlink:to="loc_agio_LesseeOperatingLeaseRemainingLeaseTerm_96161408-b9fd-4e5f-8ca7-168379f8346e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_60b5aa9a-ae56-46c6-a8b7-8b6fdc873863" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ed6da2d3-db90-4f42-a6a4-75bc9a40b130" xlink:to="loc_us-gaap_OperatingLeaseCost_60b5aa9a-ae56-46c6-a8b7-8b6fdc873863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eb0c8764-1f23-459a-8d5b-6a7357fd4a14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ed6da2d3-db90-4f42-a6a4-75bc9a40b130" xlink:to="loc_us-gaap_OperatingLeasePayments_eb0c8764-1f23-459a-8d5b-6a7357fd4a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_766656ae-7f91-4015-a3b3-5cc333ab3d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ed6da2d3-db90-4f42-a6a4-75bc9a40b130" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_766656ae-7f91-4015-a3b3-5cc333ab3d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bf68adb7-f2db-43df-94f5-567ab697b943" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ed6da2d3-db90-4f42-a6a4-75bc9a40b130" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bf68adb7-f2db-43df-94f5-567ab697b943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7f0ba1f4-7b33-423f-889f-b4fd6ab9282b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7f0ba1f4-7b33-423f-889f-b4fd6ab9282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a61634e3-4d03-429e-b2cb-79fe52cc9ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a61634e3-4d03-429e-b2cb-79fe52cc9ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1da8ca8a-d1f8-4913-af28-469fe84ffa72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1da8ca8a-d1f8-4913-af28-469fe84ffa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a48dd59b-3a6d-4e65-954a-c69e8a697855" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a48dd59b-3a6d-4e65-954a-c69e8a697855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9b68a45d-be84-4e5f-93ee-3f2aa30348ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9b68a45d-be84-4e5f-93ee-3f2aa30348ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_1d51b3d7-226d-44de-b9b2-62f19debc3bb" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_1d51b3d7-226d-44de-b9b2-62f19debc3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_94aeb3e5-f6df-4705-a149-b0ca7c6373f9" xlink:href="agio-20200331.xsd#agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_94aeb3e5-f6df-4705-a149-b0ca7c6373f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a75469d0-f96c-415e-8d4d-f7398ce5c360" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a75469d0-f96c-415e-8d4d-f7398ce5c360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9d63386-8965-4c12-9a1a-f05e1c612706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9d63386-8965-4c12-9a1a-f05e1c612706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4f11b541-6df8-4005-a45e-0b35797e856a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39e98910-0096-4ef9-abec-c8cbe3bd8513" xlink:to="loc_us-gaap_OperatingLeaseLiability_4f11b541-6df8-4005-a45e-0b35797e856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20200331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1c308689-2f4c-4e14-9a2d-be74d2fa18a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_86139ff8-f611-49f1-8b6b-5ddd66d2b606" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1c308689-2f4c-4e14-9a2d-be74d2fa18a8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_86139ff8-f611-49f1-8b6b-5ddd66d2b606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_75bb6260-dcbc-4f4c-aede-c6da191c84c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3c1e6d43-01e7-4be7-9b92-c7d8db65afbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_75bb6260-dcbc-4f4c-aede-c6da191c84c0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3c1e6d43-01e7-4be7-9b92-c7d8db65afbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_cbd39302-3536-469c-a9cd-32037810c1be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f459cd27-9e72-4506-bab0-cd267e6d4d08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cbd39302-3536-469c-a9cd-32037810c1be" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f459cd27-9e72-4506-bab0-cd267e6d4d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_39a9d624-1985-4782-a583-a1216d7f60ae" xlink:href="agio-20200331.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cbd39302-3536-469c-a9cd-32037810c1be" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_39a9d624-1985-4782-a583-a1216d7f60ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d867b541-d069-4686-8e75-57ac3df1c797" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cbd39302-3536-469c-a9cd-32037810c1be" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d867b541-d069-4686-8e75-57ac3df1c797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d67d8d0a-22c6-43ba-9329-864a67974e68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cbd39302-3536-469c-a9cd-32037810c1be" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d67d8d0a-22c6-43ba-9329-864a67974e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a5473437-ab6c-4dca-813c-e70a375dc51e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cbd39302-3536-469c-a9cd-32037810c1be" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a5473437-ab6c-4dca-813c-e70a375dc51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenue"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19ba4043-7b7c-4edf-a9ef-4b9cc9b1cf05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a266554a-5ced-41bc-bea7-f5051689632e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19ba4043-7b7c-4edf-a9ef-4b9cc9b1cf05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a266554a-5ced-41bc-bea7-f5051689632e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_948ef507-73d7-42cc-b971-c49115a59b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b91f5364-9978-4bdf-9e6b-a0cc280f13ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_948ef507-73d7-42cc-b971-c49115a59b3f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b91f5364-9978-4bdf-9e6b-a0cc280f13ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1d141824-c774-4f3a-89fe-ba3890a76dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_948ef507-73d7-42cc-b971-c49115a59b3f" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1d141824-c774-4f3a-89fe-ba3890a76dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_b75ee180-db0f-4241-93ec-7e976bf490c3" xlink:href="agio-20200331.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_948ef507-73d7-42cc-b971-c49115a59b3f" xlink:to="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_b75ee180-db0f-4241-93ec-7e976bf490c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_be46ceea-616a-4a20-b6fa-a5b9ff97dc85" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_948ef507-73d7-42cc-b971-c49115a59b3f" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_be46ceea-616a-4a20-b6fa-a5b9ff97dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d37ea494-7b9d-4596-91cf-72628e887985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8113e3e7-4762-4086-9a11-bd3e35adb430" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d37ea494-7b9d-4596-91cf-72628e887985" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8113e3e7-4762-4086-9a11-bd3e35adb430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea79f477-e60c-4629-9ebd-d61f04d566da" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8113e3e7-4762-4086-9a11-bd3e35adb430" xlink:to="loc_srt_ProductOrServiceAxis_ea79f477-e60c-4629-9ebd-d61f04d566da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10ec0b90-0502-4e66-b717-0f7f53ca82e6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ea79f477-e60c-4629-9ebd-d61f04d566da" xlink:to="loc_srt_ProductsAndServicesDomain_10ec0b90-0502-4e66-b717-0f7f53ca82e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c93036fa-3c94-470e-9824-9cc8e23d06c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10ec0b90-0502-4e66-b717-0f7f53ca82e6" xlink:to="loc_us-gaap_ProductMember_c93036fa-3c94-470e-9824-9cc8e23d06c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e1cd66ac-c45a-43af-8286-1c6d2ee68cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8113e3e7-4762-4086-9a11-bd3e35adb430" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e1cd66ac-c45a-43af-8286-1c6d2ee68cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f52d284f-ae29-42ae-8660-c12e10f11570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e1cd66ac-c45a-43af-8286-1c6d2ee68cab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f52d284f-ae29-42ae-8660-c12e10f11570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4e657a0f-f108-4aa8-a390-b1ba49c55cce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:href="agio-20200331.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4e657a0f-f108-4aa8-a390-b1ba49c55cce" xlink:to="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_57e923a1-289b-47dd-9502-407400f7406c" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_57e923a1-289b-47dd-9502-407400f7406c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_4b80b76b-11c9-4d72-b371-78eaec0f1f8a" xlink:href="agio-20200331.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_4b80b76b-11c9-4d72-b371-78eaec0f1f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_4f135110-be4c-4f84-8ab0-ce3bff635fde" xlink:href="agio-20200331.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_4f135110-be4c-4f84-8ab0-ce3bff635fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_fed804b3-2c06-47a2-8cdc-4d0d4d27d65e" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_fed804b3-2c06-47a2-8cdc-4d0d4d27d65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_db871f9f-313b-497f-99a6-322226699bcc" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_db871f9f-313b-497f-99a6-322226699bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_6731af2f-75e7-43a2-a8a0-ef1638b2b1b1" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_d74510d1-bf7d-42d5-b671-33657b0baae5" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_6731af2f-75e7-43a2-a8a0-ef1638b2b1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:href="agio-20200331.xsd#agio_GovernmentRebatesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4e657a0f-f108-4aa8-a390-b1ba49c55cce" xlink:to="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_4946ee84-c6a4-4069-abab-b27ec8b6eeac" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:to="loc_agio_ContractWithCustomerRebateReserve_4946ee84-c6a4-4069-abab-b27ec8b6eeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_8f55f541-788a-4bfe-ad8c-afab291869e7" xlink:href="agio-20200331.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_8f55f541-788a-4bfe-ad8c-afab291869e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_bd00b29a-4790-497f-93cd-e89ff7532fc3" xlink:href="agio-20200331.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_bd00b29a-4790-497f-93cd-e89ff7532fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_b494fdcd-febe-4b9c-b60e-d198fe2282c1" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_b494fdcd-febe-4b9c-b60e-d198fe2282c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_ae99f9b7-988c-4c09-88d2-9617fdf22d11" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_ae99f9b7-988c-4c09-88d2-9617fdf22d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_549596e5-faf6-4f25-8ae3-cd7e4bed915b" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_593e1730-b622-4844-8ec3-ddfd6670bae3" xlink:to="loc_agio_ContractWithCustomerRebateReserve_549596e5-faf6-4f25-8ae3-cd7e4bed915b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:href="agio-20200331.xsd#agio_ProductReturnsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4e657a0f-f108-4aa8-a390-b1ba49c55cce" xlink:to="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_3ec7caec-cf24-471e-89f3-73a6472b9d30" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_3ec7caec-cf24-471e-89f3-73a6472b9d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_d8c96de1-57da-4bfa-a5a1-e358c805f786" xlink:href="agio-20200331.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_d8c96de1-57da-4bfa-a5a1-e358c805f786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_854df83f-020a-4fa0-ab83-f46bfa7f40e7" xlink:href="agio-20200331.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_854df83f-020a-4fa0-ab83-f46bfa7f40e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_0b8861b1-e998-415e-9438-7d4664b95fbc" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_0b8861b1-e998-415e-9438-7d4664b95fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_0b8bcc71-f45e-4edc-b55b-389acf2732ec" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_0b8bcc71-f45e-4edc-b55b-389acf2732ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_d39992be-7f7b-4a69-8f0d-c1033dd5231e" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_07a00110-1621-4b69-bfd3-b6b7a5448c5c" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_d39992be-7f7b-4a69-8f0d-c1033dd5231e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4bca675f-0d98-4833-9bf3-eba5693c8c41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4e657a0f-f108-4aa8-a390-b1ba49c55cce" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4bca675f-0d98-4833-9bf3-eba5693c8c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_8736a64e-6044-4b3c-977a-6b3335f4981e" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4bca675f-0d98-4833-9bf3-eba5693c8c41" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_8736a64e-6044-4b3c-977a-6b3335f4981e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_de982a1e-6ad4-48b8-b6ed-135b9585e4eb" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4bca675f-0d98-4833-9bf3-eba5693c8c41" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_de982a1e-6ad4-48b8-b6ed-135b9585e4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_fbde81b9-6f45-4156-9112-d3a6de0e6994" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4bca675f-0d98-4833-9bf3-eba5693c8c41" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_fbde81b9-6f45-4156-9112-d3a6de0e6994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_13de635b-cb7d-40c0-ae53-244de5d1477f" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4bca675f-0d98-4833-9bf3-eba5693c8c41" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_13de635b-cb7d-40c0-ae53-244de5d1477f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_585f792d-916f-4f54-b668-fe28ad61467c" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4bca675f-0d98-4833-9bf3-eba5693c8c41" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_585f792d-916f-4f54-b668-fe28ad61467c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db17bd56-65e7-490f-adcc-0fc15637edf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_456a51f9-9dbf-4577-9fb8-288448bcf353" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db17bd56-65e7-490f-adcc-0fc15637edf6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_456a51f9-9dbf-4577-9fb8-288448bcf353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_a69f92ac-30e5-4324-9e87-a280f63fdf4d" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db17bd56-65e7-490f-adcc-0fc15637edf6" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_a69f92ac-30e5-4324-9e87-a280f63fdf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_d05a19ec-f1e0-4361-86ee-85f34082feff" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_db17bd56-65e7-490f-adcc-0fc15637edf6" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_d05a19ec-f1e0-4361-86ee-85f34082feff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_09b99e51-9b12-4c5a-b486-fad74109e8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_f9912713-f130-4d31-90c5-54f5190174b6" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_09b99e51-9b12-4c5a-b486-fad74109e8d8" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_f9912713-f130-4d31-90c5-54f5190174b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_dd664779-48b0-4174-a64a-1135fdd8b136" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_f9912713-f130-4d31-90c5-54f5190174b6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_dd664779-48b0-4174-a64a-1135fdd8b136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractwithCustomerAssetRevenueRecognized_cd6fb8d7-2002-4681-8513-ba203443b722" xlink:href="agio-20200331.xsd#agio_ContractwithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_f9912713-f130-4d31-90c5-54f5190174b6" xlink:to="loc_agio_ContractwithCustomerAssetRevenueRecognized_cd6fb8d7-2002-4681-8513-ba203443b722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_7431b910-ead1-4503-98d0-e2a18314dc4c" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_f9912713-f130-4d31-90c5-54f5190174b6" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_7431b910-ead1-4503-98d0-e2a18314dc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b23482fb-0c83-429d-be43-6a51ec27f128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_f9912713-f130-4d31-90c5-54f5190174b6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b23482fb-0c83-429d-be43-6a51ec27f128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_3f83f62e-c0e3-4742-9693-514cf9e4d5df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_fa46ac93-4e78-47e6-a010-1b87129c8a86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_3f83f62e-c0e3-4742-9693-514cf9e4d5df" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_fa46ac93-4e78-47e6-a010-1b87129c8a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c3b4598d-8578-40b0-b587-8a73e9c2001b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_a6558317-ab5b-4ca6-9d07-4ce9375cb39f" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c3b4598d-8578-40b0-b587-8a73e9c2001b" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_a6558317-ab5b-4ca6-9d07-4ce9375cb39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_fcaae157-ed7e-4757-bbc1-a0416d401aff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c3b4598d-8578-40b0-b587-8a73e9c2001b" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_fcaae157-ed7e-4757-bbc1-a0416d401aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_c1841695-13a4-468a-9a2b-315fc2158a7d" xlink:href="agio-20200331.xsd#agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c3b4598d-8578-40b0-b587-8a73e9c2001b" xlink:to="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_c1841695-13a4-468a-9a2b-315fc2158a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_604081af-227d-4402-a1ef-7f7089d265ab" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c3b4598d-8578-40b0-b587-8a73e9c2001b" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_604081af-227d-4402-a1ef-7f7089d265ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock_615cb099-ad53-47bf-ba4a-cdcfc6c42c90" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_c3b4598d-8578-40b0-b587-8a73e9c2001b" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock_615cb099-ad53-47bf-ba4a-cdcfc6c42c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_aab366d9-c442-47ec-ac2c-55fe5725aa0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_aab366d9-c442-47ec-ac2c-55fe5725aa0b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_98939435-b1af-489b-aa67-4a0050a14139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:to="loc_us-gaap_TypeOfArrangementAxis_98939435-b1af-489b-aa67-4a0050a14139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_98939435-b1af-489b-aa67-4a0050a14139" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_d72fe1c2-8aae-4617-b09e-26f767aa203a" xlink:href="agio-20200331.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:to="loc_agio_Agreement2010Member_d72fe1c2-8aae-4617-b09e-26f767aa203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MasterResearchAndCollaborationAgreementMember_3f1c1443-21ed-449b-b46f-b3cf53314bd7" xlink:href="agio-20200331.xsd#agio_MasterResearchAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab3d108b-d287-42e1-a805-e840a5bfd6b2" xlink:to="loc_agio_MasterResearchAndCollaborationAgreementMember_3f1c1443-21ed-449b-b46f-b3cf53314bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b988291f-083c-46f0-af72-a7b31e4fafeb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:to="loc_srt_CounterpartyNameAxis_b988291f-083c-46f0-af72-a7b31e4fafeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb7974c3-c7f2-41d2-81c1-c260861c9ef3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b988291f-083c-46f0-af72-a7b31e4fafeb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb7974c3-c7f2-41d2-81c1-c260861c9ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_8179ab9d-4d4a-4188-b6da-d02ffe511f20" xlink:href="agio-20200331.xsd#agio_CelgeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bb7974c3-c7f2-41d2-81c1-c260861c9ef3" xlink:to="loc_agio_CelgeneMember_8179ab9d-4d4a-4188-b6da-d02ffe511f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b6ed6ae-522d-4805-b249-79f168137991" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:to="loc_srt_RangeAxis_7b6ed6ae-522d-4805-b249-79f168137991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f98278fd-00a4-422b-be34-373aba5e6514" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b6ed6ae-522d-4805-b249-79f168137991" xlink:to="loc_srt_RangeMember_f98278fd-00a4-422b-be34-373aba5e6514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_90e7cd89-d15e-48b6-89ca-f6b19f0ec88d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f98278fd-00a4-422b-be34-373aba5e6514" xlink:to="loc_srt_MaximumMember_90e7cd89-d15e-48b6-89ca-f6b19f0ec88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4e1249f-99fe-4c08-a35e-149afaf2cc95" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_0a690807-5d80-497c-a781-0c5d730db7b8" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_0a690807-5d80-497c-a781-0c5d730db7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram_14aa0d3b-7d75-4341-bc1d-94c6753026a8" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram_14aa0d3b-7d75-4341-bc1d-94c6753026a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram_8209f560-9612-473c-8bce-6fa448608fdf" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram_8209f560-9612-473c-8bce-6fa448608fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement_f19eab56-47a5-4639-a449-fde0eafaadb9" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement_f19eab56-47a5-4639-a449-fde0eafaadb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions_ff009787-26fc-4e86-b24f-8125c629549b" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions_ff009787-26fc-4e86-b24f-8125c629549b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions_79034d12-6464-4560-9354-1625e8393356" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions_79034d12-6464-4560-9354-1625e8393356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm_18fa6d5c-7515-47a1-82b8-a75f95ef58b7" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm_18fa6d5c-7515-47a1-82b8-a75f95ef58b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_fc49fb07-2e5c-4868-848b-871a5718f098" xlink:href="agio-20200331.xsd#agio_UpfrontPaymentAgreementExtensionFeeReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_fc49fb07-2e5c-4868-848b-871a5718f098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OptionExerciseFeeReceivable_755025b0-ef74-41f7-9a36-40cf7a1df572" xlink:href="agio-20200331.xsd#agio_OptionExerciseFeeReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c259072c-e4be-4855-8359-5e2d4b8dab04" xlink:to="loc_agio_OptionExerciseFeeReceivable_755025b0-ef74-41f7-9a36-40cf7a1df572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_d0083830-bcb2-4154-a793-bed171ddbdac" xlink:href="agio-20200331.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCollaborationRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_1e80a0c3-36fc-429e-a70b-32d8286d63e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c6a48a49-daa2-4baf-a6c8-db10fbc78a77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_1e80a0c3-36fc-429e-a70b-32d8286d63e5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c6a48a49-daa2-4baf-a6c8-db10fbc78a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c6a48a49-daa2-4baf-a6c8-db10fbc78a77" xlink:to="loc_srt_ProductOrServiceAxis_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e19ef9fc-e54d-4ff7-a21d-d7c164e8fd83" xlink:to="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_611e0944-76bc-41d4-968b-83947e6d1e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_us-gaap_LicenseAndServiceMember_611e0944-76bc-41d4-968b-83947e6d1e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchServicesMember_83147404-15b9-4095-a622-e5a4be67e76a" xlink:href="agio-20200331.xsd#agio_ResearchServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_agio_ResearchServicesMember_83147404-15b9-4095-a622-e5a4be67e76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CommercializationActivityMember_060b3ac1-716c-46ce-b773-ecaa5f5d702d" xlink:href="agio-20200331.xsd#agio_CommercializationActivityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_agio_CommercializationActivityMember_060b3ac1-716c-46ce-b773-ecaa5f5d702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_7a0c5cb1-3c20-491d-a0e0-bad39fe7b3c5" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4797798e-e85b-4617-906e-da109d186f82" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_7a0c5cb1-3c20-491d-a0e0-bad39fe7b3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5294c129-134d-479e-b040-59d7bfc217c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c6a48a49-daa2-4baf-a6c8-db10fbc78a77" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5294c129-134d-479e-b040-59d7bfc217c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54b6b2c8-7e91-4dd0-a8fe-0ade37661f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5294c129-134d-479e-b040-59d7bfc217c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54b6b2c8-7e91-4dd0-a8fe-0ade37661f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_492a3139-ca13-4d51-a79d-3bd0178634bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityTable_65125af6-2a6c-4db6-a529-ccb685dd3f1f" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_492a3139-ca13-4d51-a79d-3bd0178634bc" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityTable_65125af6-2a6c-4db6-a529-ccb685dd3f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a6737603-33de-4892-855c-ce63fb1eb37d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable_65125af6-2a6c-4db6-a529-ccb685dd3f1f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a6737603-33de-4892-855c-ce63fb1eb37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a6737603-33de-4892-855c-ce63fb1eb37d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_f12c5224-22b2-4dd3-a050-ba6496ef1d06" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:to="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_f12c5224-22b2-4dd3-a050-ba6496ef1d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_d95ba119-1844-4964-ab87-9d74700a8f78" xlink:href="agio-20200331.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_d95ba119-1844-4964-ab87-9d74700a8f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredRevenueCurrentMember_b031050e-7f06-43bb-aa75-fe9e7184a230" xlink:href="agio-20200331.xsd#agio_DeferredRevenueCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d966f1a6-9225-4874-86c8-6fa974c0c0a0" xlink:to="loc_agio_DeferredRevenueCurrentMember_b031050e-7f06-43bb-aa75-fe9e7184a230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable_65125af6-2a6c-4db6-a529-ccb685dd3f1f" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_46e0f30e-8971-4e65-823e-ccbfcfd56f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_46e0f30e-8971-4e65-823e-ccbfcfd56f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractwithCustomerAssetRevenueRecognized_07917041-61ad-40ea-9e52-aa5230f54496" xlink:href="agio-20200331.xsd#agio_ContractwithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:to="loc_agio_ContractwithCustomerAssetRevenueRecognized_07917041-61ad-40ea-9e52-aa5230f54496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_4dc57256-9c10-4249-aa34-bbc55a052a76" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_4dc57256-9c10-4249-aa34-bbc55a052a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_59211b32-1c6d-4b83-b890-059ada914bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ecc61978-4291-4754-8294-861987b86892" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_59211b32-1c6d-4b83-b890-059ada914bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_d4da47d6-a885-4843-a6f4-47f7e68bdef5" xlink:to="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_02170498-024e-4b7c-a140-bef2fce2f309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:to="loc_us-gaap_ContractWithCustomerLiability_02170498-024e-4b7c-a140-bef2fce2f309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fe0f49c5-314c-47f4-8a1d-a0389e05b949" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fe0f49c5-314c-47f4-8a1d-a0389e05b949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_0394f537-d60d-4231-8347-1f83f6f14f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_0394f537-d60d-4231-8347-1f83f6f14f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a1585877-2114-40d7-9292-af6d463058d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d0bc2667-63e6-4cfc-b36e-694460224938" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a1585877-2114-40d7-9292-af6d463058d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_8869e7a6-d489-4c3c-a9a1-6b2a85182b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ebf2f18d-59ec-4051-9081-36e820721d56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_8869e7a6-d489-4c3c-a9a1-6b2a85182b2c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ebf2f18d-59ec-4051-9081-36e820721d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a03fca1a-2c0a-4bb3-93ae-ab5b3bf7d510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_8869e7a6-d489-4c3c-a9a1-6b2a85182b2c" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a03fca1a-2c0a-4bb3-93ae-ab5b3bf7d510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ab776633-5ac3-49d2-a5d1-0db6711b7f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ab776633-5ac3-49d2-a5d1-0db6711b7f6f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dab12926-0a3a-4987-b04a-414832786d57" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:to="loc_srt_ProductOrServiceAxis_dab12926-0a3a-4987-b04a-414832786d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dab12926-0a3a-4987-b04a-414832786d57" xlink:to="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_18b575fd-5d21-46a0-9b63-3db65e4b3e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:to="loc_us-gaap_RoyaltyMember_18b575fd-5d21-46a0-9b63-3db65e4b3e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_6c23a82c-aa41-415a-82ab-4ff3a96d0a8e" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_345d0804-5363-4384-856e-026a9762694a" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_6c23a82c-aa41-415a-82ab-4ff3a96d0a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5a2dc791-468b-4c37-baff-ab4fe6f204e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5a2dc791-468b-4c37-baff-ab4fe6f204e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5047658b-e292-49cc-9522-312a1127b609" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5a2dc791-468b-4c37-baff-ab4fe6f204e2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5047658b-e292-49cc-9522-312a1127b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_d96eccc4-a239-4d62-a47e-a8ebc0e33839" xlink:href="agio-20200331.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5047658b-e292-49cc-9522-312a1127b609" xlink:to="loc_agio_Agreement2010Member_d96eccc4-a239-4d62-a47e-a8ebc0e33839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c88e5a74-e68e-4b97-b5cc-01481c992302" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ef706513-42d6-41c3-bbd2-e3375e83e717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ef706513-42d6-41c3-bbd2-e3375e83e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_7ccfe1b4-2cc6-4d26-99c7-a65c9b445556" xlink:href="agio-20200331.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_7ccfe1b4-2cc6-4d26-99c7-a65c9b445556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_32c46594-f7dc-4c1d-92a0-9ea34ab0cd9b" xlink:href="agio-20200331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aacd2042-1cf5-4ab5-a006-463adadef8c6" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_32c46594-f7dc-4c1d-92a0-9ea34ab0cd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_48331119-db53-46c3-becc-d56a82647cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_48331119-db53-46c3-becc-d56a82647cee" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_21a5b7fc-a0ac-49df-93b8-667e1ab30878" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_srt_CounterpartyNameAxis_21a5b7fc-a0ac-49df-93b8-667e1ab30878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37fd76ea-4f7a-4c9a-8aa1-117b670cbdca" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_21a5b7fc-a0ac-49df-93b8-667e1ab30878" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37fd76ea-4f7a-4c9a-8aa1-117b670cbdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStonePharmaceuticalsMember_7ea71e79-56f3-4e8d-924f-2447e93ff94d" xlink:href="agio-20200331.xsd#agio_CStonePharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37fd76ea-4f7a-4c9a-8aa1-117b670cbdca" xlink:to="loc_agio_CStonePharmaceuticalsMember_7ea71e79-56f3-4e8d-924f-2447e93ff94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7b54d2-f31b-47c8-8630-e8f41a8b93e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a8bbc4f-140c-4b48-9ed9-b5d60b841c04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7b54d2-f31b-47c8-8630-e8f41a8b93e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_267af13d-b277-47e2-847a-7d32339d602f" xlink:href="agio-20200331.xsd#agio_CStoneAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7b54d2-f31b-47c8-8630-e8f41a8b93e5" xlink:to="loc_agio_CStoneAgreementMember_267af13d-b277-47e2-847a-7d32339d602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a8de7513-ac89-4f2c-b13c-fcc736073a08" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_srt_ProductOrServiceAxis_a8de7513-ac89-4f2c-b13c-fcc736073a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a8de7513-ac89-4f2c-b13c-fcc736073a08" xlink:to="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_dfba0782-6481-4f50-ad72-d6fe15473d5c" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_dfba0782-6481-4f50-ad72-d6fe15473d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_1da1c4dd-59ad-4222-9514-f7c8594be5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f46c5bd7-2f24-427c-abc6-c2f8ad71465f" xlink:to="loc_us-gaap_RoyaltyMember_1da1c4dd-59ad-4222-9514-f7c8594be5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2847cd6-0b48-4217-a82c-b217707b83db" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_srt_RangeAxis_e2847cd6-0b48-4217-a82c-b217707b83db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e2847cd6-0b48-4217-a82c-b217707b83db" xlink:to="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_777aa1e3-19a2-494c-ba83-aea74507472a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:to="loc_srt_MinimumMember_777aa1e3-19a2-494c-ba83-aea74507472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7047e866-c83a-48b9-8f62-f75642de3d4d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a4105d6b-a1e5-489f-a62e-09e6403a1658" xlink:to="loc_srt_MaximumMember_7047e866-c83a-48b9-8f62-f75642de3d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ab29ac8-dab7-4e18-b828-5708fe308cfc" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_535bc5a9-2f17-4576-bf1d-4ac81a175427" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_535bc5a9-2f17-4576-bf1d-4ac81a175427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_47a0f938-6a17-4524-8aef-6deafd4dbd83" xlink:href="agio-20200331.xsd#agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_47a0f938-6a17-4524-8aef-6deafd4dbd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyPercentageRemitted_2504dc5d-8b83-41e9-ae1e-38899e13e3e1" xlink:href="agio-20200331.xsd#agio_RoyaltyPercentageRemitted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_RoyaltyPercentageRemitted_2504dc5d-8b83-41e9-ae1e-38899e13e3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_dd691756-a9c3-4f37-b252-69151f3dea23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_dd691756-a9c3-4f37-b252-69151f3dea23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cb8436f-f722-4954-abae-82f0b7cb034e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cb8436f-f722-4954-abae-82f0b7cb034e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_9830dac5-f9c9-4d8f-b97a-b78596509de5" xlink:href="agio-20200331.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b2387385-0361-4143-9a2b-88c1ac5a38fc" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_9830dac5-f9c9-4d8f-b97a-b78596509de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable_9a4d7d64-4ae6-4841-91c9-3db57bc9c16d" xlink:href="agio-20200331.xsd#agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_d34750bf-975e-421d-9e4b-4ff5bce1a11f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_d34750bf-975e-421d-9e4b-4ff5bce1a11f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:to="loc_srt_ProductOrServiceAxis_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f984c8b3-5a1b-4d39-b0e5-4af3a8d6bd8e" xlink:to="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_5a60f026-0eda-4cb0-8b6d-08d351c74db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:to="loc_us-gaap_LicenseAndServiceMember_5a60f026-0eda-4cb0-8b6d-08d351c74db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_7c8d2d6a-08a3-4f17-af52-f20a6ece6550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:to="loc_us-gaap_ServiceOtherMember_7c8d2d6a-08a3-4f17-af52-f20a6ece6550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_10c30a59-1ac8-4b1c-863c-fcd80feb53f8" xlink:href="agio-20200331.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92ee879a-b375-4219-8e40-6567fd6b65a5" xlink:to="loc_agio_CollaborationRevenueOtherMember_10c30a59-1ac8-4b1c-863c-fcd80feb53f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_84a62826-c46c-4ec2-92f1-16eed67c9469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:to="loc_us-gaap_TypeOfArrangementAxis_84a62826-c46c-4ec2-92f1-16eed67c9469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7572aa62-ea14-492e-af83-62238635d1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84a62826-c46c-4ec2-92f1-16eed67c9469" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7572aa62-ea14-492e-af83-62238635d1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_f2cdd600-f83b-4b0e-aa37-ea6d503b7b4b" xlink:href="agio-20200331.xsd#agio_CStoneAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7572aa62-ea14-492e-af83-62238635d1f0" xlink:to="loc_agio_CStoneAgreementMember_f2cdd600-f83b-4b0e-aa37-ea6d503b7b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5820401c-97c5-46d1-bdb0-dbf02c786ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7e9ad3cc-6f14-493c-b098-651314181876" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5820401c-97c5-46d1-bdb0-dbf02c786ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9558bfaf-18a3-4211-b799-d321166819b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5820401c-97c5-46d1-bdb0-dbf02c786ac7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9558bfaf-18a3-4211-b799-d321166819b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_87fa1b1f-5ed5-41d2-9b3c-8c65db9c1890" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_87fa1b1f-5ed5-41d2-9b3c-8c65db9c1890" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9af26a2b-9e86-4c36-8f8e-c15098d69844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9af26a2b-9e86-4c36-8f8e-c15098d69844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7ef7654b-6d00-4fab-a993-341a146a341a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9af26a2b-9e86-4c36-8f8e-c15098d69844" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7ef7654b-6d00-4fab-a993-341a146a341a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_f11018b3-4177-4836-98a6-c93fce03311d" xlink:href="agio-20200331.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7ef7654b-6d00-4fab-a993-341a146a341a" xlink:to="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_f11018b3-4177-4836-98a6-c93fce03311d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e7211ff-1406-493f-93d7-07d3ebf0569e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e7211ff-1406-493f-93d7-07d3ebf0569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb5dfe7-ab58-4310-b9ad-fc1633dc5e69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e7211ff-1406-493f-93d7-07d3ebf0569e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb5dfe7-ab58-4310-b9ad-fc1633dc5e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_842343a5-fe5e-4a97-8c12-a1b456f23ac3" xlink:href="agio-20200331.xsd#agio_CStoneAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb5dfe7-ab58-4310-b9ad-fc1633dc5e69" xlink:to="loc_agio_CStoneAgreementMember_842343a5-fe5e-4a97-8c12-a1b456f23ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7e68584-1499-4fb2-aa47-a189595eebf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9dc4e34-5a28-46f7-9548-1a2e10894d70" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7e68584-1499-4fb2-aa47-a189595eebf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:href="agio-20200331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7e68584-1499-4fb2-aa47-a189595eebf0" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_fdd517a1-5d87-4a27-b075-a9d53df182c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_fdd517a1-5d87-4a27-b075-a9d53df182c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_0b4d3229-c904-4666-aea8-d5bfcea8c5f5" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_0b4d3229-c904-4666-aea8-d5bfcea8c5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_fb64dee3-e290-4c3e-acb4-8122e8216ccb" xlink:href="agio-20200331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_fb64dee3-e290-4c3e-acb4-8122e8216ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_4bbc8042-d1a1-46cf-a91e-785d5b4fd857" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_90521ebf-625e-42cb-900b-6500b580fc3b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_4bbc8042-d1a1-46cf-a91e-785d5b4fd857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9ebf9bd-8038-4e71-bc2c-ee53617516f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aa7cb155-f96e-4e37-b9ab-145a58c8eaed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9ebf9bd-8038-4e71-bc2c-ee53617516f6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aa7cb155-f96e-4e37-b9ab-145a58c8eaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef64aac-b112-4861-a7e8-b79026e421b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4f0b6477-7dd0-4aa1-aa99-fcf242783407" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef64aac-b112-4861-a7e8-b79026e421b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4f0b6477-7dd0-4aa1-aa99-fcf242783407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4456b4fb-8bbe-4591-96b7-da04d48f02b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef64aac-b112-4861-a7e8-b79026e421b5" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4456b4fb-8bbe-4591-96b7-da04d48f02b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_10a0d24c-d65e-4459-bdd7-d2f429db46a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef64aac-b112-4861-a7e8-b79026e421b5" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_10a0d24c-d65e-4459-bdd7-d2f429db46a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_a6fdf721-d8da-4690-bf58-b3b0dd5a7b46" xlink:href="agio-20200331.xsd#agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef64aac-b112-4861-a7e8-b79026e421b5" xlink:to="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_a6fdf721-d8da-4690-bf58-b3b0dd5a7b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c7d4c7e6-cea1-47d2-ba4b-98a4358675af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef64aac-b112-4861-a7e8-b79026e421b5" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c7d4c7e6-cea1-47d2-ba4b-98a4358675af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_072c3938-4ebe-4a6a-ad8f-b5780a60cae6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef64aac-b112-4861-a7e8-b79026e421b5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_072c3938-4ebe-4a6a-ad8f-b5780a60cae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4001c17c-47ea-48c7-b608-e9bb4b0354f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4001c17c-47ea-48c7-b608-e9bb4b0354f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fde287dc-843c-4838-9ad9-762199a771ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:to="loc_us-gaap_PlanNameAxis_fde287dc-843c-4838-9ad9-762199a771ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fde287dc-843c-4838-9ad9-762199a771ba" xlink:to="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_ccb3c504-9489-4a75-839d-5cffde9a9511" xlink:href="agio-20200331.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_ccb3c504-9489-4a75-839d-5cffde9a9511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_2f60c83d-d277-4050-ae4d-1fb0f712191d" xlink:href="agio-20200331.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_2f60c83d-d277-4050-ae4d-1fb0f712191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_18f286ef-a52f-4cee-93f3-8c5f93b245d8" xlink:href="agio-20200331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1e382255-cd7e-4c0d-b782-2b4a819b0803" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_18f286ef-a52f-4cee-93f3-8c5f93b245d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc76c103-163d-4e6e-a314-d83421e3497d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:to="loc_us-gaap_AwardTypeAxis_cc76c103-163d-4e6e-a314-d83421e3497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc76c103-163d-4e6e-a314-d83421e3497d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d758d9f6-bfad-4640-b595-ef4b0a1bdd3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d758d9f6-bfad-4640-b595-ef4b0a1bdd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember_855dc571-b817-40f8-89ae-dd0253e3e752" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember_855dc571-b817-40f8-89ae-dd0253e3e752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_b0a41cd1-9d3c-4930-891b-bdbf41fcec80" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_b0a41cd1-9d3c-4930-891b-bdbf41fcec80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_6321b52d-1f67-4ecf-89be-fb03d80d247d" xlink:href="agio-20200331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6ba03d4-6851-4d2f-8c53-e03bc700129c" xlink:to="loc_agio_MarketBasedStockUnitsMember_6321b52d-1f67-4ecf-89be-fb03d80d247d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416cdd43-a546-47c4-ba5e-c47f65b46225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a9635c52-bfb8-4ea2-af83-5ad5c5484a22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a9635c52-bfb8-4ea2-af83-5ad5c5484a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_837fdce8-4afd-4400-aa5b-5446f375a4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_837fdce8-4afd-4400-aa5b-5446f375a4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0450fab8-9ad4-4f70-8837-1e31a9dddfbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0450fab8-9ad4-4f70-8837-1e31a9dddfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1646e41-7211-4027-8366-936b9a046096" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1646e41-7211-4027-8366-936b9a046096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5cb1e903-b2c5-4a6e-9013-ba83830fddc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5cb1e903-b2c5-4a6e-9013-ba83830fddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_71828391-b9b2-4b4b-9454-24e433038c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_71828391-b9b2-4b4b-9454-24e433038c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_dbc3a8ab-4fae-4fb2-a192-ef9e679d8036" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6de7dd83-420e-41f3-b9d3-86d8288481f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_dbc3a8ab-4fae-4fb2-a192-ef9e679d8036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_643f9d26-5cac-46f9-9497-70fed4251eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d085846-3e1c-4fd7-a295-27122a263562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_643f9d26-5cac-46f9-9497-70fed4251eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d085846-3e1c-4fd7-a295-27122a263562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82725cbc-f3fe-48c4-9c1e-33ea07c2bdba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d085846-3e1c-4fd7-a295-27122a263562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82725cbc-f3fe-48c4-9c1e-33ea07c2bdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_795ea3d7-b54e-4c5c-88d5-172128d79104" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d085846-3e1c-4fd7-a295-27122a263562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_795ea3d7-b54e-4c5c-88d5-172128d79104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c62b10fb-d9ac-4725-a74f-30612402f695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d085846-3e1c-4fd7-a295-27122a263562" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c62b10fb-d9ac-4725-a74f-30612402f695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e347c95c-cc8f-4370-abe5-08e5495d40b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d085846-3e1c-4fd7-a295-27122a263562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e347c95c-cc8f-4370-abe5-08e5495d40b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa4c2f1f-ad0d-4c1b-8881-f226bc802c32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d085846-3e1c-4fd7-a295-27122a263562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa4c2f1f-ad0d-4c1b-8881-f226bc802c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12bf785f-b336-4e00-83a9-da8683fed190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_643f9d26-5cac-46f9-9497-70fed4251eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12bf785f-b336-4e00-83a9-da8683fed190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_460402a5-2271-4885-9543-6f7e42a485a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_643f9d26-5cac-46f9-9497-70fed4251eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_460402a5-2271-4885-9543-6f7e42a485a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_88f21943-c14a-478e-b611-3231c4065993" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_643f9d26-5cac-46f9-9497-70fed4251eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_88f21943-c14a-478e-b611-3231c4065993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e544a0b9-aa93-4ee2-9d73-955fcfa4cd38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_88f21943-c14a-478e-b611-3231c4065993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e544a0b9-aa93-4ee2-9d73-955fcfa4cd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c03271fd-96c6-4e65-ae5f-0d676ee5aaf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_88f21943-c14a-478e-b611-3231c4065993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c03271fd-96c6-4e65-ae5f-0d676ee5aaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_092aba5c-7cbf-4bf6-8db2-bf318c5117f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_88f21943-c14a-478e-b611-3231c4065993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_092aba5c-7cbf-4bf6-8db2-bf318c5117f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3a17493a-3035-474c-a68c-386c94ec0024" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_88f21943-c14a-478e-b611-3231c4065993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3a17493a-3035-474c-a68c-386c94ec0024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d94297f9-facf-40fa-9c80-635f8b313b98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_88f21943-c14a-478e-b611-3231c4065993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d94297f9-facf-40fa-9c80-635f8b313b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8688ae32-f5db-44b8-84ac-f01ac1af8897" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_643f9d26-5cac-46f9-9497-70fed4251eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8688ae32-f5db-44b8-84ac-f01ac1af8897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3d7f29dc-9841-44e7-8d0a-ea4d5173f73f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_643f9d26-5cac-46f9-9497-70fed4251eb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3d7f29dc-9841-44e7-8d0a-ea4d5173f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_faa6f1eb-3034-42e2-afff-13031211d90f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bee5043c-8ea2-4f9b-9e03-d5c86c8f18f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_faa6f1eb-3034-42e2-afff-13031211d90f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bee5043c-8ea2-4f9b-9e03-d5c86c8f18f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bc20bbb1-251c-4586-8b79-5ebdb20e9896" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bee5043c-8ea2-4f9b-9e03-d5c86c8f18f5" xlink:to="loc_us-gaap_AwardTypeAxis_bc20bbb1-251c-4586-8b79-5ebdb20e9896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec0ab0dc-fe9f-4d02-b82b-8b43d0c10dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bc20bbb1-251c-4586-8b79-5ebdb20e9896" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec0ab0dc-fe9f-4d02-b82b-8b43d0c10dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_45c86c96-6473-4681-8d0f-c689b014d5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec0ab0dc-fe9f-4d02-b82b-8b43d0c10dc7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_45c86c96-6473-4681-8d0f-c689b014d5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bee5043c-8ea2-4f9b-9e03-d5c86c8f18f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f40a1c4a-67c0-4693-9d6f-b21a8e137ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f40a1c4a-67c0-4693-9d6f-b21a8e137ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06a4f7f8-e04a-4534-9fee-bca32e7f9a14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06a4f7f8-e04a-4534-9fee-bca32e7f9a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6c72c39-820b-4af8-81f9-3984fc6c4263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6c72c39-820b-4af8-81f9-3984fc6c4263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5b3ce53a-4c31-46ea-bcc0-2b12be96187e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5b3ce53a-4c31-46ea-bcc0-2b12be96187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0057a35c-d335-4115-bcfc-99eec5aeff56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4eff57ec-f32c-4059-bd5a-ea8e77331fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0057a35c-d335-4115-bcfc-99eec5aeff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec88e1be-d467-4377-94cf-46a0c238a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3539cdc-39b5-479f-8865-eacacab58f25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3539cdc-39b5-479f-8865-eacacab58f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8009c5a9-5a25-4495-9e0e-c1a002217c11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8009c5a9-5a25-4495-9e0e-c1a002217c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2c58b3de-6517-409e-8256-7a199b0b3725" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2c58b3de-6517-409e-8256-7a199b0b3725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0606933c-cc6a-40db-811a-4f6b23172686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0606933c-cc6a-40db-811a-4f6b23172686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_54852c55-d2ae-4870-939f-9af32a09f274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9f7fed81-d179-47ea-8987-147aa144ca7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_54852c55-d2ae-4870-939f-9af32a09f274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f9a56dc5-0f23-4cf2-a0ec-7db4cc6ddcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14d097ca-cc40-4fb2-be91-46f4e6df4112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f9a56dc5-0f23-4cf2-a0ec-7db4cc6ddcdf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14d097ca-cc40-4fb2-be91-46f4e6df4112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfdb4004-5f25-45e4-a8ad-b15544578eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14d097ca-cc40-4fb2-be91-46f4e6df4112" xlink:to="loc_us-gaap_AwardTypeAxis_bfdb4004-5f25-45e4-a8ad-b15544578eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bfdb4004-5f25-45e4-a8ad-b15544578eb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_452191af-d087-4a14-b1f2-7f064e62ccdb" xlink:href="agio-20200331.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:to="loc_agio_PerformanceBasedStockUnitMember_452191af-d087-4a14-b1f2-7f064e62ccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_923a189b-cb15-467b-a162-ad5348bba4be" xlink:href="agio-20200331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb956b44-2d58-4ece-b004-d53c407f875f" xlink:to="loc_agio_MarketBasedStockUnitsMember_923a189b-cb15-467b-a162-ad5348bba4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14d097ca-cc40-4fb2-be91-46f4e6df4112" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c35f9c09-9f36-49fe-93fb-0811a39ed033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c35f9c09-9f36-49fe-93fb-0811a39ed033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c19e8a0d-4e7b-46b6-8a08-4f543238dd90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c19e8a0d-4e7b-46b6-8a08-4f543238dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2ca1919-35f1-46a9-9df0-74a589269a03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a2ca1919-35f1-46a9-9df0-74a589269a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee5a3aa8-009b-4816-8994-e71dc1db4ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48eb654d-4d3d-42c3-b3ba-aa332a617414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee5a3aa8-009b-4816-8994-e71dc1db4ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef0f5afd-3b32-41b0-8fb6-3538b1c7a5f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_470664fc-fa6c-4b79-a295-e4df589546b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_470664fc-fa6c-4b79-a295-e4df589546b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cb3b10d1-ddc1-456a-a2d8-d4f3a82e5b65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cb3b10d1-ddc1-456a-a2d8-d4f3a82e5b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be3b94c6-8f0d-4cdb-86cb-a75c0f163377" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be3b94c6-8f0d-4cdb-86cb-a75c0f163377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_359e5dc0-79b1-4972-9b4c-dd342759469e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e235d38f-0b5d-4209-a912-7fa4968b1534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_359e5dc0-79b1-4972-9b4c-dd342759469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e95afd05-030c-4390-ab08-82027bb37a19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e97087-f639-48af-8620-8d0abc537d05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e95afd05-030c-4390-ab08-82027bb37a19" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e97087-f639-48af-8620-8d0abc537d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e97087-f639-48af-8620-8d0abc537d05" xlink:to="loc_us-gaap_AwardTypeAxis_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_407f5d4c-4284-4db6-982b-c8b5ed1e8b5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5b7b3d47-8490-496b-95d4-5edffea3e533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5b7b3d47-8490-496b-95d4-5edffea3e533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b566ef5a-4958-4ff4-8f11-614519b0a596" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b566ef5a-4958-4ff4-8f11-614519b0a596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_809e21b9-bdff-48be-a99e-ba24c1f17a91" xlink:href="agio-20200331.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_agio_PerformanceBasedStockUnitMember_809e21b9-bdff-48be-a99e-ba24c1f17a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_574daae5-36a7-41a2-9f1a-11814d614ad0" xlink:href="agio-20200331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_574daae5-36a7-41a2-9f1a-11814d614ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember_774bea0f-339a-47f2-a6d8-df38109c6d1a" xlink:href="agio-20200331.xsd#agio_OtherStockAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ae39f95-d228-4e0b-8c7c-f1098438ac9b" xlink:to="loc_agio_OtherStockAwardsMember_774bea0f-339a-47f2-a6d8-df38109c6d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccb00860-6aa2-4837-a0e3-4901038d94d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e97087-f639-48af-8620-8d0abc537d05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccb00860-6aa2-4837-a0e3-4901038d94d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3115b-22cc-4b22-a5ae-6ec784a1bdb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccb00860-6aa2-4837-a0e3-4901038d94d9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3115b-22cc-4b22-a5ae-6ec784a1bdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6dd50af2-163a-4ea6-8217-1f16c1990d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62d31ed3-ab1b-4813-ad84-7e3ac066b78e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6dd50af2-163a-4ea6-8217-1f16c1990d2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62d31ed3-ab1b-4813-ad84-7e3ac066b78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2381896-14d0-48c1-a637-f7f1b2fe8216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62d31ed3-ab1b-4813-ad84-7e3ac066b78e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2381896-14d0-48c1-a637-f7f1b2fe8216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2381896-14d0-48c1-a637-f7f1b2fe8216" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bf7f2d4c-a84c-4c5d-89ee-b2e47a0db6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bf7f2d4c-a84c-4c5d-89ee-b2e47a0db6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a070d564-028d-4cc2-b2f6-e9261a6e5b08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2092d34-d807-4ec1-bad4-29e0df3ddf9e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a070d564-028d-4cc2-b2f6-e9261a6e5b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ff8b8-f3b0-4c26-a630-f0204562a3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62d31ed3-ab1b-4813-ad84-7e3ac066b78e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ff8b8-f3b0-4c26-a630-f0204562a3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa9622c5-7f79-4b75-a093-808f5ef017d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ff8b8-f3b0-4c26-a630-f0204562a3a0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa9622c5-7f79-4b75-a093-808f5ef017d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShare" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShare"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d2293e74-123c-438d-a694-cd35991bf1da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2cab3f36-3f21-49fa-ab24-4e5b3cb987f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d2293e74-123c-438d-a694-cd35991bf1da" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2cab3f36-3f21-49fa-ab24-4e5b3cb987f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShareTables" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShareTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c5e37c6f-2f6b-4c75-bcbc-1ea2af649158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c81e064b-2878-4ac5-a35f-424492975322" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c5e37c6f-2f6b-4c75-bcbc-1ea2af649158" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c81e064b-2878-4ac5-a35f-424492975322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20200331.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ffbdbb52-5e01-4a31-b919-0a17378c8b45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52423c35-1cbc-4eed-bcc0-957ed395c2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ffbdbb52-5e01-4a31-b919-0a17378c8b45" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52423c35-1cbc-4eed-bcc0-957ed395c2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02296a16-2f98-40b2-817e-a2656f5f9362" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52423c35-1cbc-4eed-bcc0-957ed395c2c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02296a16-2f98-40b2-817e-a2656f5f9362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02296a16-2f98-40b2-817e-a2656f5f9362" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b4ef12b-cf14-48ef-8c58-2da86d8b3f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b4ef12b-cf14-48ef-8c58-2da86d8b3f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4b8b9d39-5ea1-4972-9008-36bfbc5266ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4b8b9d39-5ea1-4972-9008-36bfbc5266ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_4515764e-75f5-4717-8593-376bafb8112d" xlink:href="agio-20200331.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_agio_PerformanceStockUnitMember_4515764e-75f5-4717-8593-376bafb8112d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_3a440c98-63d0-4d69-9630-c3b8f65c72bb" xlink:href="agio-20200331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af61e4-3b30-479f-ae92-79f33fd0fdfd" xlink:to="loc_agio_EmployeePurchasePlanMember_3a440c98-63d0-4d69-9630-c3b8f65c72bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2397fe9a-31c4-48a6-bc87-9297bc77a298" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_52423c35-1cbc-4eed-bcc0-957ed395c2c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2397fe9a-31c4-48a6-bc87-9297bc77a298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1125f626-e920-4e0a-b31a-287a7317a40f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2397fe9a-31c4-48a6-bc87-9297bc77a298" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1125f626-e920-4e0a-b31a-287a7317a40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X0$&17AI9@  34T *@    @ "@$2  ,    !  $   $2  ,    !  $
M  $:  4    !    A@$;  4    !    C@$H  ,    !  (   $Q  (    .
M    E@$R  (    4    I $\  (    0    N (3  ,    !  $  (=I  0
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M#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  (
M"0 & #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !
M     -,M2% @(
M                $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H
M  )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I
M97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M#')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D
M97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@
M245#-C$Y-C8M,BXQ
M                      !865H@        \U$  0    $6S%A96B
M                6%E:(        &^B   X]0   Y!865H@        8ID
M +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT
M=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C
M+F-H
M     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:
M(       3 E6 %    !7'^=M96%S          $
M   "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D
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MK@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS
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M_;K^2_[<_VW____:  P# 0 "$0,1 #\ _?R@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MK;3]3:]TM)YC:AV /MR@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MYDN([JV\W",8Y3&7V$X /ZFZ "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /P)_X/<_@WK%U8?L3_ !\BLU?0M'?XA_"J[OE6
M5G@U+6'T_P 56EO)A_*2*:#3;EU+1;F>)@'X*D _GY/4_6@ H * "@#]/_\
M@T@^#_B#XA?\%;_!WC:ST^]G\,?"'X6?$OQ+XFU.T*"'39]6T*30?#L=VS1R
M*8;_ %6[$ 5=K/L;:X(H _J]H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M!I;&_P!0_L^1RUHR@ _3J@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M//>F1UEL];U\7.J6#Q[K(VS.QH _3@#' X'8=AVP/04 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 CNL:L[LJ(BEW=R%1$4$LS,2 JJ 222 !R>* /*_C)^W%^Q]^SY;/=?&;]I
M3X-?#U(Q,TD7B#Q]X=@O(Q;C=-YEC'?2WB;!P0T"DG*CYN* /G3QC_P<;_\
M!&WP?'<N?VT_ 'B>2VC$GD>#K/7-=DG)D\OR[:1--@MII1RY59]OE@N&/ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M\3W]E/=>%_A9X<:+7?B3XK:+S(E&E^&[>=)X;/[2JP7.I7SVUI:A_-9G"D4
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MEC9622-V4@]<YH N4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M99(X/$?Q+U*S2UN=7NKR(0RP>')9)-%TGRXWBMC>O<S. ?GD22<DDD]2>2:
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M I_\MJR_S_DT ? G@#_D?/!/_8W>&_\ T\V= ']W?P,_Y(G\'O\ LEOP^/\
MY:6D?YXH ZJ@ H * "@ H * $8A068A0H))8X  &223P !R2>@YH _'/_@NO
M_P '.O@_]CJ]\8?LI?L.7NC?$']IC3S/H?CGXH2PP:QX$^#]Y+"Z7%CI:RPW
M&E^+?&MD9$66W$EQI6AW:36^IQR7L)MT /YM/BO\7_B?\=/'?B#XF?%_QWXH
M^(WCSQ1?SZEKGBCQ;K%[K6K7]U<.7<O<WLTSI$F0D%O$4@MXE2&&-(T50 <X
M 6(4 DD@  9)).  .Y/84 ?2/['_ /P2-_X*%?MT7=@O[/'[-?CO7_#^H2>5
M%X]\1V1\&_#R-_,$96;QCXC%AHX<'<Q6.>1MB.V  -P!^A'P=_X,L_VXO%VG
M6>H?%_\ :'^!_P (;IVC-[X?M;+7/'^H0QE%:58=0T.YMM)DD20F(-Y^PX,H
M#+A6 /9[#_@R*C&FPC4OVVU;5_LY^T-9?#B1=/-UAMIA2?53.+?=MR'<R;<\
MYQ0!YC\3?^#)[]K'1+&ZO_A=^UC\%_'-Q%$6MM!UGPMXG\*WUS*/,(C&I3WE
M[IJ!AY:AI3& Q8D8 H ^#/VQ/^"$/_!3W]B"TO-<^+_[-GB+6O!ME%<75UXZ
M^%ES:?$SPK86$+';>ZQ?^%'OVT6.6/#A-3BMWB)\N4)(-I /D*XM[BTFDMKJ
M":VN(6*2P7$;PS1..JR12*KHP[JR@CTH M>'O$?B#PEK6F^(_"NMZMX<\0Z-
M=P7^D:YH6H76E:OIE];2+-;W=AJ-C+!=VES!*BR0S02I)'(H9&##- '[Q?\
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MQ5I$NR\T?7-/=MLMK=11^=$T5U;F2WFC=@#UF@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * #- $&HZ
MGINCV5QJ6JW]GINGVD3SW5[?7$5K:V\,:[I)9IYG2..-%Y9F8 #J:JE2JUZD
M*5&G.K5J24(4Z<7.<Y/:,8Q3;;Z)(BOB*&%I3KXFM2H4:493J5:U2-.G"$5>
M4ISFU&*BM6VTDMSYA_:'_P""O_[&GP"DO-*A\;R?%;Q7:J6_X1WX:K%K4;,
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MVWT/?NM[BT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_B[IE_:_"7PM/Y5W:>$K",K;7_Q'\5V@<L--TIY1'HVGRA6UG5MB /96M\R
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M^DSI;20Z=)>:E:)''XBTVPE<3G1=:2XL[AE(;RW*RH ?S2?\%>?^""?[5?\
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M(HHT4*B*J@8% %B@ H * &RQ13QO#/''-%(I22*5%DC=6&"KHP*LI'!!!!H
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M'TP(W]F>&-*M[2?4KT1)%-JVM:@$^VZOJ]V$\R\U&]FEN+F9GD=MSF@#T>@
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M.5< Y<^(,534Z?\ ;6*;I95&IRI*>'H\T<3BN2:WJ4Z5*<4G&;6C_._]H/\
M;B_:@_:>O9I?BQ\5-=OM'>[>\MO".B3RZ%X2L)7&T_9-'LI0H&S"?OII_E Y
MR*_5.%O#G@[@^G%9+DV&IU_9QISQV(C'$XVJHNZ=3$58N3=]?=4%?I;0_"^-
M_&+Q#\0JLI<2<18NMAG5E6IY=A92PF74').,HTL+2DH*/+9+VCJ-6WN>3  9
M/J23[D\DDGDDGDD\D^Y.?<[66UUT[Z;))65E:UO):'S#U=]6_/5]NW;_ (%K
MA0 4 % !_+UH_K_A^P?T_+]/Q&//#&0))40D@ ,P&23@#KU)[=?:GRR[-[[)
M]-]TOO'&,I?"G+2_NIRT2N]K[(ZCPS\&?B_XU6-_!WPL^(?BI)@#$WAWP=X@
MUA9 >Z-I]A<!^ 3\N>AKBQG$&0Y<VLPSK*\%R_%]:QV&H<O9-5:L&G]YZ&6\
M(<4YPE+*^'<ZS&,E>$L%EN+Q*FG;X?94I7W]/.UK][X=_P""?/[:_BE()-(_
M9L^)NVX>-(O[4T230R3(-R^8NLM8M$N/O-*%5#\K,#Q7FXKQ0\/<&Y*OQ;D]
MX*3E[+$K$?#:_+]7]IS;JR6^MMCVL#X'^+.8J+P_ ?$*4Y*,77P3PMVU=7^M
M2HM*VMY62TO:YU5K_P $E/\ @H=>0)<0_LX:TL;YVBX\6>!;:3@D9,,_B..5
M02.-R+D<C(P3Q3\</"VG)P?%>';5F^7!9E):JZM*.$DGIYGI4_HQ^-U2"G'@
M;&I/I/'Y/"7;6,\QC)>5UKT)/^'17_!1+_HW+5/_  L_ '_S35/_ !'/PL_Z
M*NC_ .$&:?\ S$5_Q+!XW_\ 1#XO_P ..2?_ #S$;_@D9_P4252Q_9QU4A02
M0OC+P"QX&>%'B;+$]  "2> *%XY>%C_YJN@KZ:X',TOFW@[(']&'QO2;_P!1
M\7HK_P#(QR5[=DLSN8VJ_P#!,C]O/1K?[5??LV>-O)W%,V<VBZE)N 8_ZFPU
M*XFQA3\VS!. "21731\7_#6O/DI\6Y=S;^^J])=/M5:4(WU6ET_(Y,5]'KQD
MPD/:5>!,Y<;M?N_JE:6EW\-'%5)6=G9\MGHDVV<1X@_93_:;\*"1O$/[/_Q?
MTN*+;YES/\/_ !.;)=V2,WL>FO:YP"<"4GCI7HX7C7@_&V6%XGR.LY7:A#,\
M(ZFG_3MU5+?:Z2\SQ\9X9^(67IRQO!7$V&C%V<ZF38]4[VO;VGL.1NW12Z-.
MS1PFI6EWH]V]AJUK<:9?1DA[/4(9+.Z0@E2'@N%CD4A@5(91@@CJ#7I4JE*M
M"-6C4A6IRVG3E&<'Z23Y9>D6WJNYX];#8C#U)TJ]"M1J4])TZE*<)PDMXRBU
M>+76ZOY$><C(.0>F,?Y_SC@\4_5I??\ CI^3,U]_]?)DVFZCJ6C7<5_I&H7V
MDWT#I+%>:9=W%C=1R1L&1UGM9(I,JRAAEB,CIQ4UJ5'$0E3KTZ=:G)-.%:$*
ML+-6:Y9J2V;^Y%X;$XG!U%6PN(K8:M'X:E"I.G.%G=<M2$E-:Z[[ZGTY^SS_
M ,%>_P!LSX"26.GW?CA/BQX1MGA27P]\1TDU2Z6Q@"!;'3->1DOM-C"($1]M
MR44D8Q@#X_BGP*X!XFC4JT\N_L3'S4VL7E<E1@ZLK_O*V&:=.L[N[2Y+V/T3
M@;Z47BGP;.C1KYO_ *Q97"<%+!9VIXN<:$%%>RPV*<U6H?#H[S2NTHI:'W]^
MS)_P7#_9A^,DEIH/Q7BOO@5XMF$$/F>("VH>#[Z\GD5!%8:[9)++:PKG<]QK
M5IIT*+@M*%YK\QXP^CKQAD"GBLEE2XDP,>9VPO[K'TX15VZF&J6C-NVBH5*D
MGT@V?M?A]]+WP]XJ=/!\2QK<'9G/DBI8Z2KY77J3ERJ-#%T>:I3764L52HQB
MK\T[*Y]F:!XAT+Q5I%AX@\-:QINOZ%JD"76FZQH][;ZCIM_;O]V:TO+626">
M)NSQ2,I]>M? 8G#8G!XBIA<70JX;$T9.%:A7A*E5I3C:\:E.:C*$E?522LVE
MJ?JN"QV#S+"T<;E^*P^-P>)@JF'Q6%K4Z^'K4WM.E6IRE"<7WC)KST=KE0:A
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <W\9/ D
MWQ0^$OQ,^&UO?C2KCQ]X#\6>#H-3;?MT^7Q)H=]I$=Z?+#28MGNQ-\@+_)\H
M)XH _A]_;._9(^.7[%?[0'Q!^"'Q[\!^)?!/BGPYXFURWT^;7=.N;>S\5:)%
MJ4Z:=XG\.ZE*OV37-'U6U,-U!J%A/<0[Y'@D=;B*6- #[?\ ^" ?_! [Q[_P
M4F^*6E_&C]H#PYXH\$?L8>!KRQU74=8GM9](O/C1J<%S%/%X,\'75Q&K2:+-
M&C_\)!XCM4E@MX2+*S>2\DF%N ?U6?#CX;^!?A#X&\+_  U^&?A71/!/@7P9
MHNG^'_#/ACP]86^FZ5I.DZ7:Q6=E:VUK;)'&/+MX8U>1@TLS@R2N\C,Q -N@
M H * "@ H * "@#P'_@I-_P3W^"W_!2?]E[QQ^SS\8-&MI;B^TZ_U+X<^,$M
MX6UKX?>/XK*9=#\3:/<.N]/*NC#%J=H'2+4M/::TG(#JR '\8/[4W[-7Q0_8
M_P#C_P#%']F[XR:3_8_Q#^$_BK4/"^O0Q^8UC>/9R8MM6TJXD2/[9I.JVIAO
MM.O$!CN;6:.1"0: -+]BK]JGQ]^Q/^U'\%_VG?AM>3VWB7X4>--+U][:"4P_
MVWH+2&S\3^')WR +;Q%X>N=2T:=CD1QWAE W(* /[>_@#\9O"'[1/P3^%OQR
M\!:A:ZGX0^*G@G0/&FAW=E.MS;FVUJQBN9+=9U 65[*Z:>QF8 #S[>3TH Z^
M@ H * "@ H \^_:J_:0^'G[(7[.WQ=_:4^*EZ+'P)\(/!VH^+-;(EBBGOG@,
M=KI6C633ND1U'7M9NM/T734D=$DOKZW1G526 !_%3^WU^VM\5O\ @H%^U+\4
MOVF_BWJMY>:OXYUZY?P_HTLTAT_P?X.M)&@\-^%=(M#--!96>EZ:L(FCMG,<
MU_)>79+/<$T >;?#3X;>-_C#\0/!_P +OAMX;U3Q?X\\>^(-.\,>%/#6C6TE
MYJ6L:UJDZV]I:6MO$K.Q+-YDKXV0P))-*R1QNP /ZR_^"#__  0E^&'_  2X
M^%FG_$KXD6>C>._VQOB!HEI-XV\:/ EW8_#O3[ZWBNSX!\$_:8!+9O8O*UMX
MBUJ!A)K%Y"%A?[!!"9@#]%: "@ H * "@ H * ,+XF?#/P%\8_ 7BOX7_$_P
MKHWC;P#XWT34?#OBGPOX@L8-0TK5](U2UEL[RUN;:='3YX)G"2H%FADVRPNC
MHI !_*-_P<$?\$*?$O\ P2X^*:?%SX-PZIXJ_8W^*VOWR^#M2E\^_P!4^$^N
MW,US=Q?#OQ=>>4OGP"U7=X<UYOW>HVT?V:[:'4%$,@!^;(H _H=_X-#_ /@K
M9?\ C71M2_X)G?'+Q/>:EK_A72]0\6_LTZUK=^DDDWA6PQ-XG^&4,U[<^?/+
MH_G+KGAG3[6*7R]*CUT-Y<-E$  ?N_0 4 % !0 4 % '\BO_  =*?\IB/C__
M -@?P+_ZC5E0!\"?#_\ Y'SP3_V-WAO_ -/-G0!_=Y\#/^2)_!W_ +)9\/O_
M %$M(H ZF@ H * "@ H ^7/^"P'_  45\*?\$S/V(OB=^T)J;V5[X]GM7\%_
M![PO=3[)/$7Q)\0V=Y'H0:*+?/\ V;I/DS:MJ=PD;110VBPRLK7,08 _C%^*
M/Q-\;?&;XC>-OBO\2->OO$_COXA>)M9\6^*M=U&:2>ZU'6]=OI]0OYV:5W9(
MO/G=;>!6\NV@6*"$+%$B@ [G]BC]C?XT?MY?M&_#W]FKX%:!-K?C/QSJD,5S
M=['.F^%O#D$L1U[Q=KLZC_1M&T"Q>2]O9!ND=8Q##')-)'&P!_8/_P $L?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * #(]1^= !0 4 % !0 4 % !0
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M\"?#_P#Y'SP3_P!C=X;_ /3S9T ?W>? S_DB?P=_[)9\/O\ U$M(H ZF@ H
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MV::LTUNFMTUYGZ?&49)2BU)-*46M5*,M4XM:--:IIZH=0,* "@ H * "@ H
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M'^"'Q7N+*QW7E[:7-O=:UX&UW5KI%^6VTHV6HZ#&\S,=VI6,*[57D _GU_\
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M$B^TKKNJB[WB *GV@W D^TEAYC3[S*2Y8T ?9% !0 4 % !0 4 % !0 4 %
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M[!QP?"N0X++59JIB>3V^/K7=Y>VQU=U,543E>3@ZO(F_A73T7%>4>[8* "@
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M_NM \;:O?^-M"U9(&P_V -J]YI4<PR@FL'A)5D*@ _5B@ H * "@ H * "@
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MZ">OL[MR/8,5X1]0% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MI'[1A\10Q5&EB<-6I5\/7A&K1K49QJ4ZM.:4HSA.+:E%IW33=R>I+"@ H *
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MW=I,$GMIT>*5%9: .IH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * .#_:*_:)^'/[,GPVU+XE?$B_EBLH)8].T+0-/077B+QCXDO PTSPOX9T
MU3YNHZSJ4J%88(@PCB6:YF*P1.P]+A7A;->,,WHY/E-)2J23JXG$U6X87 82
MFU[;&8RM\-+#THV;E)KFE*,(OFDD>-QSQSD7A_D.(S[/J[C2@U0P>#H6J8[-
M,=4O[#+\!0;3KXJNXOEBKJ,%*I*T8R:^%M8_8H_;#_X*B_$.W^+7[5>L:G^S
MK\!;-TE^'?P=@9+CQ=#H;L[Q7-YIC(;&RUJ\PW]IZAK2"_"S0K9Q&VAB!_1\
M/XA<!^#>52R3@NA2XIXFG_R-,_:4<#+$62<(5DO:3P\%;V5/#OV=XR=23G*5
MOQ_&>$OB?](?/(<2^(V*K\$\&4G?(^&(WEF,,'*[A4GAN;V5/%U&FZV)QJC6
ME&<8TJ7LZ:O]A_LZ?L%_LN?LNV-HGPN^%VA0:];Q[9?&>NVZ:_XON7DBCCN"
M==U-9[RWAG9#+]DM7AMHW=O+C48 ^$XK\2N,N,JLWG.<XF6&FW;+\-)X7 Q2
MDY07U:BX4Y2@FH^TFI3:2YF]3]0X%\&?#OP\HTH\.\/82&,IK7-<;!8W,Y2E
M"$:C6,Q"G5I0J."DZ=)P@GLM%;V$*  H   P !@  <  < #MQ@>G%>#^;UOO
MN[GU*5E;I_73;^NPM !0 4 % !0 4 !H YGXB_!CX3_%S27T/XF_#OP?XYTI
MMY%GXET'3M5CC=U*F6(W,#O%* <K+&RR(P#*P(!KKRK/\[R.LL1D^:X_+JVE
MYX3$U:-TOLR4)).+ZQ=T^QY^><*<-\38?ZKG^1Y7F]"[:IX_!4,0HR::YH.<
M'*$E=M2C)-.S331\2?M-?\$$?@MX^:^\0?L[>+;SX0>(9]TJ^&]::ZU_P1<W
M,CO([[F%QK&E1 $)%;V#/;H  (U K]$X0^DOQ#EGL\+Q5@J>>X6/NO%X94\+
MF,(J*23MRT*[OJY5+3;>[;/R3Q ^AAPEG?ML9P/F-3AG'33:P6,E6QF4N<I.
M<I)WEB<,FW:,*?/2BFK05K/\\OVEO^"?/[4_[*;W5]\3?AQJ%QX.AF>.+Q_X
M7637?"DD8E6&":]O;1'.BR7;'-O::H+>X?:VU"!FOU+A#Q1X,XU4*649M2AC
MY0BWE>,:PV-3<5*I&G3FU]85-OWZE'G@NY^&^('@=XB^'#J5L^R*O/+(SE&&
M;X!/%Y;*/M%3IN=>DI/#RJMIQIXF-.IO:+2N>*Y^O^?7T/L<'I7T/GI]_P _
MG=:K\CY#_AOFMT_-?YA0 4 % $^F6$NJZE8:7!+9V\^I7MM80SZA=PV%A#-=
M2K#'+?7URR6]G:([AI[J=UB@B#22,JJ34UJBHTJM:49RC2ISJRC2A*I4E&G&
M4W&G3BG*I4:B^6$4Y2=DB\+AYXK$4,-"5*$\16I4(SK5(T:,)59Q@I5:LVH4
MZ<7).<Y-1C&\F[(_7;_@GO\ \$:_A#\,],\,?&3XYZEX?^-?CF_L['6]!T?3
MY8-5^&OAWSXHKNUGM]N^#Q/?)O!-Y<F:PCECCEL5.-]?AGBEX^9[G%;&9!PY
M0Q7#V74JE3#XG$58SH9MBG!N%2,DVI82G)QUA&U22;51[(_J#P/^BMPQP[A\
MNXJXNKX'BK.*U&CBL'A</)8G(<$IQ52G)/X,QKQC-1=2:>'3CS4HM^]+[XM[
M>"TABMK6&*VMX46.&""-(88HU&%2**-51$4<*J@  <"OS.4I3E*<Y2G.3;E*
M3;DV]VVVVV^K;9^T0A"G&,*<(TX12C&$(J$(I*R48Q2226R6BZ#Z0PH * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ",T?U_7^
M0'E'[3/[%G[/'[67AV;1?B]X!TW4]16!X]+\7Z=&NE^+]&DVR&)['7K18[X0
MI,ZS26<LLEK<&-4EC9.*]KA#Q XIX(Q,:^19G6HT>9.M@*K]M@<0M%)5,-.]
M/F<4XQJ149PNW&2/G./_  IX(\2<#4PO$V3T*^(Y.7#YG0BL/F>%:NX.EC*:
M55P4WSRHS<J51JTXM'R3I?PR_;I_X)5Z@][\-KK7/VN?V/XI7N-6\$RI)/\
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M+D\GV&3Z \9 /XB* /UL_P"#,_\ Y2J>/O\ LTGXF_\ J<?"^@#^I"@ H *
M"@#Y#_X+R?\ *)?]M+_LE%__ .EEK0!_%_0!^W?_  90?\G.?M6_]DK\.?\
MIZFH _I!H * "@ H * "@ H * "@ H * /-/VT/^30?VI?\ LWKXQ_\ JOO$
M% '\*VJ_\A34O^O^\_\ 2B2@#]0?^#0K_E+;I7_9#?B;_P"@Z/0!_5G0 4 %
M !0 4 ?R*_\ !TI_RF(^/_\ V!_ O_J-65 'P)\/_P#D?/!/_8W>&_\ T\V=
M ']WGP,_Y(G\'?\ LEGP^_\ 42TB@#J: "@ H * /R/_ .#S3_E%I\-_^SM?
MAS_Z@GQ.H _ESH _IS_X,LO^4<OQ[_[.MU[_ -5QX H _8F@ H * "@ H *
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M-(M[#%]I$L%KJ<$<NFZAY9EL[B1"* /H&@ H * "@ H * "@ H * "@ H *
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MCBL%34<FSMJ7/+"Y]ET.6CB*-=^Y5K1@ZJ@VU%S2DNB^!7[4FO:KX@M_@O\
MM*>$%^#?Q\M;-7BM9;F.;X>_$E(^&U/X9^*W=;'6)YHQ]JNO#+2IX@TR-F-Q
M8"%-]<O$G!N&H86?$/"..>?\,3J-.<82CFF47M^YSC I>UH1BWR0QG*\+6=E
M&JYOE.[@WQ%QN)QL.$^/LK7"O&M.DG"E.HIY'G\5OB.'LRNJ.+FX_O*N7\RQ
MN'3E[2ARJY[6#GWZ?3D=J^>_K_ASZV]]M?\ AKBT % !0 4 % !0 4 % !0
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M0!_5G0 4 % !0 4 ?R*_\'2G_*8CX_\ _8'\"_\ J-65 'P)\/\ _D?/!/\
MV-WAO_T\V= ']WGP,_Y(G\'?^R6?#[_U$M(H ZF@ H * "@#\C_^#S3_ )1:
M?#?_ +.U^'/_ *@GQ.H _ESH _IS_P"#++_E'+\>_P#LZW7O_5<> * /V)H
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MUXDEA9O+DN/#7]KV;,,Q3NIW4 ?4R2)*BR1.DD;C*NC!T8>JLI*D>X)H 6@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ,T
M <3\=/VBO@W^S=X/N?&_QC\=:+X-T:**5K2._N%;4]7FBVC[)HVE1;[_ %*Y
M+O&C):P2+#YBR3O%$&D7T.&^%<^XMQT,NR'+<1CZ\FE-TH/V-"+N^?$5G:G1
MBDF[SDF[6BF[(\CC#CGA;@/*ZF;<4YQA,KPL8MTHUJB^L8J:_P"76%P\;UJ]
M1MQ5J<&H\R<W%.Y^4W[<G_!:_P"*GQS_ +4^'W[.D6I_"3X7W,5Q8:AXBF98
MOB#XIMY-T;E+JTG>#PYI\T3.C6UL]W=7$;*[7-NX"#]J\./H]Y-PY[#->*I4
M<[SB#A4I82*<LKP4E9I<DXQEBJL)6Y:DE"$'=*$E=O\ F_QA^EMQ#Q>L5D?
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MA&$YQIY?G4K*,JF7RJ2;I5W+XL'4ES^_'V,JJB^7[+!S7P)^J_@% !0 4 %
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M1GFNKVY\4^+-<UQ[B>=B\LCKJ-]<(-[,3M551<X554 4 <Y0 4 &/I^?^?\
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M7_J;:!0!_'K0!^]__!D#_P C/^W=_P!@'X3_ /IPU^@#^@V@ H * "@ H *
M,WQ?X.\*>/\ PWK'@[QQX<T7Q;X5U^RGTW6O#WB'3;75M'U.QN8VBGMKRPO8
MIK>:-XW889,KG<A5@" #\2?^"J7_  :!_#OXEWNM_&#_ ()M^(-)^$OB6Y%]
MJFL?L_>,KF<_#[4;MY9[IHOAWK=K9RW7A)%@$%C8>'=2@OM-:=C,VKV,6(@
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M7QN^)?P:^ >@W^QKRU:_U/Q[XRTV,R*&,VA:3!IVD-(J[F6(>)0S%0,J&#$
M^YOV=/\ @R__ &*? \=K=_M&_';XN?&W5;8QR-!X133/AAX?N9E?<XN;%E\5
MZB]LRX7R8]5ADP23,3B@#[H_9X_X(;_\$K_V8KFTU/X8_L>_"]_$%LL ?Q'X
MTL+GQYJUV]N[/%+<GQ9<ZK8AU9V^6WLK>$YYB))) -[_ (*@>$_"W@O_ ():
M?M[Z1X.\-:!X2TF']DCX["+3/#.C:=H6GQ#_ (5UKJXCLM+MK6V0;<KA8AP2
M.] '\2] 'ZV?\&9__*53Q]_V:3\3?_4X^%] ']2% !0 4 % 'R'_ ,%Y/^42
M_P"VE_V2B_\ _2RUH _B_H _;O\ X,H/^3G/VK?^R5^'/_3U-0!_2#0 4 %
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MIIK=---?)ZBC*,DG&2DGLXM-._9JZ?JAU PH * "@ H * "@ H * "@ H *
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M59CG.-H9;E6"Q&/Q^+J1I8;"X:E.M6JU)R48QA""<FW)I72=KZK<_0_]B_\
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M4H3A.-TTT[V=FMFDTS3K$Z H * "@ H * "@ H * "@ H * "@ H * "@ H
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MAWHKS?Z_K^M3V?Z_KT_$* "@ H * "@ H * /GG_ (*0_P#!2_\ 9K_X)A_
MC4?C3^T%XC\N[O4O=/\ AU\/-(>"?QA\1O%4=G+/9Z+H>GO+&ZVGG)'_ &OK
M$@-II%FSW,HE=4@D /Y-/^"H7_!7S]J__@J;\5=1\6_&3Q3=>'OA;8ZE)-\.
M_@5X<O9X? 7@G3XV=+-VMOEDU_Q 86+7FOZNUS=M<370L5L+.5;1 #Y4_E_G
M_.: .M^#/P'^,O[1'C?2?AQ\#OAGXS^*7C?6[J.ST[P[X+T&_P!;OY9YL^6)
M1:0O%:1O@@3WDMO!N^7S-Q (!^J/[%/_  9Y_MS_ !QM],\3_M3>-O"7[*_A
M._@M[U-">/\ X3OXEB)MK36&I>'K.XTW3= O]I:-6N=5OA"X+R6\B@1N ?IS
M^R[_ ,&DG_!++X$@7?Q5T+X@?M2:JZ6[S#XJ>)KC1M$@NXT7S3I^E_#S_A$Y
M4M'F!98+V]O9-H"2S2@MD ^Y/@Q_P3[_ &(_V>H+"+X,?LL_!/P!+IH"V6I:
M1X$T6;780 BC_BHM2M[W79/]6A!EU%SE0WWB<@'L(&  . .![#T_"@ H * "
M@#Y[_P""LW_*,7]OO_LTGX[?^J\UV@#^(>@#];/^#,__ )2J>/O^S2?B;_ZG
M'POH _J0H * "@ H ^0_^"\G_*)?]M+_ +)1?_\ I9:T ?Q?T ?MW_P90?\
M)SG[5O\ V2OPY_Z>IJ /Z0: "@ H * "@ H * "@ H * "@#S3]M#_DT']J7
M_LWKXQ_^J^\04 ?PK:K_ ,A34O\ K_O/_2B2@#]0?^#0K_E+;I7_ &0WXF_^
M@Z/0!_5G0 4 % !0 4 ?R*_\'2G_ "F(^/\ _P!@?P+_ .HU94 ? GP__P"1
M\\$_]C=X;_\ 3S9T ?W>? S_ )(G\'?^R6?#[_U$M(H ZF@ H * "@#\C_\
M@\T_Y1:?#?\ [.U^'/\ Z@GQ.H _ESH _IS_ .#++_E'+\>_^SK=>_\ 5<>
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M+ X:MB\7B:D:5##T*<JE6K4D[1C"$4VW?>RLEJWH89CF6 RC!8C,LSQ>'P&
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M+_\ ]++6@#^+^@#]N_\ @R@_Y.<_:M_[)7X<_P#3U-0!_2#0 4 % !0 4 %
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M  <O?\H9?VOO^P%X2_\ 4VT"@#^/6@#][_\ @R!_Y&?]N[_L _"?_P!.&OT
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MENFO4^WR7Z9_A5C[+-*&?9&^5/\ >X&6/CS-_#S8)3=K:\W(M/LW5CU?2_\
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MDEKT9Y_XP_X+2_L!^$)9;=_B?K>O7,9=43PSX*\1:Q;S.B1/M%[;V9M$5A*
MLCR*K,DB@ED(KU,!]'_Q.QT8S63X;#0=KO%YCA:$HI\RNZ<I^T;]UNW+U71H
M\/,OI7^"^6RJ4_\ 6#%XVK!.RP&58W$PFURNT:L::IJZDK-R6JEORGE_C3_@
MX._9JT>.5/!/PN^)OC6X(G6"64:7X<M X9TMY9_[2<W/DOB.5UBA:14<IPZD
MCV,O^B]Q=7<7F&<91@(WAS1@ZN*J6:7-R^S2A=:J[?+=72:T/G<U^FWX?X7F
MAE609]F=2T^2=3V&!HWC=0<G5YZEIZ.RA=)VT9\\_%'_ (. ?VG/$PN[/X:_
M#[X>?#BV+.++5+B.]\3:RB$_(\]OJ+-I1D 'W4B*9[]A]5DWT8>#\)[.IF^:
M9IFL[+VE&,J>$H.6ETI4HQK<N^O.I6?E=_#<1?38X^QZJTN'\ER7(H.35&O*
M%3,,0H='-8B2H<[714>6]UJ?,/QD_;B_:O\ CW+>'XF?&WQGJ>GW^1<^'=*U
M*7P_X7D#!@P/A[2'MM-^Z[+_ *G[N!T Q]AD'ASP5PS"FLHX>R^E5I?!BZU*
M&)QB6EO]JK\]:6R^V];]&?GG%GC%XD<:5*_]O\69KB*%?2>"H8F>#R][K3!8
M-T<+9IO1TFK;-:(\J=FD<R2,\DC?>DD=I';ZNY9C^)KVTE%)12BELDDEKY)6
M_ ^:G.=23G4G.<GO*<I2D_5MM]>^VFR0G%%O5?>A?U;_ ( 4 6]#T#7O%&I6
MNC^&=%U7Q#J]].MM9:7HMA<ZE?W=Q(<1P6]K:1R2R2N>%15+$]!Z9XG%8;!T
MIU\7B*.%H4XN<ZM>I3HTX0BKRE*=222275FV"R_'9E7IX7+\'B<;B*TXTZ5#
M"T*M>K.I/2,8PHPG.3D]$E&_:Y]F_LM_\$/OVE?C1#I'BCXNW-I\#O U^L5T
M;/58A?\ CZ\LV<"2./00Z_V)= !_DUN.,\ B-@>/@>,OI%<(\/RKX/(H3XBS
M&DY0YZ+=/+:=1*\6\5;_ &FGYX;FWLVFC]7\.OH@<><50PN8\3U*?"64UN2I
M[/$I5<WK4FVIP6 ^/"55:\7C/9VZTY)IK](?V6/^":?[*_[)T=OJ'@OP1#XF
M\;QI$9O'_C58M=\0BX1&1Y]+^U1O:Z")@Q$L6D16ZM@!BU?DW&?BYQGQLY4L
MPS"6#RYN7+E> ;P^%Y6U+EK.%JF)Y7K&5=R:;>BZ?O7AUX!^'/AM&G7RG**>
M89O%04LZS6%/%8WG@FG/#\\73P?.G[ZP\8<VTG*Q[\JJH"J H "@   !>  !
MP  ,#%?,/>^[WOZ[_?U[GVJ25DDE;316VZ?(6@ H * "@ H * "@ H * /G#
M]O;_ ()P?"/]MGPO+>W=O#X.^,.BZ?<1>$OB)IT 29G",\&E>)H(@@UG1GGV
M_P"O$EU8J9GL7C,LJR?5^&GBQGGAYC8TZ<Y8[(:]1/'955;<4FTI5\)*6E"L
MH7TC:%5V4[\JM\)XS^ _#'BWESK580RSBC"49QRW.Z,$I-V;AALPA%?[3A93
MM9R4JM%.3HR7-*+_ !/_ &AOV=?BK^R_\2]:^%GQ;\/3Z+K^E3,;.^C5Y=%\
M1:8S,+76M U#'DWUA=HNX&-WDMY!);7 6>)U']"\+<5Y+QCE&'SG),5'$8:O
M%>TIMVQ&$K+X\/B:5E*G5@^DE:46I1;C),_D?CO@/B3PZX@Q?#O$N!J83%X>
M<G1K)2EA<;AFW[+%83$65.O1FD_>AK"2E"HHRBT<-7I'C!1_78#Z _80_P""
MA'Q9_8A\;1SZ+-<>*_A1K=["?&WPWO;DBTNX"5CEU70))2R:5KMO$ \4T86&
MZ*+!=K)$QQ\OXE>%V2>(F7..(C'!9WAZ;679M3BO:0EJXT<5%6=?#2=U)2;=
M.[<&FT?<>#/CCQ+X29Q"6'J3S'AO&58?VMD=:;]E4@K1>(PDG?ZKBZ<-8SA:
M-3DC3JQE#;]N?V<_VF/A%^U-\.]+^)/P@\46FO:1>Q1#4-/9E@USP]J#(#/I
M6NZ6["ZT^]@?*E9HU650)86>-@:_GCBKA'/>#,UK93GN#J8:O3E+V59)RPV*
MI)OEK8:M9PJTY+6\9-K9I-:_UUP+Q]PSXB9'A\^X8S"GC,-5C'V]!M1QF!K.
M-Y8?&8=OVE&K'6W-&TXVG"\6F=_7F'M!0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YA^U!^UW\%/V2/ USXU^+7B
MBUL9621-!\*6,L5UXK\4WZH#%8:)HZ.;JX+R-&DUWY7V6T$BO<2*I&?8X.X&
MXAXXS*&79)@YU8\T?K6-J)T\%@Z;U=2O7DE"*44Y*'-SS:Y8IZGS_B%XF<)^
M&F3U,VXES"%.;BU@\MH2C4S',:VT:6%PJ;J23DX^TJ\OLZ*G&5244U?Y?^%W
MP@_:&_X*;>)]-^-O[5L.M_"K]D^PU)-6^%O[-=I<7.FW_CN"TNEDTS7OB24:
M&>[L94ACNX(9U"733,^GI'I\BL_V&<Y[PMX08.KP]P5+#9SQK4HNAG'%M2-.
MM#+95(6JX;*OCA"I%R<&X>]#D7M6ZL6E^>\/<,<:_2 Q]#BSQ%CC.'O#>GB/
MK/#W U*I5PU3.*5*K%X?%YVOW5:I1J1BJMJT4JZJOZM3AAVY2^YM(T?2] TO
M3]$T33[/2M(TJTM[#3M-L+>*UL[*SM8D@M[:VMX52.**&)$CC1% 55  K\ZK
MUZV*K5,1B*M2O7K3E5JU:LY3J5*DVY2G.4FW*4I-MMMZL_7\+AL/@L/1PF#H
MTL-AL/2A1H4*,(TZ5*E3BH4Z=.G%*,80BE%12LDD6:@L* "@ H * "@ H *
M/YW/^#R/_@HY?>(_B)\-_P#@G1\.M=N[;0/ UII_Q7^-[:==H+37/$.M6]Y:
M^#O"EY):R;I(="LOMNK:KI=Y\JZE/I$[0K):HU 'X34 ?L9_P;#_ /!"VP_;
M'\7P?MR?M3>%X[_]FSX<:_)8_#7P'K4%S"GQ8^(&D-97PUJ[MY%6+4/ ?AJ1
MA;W*2+)::[JS/9([)IM\B@']-6G:=8:186>EZ796NG:;I]M#9V-A901VUI:6
MMNBQP6]M;Q*D4,,4:JD<:*JJJ@ 8 H FH * "@ H * "@ H * /GO_@K-_RC
M%_;[_P"S2?CM_P"J\UV@#^(>@#];/^#,_P#Y2J>/O^S2?B;_ .IQ\+Z /ZD*
M "@ H * /D/_ (+R?\HE_P!M+_LE%_\ ^EEK0!_%_0!^W?\ P9/_ /)SG[5O
M_9*_#G_IZFH _I!H * "@ H * "@ H * "@ H * /-/VT/\ DT']J3_LWKXQ
M_P#JOO$% '\*VJ_\A34O^O\ O/\ THDH _4'_@T*_P"4MNE?]D-^)O\ Z#H]
M ']6= !0 4 % !0!_(K_ ,'2G_*8CX__ /8'\"_^HU94 ? GP_\ ^1\\$_\
M8W>&_P#T\V= ']WGP,_Y(G\'?^R6?#[_ -1+2* .IH * "@ H _(_P#X/-/^
M46GPW_[.U^'/_J"?$Z@#^7.@#^G/_@RR_P"4<OQ[_P"SK=>_]5QX H _8F@
MH * "@ H * "@ H * "@ H ^#?\ @Y>_Y0R_M??]@+PE_P"IMH% '\>M '[W
M_P#!D#_R,_[=W_8!^$__ *<-?H _H-H * "@ H * "@ H * "@ H * "@ H
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MWACP="EN"9;>QU+4X%UC4 %1SC3=(6^U!L*QV6S84\9 /[?OV:_@#X _9;^
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MM[VAU.!7'_7]?U^!Z/\ 7Y?Y!B@ H * "@ H * "@ H * "@ H * "@ H *
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MYCA\VR/'XG+,QPE2-3#XK"UITJE.<6FFI1:NM/>C*\9)M24EH?JS_P $_O\
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M"9/*:]ZE@545ZF)3E457&3UDY-48QC[TOL;'^?\ /^?PKX,_4OZ_+_(* "@
MH * "@ H * "@ H \E_;W\17OA#]AW]L+Q7IKRQZCX;_ &9/CEKEC)!*8)H[
MO2_AKXDO;=XIE5C%(DL*LL@5BC -@XQ0!_#%?7<M_>W=].S//>W5Q=S.[;W>
M6XE>:1G; W,SN2S8&22<#- 'Z8?\&E?PJTWXE_\ !7SP1JNHPV\K?";X/_$O
MXH:>;B,2&'4=.?P_X8@F@RP\N=4\5RJLB@E0[?+C+  _K'H * "@ H * "@
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M>R;QY6+4>850%@ ?V?(RNJNC!T<!D=2&5E8;E92."I!!!'4<\]: %H * "@
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M0?&G@GXAS)]H8SBRU_3;W086-M]U(FFT:4+,.9'!0Y\L4 ?NO0 4 % !0 4
M% !0 4 % !0 4 ?F3_P=H_$V+X?_ /!(OQUHS7C6T_Q.^*'P\\!6\*3/$;WS
M[J^UZ> K'%)YL:VVA2S/'(8HR(@3(&"JP!_)S0!_0O\ \&0_@26/X?\ [;GQ
M,^R2"&\\8^ O @OMS>4TNF:)_P ) UH$QL$D:ZLLQ?<6*R*"H !(!^\M !0
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MVOF_$6;8+*<OP\)3G7QE:-/F4=XT:=_:UZFNE*C"=1](Z'YO?MD_\%YY[O\
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M*O"/]I9YB(J688^I:\N:;O[##\]W3PU%J$$TFZCBIGL]> ?5A0 4 % !0 4
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M\-- N[:>*73-9\=37B2?$+6[&2W=X;NS_M&RL]*LKMG9F33IR@1)#N /S-H
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MXTN9]:\"6"DLJ;KR]?4;12W(DG39DG:P!_5EF@ H * "@ H * "@ H * "@
MH _GR_X/5OVN=+U'7OV8OV+?#FKM+J/AZVUOXT_$C3$4/#'_ &P$T'P"K2JS
M*ES%'8^*9YH'"S+%<V[E1&Z,X!^"% ']7G_!I/\ LVM\$/\ @E/X=^(MS&8-
M0_:7^(WBOXJ7,$B2).EKH]PWP\TR2028^6YL_":7-OL 1K:6*0%O,S0!^H%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\W/_  >U:SIMY^U;^QSHEO<I
M)JFB_!?X@W.I6J_?MH-7\5>'6TZ1_:X%C<[?^N1H _$F@#^R_P#X-\8)[?\
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M1Y?A<LR["4X4J&%PE&%&G&,(J*<E!)SJ-+WZDW*I4E[TY2;-FN<Z@H * "@
MH * "@ H * "@ H * ,+XH>#;+XB?#7X@> -2 .G^-O!?B?PI?!D613:>(-%
MO=*N-R,"CKY5TV58%6'!!S@@'\)OQZ\ ZM\*_C;\6OAQKMC+INJ^"/B-XR\,
MWEC,ACDMY-'\0:A9*I4JA :.%)$)1<HRD* 10![U_P $5?VG]._9#_X*<?LE
M_&77KF:V\+6OQ-TOPCXL,3;%?0/'>[PG<M<,614MK6?5;:_EDD;RX?L@F<%8
MR" ?VI03P7,$-S;31W%O<11SP3PR++#-#,HDBEBE0LDD<B,KQNC%64@J2"*
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MQIH]O*'D\+_$'2(8[#QAX=N(V=IX_P"S]9BN/L;SA'N["2UO57R[A20#W>@
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M48R]A/1R66T)J4<(KIVJQ;Q#BW&53E=G].8%?'GZ"% !0 4 % !0 4 % !0
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M;:S>1-K6L:C>![/PWH33"2VM]2O(IS=744L%O;R-&Q !\J?\$^?^#M_]E/\
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M_ASQ=X/UO4O#GB30=4MY+74-(UK2+N6QU"PN[>55DBFM[F&2-E91G 89!!H
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M:R3^7>^+-2M)9(D\=^.?L\\L-YJERBI+I&FY%MHELRJL?VYYYB ?GY_GW^E
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M*XOT5OZ[_,]&P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^+O\
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M^KB2_L(OBI\9F72?#\4;0R)9:UX>\(:?)-JE]+',8YOL?B+^SHF4;98FP48
M_$K]LC]OS]K/]O;XA7OQ'_:@^,?BGXBZE->W=WI.@7-]/:^"_"<5[+YTFG^$
MO"=O(NCZ#8JP&V&SME8XR\C]: /',YP.?\^G^'X4 ?J-_P $ O\ @WX^(_\
MP40^('AC]HO]HGP]?^#_ -BKPEJ_VVZ_M+[5IFM?&^_TYSY?AGPDBA+A/#HO
M BZ]XC)CMC;0W5A82RWC84 _JC\'>#_#'P_\*^'O!'@O1-.\-^$_"FDV.A>'
MM!TFVCL]-TG2=-@2VL[*SMH56.*&&%%555>3ECEB30!I4 % !0 4 % !0 4
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M]M#_ )-!_:D_[-Z^,?\ ZK[Q!0!_"OJO_(4U+_K_ +S_ -*)* /U!_X-"O\
ME+;I7_9#?B;_ .@Z/0!_5G0 4 % !0 4 ?R*_P#!TI_RF(^/_P#V!_ O_J-6
M5 'P)\/_ /D?/!/_ &-WAO\ ]/-G0!_=Y\#/^2)_!W_LEGP^_P#42TB@#J:
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MEN&I8/+L)A\%A:,(TZ>'PU*G1I0A"/+&*A345HDELWW9=K,V"@ H * "@ H
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MPM]+T30-#L;;3=)TK3K2,16UG8V-I'%;V\$4:@*D:#/+-EV8D OT % !0 4
M% !0 4 % !0 4 % 'AO[97_!-[]BW]OGPI)X6_:B^ W@KXBR1VM[;Z/XLFTZ
M/3?'/AF6_B$,]]X=\6:>(-7TZ]"*/)E^T2K&V66/=R0#\EOVM/\ @RI^&>M3
M:SXA_8S_ &F]=\%SW,S-H_PY^,&B_P#"0:#IT.QV5&\<Z9=-KUUF7RT/GZ*S
M+%EO,D;((!\._%G_ (-'/^"NGP^NYX/!?@[X3?&BWB,?EWO@GXG:#HL=P'^\
M8X?'TGA2=6BXWB14!.1&SC!(!Y-J?_!MS_P67TG4+O3;G]C;Q++/9R^3+)8^
M,/A_J-F[;5;-O?6/B>XM+J/##$MO-)&3D!B0: -OP5_P;!_\%H/&GE31_LJ1
M>';&2ZDM9;WQ3\3_ (8Z+Y!BV;Y6T^X\5_VI+!\XV30V,D4A5Q&Y9&  /I7]
MG[_@S"_;B\9ZEHMY^T!\;/@Y\(/"US)_Q.K/PW<ZKX[\:V$0=5(@LXK'3_#D
MTNS<Z8UZ1"0$;;DF@#],OV*_^#4__@F5^RKJ&B^+/B-X=U_]JOX@:3'&?[4^
M+K)%X+:\C,4B7]O\.M.N9M&CNH;B+SH)+R[U#RU/E!=AD\T _27PUX7\-^#=
M$T_PWX2T#1_#'A_2K>*TTW1-!TZTTK2[&VAC2**&VLK**&VB1(XT0;(Q\JC)
M.,T 7Z /-/VT/^30?VI?^S>OC'_ZK[Q!0!_"MJO_ "%-2_Z_[S_THDH _4'_
M (-"O^4MNE?]D-^)O_H.CT ?U9T % !0 4 % '\HO_!VI\#OB%\-_P#@JGXK
M^(OB'0M1B\$?&/P)X2\1>"/$XL;I=%U,:5I\>CZUI4&HO$+6;5-&NX(?[0M8
MI3+;QWMG*Z!+B)F /SM_9_\  'C#XI_&_P"$OP]\ Z!JGB?Q?XM^(O@_1-"T
M31[&ZU&_O;Z]UZQBC$=K9QRW#11 M/=2JFRWMHI;B5DCB9@ ?W8?#'0;[PK\
M-?A[X8U/RO[2\.>!_">@ZAY+%H?MVCZ!I^G7?DL>6B\^WD\LD9*X)YH W* "
M@ H * "@ H * .<^+/PC^&GQU^'OBGX4_%[P5X>^(7P\\::3=Z)XE\*>)].@
MU/2=4T^]A>":*6"=&\N0(Y,-S"8[BWD"RP2QR*& !^ /_!5?_@T"\:^%[[7?
MB_\ \$S=6;QGX9F:XU+4?V=/&FJV]GXET13F22W\ ^+-3NEM-?M%^>2/3-<F
MTV]@0I:V<]ZZ1JX!^)7Q7^#7Q8^!?C#5/A_\8_AUXR^&?C/1IY(-0\.^-?#V
MJ>'=3B,<LD7G1VNJ6MM)<6DK1L;:]MQ);7,>)()I(V5J .9H  <<C@CD$=J
M)?MMX%9!=W(1RK.OGR[7*Y*EEWX8J22I()&3C&: (V9G)9V9F)Y9B68GW)))
MH 2@#0\+>$_%/CC7M,\+^"_#>O>+O$NLW4=CI'A[PSI%_KFMZI>S'$5IIVEZ
M9;W5[>7,IXC@MX))'/W5- 'ZV_\ !+/_ (--?VIOVFM2\)?%/]ML7O[-?P&O
M$LM:_P"$/:2VG^,OC+2IX8KN"T&C+(1X(ANU+VEW+X@,&NV!;S4T=MHW ']%
M_P"R/^QK^SE^PU\(-%^!_P"S-\,]"^&W@31TC>>'3( ^K>(=3$2QSZ]XHUF7
M=?Z[K=Z09+J_OI7=G=A&L<9V4 >H4 % !0 4 % !0 4 % 'EG[7O[&'[.'[=
M7P>USX'?M-?#31/B-X&UE"\"7\(BUKP]J:9-KKOA?6X@-0T+6;*3$MM>V4R$
M,H65)8BT9 /YVO\ @J%_P:3_ +4?[.%_XH^*/[#]U<?M)_!.U^WZP_@6:2UL
M/C%X/TN%)+N2U339;@0>.+>RCQ:6TFBRR:_?&/S6T<EVV@'Y(>,O GC;X=:]
M?>%?B!X/\3^!_$VER^1J7A[Q=H.J>'-;T^8<^5>Z5K%K9WUK)CG9/ C8[4 9
M5 !0!*M]>HKJEY=(LB[75;B55=000K@. R@@'!R,@<<4 1O))(=TCO(0,9=B
MQP.V6)./:@!* %"EB H))Z <D^P Y)]J /IW]@G_ ((_?MY?\%&/$UAI?[/_
M ,%/$*>#IFM9=3^+?C>QO/"/PPTG39KM+2?44\4:K;PVNOM9,XDN-,\-#5]7
M\O!2R;<FX _HR_X) _\ !M=^RQ_P3>FT'XR?%*2P_:+_ &IX=.AD3QEXBTB,
M>#/AOJ=Q!$+Z/X=>'KF2YC-W"YNK6'Q3J42:K/9SNB6UF2" #]+       ,
M#H . ![#M[4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 A4'(/
M0YX[<^H[Y[T?U]VWW:6[606WOL]_->??\K:6.#^*7[+O[//QJL9-/^*'P?\
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MXEC[3ZGQGDU9*WLO;X+&4.;OS\DZ_)KM;FOK<RO^(>K]I#M\8_A+^7B;\?\
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MN )VVB!CU!KYC.?%SQ#SR,Z>,XEQT*%1^]AL))86BO**I)37E[[M]]_MN'O
M'PFX9=&IE_!^75<30^#%Y@IX_$>>M>3IJ]E>U)7LKW2/;=(T#0M MQ::%HVE
M:+:@ "VTG3K33K<!>@$-G##'@=AMP.V*^>KXG$XF7/B<37Q$VV^:O5G5E=];
MU')Z]==3ZS"X/"8*'LL%A<-A*:22IX:A2H05O[M*,(VVTM;0MX_K4>KO_ET]
M;&O_  ?Q"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M$% '\*VJ?\A/4?\ K_O/_2B2@#]0O^#0K_E+;I7_ &0WXF_^@Z/0!_5G0 4
M% !0 4 >;_M-_LA_LU?ME> &^&'[3OP<\%?&/P5]I2]M])\7:4ET^GWL8.R\
MTK486@U32KA3AS)87EOO=(VE#F--H!YO^R?_ ,$C/^"=G[$?C*X^(O[-G[+W
MP^^'_C^XM)+ >-!;7>M^([2RE=))+?3=1URZOWTM7:-2TFG+;3L"RM*R,5H
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M=:/;VEC\&=>CU.9HKJ[TKQZWV?1E5HE$VH_;=-M)?+<.SK]DCN6VQ/E02H8
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 &* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /$/^"E?C:U^'G_!/K]M#Q;=
M73V9TW]F;XSQV=S&L;M'JNH> ==T[22$E9$8'4KJU# D_*6PKG"D _ATED>:
M62:1B\DKM)(QZL[DL['W+$G^@H _63_@SA\)?V]_P5-\4Z[+%>&#PA^S9\0=
M32>W9%MX[^^U_P 'Z5;17N0S/%-;7=\T:+M)FA1MV%*D _J6H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _-#_@Z
MX_:<TWX"_P#!*+Q_X$34);/Q9^T9XQ\*_"KPVMI<I%>"WAOD\6^(YC$)$F>R
M?0] O-/N75'C!OXT?'FI0!_)E_\ JH _>W_@R4^ >JMXK_;(_:2U/2MFB)H7
M@'X6>$=8:-LSZDU]K6O>+[.*4H%58+;_ (1AY561F<RKN10@W ']!] !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^[U/4;VX<R3W=]?7$ES=W,TC<O+//+)+(QZLQ- 'VG_P0(_X)S:G_P %&/\
M@H-\,/!FLZ5>2_!?X4WUI\6OC+JRVY:Q_P"$>\)ZA97>F^&&N)5^R->>*M:-
MAIILG<S3:4=5N(XF6V=D /[&].TZQTC3[#2=,M(+#3=,L[73M.L;6-8;:SL;
M*!+:TM+>% $B@M[>*.&*- %2-%50  * )J "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H \U_;(\&>+_B-^R7^TMX!^'XG?QSXS^!?Q2\+^$([9_+N)?$FM^#
M-8T_1XH)=R&*:6^N((XY0ZF-F$BL"H- '\+GBCP[KOA#Q+K_ (5\4Z?=Z3XE
M\-ZSJ6AZ_IE\K)>:?K&EW<UEJ-G=*QW">WNX98I<YRRD@G.: /5?V$OVZOV@
M/^">'[0WA+]HW]G;Q1)H7BO0)5LM<T6Z,DWAOQSX4N+BWEUCP?XJTX.L=_H^
MK1V\8;)$UG=1V]]:ND]O&: /ZOO^"2O_  7/_9,_X*I>"M+T[POK-G\+OVD+
M+3P_C/\ 9_\ %.I6Z>(4GM(':_UCP7=$BV\5^&I'@N;J"2QEDU73K#R&URQL
M9I%5@#[:H * "@ H * "@ H _/[_ (+*_P#!?C]FK_@EQX,UKP1X?U/1OC#^
MUOJ-DT'AGX,Z/J*S+X3FNX&^R^(OB5>V^Z/0M,MB\5S'H[3+KNJ1O$]K9&T9
MYU /Y2OVK?VJ_CC^VE\<_''[1/[0WC.\\<?$SQ]J37^JZC-F#3M.M4S'8:%X
M>TP22P:-X>T>V"6>DZ5:D06=M&J#<VYV .7^&/PR\=?&3X@>$/A;\,_#6I>,
M/'OCS7M.\->%?#6CP&XU#5M8U2YCM;2UA0$*JF20&6>1TAMX5>:>2..-V4 _
ML._X(<?\$I_"_P#P2J_8^T?X=WG]GZS\=?B<VE>.OCQXNM8%S<>*I--1+3PG
MI]TT:3R:#X.BN+G3K$/\LMW-J-V-PN0: /M"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZ;8SW!>2YH _62@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
; H * "@ H * "@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781040000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,218,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 687,537<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 1,794,283<span></span>
</td>
<td class="num">$ (2,171)<span></span>
</td>
<td class="num">$ (1,104,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">6,003<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(93,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,078)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,659,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">620,257<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,818,393<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="num">(1,197,711)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,401,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 640,528<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">2,156,363<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="num">(1,516,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="nump">133,256<span></span>
</td>
<td class="nump">388,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">$ 5,465<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">19,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,256)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,789,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 625,299<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 2,181,517<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="num">$ (1,556,361)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781289456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 89,093<span></span>
</td>
<td class="nump">$ 80,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">439,528<span></span>
</td>
<td class="nump">483,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">11,813<span></span>
</td>
<td class="nump">8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CollaborationReceivableDuefromRelatedPartiesCurrent', window );">Collaboration receivable &#8211; related party</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CollaborationReceivableOtherCurrent', window );">Collaboration receivable &#8211; other</a></td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent', window );">Royalty receivable &#8211; related party</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">9,778<span></span>
</td>
<td class="nump">7,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">29,152<span></span>
</td>
<td class="nump">24,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">587,274<span></span>
</td>
<td class="nump">611,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">84,503<span></span>
</td>
<td class="nump">152,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">91,440<span></span>
</td>
<td class="nump">93,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,840<span></span>
</td>
<td class="nump">31,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease assets</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">799,738<span></span>
</td>
<td class="nump">890,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">18,707<span></span>
</td>
<td class="nump">21,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">39,631<span></span>
</td>
<td class="nump">53,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue &#8211; related party</a></td>
<td class="nump">4,748<span></span>
</td>
<td class="nump">10,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,466<span></span>
</td>
<td class="nump">6,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Financing lease liabilities</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">69,858<span></span>
</td>
<td class="nump">92,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion &#8211; related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">104,010<span></span>
</td>
<td class="nump">106,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Financing lease liabilities, net of current portion</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">174,439<span></span>
</td>
<td class="nump">250,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March 31, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized; 68,789,925 and 68,401,105 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,181,517<span></span>
</td>
<td class="nump">2,156,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,556,361)<span></span>
</td>
<td class="num">(1,516,105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">625,299<span></span>
</td>
<td class="nump">640,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 799,738<span></span>
</td>
<td class="nump">$ 890,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CollaborationReceivableDuefromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CollaborationReceivableDuefromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CollaborationReceivableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CollaborationReceivableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RoyaltyReceivableDuefromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781331920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents stock option activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.590%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.061%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exercise Price</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,201,485&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">792,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(133,256)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited/Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(110,904)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,749,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,874,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,749,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Unvested Stock Unit Activity</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents RSU activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766,953&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">744,447&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192,870)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,655)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,290,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Performance-Based Units</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents PSU activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.736%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.766%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.768%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.64&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238,765&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.03&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock', window );">Schedule of Market-Based Units Activity</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:67.838%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.787%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.790%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,603&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance-based stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">328&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.707%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.283%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market-Based Units Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767255248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Minimum Rental Commitments Under Uncancelable Leases</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:85.317%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.683%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,773&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Undiscounted minimum rental commitments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,226&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,750)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,476&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763087840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three months ended March 31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2020, our results of operations and stockholders' equity for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Significant and Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant accounting policies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses (Topic 326),</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent accounting pronouncements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments &#8211; Debt and Equity Securities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses</span>, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product Revenue</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We sell TIBSOVO&#174;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers in the U.S., or collectively, the Customers. The Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The performance obligation related to the sale of TIBSOVO&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reserves for Variable Consideration</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contractual Adjustments</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Rebates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government rebates consist of Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Returns</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Share</a></td>
<td class="text">March&#160;31, 2020 are not considered to be common stock equivalents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777853888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Revenue - Schedule of Revenue-Related Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Reduction of accounts receivable</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAllowanceAndReservesLiability', window );">Component of accrued expenses</a></td>
<td class="nump">4,635<span></span>
</td>
<td class="nump">3,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">$ 5,342<span></span>
</td>
<td class="nump">$ 3,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAllowanceAndReservesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAllowanceAndReservesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6949916752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">$ 8,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractwithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">27,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(24,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">11,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Additions</a></td>
<td class="nump">59,248<span></span>
</td>
<td class="nump">$ 16,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember', window );">Collaboration receivable &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractwithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(2,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember', window );">Royalty receivable &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractwithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">3,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(2,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_DeferredRevenueCurrentMember', window );">Deferred revenue &#8211; related party, current and net of current portions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, beginning balance</a></td>
<td class="nump">61,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Additions</a></td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Deductions</a></td>
<td class="num">(57,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, ending balance</a></td>
<td class="nump">$ 4,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractwithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractwithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_DeferredRevenueCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_DeferredRevenueCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780591120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 87,098<span></span>
</td>
<td class="nump">$ 30,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and other services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and other services | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember', window );">Other services | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">801<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember', window );">Collaboration revenue &#8211; other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember', window );">Collaboration revenue &#8211; other | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777939808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember', window );">Performance-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">218,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">20,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">238,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 55.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Granted (in usd per share) | $ / shares</a></td>
<td class="nump">48.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Vested (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 55.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">42,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">42,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767451072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">$ 8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(24,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">11,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember', window );">Collaboration receivable - other | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">$ 2,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>26
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$W:#L0?[CXVO@K*%7W<AOP!02P,$%     @ Z$V>4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MF34?9JRQBN:P($O=&'1F0H$,8! ('*@AY/D#QM!4EF18&LSXD2$,G,*.K@C
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MP_JWU2)U*+QU(!_F44WJ9Z?79+9<SMZ*+,C!3<49)-M>XD\D_ERQ6RJB=)0
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M7!BGS-<5W \I9H@^"MS%*']_5P W'D",Q^D*N(:2$L(SJRL(K/=ESQP&W'8
MLQT?!6X5 /_1%GQI [*TW;8P]ZO([8\X!LH\'P? ES4@RQI\%/@2!&Q3XVL)
MO@0!V]8X+4G=_==\TS+VQ$6!/OI8<J+9)KH6[<&<-[I@*\^-ZK>KL]'I3',/
M_2;<&E_KL\YP,GFC&0Y*7XOV4#9=\"B5WN*;C?A>2B6T2.W187#49[/IH1)[
MU=]F^KX=#BC#@Y*G\? 532? U5]02P,$%     @ Z$V>4 B)@ T; @  Q 4
M !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q]5%V/FS 0_"N(]Y[!?"41
M(%U2G5JIE:*KKGUVR":@LS%G.^'Z[VL;PG'$ZDOL769G9QQ[\YZ+5UD#*.^=
MT586?JU4MT%(5C4P(A]X!ZW^<N*"$:5#<4:R$T".MHA1A(,@18PTK5_F-K<7
M9<XOBC8M[(4G+XP1\7<+E/>%'_JWQ'-SKI5)H#+OR!E^@7KI]D)':&(Y-@Q:
MV?#6$W J_,=PL\L,W@)^-]#+V=XS3@Z<OYK@^['P R,(*%3*,!"]7&$'E!HB
M+>-MY/2GEJ9POK^Q/UGOVLN!2-AQ^J<YJKKP5[YWA!.Y4/7,^V\P^DE\;S3_
M ZY -=PHT3TJ3J7]]:J+5)R-+%H*(^_#VK1V[4?^6YF[ (\%>"K0O?]7$(T%
MT4=!;,T/RJS5KT21,A>\]\3P9W7$W(EP$^G#K$S2GIW]IMU*G;V6(0YS=#5$
M(V8[8/ <,R&09I]:8%>++;XKQY\;[.X181"[6T1.%Y$EB#ZYP&Z"V$D06X)X
M3A#&BV,8,*G%M!;S)0YPDB[,.&#K*,A6;CF)4T[B\!.Y"5(G07KO!R_]#)AD
M+C3$JX6;>U"8KC*WE,PI)7-(2192,M?11JN%XIT#M@ZC]?(VHMGE9R#.=DY(
MK^*75IEK-LM.H^@1F\>SR&_UB!HFR@?-,-]^$G%N6ND=N-)/TSZ@$^<*M,K@
M09]6K4?J%% X*;/-]%X,@V4(%._&F8FFP5W^ U!+ P04    " #H39Y02H7J
M#Z<#  ""#P  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;(57VVZC2!#]
M%<2[AZZFNVDBV]+&$VM&FI6B6>WN,[';,1HN7B#QS-]O@PD3JLKQB[GX5-6I
M0U.'7I[KYD=[=*X+?I9%U:["8]>=[J*HW1U=F;6?ZI.K_#^'NBFSSE\VSU%[
M:ERV'X+*(I)"F*C,\BI<+X=[C\UZ6;]T15ZYQR9H7\HR:W[=NZ(^KT((WVY\
MSY^/77\C6B]/V;/[RW5_GQX;?Q5-6?9YZ:HVKZN@<8=5^ ?<;2'M P;$/[D[
MM^_.@[Z5I[K^T5]\W:]"T3-RA=MU?8K,'U[=QA5%G\GS^&],&DXU^\#WYV_9
MMT/SOIFGK'6;NO@WWW?'56C#8.\.V4O1?:_/7]S8D Z#L?MO[M45'MXS\35V
M==$.O\'NI>WJ<LSBJ939S\LQKX;C><S_%L8'R#% 3@$ 'P;$8T#\.R#^,$"-
M 6H*D,F' 7H,T%- _'& &0/,[PI#T]%%K$']SUF7K9=-?0Z:RP(Z9?TZA3OC
MG^^NOSD\SN$__P!:?_=U#=(LH]<^T8BYOV#D#)/,,1L.8^>8SQPFG6,>&$PL
MYI@MAX$)$_E^IZ8EV[0<$JA9 HD:NF#T@*D&C+82K-$Q7REF*\5,I1C)>\&8
M=Y6,372,%:8PC06F$$A2)2VJ^$!Q"PD)()D9%(!0)KZB@&(54(P""K6FB-9*
M 1C+U]%L'<W4T4AI3>H8(9 X&TU%1#*S:21/UK!D#4,6OW6&5 $+ C_R6Z@9
MF80EDS!DT.*[3V@9OTC1LKH!FE&Q+!5+J0!:+/>65%FDL4B0,-N;L!F=E*63
M,LJ@.IN4F1-&IWY6\)5 \'-8,+52/(@%77E22$V&L:"S(L7#F.;R*\?&*1X6
M#'"AK,(SF4$!I$D"UW2XXD= =5 "]P=4!ZN$GT[Z2C'>!X Q @58=$GGLQ(:
MN]N&PQ$'I*XB09O8$-$9H)!8<PI:@ 9S70;>I(!S*?S:C:#9>HECJ0V6@>)B
M:ZT45RCQK@&<;>!Q/H)FRUP9C0E1%![H0 W()U)7&//^ YP!D2\I:AV0FE1@
M/K=@<T*\QP!G,GBN _6/!?EP>[B%FM/A7088FR&S':B%+)0@BVQ[&S>GQ+L-
M,':C\'<@4"/QIF;35%Y[R7@O <9,%/X4'$&S&2*U3%-,BL&1 4\Q_OO5SP=L
MVPPP(>.=8ORHZ2<7'N_1NYU'OSO],VN>\ZH-GNK.;V*&K<:AKCOGLXI/7M6C
MWQ!/%X4[=/UIXL^;RZ[P<M'5IW''&TW;[O7_4$L#!!0    ( .A-GE"^S0".
MD00  .85   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?9C=;N,V$(5?
MQ?!]5N0,*4J!8R#68M$"+1!LL>VU8C.QL9+E2DJ\??M2/^NU9X:YL2WY<'B&
M%#^.N#HW[?=N[WV_^%%7Q^YAN>_[TWV2=-N]K\ON4W/RQ_#/2]/691\NV]>D
M.[6^W(V-ZBH!I=*D+@_'Y7HUWGMJUZOFK:\.1__4+KJWNB[;_S:^:LX/2[W\
M>>/KX77?#S>2]>I4OOJ_?/_M]-2&J^0297>H_;$[-,=%ZU\>EH_ZOL!L:# J
M_C[X<W?U>S&D\MPTWX>+WW</2S4X\I7?]D.(,GR]^\)7U1 I^/AW#KJ\]#DT
MO/[],_J7,?F0S'/9^:*I_CGL^OW#,ELN=OZE?*OZK\WY-S\G9)>+.?L__+NO
M@GQP$OK8-E4W?BZV;UW?U'.48*4N?TS?A^/X?9[^<6YN)C> N0%<&H2^/VJ
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M/CA4G\(@[7VYNUQ4_J4??KKPNYU.'J>+OCG-IZK)Y6AW_3]02P,$%     @
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MZ1YQ>("IGT^43,U_@S-(GQZ4^!H%2AN_I.BM0S6Q>"E*O(QGJ^,Y3/P7V#J
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M0NW#\1;/=AJSR?"FGW\06[YQ\0Y02P,$%     @ Z$V>4)F'Z &U 0  T@,
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MW/NS&<=L-!QVTP]B\S?.WP%02P,$%     @ Z$V>4%67['ZU 0  T@,  !D
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M=',O<VAE970Q-2YX;6Q]4]MNG# 0_17+'Q"S+$W2%2!E4T6IU$JK5&V?O3"
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M/+YL[']MC >4LKG"$6KQ@\V&A-J'XPV>[3AFH^%--_T@-G_CX@]02P,$%
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M'XX?\6RG,9L,;_KY!['E&Q=_ %!+ P04    " #H39Y0G[,L9[8!  #2 P
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MQUL\VW',1L.;;OI!;/[&^3M02P,$%     @ Z$V>4,C'1,>V 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL;5/;;MP@$/T5Q >$7;Q)5BO;
M4C95E$JMM$K4]IFUQQ<%& ?P.OW[ '8<-_4+,,,Y9RX,Z8#FQ38 CKPIJ6U&
M&^>Z V.V:$ )>X4=:']3H5'">=/4S'8&1!E)2C*^V=PP)5I-\S3Z3B9/L7>R
MU7 RQ/9*"?/W"!*'C&[IA^.IK1L7'"Q/.U'#,[A?W<EXB\TJ9:M VQ8U,5!E
M]&Y[..X"/@)^MS#8Q9F$2LZ(+\'X7F9T$Q(""84+"L)O%[@'*8.03^-UTJ1S
MR$!<GC_4'V+MOI:SL'"/\D];NB:C>TI*J$0OW1,.CS#5<TW)5/P/N(#T\)")
MCU&@M'$E16\=JDG%IZ+$V[BW.N[#>),D$VV=P"<"GPG[&(>-@6+FWX03>6IP
M(&;L?2?"$V\/W/>F",[8BGCGD[?>>\DYOTG9)0A-F..(X0O,=D8PKSZ'X&LA
MCOP_.E^G)ZL9)I&>+*/O]^L"NU6!7138_5/B[9<2US!?@[!%3Q68.DZ3)07V
M.D[RPCL/[!V/;_()'Z?]IS!UJRTYH_,O&_M?(3KPJ6RN_ @U_H/-AH3*A>.M
M/YMQS$;#83?](#9_X_P=4$L#!!0    ( .A-GE"S=RK\X $   $%   9
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M<#7NNK=W-8[^:!C935N-SJNU^ M02P,$%     @ Z$V>4,\AK-GV 0  RP4
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M__!**0W84E8/]O]1V<DZ!1Q*X[9[NU?#?!D"(]MQ=))I?F?_ %!+ P04
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MZ[Y"7\_"]_KBO\,-J()K)2I'P:@P_UYQ%9+5/8N24I-WNU:-63M[DH9]F#L
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ME@?AKHU$/($\PKPB5%J%*4QQV60LR7"/0C*_4C9A"-./ /UXHE@D3"LJ/Y#
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M'Y-]]K/;N6I[.:C=\S!^U?Y[=WY#=#X8VN/\]JNXO();_P=02P,$%     @
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M\CQ15D"Q6+ 6&O7DR#C%4FWYR1,M!WPP)$H\Y/N)1W'=N'EF8CN>9^PL2=W
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MZ^LKSC!!(&8VQ,2EF/#<MY1PC G",;,Y)B[(*?4D!#C'$+LZ/+9T)J/_6$N
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MP9T @05"4" $(@A'I6@QD<54%A/[[0]VBD"G"' :%7338L*!4Q@^<YJ!3C/
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MU#*4:];-SVXC:--_&SC#!TKZ'U!+ P04    " #H39Y0V7RS=QL#  #%#
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R55VUOFS 0_BN([RO<8=ZJ
M)%*3:=JD3:HZ;?M,$R=!!<S 2;I_/V-H2O!Y8E\"=NZ>Y^ZX!Q^+BVA>VB/G
MTGDMBZI=ND<IZWO/:[='7F;MG:AYI?[9BZ;,I%HV!Z^M&Y[MM%-9>.C[D5=F
M>>6N%GKOL5DMQ$D6><4?&Z<]E676_%GS0ER6+KAO&T_YX2B[#6^UJ+,#_\[E
MC_JQ42OOBK++2UZUN:B<AN^7[@/<;S#N'+3%SYQ?VM&]TZ7R+,1+M_BR6[I^
M%Q$O^%9V$)FZG/F&%T6'I.+X/8"Z5\[.<7S_AOY))Z^2><Y:OA'%KWPGCTLW
M<9T=WV>G0CZ)RV<^)!2ZSI#]5W[FA3+O(E$<6U&T^M?9GEHIR@%%A5)FK_TU
MK_3U,N"_N=$..#C@U4%Q_\LA&!R"=P>FD^\CTZE^S&2V6C3BXC3]TZJSKBG@
M/E#%W':;NG;Z/Y5MJW;/*P:P\,X=T&"S[FUP9/-NX2GT*P52%&LTW/&68&-:
M@,]HBH#,(M  P0@@2"P C 1@&H#= (23,O0VD;:IM$V2ADBSA"1+2+!$$Y;>
M)ARQ8!RA)9F(I(D(FGA"$QDT'Y#%44#SQ"1/3/ D$Y[8X %(P$*3D#2)\7 9
M6,J>D@#IC+*G1IQABFR2S28U6@ B!CX=#/BTXGPC'%O9P:)9F-_N0&KR 7!&
MPP]&-P\O#%(+$:U,"&84?S :$P5!8'G&0"L8* E/NWXPNFU[3&VUHU4,E(RG
M?0^$CL,XMA#1.@93R%%H0: 5"O%_= JM/DCF=$IB9IOZ-EW0*H4Y,@53IZI3
M+!DA+4 T!6AVRF!TVRFIE8D6*L*,3AF,;E.RU0YI.:,I9V9[R2(M5#3/4.MK
M%FD)HBE!!FR:KBG!"$)KL+0$<<Y)BJ8$P]CR]D):@3CG*$7B+ WC@-EZA98J
MFJ<I@ZG.!J/Q <3BT2G5$WFCX:_DS4'/R:VS%:=*=F/6:/<ZBS]@-SQ.]M=J
M1N\GZG>8?L#_EC6'O&J=9R'5:*H'R+T0DJL@_3M5B:/ZIK@N"KZ7W6VL[IM^
ML.X74M3#1X-W_7)9_0502P,$%     @ Z$V>4+IH>73T 0  [00  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL?53;;IPP$/T5BP^(N6Z2%2"%K:I6
M:J55JJ;/7A@NBHVI;9;T[VL;EA"@?<&>X<R9,_:,XX&+5UD#*/3&:"L3IU:J
M.V(L\QH8D7>\@U;_*;E@1&E35%AV DAA@QC%ONL>,"--ZZ2Q]9U%&O->T::%
MLT"R9XR(/QE0/B2.Y]P<STU5*^/ :=R1"GZ ^MF=A;;PS%(T#%K9\!8)*!/G
MR3N>(H.W@)<&!KG8(U/)A?-78WPM$L<U@H!"K@P#T<L53D"I(=(R?D^<SIS2
M!"[W-_;/MG9=RX5(.''ZJRE4G3@/#BJ@)#U5SWSX E,]D8.FXK_!%:B&&R4Z
M1\ZIM%^4]U)Q-K%H*8R\C6O3VG68^&]A^P'^%.#/ 5[TWX!@"@C> T);_*C,
MEOJ)*)+&@@](C)?5$=,3WC'0AYD;IST[^T]7*[7WFH;>(<970S1ALA'C+S#>
MC,":?4[A[Z7(_$VX_S'!:8OPW' _1;!;16 )@B7!XS\(PEV"T!*$'X[A?G4,
M(^9@,:W%1(]^^+"J98OR#J'G[HN)=L5$.V)6:;)HD\9="=DB_/6UX467,!"5
M'2B)<MZWRMS'PCO/[)-ONFSES_0LCZ/W3C,^!-^)J)I6H@M7NH=MIY6<*] *
MW3LML=9OSVQ0*)79WNN]&"=P-!3OIL<%SR]<^A=02P,$%     @ Z$V>4.9%
M^HH3 @  M04  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULC53;CILP
M$/T5Q >LN>8F0-ID5;52*T5;M7UVR'#1VIC:3MC^?7TA+"7>:O,0[.',.6<&
M>[*!\1?1 $COE9).Y'XC9;]#2)0-4"P>6 ^=>E,Q3K%46UXCT7/ 9Y-$"8J"
M8(4H;CN_R$SLR(N,721I.SAR3UPHQ?S/'@@;<C_T;X'GMFZD#J BZW$-WT'^
MZ(]<[=#$<FXI=*)EG<>AROW'<'?8:+P!_&QA$+.UIRLY,?:B-U_.N1]H0T"@
ME)H!J\<5#D"()E(V?H^<_B2I$^?K&_LG4[NJY80%'!CYU9YED_L;WSM#A2]$
M/K/A,XSUI+XW%O\5KD 47#M1&B4CPOQ[Y45(1D<6987B5_ML._,<1OY;FCLA
M&A.B*4%I_R\A'A/BMX3$%&^=F5*?L,1%QMG@<?NQ>JS/1+B+53-+'32],^]4
MM4)%KT42;C-TU40C9F\QT0P33@BDV">)R"6QC^[2HW\%#O>(,$C<$K&SBM@0
MQ#.">/L.0>(D2 Q!,F]#%"S:8#$K@^E&EVF@?VZEU*F4.I3"A9+%I#.EA9=#
M>N?E'1,KIXG5G8EX&[L)UDZ"]<<;OG$2;!QM6!R+_>:NR-CV>UDKFIUV"KPV
M@T%X);MT4I^K672:/8^1OBV+^%[-)#M"WFCL0/N&>=UVPCLQJ>ZBN3$58Q*4
MS^!!?8U&S=!I0Z"2>KE6:VXGB=U(UH]#$DV3NO@+4$L#!!0    ( .A-GE +
M4I#J)@,  &P-   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;)57;6^;
M,!#^*X@?4.RS>:N22&VJ:9,VJ>JT[3--G 05< 9.T_W[V>!2@H^(YD.PS7-W
MSYW]&'MQEO5+<Q!">6]E435+_Z#4\38(FLU!E%ES(X^BTF]VLBXSI;OU/FB.
MM<BVK5%9!$!(%)197OFK13OV6*\6\J2*O!*/M=><RC*K_]V+0IZ7/O7?!Y[R
M_4&9@6"U.&9[\5.H7\?'6O>"WLLV+T75Y++R:K%;^G?T]@$28] B?N?BW S:
MGDGE6<H7T_FV7?K$,!*%V"CC(M./5[$616$\:1Y_K5._CVD,A^UW[U_:Y'4R
MSUDCUK+XDV_58>DGOK<5N^Q4J"=Y_BIL0J'OV>R_BU=1:+AAHF-L9-&T_][F
MU"A96B^:2IF]=<^\:I]GZ__=##< :P"]@8Y]S8!9 S;7@%L#_F' VVIUJ;2U
M><A4MEK4\NS5W?0>,[.*Z"W7U=^8P;;8[3M=GD:/OJXXL$7P:AQ9S'V'@0&&
MI>02LW8QM$<$FD%/ S :]^"8<^"C$"X&+A$/+H(2CM-@:#58ZX!=9#KA@*,.
M>.N 7^0Q+E6'B5I,95F&Q/SP2"$:*70BL9".(G68<! IB4F:#"-UA0L=2HP
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M0#06R$)8( 8%8B<0_R> )YOL;*BS:9Q-FB0YC6 .!3D4X) )A\XYL;E2F).
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M8_Q$=&\R<VA;8;_3XJ4^O:7!AB3H9H"ZF'T;0P8QN(] &KVG(!#%GDS2@XC
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M+=KYI]THWG2S'>H'S/074$L#!!0    ( .A-GE"+;]&HF0(  , )   9
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MT?84[43QINN7O+YI6_T#4$L#!!0    ( .A-GE#Y73V>,P(  (@&   9
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M-VU(%FT8,*G%M(/*/,WQPHL#E04X<XM)G&(2AYC<39 Z"=+'V[%R$JP>:,>
M269&\R2-%]VX!P48QZ%;2^;4DMUI23!V$^1.@OSQ;NB!Y+PD^(%^C*";-X^#
M,%UTQ '+<)HN]*#9_64@3G;42:_BYU:9FS*+3N/T)33W?Q'?F#%KY\('S3"C
MOQ-Q:EKI[;G2T\7.@"/G"K1(_*3?6*T_"].!PE&9[4KOQ3 ;AX/BW3CWT?3Q
M*?\!4$L#!!0    ( .A-GE"G$;6P@0(  +X(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;)56[8Z;,!!\%<0#'-CF,TJ0DE15*[52=%7;WPYQ CK
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M$_VF(&>AEJ%<LW:BMAM!Z^YKP>D_69)_4$L#!!0    ( .A-GE#WK:MBOD<
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MXD4.TV8EG#7\5>;;=$,'_S+>QL!%\$22J@11_?'ZE7?RXM1[X:69]^$NKTL
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MV#GQ;-1%\XRSW*JF'&"1C]C ]A/M!:D43@DW9ZQ]Q48H(&!<%(_X(\7.NTY
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MG^ (4]#7AFV?]?T0QE;-+$ZBL3^?@HK25S0&[P5C?P*:5U<CK===96U< L?
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M+W:8[!,^=R$\C5&,C-B[]/:.TF%%JK^Y?M$^G+(38?-9\M#09Q2E <GBG00
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M.GE]]B2"@9<3O 1Z'L&3T?*4OIN&"^_[/!NMN[82!GX(8X=S QT#?PIXX=Y
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MVG7O>OR@0IG$UA9C\?\?\N*G49J-0&7$!&P/N- ".QLM@'N]P;))--/XDMT
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M=Q:--TO[U\VI$CF5+N?OL:%[B]\['0/=Q>_ZE:_*LOKC_P=02P,$%     @
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MRM=;@=[*U]N WL;7VX#>QM?;@-YVA;,2=%C"U]N WL;7VX#>QM?;@-[&U]N
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M9VO7'_/9\/^1Q1M02P$"% ,4    " #H39Y0'R// \     3 @  "P
M        @ $     7W)E;',O+G)E;'-02P$"% ,4    " #H39Y0)^B'#H(
M  "Q    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( .A-GE!VFB$A[P   "L"   1              "  9D!  !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .A-GE"97)PC$ 8  )PG   3
M          "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MZ$V>4$N1FV,U P  .@\  !@              ( !^ @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .A-GE#X;O"S<P0  ),5   8
M          "  6,,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #H39Y0F*EE+#\"  "W!P  &               @ $,$0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ Z$V>4$_AR[AD P  #0X
M !@              ( !@1,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+
M 0(4 Q0    ( .A-GE (B8 -&P(  ,0%   8              "  1L7  !X
M;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #H39Y02H7J#Z<#
M  ""#P  &               @ %L&0  >&PO=V]R:W-H965T<R]S:&5E=#8N
M>&UL4$L! A0#%     @ Z$V>4+[- (Z1!   YA4  !@              ( !
M21T  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .A-GE#&
MNXS>KP$  -(#   8              "  1 B  !X;"]W;W)K<VAE971S+W-H
M965T."YX;6Q02P$"% ,4    " #H39Y0 1\.';0!  #2 P  &
M    @ 'U(P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MZ$V>4)F'Z &U 0  T@,  !D              ( !WR4  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #H39Y059?L?K4!  #2 P  &0
M            @ '+)P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( .A-GE!9 6;XM0$  - #   9              "  ;<I  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ Z$V>4(7E/R2T 0
MT@,  !D              ( !HRL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #H39Y0,K2]:;4!  #2 P  &0              @ &.
M+0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .A-GE [
MFC(<LP$  -(#   9              "  7HO  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ Z$V>4!>Y.>2U 0  T@,  !D
M     ( !9#$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .A-GE!G@+]ELP$  -(#   9              "
M 5@[  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ Z$V>
M4/\^3#RW 0  T@,  !D              ( !0CT  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #H39Y0SAP1[;8!  #2 P  &0
M        @ $P/P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( .A-GE"?LRQGM@$  -(#   9              "  1U!  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ Z$V>4,C'1,>V 0  T@,
M !D              ( !"D,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #H39Y0LW<J_. !   !!0  &0              @ 'W1
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .A-GE!EV.YK
M[P$  &8%   9              "  0Y'  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ Z$V>4,\AK-GV 0  RP4  !D
M ( !-$D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #H
M39Y0:2F@U[<!  #2 P  &0              @ %A2P  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .A-GE [OLIYG@$  %P#   9
M          "  4]-  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ Z$V>4-PF!8!/!   MAD  !D              ( !)$\  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #H39Y0DLOU<Z8!  "9
M P  &0              @ &J4P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( .A-GE :>42=+P(  %@&   9              "  8=5
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ Z$V>4& 8
M?C_\!   CAL  !D              ( ![5<  'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " #H39Y0\O',/?L!  !P!0  &0
M    @ $@70  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M .A-GE"O2FZ^,P(  +<&   9              "  5)?  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ Z$V>4-2Y,.(Z @  !@<  !D
M             ( !O&$  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #H39Y07%^S#!8"   #!@  &0              @ $M9   >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .A-GE!W","C"@(
M '4%   9              "  7IF  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ Z$V>4(T+D^I' P  _0T  !D              ( !
MNV@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #H39Y0
MO++##.,!  #F!   &0              @ $Y;   >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .A-GE"9P634]0$   L%   9
M      "  5-N  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ Z$V>4%#T/,AQ @  DP@  !D              ( !?W   'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #H39Y0"E7>9GL"  "L"
M&0              @ $G<P  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( .A-GE#9?+-W&P,  ,4,   9              "  =EU  !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ Z$V>4+IH>73T
M 0  [00  !D              ( !*WD  'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #H39Y0YD7ZBA,"  "U!0  &0
M@ %6>P  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .A-
MGE +4I#J)@,  &P-   9              "  :!]  !X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ Z$V>4,_.(T.2 @  M0D  !D
M         ( !_8   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    " #H39Y09J_U;#<"  #'!@  &0              @ '&@P  >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( .A-GE!&7YWA& ,  "(-
M   9              "  32&  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ Z$V>4/+#@TBN @  >0D  !D              ( !@XD
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #H39Y0;H:A
MD7,"  #;!P  &0              @ %HC   >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( .A-GE!$@M=VK (  &P*   9
M  "  1*/  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MZ$V>4(MOT:B9 @  P D  !D              ( !]9$  'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #H39Y0^5T]GC,"  "(!@  &0
M            @ '%E   >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( .A-GE"G$;6P@0(  +X(   9              "  2^7  !X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ Z$V>4/>MJV*^1P
M%$T! !0              ( !YYD  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ Z$V>4(6;Z\1) @  ?@L   T              ( !U^$  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #H39Y0F*T;E&P$  #N)0  #P
M        @ %+Y   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Z$V>4,VC
M$6(# @  H"(  !H              ( !Y.@  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ Z$V>4-<FG)W< 0  1R(  !,
M     ( !'^L  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $( 0@  $@
&+.T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767259376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accounting analysis and revenue recognition</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaboration and license agreements typically involve us granting licenses of our intellectual property and performing research and development services in exchange of upfront fees, milestone payments and royalty payments. Since December 31, 2019, there have been no material changes to the key terms of our collaboration or license agreements. For further information on the terms and conditions of our existing collaboration and license agreements, please see the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For arrangements that include sales-based royalties and sales-based milestones and in which the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Milestone revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At each reporting period we evaluate whether milestones are considered probable of being reached and, to the extent that a significant reversal would not occur in future periods, estimate the amount to be included in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are considered constrained and are excluded from the transaction price until those approvals are received.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Celgene Corporation</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into the following collaboration agreements, or collectively, the Collaboration Agreements, with Celgene, a wholly-owned subsidiary of Bristol-Myers Squibb Company, or BMS, which is a related party through ownership of our common stock: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In April 2010, we entered into a discovery and development collaboration and license agreement focused on cancer metabolism, or the 2010 Agreement, which was amended in October 2011 and July 2014. The discovery phase of the 2010 Agreement expired in April 2016. On August 15, 2016, we terminated the 2010 Agreement as to the program directed to the isocitrate dehydrogenase 1, or IDH1, target, for which ivosidenib was the lead development candidate. Accordingly, the sole program remaining under the 2010 Agreement is IDHIFA&#174; (enasidenib), a co-commercialized licensed program for which Celgene leads and funds global development and commercialization activities. Under the remaining terms of the 2010 Agreement, we are eligible to receive up to $80.0&#160;million in potential milestone payments for the enasidenib program. The potential milestone payments are comprised of: (i) up to $55.0 million in milestone payments upon achievement of specified ex-U.S. regulatory milestone events, and (ii) a $25.0 million milestone payment upon achievement of a specified ex-U.S. commercial milestone event, as well as royalties at tiered, low-double digit to mid-teen percentage rates on net sales of IDHIFA&#174;.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In April&#160;2015, we entered into a joint worldwide development and profit share collaboration and license agreement with Celgene, and our wholly owned subsidiary, Agios International Sarl, entered into a collaboration and license agreement with Celgene International II Sarl, or collectively, the AG-881 Agreements, to establish a worldwide collaboration focused on the development and commercialization of vorasidenib products. Under the AG-881 Agreements, we and Celgene split all worldwide development costs for vorasidenib, subject to specified exceptions. The AG-881 Agreements were terminated effective September 4, 2018, upon which we received sole global rights to vorasidenib. In connection with the termination of the AG-881 Agreements, Celgene will be eligible to receive royalties from us at a low single-digit percentage rate on worldwide net sales of products containing vorasidenib.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">In May&#160;2016, we entered into a master research and collaboration agreement with Celgene, or the 2016 Agreement, focused on metabolic immuno-oncology, or MIO. The initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzI5ODUzNDkxMzg3MA_e91388f5-9090-44e2-9f63-c9d6bd473913">four</span>-year research term of the 2016 Agreement ends May 2020. On March 25, 2020 Celgene declined the option to extend the research agreement for up to two, or in specified cases, up to four additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQ4NQ_1f9fa6ea-bf2b-47b0-80ab-ef3b836dafa9">one</span>-year terms which would have required the payment of a $40.0&#160;million extension fee. Further, on April 10, 2020 Celgene notified us that they will be declining to elect any program as a continuation program under the 2016 agreement. Celgene had designated AG-270, our inhibitor of  methionine adenosyltransferase 2a,  or MAT2A, as a development candidate under the 2016 Agreement. On March 25, 2020, Celgene notified us of their decision to decline their option to enter into a Development &amp; Commercialization Agreement with respect to the MAT2A program under the 2016 Agreement which would have required the payment of a $30.0&#160;million fee. As a result of the decisions, the research services will be fully satisfied as of May 17, 2020, no additional performance obligations remain under the 2016 Agreement and we are no longer eligible for any milestone payments for the 2016 agreement.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration revenue</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Licenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">On-going research and development services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were not considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercialization activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue - related party</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets and liabilities during the three months ended March 31, 2020:</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.929%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.724%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Collaboration receivable &#8211; related party </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,539&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,294)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,577&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Royalty receivable &#8211; related party </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue &#8211; related party, current and net of current portions </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57,344)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period and unbilled amounts related to future reimbursable costs. Deductions to receivables relate to collection of receivables during the reporting period.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. </span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(3)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in collaboration revenue from on-going research and development services during the three months ended March 31, 2020 is primarily due to the fact that subsequent to Celgene&#8217;s decision to decline extending the research term, the Company updated its estimate of the future costs that will be incurred to complete one of its performance obligations under the 2016 collaboration Agreement that is recognized overtime using an input method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.561%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.429%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance obligations satisfied in previous periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $10.5 million. This amount is expected to be recognized as performance obligations are satisfied through September 2023. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the underlying performance obligation, or delivery of the enasidenib license, had been satisfied as of June 2014, royalty revenue is recognized as the related sales occur. During the three months ended March 31, 2020 and 2019, we recognized the following as royalty revenue:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty revenue &#8211; related party</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Milestone revenue</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">No milestones were achieved during the three months ended March 31, 2020 or 2019. The next potential milestone expected to be achieved under our Collaboration Agreements is the first regulatory approval of enasidenib in any of China, Japan or a major European country, which would result in a milestone payment of $35.0 million under the 2010 Agreement.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CStone Pharmaceuticals </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, we and CStone Pharmaceuticals, or CStone, entered into an exclusive license agreement, or the CStone Agreement, to grant CStone specified intellectual property licenses to enable CStone to develop and commercialize certain products containing ivosidenib in mainland China, Hong Kong, Macau and Taiwan, or the CStone Territory. We retain development and commercialization rights for the rest of the world. On March 2, 2020, we amended the CStone Agreement to include Singapore as part of the CStone Territory. Pursuant to the CStone Agreement, CStone will initially be responsible for the development and commercialization of ivosidenib in acute myeloid leukemia, or AML, cholangiocarcinoma, and, at our discretion, brain cancer indications. CStone is responsible for all costs it incurs in developing, obtaining regulatory approval of, and commercializing ivosidenib in the CStone Territory, as well as certain costs incurred by us. Pursuant to the CStone Agreement, we received an initial upfront payment in the amount of $12.0 million and are entitled to receive up to an additional $407.0 million in milestone payments upon the achievement of certain development, regulatory and sales milestone events. We </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">will also be entitled to receive tiered royalties, ranging from 15% to 19% percent, on annual net sales, if any, of ivosidenib in the CStone Territory.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue -other:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.976%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License and other services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were not considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">970&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue - other</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">970&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets during the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.929%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.724%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets (1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration receivable - other</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(888)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,033&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)     Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $0.5 million.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The license was determined to be the predominant item to which sales-based royalties and sales-based milestones relate. As the license was delivered in June 2018, we will recognize royalty revenue when the related sales occur. To date, no royalties have been received under the CStone Agreement.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Milestone revenue</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No milestones were earned during the three months ended March 31, 2020 and 2019. The next potential milestone expected to be achieved under the CStone Agreement is the dosing of the first patient in a local study in a solid tumor indication in mainland China. Achievement of this event will result in a milestone payment of $5.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763955328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory, which consists of commercial supply of TIBSOVO&#174;, consists of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.697%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>326</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Overview and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/OverviewandBasisofPresentation</Role>
      <ShortName>Overview and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Product Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenue</Role>
      <ShortName>Product Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148111 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://agios.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2205202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://agios.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/MarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Product Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueTables</Role>
      <ShortName>Product Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ProductRevenue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ShareBasedPayments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2349309 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/LossperShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Overview and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails</Role>
      <ShortName>Overview and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryScheduleofInventoryDetails</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2426410 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Revenue-Related Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails</Role>
      <ShortName>Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432414 - Disclosure - Collaboration and License Agreements - Celegene Purchase Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements - Celegene Purchase Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Collaboration and License Agreements - Collaboration Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Collaboration Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails</Role>
      <ShortName>Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails</Role>
      <ShortName>Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails</Role>
      <ShortName>Share-Based Payments - Summary of Unvested RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails</Role>
      <ShortName>Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="agio-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="agio-20200331.htm">agio-20200331.htm</File>
    <File>agio-20200331.xsd</File>
    <File>agio-20200331_cal.xml</File>
    <File>agio-20200331_def.xml</File>
    <File>agio-20200331_lab.xml</File>
    <File>agio-20200331_pre.xml</File>
    <File>exhibit101-letteragree.htm</File>
    <File>exhibit102-agiosamendm.htm</File>
    <File>exhibit103-agioscstone.htm</File>
    <File>exhibit104-agioscstone.htm</File>
    <File>exhibit31-1x03x31x20.htm</File>
    <File>exhibit31-2x03x31x20.htm</File>
    <File>exhibit32-1x03x31x20.htm</File>
    <File>exhibit32-2x03x31x20.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781747744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 524,031<span></span>
</td>
<td class="nump">$ 636,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">74,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">524,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">598,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">74,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">163,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">100,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">259,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">54,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">54,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">54,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">19,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">524,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">544,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">19,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">163,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">100,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">259,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6949523664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">8,589<span></span>
</td>
<td class="nump">6,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 9,778<span></span>
</td>
<td class="nump">$ 7,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6712756064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 87,098<span></span>
</td>
<td class="nump">$ 30,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 22,674<span></span>
</td>
<td class="nump">$ 9,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6948066672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,690<span></span>
</td>
<td class="nump">$ 18,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,603<span></span>
</td>
<td class="nump">13,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,132<span></span>
</td>
<td class="nump">4,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember', window );">Performance-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_EmployeeStockPurchasePlan2013Member', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember', window );">Other Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_EmployeeStockPurchasePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_EmployeeStockPurchasePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763051936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="nump">$ 58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember', window );">Performance Stock Unit, Probable of Meeting Vesting Criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember', window );">2007 Plan and 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">11,030,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">2,708,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan | Performance Stock Unit, Not Probable of Meeting Vesting Criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="nump">$ 11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">528,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under 2013 ESPP (in shares)</a></td>
<td class="nump">62,694<span></span>
</td>
<td class="nump">32,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Opportunity to purchase of common stock (in shares)</a></td>
<td class="nump">836,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6940023520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2013 Stock Incentive Plan</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based stock units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of March&#160;31, 2020, the total number of shares reserved under the 2007 Plan and the 2013 Plan was 11,030,628, and we had 2,708,920 shares available for future issuance under the 2013 Plan.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock options</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents stock option activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.590%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.061%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exercise Price</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,201,485&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">792,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(133,256)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited/Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(110,904)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,749,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,874,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,749,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March&#160;31, 2020, there was approximately $104.0 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.7 years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted stock units</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents RSU activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766,953&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">744,447&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192,870)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,655)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,290,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was approximately $58.3 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 2.2 years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance-based stock units </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents PSU activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.736%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.766%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.768%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.64&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238,765&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.03&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was approximately $0.5&#160;million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, which we expect to recognize over a weighted-average period of 0.1 years, and $11.3 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Market-based stock units</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:67.838%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.787%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.790%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested shares at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of March&#160;31, 2020, there was approximately $0.5 million of total unrecognized compensation expense related to MSUs, which we expect to recognize over the remaining derived service period of 0.5 years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2013 Employee Stock Purchase Plan</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued 62,694 and 32,410 shares of common stock during the three months ended March 31, 2020 and 2019, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 836,363 shares of our common stock. As of March&#160;31, 2020, we had 528,952 shares of common stock available for future issuance under the 2013 ESPP.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based compensation expense</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,603&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance-based stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">328&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.707%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.283%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6940058224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of eight years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal option is not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. Operating lease costs for the three months ended March 31, 2020 and 2019 were $3.8 million and $3.1&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2020 and 2019 were $3.9 million and $3.1&#160;million, respectively.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not entered into any material short-term leases or financing leases as of March&#160;31, 2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:85.317%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.683%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,773&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Undiscounted minimum rental commitments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,226&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,750)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,476&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>In arriving at the operating lease liabilities as of March&#160;31, 2020 and December&#160;31, 2019, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 7.9 years and 8.2 years, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763275472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 7,006<span></span>
</td>
<td class="nump">$ 18,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">18,661<span></span>
</td>
<td class="nump">21,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">9,238<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">4,726<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 39,631<span></span>
</td>
<td class="nump">$ 53,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6947747952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Overview and Basis of Presentation - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 613.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781092128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 523,965<span></span>
</td>
<td class="nump">$ 636,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,520<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,454)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">524,031<span></span>
</td>
<td class="nump">636,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">439,094<span></span>
</td>
<td class="nump">483,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(739)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">439,528<span></span>
</td>
<td class="nump">483,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">141,490<span></span>
</td>
<td class="nump">178,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">142,325<span></span>
</td>
<td class="nump">178,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">89,008<span></span>
</td>
<td class="nump">80,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">89,243<span></span>
</td>
<td class="nump">80,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">208,596<span></span>
</td>
<td class="nump">224,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(718)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">207,960<span></span>
</td>
<td class="nump">224,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">84,871<span></span>
</td>
<td class="nump">152,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(715)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">84,503<span></span>
</td>
<td class="nump">152,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">21,282<span></span>
</td>
<td class="nump">35,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">21,553<span></span>
</td>
<td class="nump">35,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,260<span></span>
</td>
<td class="nump">17,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">11,249<span></span>
</td>
<td class="nump">17,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">52,329<span></span>
</td>
<td class="nump">99,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 51,701<span></span>
</td>
<td class="nump">$ 100,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777876816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,256)<span></span>
</td>
<td class="num">$ (93,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,474<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">19,690<span></span>
</td>
<td class="nump">18,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of premium and discounts on investments</a></td>
<td class="nump">126<span></span>
</td>
<td class="num">(1,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_OperatingLeaseRightOfUseAssetAmortization', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,203<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Accounts receivable, net</a></td>
<td class="num">(2,861)<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent', window );">Collaboration receivable &#8211; related party</a></td>
<td class="num">(1,038)<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent', window );">Collaboration receivable &#8211; other</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent', window );">Royalty receivable &#8211; related party</a></td>
<td class="num">(400)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,447)<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="num">(6,774)<span></span>
</td>
<td class="num">(2,173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(4,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses</a></td>
<td class="num">(14,967)<span></span>
</td>
<td class="num">(5,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty', window );">Deferred revenue &#8211; related party</a></td>
<td class="num">(56,765)<span></span>
</td>
<td class="num">(15,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,229)<span></span>
</td>
<td class="num">(2,129)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(105,358)<span></span>
</td>
<td class="num">(103,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(54,911)<span></span>
</td>
<td class="num">(77,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">167,501<span></span>
</td>
<td class="nump">210,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,455)<span></span>
</td>
<td class="num">(2,038)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">108,135<span></span>
</td>
<td class="nump">131,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on financing lease obligations</a></td>
<td class="num">(80)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from stock option exercises and employee stock purchase plan</a></td>
<td class="nump">5,465<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,385<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">32,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">80,931<span></span>
</td>
<td class="nump">70,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">89,093<span></span>
</td>
<td class="nump">103,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions to property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">5,444<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets', window );">Proceeds from stock option exercises in other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining operating lease assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Financing lease liabilities arising from obtaining financing lease assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767328256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">68,789,925<span></span>
</td>
<td class="nump">68,401,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">68,789,925<span></span>
</td>
<td class="nump">68,401,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781314016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6764241168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of March&#160;31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:48.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">524,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">524,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">544,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">598,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777855072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Excluded from Calculation of Diluted Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:70.834%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.215%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.217%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,749,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,482,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,290,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709,162&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance-based stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,132,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,198,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781543904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,098,000<span></span>
</td>
<td class="nump">$ 30,227,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized', window );">Milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember', window );">Collaboration revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,097,000<span></span>
</td>
<td class="nump">17,919,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,334,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts', window );">Initial payment received</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized', window );">Milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RoyaltyPercentageRemitted', window );">Royalty percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RoyaltyPercentageRemitted', window );">Royalty percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement | Royalty revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RoyaltyPercentageRemitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RoyaltyPercentageRemitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781738800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractualAdjustmentsRollForward', window );"><strong>Contractual Adjustments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contract adjustments, beginning balance</a></td>
<td class="nump">$ 874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CurrentYearProvisionForContractualAdjustments', window );">Contractual adjustments, current provisions relating to sales in the current year</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PriorYearProvisionForContractualAdjustments', window );">Contractual adjustments, adjustments relating to prior year</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear', window );">Contractual adjustments, payments/returns relating to sales in the current year</a></td>
<td class="num">(2,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear', window );">Contractual adjustments, payments/returns relating to sales in the prior year</a></td>
<td class="num">(653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contract adjustments, ending balance</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_GovernmentRebatesRollForward', window );"><strong>Government Rebates [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, beginning balance</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CurrentYearProvisionsForRebateReserve', window );">Government rebates, current provisions relating to sales in the current year</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PriorYearProvisionsForRebateReserve', window );">Government rebates, adjustments relating to prior years</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear', window );">Government rebates, payments/returns relating to sales in the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears', window );">Government rebates, payments/returns relating to sales in the prior years</a></td>
<td class="num">(677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, ending balance</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProductReturnsRollForward', window );"><strong>Product Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, beginning balance</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInCurrentYear', window );">Returns, current provisions relating to sales in the current year</a></td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInPriorYears', window );">Returns, adjustments relating to prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries', window );">Returns, payments/returns relating to sales in the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries', window );">Returns, payments/returns relating to sales in the prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, ending balance</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Allowance for Doubtful Accounts Receivable [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">$ 3,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveProvisions', window );">Total allowances and reserves, current provisions relating to sales in the current year</a></td>
<td class="nump">4,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveProvisions', window );">Total allowances and reserves, adjustments relating to prior years</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the current year</a></td>
<td class="num">(2,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the prior years</a></td>
<td class="num">$ (1,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractualAdjustmentReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractualAdjustmentReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractualAdjustmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractualAdjustmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GovernmentRebatesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GovernmentRebatesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProductReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProductReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781091696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Collaboration Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 87,098<span></span>
</td>
<td class="nump">$ 30,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_ResearchServicesMember', window );">On-going research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">59,220<span></span>
</td>
<td class="nump">17,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CommercializationActivityMember', window );">Commercialization activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember', window );">Collaboration revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 60,097<span></span>
</td>
<td class="nump">$ 17,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CommercializationActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CommercializationActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767489104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,132,598<span></span>
</td>
<td class="nump">7,198,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">6,749,373<span></span>
</td>
<td class="nump">6,482,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,290,875<span></span>
</td>
<td class="nump">709,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">78,920<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember', window );">Employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">13,430<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6948040832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Unvested RSUs Activity (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">766,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">744,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(192,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(27,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">1,290,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 63.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Vested (in usd per share) | $ / shares</a></td>
<td class="nump">70.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">66.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 55.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767240848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value of assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763188016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001439222-20-000039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001439222-20-000039-xbrl.zip
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M"A?%:;EU3CA<J4E1*611% @381"++G+"&9/RK#4/VL*0UI0C7MG&BES])-4
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M^OHMONC;3<V+;^073U[D]Z4\X/T;GGI;$\=I/,D<)S6)%^7GQRM34R8W2W6
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M=\=.W[A#KSV_\<>)3U?:;BX\#,]ODX Q'<^%_]?I,+9L6,X(_$SI^/GT:L]
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MWO;ZVMO=I:AVZ\O?M1<_?&E5_'>^W[;##WC]N;]O_N"5SBBVROX\IE]?_=$
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M>E&M>R@HJ5W@,.U6IZ_[M@K3EH;/WD;ML?A\%8GX9=#>G^:LS/*@@Y5 4*T
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M(71JEP6B,0R> 8F(CQ JXU\J:$ L)U1&%*4!UE<57I*R>+-:"P6A18KWEH!
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MKFK7&NWO?K@>DAVWU==X[TECN#T:Z^U6)W;JSP+>#\/N:*2WV^Y#*0&]O<F
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M[SK[==,N\W:_TYV;=IO=%]4([QT-=(3TC.4S8?GG:<TVE1^QRGK /!* <JB
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MGO."XMJ[2+)+>0U1L0IJ<4;%%T+%B1*,@T#<!0D\3'%GQ#M@K$RAQ1PK05G
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M6=+95[S6ON(/PT'_T-3M?N2"MZ-QS[ _$^Q?2Y@>F-:(&0V<E0I0Q 0PF&I
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M(QJ$81:)5.V)WE'AX^5I>^U#77+LW_KAZ+)VPF0<73J.3FTQ#]A"[00(C@E
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MZO^@F5XY168D<2E;F*[>.?Q[;Q=$725.%^=;D1T*+UOI^$^$V"V4Y>&W1B1
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MPR=7$;VE=H"@5!A42@6D@QXX!@/C2FJ%176CCJN.2<]0<!>Q0II!\&5 T*E
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M'N/Y[/8C.;JJ0$H]0D!?9&V^^]F4I&C&C\@'._/@T+.=[3=?DHZ!2>I0<#@
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MYQ\1F"7NVN^%!V[& _/J:<D8[[!-"-.\PX0G#!DN(L*.,HL#EH;3M4W-1.&
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M4E'Q4]> A$X72 @#MW!!+'(Q!,2C=T@+H9$S2H3 O>"1KVU240BH$% AH$)
M-5D>6#4#E>6!NS!0:]$,,B$YREQ "=.(N+8461HDBBH:$AU55!DP@^@#%X8H
MY%/(IY#/BR6?>COBRJK,?3'/!=M'!BRMEBA8 <P3G$-.>H44]T%Z$1/E;N*
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M])>B>$D.EXJA72*(,^U^41#KV7PZC>UV$6*;1?^'-?BWGX\"P9-"H3?*6CR
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MK;YT?DJ;K]4O=L=@;+*-+;GQ.W.F7/8+)E[!SMR _J_MG/Q1>W/)\=]>] O
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M<YPC/F)T[E5_?[7+7X7W?KGP9$855_GKCVR2$JR#I%$;F3PW@3C-K)&4D2C
M@F'Q!OYZ97<^I=VY.^^4@Q,AC2$)!8\-..7)(6MP0-(SQ7UR6A&P.[52E=%9
M>>05_%V&O\0X5Y'QJ&7DED9K  B)#=(FEC@A-_#(*_A[8OB;N=W)!6\#%\BJ
M /"'O4*:28^(B<Y[XS3-C6:UX!7\K>:QU*T\AZNS"6_8Z?MA_=['+.?H#7/_
MRF457S6T2._^;#E^#[<:JS7WSY@'<N\I77]]+',Q+S8T16&Y<L:(D!37TH(I
M2ZD-U?'A&JGJSW.>"MA9-EC/$?66(6Z\1LXZ@SS35&OM7&!F8TOB.C9/X:P\
MR\9</;![JI3$1U;=E?*KE-\+4'Z8!B=I8%9XR96(3AOBA1#>:,VTJHZ'UTOY
MS?Q4RH/+JX6BT@&4'W/(>D$0!K4GH[-)<U4<#YM<D%@IO^?U<7\K^"GF&S/.
MR&>J1HUW;]1(JT:-5:/&^S1JO*[QXH5&C3;)D+B5#%0&#RE8D<!S# (&%AE-
M;N.QB*4F.G:98LWZ=+C=#?_;LJ[5;@W/*KZHG???I%4D4FF15L$C3B1!VB6&
MA*=2Y$FWFK]DOJB]!:JGDI?I)">S9]8X?Y3)QP:U^4;&-O->9E$:C!M+E-*4
M.P6$6W!/7<T?=5F]O I&*<XW#;TK[]-+9)2JAOPDO%W\87B[*J:E7YO\:\"T
MM&XD.CO1E_UT,M68Z_]VF55G=2GFJG6^^3IOAY(W]TXILM7:KO3:[L3<$ZI:
MW!>YN#,BR!*=+]#?/7N^\E-SGCUJ)O.":U:1DE4CJT96C6PMR>_@EC<<Z/Q!
MQL(%>I4#;WAI\X%)BX]:P6="_EA,MJM-^T2.3I[ZB631\O':1UJRBN#VDNSK
MCDZF0?:*^VE5TAY>3O:"]U1((IC%P7.)@^:$.!=,="(YQW'1D<<0>H^DA2L/
M5)IQ^#*R$XZW>>,X=)K'VWB?_OO[_O%'TOCKH-78^?NHL??VM/G7_OG^WC:,
MH=F^F)W0V#D\:])]VMCY='SP]5,+GNGTH//^M-%Y^[.QMXT/CIM'C9TOYW#?
MU&C-I>:YR'"4)"#J4F;VD E902-*+%C!L#=.YN+UNF"KEYRPZAY!Q?E7X?X+
MQWUKJ362:(U)XM1S[;UFA"7IN ^*D8=(V2Y:-4W0__0B^B_V<#J/H=(%M],%
MLTPU0Z6/6$04J;*(1ZF1%HH@E[CUWJM(@MW88G7&:*4+*EU0Z8)7H O^N<K*
MX)(K\*'?\S&&09G9W,X=8F',NVG6OG-0J8?;J0<R4P\6.QH$1HP*4 \<O 03
ME$(Z".8U+#"3;F.+UJFY7')[Z;B]T@R59J@TPSIKAELH!L '@X7 (5C*@XI.
M.TP]3?D_14S,T:%[UG-6T:&'@WPVHS:T0E#!(PHD\LRQX)%5Q"+"E"5<*ZDB
MSI OGH1DYL7C_O,=Q[^. Y]/O3/;'IZ]W*,>NORHQU?,00]-=$XY"RXY9L#-
M(<(HKX00VG(G4K*F.NY8(84VW^1(R,A)D IQ3QCBDG%D,!,(^\# &HE,9](@
M6C>XXC%_0D>F8DU;'^RC@6#I>4A&2&Z9MPD[RUR4C!FIPO+:N"KDOTIX. OY
M<RN<5#HB%P* 8N08.8PMTIS!D@9'C55ER+^B4:OP\/7@X6W"WD\.B%78^_$A
M<A;V5M1IXG% 2M*(,F,H,LPH%*CUP=J8>#*%R;@$(A\T[%VA8X6.J[%VMP!'
M30@6*H1 0N0!1R>YH3Y%"P#GDK15Z'>E8&\6^HW&:ZH41MZ[S,J0##+4  HF
M39@,X$=K7%B&E:>\JJ'?%>@/\Q3U5G/\%ZMVBEI]?_7]K_;[G_<TZT&X1=?Y
ML&LGIMC/K; FY.%+C[KJ-3^"3W6'!950-PXS0]?DI9->O^R:M:[G86R5SL/N
M)Y'K[ 1@([&4P<3()2>1.)UL=,%2ZQB75#W2<=F49JWR F[A!33GF;N530$S
MSY&@F;F;8? "?' (? .JN#7.1[:Q)4E=$+9R;L#+HRA]S%KEAV'AKJ#UB7L8
M:9X"M0033;E7.B,K_&E44+S(1+AM"[=? FEU\G9/9)UK7Q1(A.4P*$3C$<?6
M(6L)0PP'9Y(.7OJPL2744Y1=5K!:P>HK@-7;'.H] *X^C.WZ9M09E73B;^S0
M'WTYV0['\)D.^&=[O3$>ORE(8M]W&]$.1OVXFS[T>X?].*A._6X)S[-3/Z<5
M]SII! 8N1MP2A71,$C'C) 'DIA&[#,]UQE?JV*\"YPJ<UQ*<;X'- ?-HH_9.
M #9G4G:EC9+210L.:HKXD<X4JW#"'5%U=J@8J%::209&;]2()^:19BHB$72B
M03B/H]_8XG7%=67V/D?#DXLD\&/6=50$O%<F!+Z,/7HA(DS$/TKFJUIM.XRI
M:VO#WJ6NFM/TJ(N=-<=_Y6ML!QYH.*C!WF_#V_#*F]@^C-U,VM^'S[4Z;M0?
M%,4DOC<89JK^(GX>:NZL-EJ@Y._'(J(.?YW $_5"$7,?=<=WGGS19"#P36DT
M!'MNR9=LUF:TK?F#\X\R&[J?YH+EJ/[\9WXQJ,U?MP6X1B+F-E,V4UOI;&6%
MI.R^\$]Z44CZEZJ$[B8>OYKC1UR^VBM;/W9Q_<+%@Z^K%P_,BD$+4+W$@]3O
M=6Z]>K.;7?K>_C1,5K.#Z:MWVGHOH<<)X&(?'-3\RQ7MC8L%Z'7182_/26Z!
M4M 79Y0,\)%V[R2[O348Q(^6OV6WDUIK4#OI@ZW7A\>#*XLERU>FG$,R/+)P
MWY$;Q/^,\E?,MG%Q:JK^&!26Y""/MEAJGQ^R!IL%OFNVG.,!#V._4R]>>M/K
MP*J 'C@)A0"V "DB;*M.EAG8U,4 2I OE4<QD%/ DIJ+,TU2B&KGI!WS5=WB
MRGPGD)K"HNUZ>,G!IK6E3!8MFHI[4TSDA<G>/H29*N:Q^*[68%Y.>X7MTXF@
MN/)3@4"UNB>C8:T3AT?7JH9%V%AWD=VYC7!E$<UGF/7:Z<*^'R[T]EE @1*
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M-&OL;?_<W?'?3 I<".-1))X#G"F"+),>&>R$8@+>5:;41"V8LK"=]8B+3-D
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M<8>5+G<9H>BE@D"L4$?E*[L7E.6KYHR[]X!7T5M9)G,+JJA$V*_%7S&@;9@
M<$EN$MY>BP=[^S/V?6L0:Q]R*NP%V_MYV?/@EB^).F]W/E8ZK,VSRM9^R2A[
MS]:?#]5JZ)H)7Y]"HJ41/NJ3";D3E%><Q\0<3E3KY**$^2-<+^<2>J*X\%@-
MS4E0J;;6/0(XKD#Z@AO'[_'NGO\)SL_1_MY'?+#S1>Q_?=?.U46-O_[^WCQ_
MCYM?&Z>7*I#V/I[!=XCF^5O2_ ICVOGTO;G7/MK_^N]V<V?[=+_S,6=VD/WS
M/U-COH]R#DAHSB4*"KPJ[B)&5G&/P*EBD:L$DA8VMF0=%KW.]>7D[Y5MEK+R
M,/C\+;_6K:?7:RI\?:1ML#[*:30('V*_4 ,/HJ'H(RJAB5$\MHDGIF1A25:J
MZ7:J:<8[I+"UFF*&O!8$<:8ELI9IQ$AB*AK&6-(;6T)O2E*II6?L?_UD/G;V
M@Q95 %T#=^>O,M'ED;R:>Q5MOVQ/YDX'-L_ETA12,GC?_5"4,__5[PT&E>:X
MC>:8IU4-5"6O)4:"*8FXD@:93& 7=7#.Q1"X!:=&&5K'?-6)55<=WIZ'Y>>.
M@>$*:Q_3,+\GX-[>0A_<"E0K*_WAL'9FI</Z,>.X MO<"<2Y]LA289 7\$_0
M,5'JP4HGF]A42+L&EODMSB36SQ:?[/G'LL9OZ26NFTZXFD-S!0SP?%B=,X)C
MV"FJ;4O0+U.'YQ.KIC)08?YM,/]LSKXVL&2$>X.LP[F&,U'D#.<H<JPQ<3@)
MF=L6, ;2(Q^57_..&VY5\>FIS@2>Q7Q^X>#X$@SF"396-O,CX.?,9G8BFN"#
M1D3YW/9%*J2I5P@[L*&E4U2;L+%%Q:;F*Q?97D,(K>+7]YG0=[U^BBW @-_>
M_CQI]:M(]HNWI.\9RAX+S*@_4R.5JKB%JFB^F<_/"29R*0*L:Z:Q)Q%41< 4
M66I\@/6F0<I<[(GK!E]6%BM#9;_J(%=%L5\FSKX$HWP)GE9F^<-A[5S"B8@!
M8ZN0(X$CKCE&3FJ&LK5NN&=12K:Q)<TFOEQ%786R5\](K]+K[?!"M=]JQ+U?
M:VY]=)P08KWE6O-$A,;,1'@A.ITMNP=ASZARZY]5G\SGUAM&B:!"(LV90#RQ
MK$^"1I1FR]W0&#G.N?6*FSI33]#AXS4G,5:Y]55N?95;?YWS<S<-5>76KX=J
MFNOIZTA,DBL43&2(DV21BSPB<'(#(]AH24R16[^$,*I22ZOM]MSY;.(%.4%C
MF"C829[*"7J(_FF52[2"+M&<,%4NT>WUSGQFOH[6414QHLYIQ%V0R!CN4&!.
M C8*:07=V&)UK7B=L"<H-W[D3;NJ^/BLO7F?TUUZHN&OUFJO6D?>RI5Z.E=J
M3GE5KM3#J;29*Y5P9$J+W-1!Y&9!UB(M-$%."*689,;DQHG";*HG*%.NU-FJ
MGR<]2'_Z%9KZ?\?!N)O#0D>J'_#R^AT_W6]QUD=KK:TK5DK;=C>\'<O:7B^_
M5!U:W4N=S==V1!R"-$RB%(Q$'!.'K/4":<)Y2$)QH?QZ'EJ]O!;U3WRF]2"J
M:X6.O&[[/*LE#RMY(G:K/;8^^G+EO;SK]6+E_#V<MIPY?S89I7G4*#')$6?.
M(DN#1<$%%H)0..06D^MVCO;R-&7A#?Y6L,;/]ZN9[XGXLEOS;0^O;$'6CT7[
ML*+9WD\ J&%LG]VJ#^_=FD+=J _O!!_?CKO-?8[]'P!8R^&RV>O^*'&P:/*V
MESNKS;^?FY(V>\/].)RUNIZO#%^5WKQ/WF9C=Z_Q\YNGTEA82N2%!B@CRB"#
MJ4),1J&8]"'"^FT1S'_1FK?HCU<TM!MU^],Y!FF9+4(1)>@.<J/XHE-L#A:,
MQNMVH9?%N.?AZ5'+'^5V965\(5\PO7>M]R-W"*R=3FC);:G><A_$5J_H/+DH
MU[_J\()Y=GVT<R[A3#?HHC)$*6]#\DX(LC3S_V(W]C#JGT7;?S(!+@L"WO7Z
MXY?RY\@KD]_&WK9H?OPFDS?4)(YL8A9QH2-R)B6DF:/!L<@LSIW0-M5%[*_E
M%1M<Z&>V5OUC;ML"Z=/2/J+/TPMI*O6S016H_"4/J6J#-&Z#M/OQ&Y7",F83
M,D$IQ&V42&OC$3;*)1\\(XG\J@W2"S1K?MD9Z=/G+U5#I%LW1-*;F-ZU;=&+
M:X@$0Z:T:HATPP&_HH9(7Q;TY6K7"U?MD&ZO@%Y[.Z2".K,4]1WPG,K?WME6
M_T)P9=V?\]^V/:JZ/3TBC'Z9^O;C-M-5QZ<5._>WBG)P*Y0FAG#IP$L.U@IO
M=-(I6?J\'9_>_F<$UOO[+GB&HX(L83='+/>.;'<<M)MZCR_JX/_3\>Y>0S3I
MW]]W]]KMW7P\<?ZIM7\,WWV^?=H\/R3-O[+O^*Y]Z2CCKX9HG']G^QWP&;]^
M$<V=]^?-O_YNY>=L[&RSW9TO>/]\F^U__?=B)RA,8[#,.N1Y0>JH([)>,B0L
MH8Y+<.*3V]A24M:-6*=C_U4'R.<_UU^[@_OJ9+Y*L+ZKWGJXH_>;JZ8+9^^%
M;9VMZFQ/%P9HI;5NI[7.Y[26XM18A7 ("G'M(S*YFI4E:GD4.N68Z)9DFWSU
MJ#1?E,Y:I4+6]2/9K)I$/9/SHRE5SAD1B?8\4.X\LY0XCVG2@22^&LR:UZJ:
MQ4XGE3JYC3J9KT]5$>NH$T8^4HMX8"8?(3MD6-"42*9-4N $<5[G7*UX.<^J
M8U[%N?G* /AJ4_Z>*/R$-OTO6TI5AOU]D7AFV!/.K(_*(9)21)P3@RSC'-$0
MM8S)"8E=T5>*51W\UL&8?]%]I<KT^]4XQE@W=7%+*OP78K"7$E,9['=1$_/E
MBDH(&0.5"">)$;?P0Q,:D:=*R,2Q,U9O;!%#ZUI=SENN6E$]^['$L]CC+QQ2
M7[0%OHB<E07^P- ZL\"-2HYY&5#(475.HT762HNTBQ)>,4%XL[&E\*98O=#Z
M&J)K%4!_D"Y550B],LGOIEBF(E19Y7=0'0M=J[P4DFFKD23>("X%J ZO8?F3
MB%$J'JW)E5BJ+L5ECL>J:5450'_5\/NBS?>Y;E:5[?[  #RSW;E,P3NI$?8Z
M("Y(1 :;@!*VUG#-P)H&VUW*S25!D2IZOGJ6?$4]>+/2@HIN<!7UUE*OP47I
M)4DA!D^Y<<+%:)G5G*=(@DSD6>D&J[*#Q]14\V4'D6OB7:#()$40=R33-]B$
MA#:21F8)5> JD#HUN*[5$S#"5RQ*JU*74/$-KI(\K&15PZOC&[R;UJR*'EZ
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MCI=F!A)ZL^I\AKHC&M^LF-!5(/8 &M5M&% ))MB#"R8SH&POI=)-(D&]60<
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MS+Q;^"=A>(MT@3[E&0)+>U%4URGE? ,HOX$Q%'%D#/&T:1] DJ>NBF+"U#'
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M[[].+(^)RHA..;N&=L=!]=NB8KYME&"U1;N;E;2[V?<;+B+<!9_,T\".FL^
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M2TH)I?S>RK[1)4/*X@,%GA*;EWV7%90-0-=!$HII@*IM.44L0$')'8= 9]B
M#\P0I&I-,5F)XKBIG0(Q098%M.I1'7#E%X% *S,L)=-SRW?<,.-J7R0!W6,E
M2&#MPB/[B90%S>^LX<ED17L)HZ5/25Y<9AI/!BQ(*K:4#F0%/+$YT8]/^R7.
M"Q7SEV$*[.=YDB:Q=QNF!?:MDR,HQO_RY?-WDNM[F186<$K<(*LS5B7TZBCM
MT2Y#(-UWV'-6EO"] -Z=P#R<]QQ,6>GW/+]\]^+]EA=U1ZH3U\\@#71;T[@
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MF9]B]^*5:^%'JBFPKTR_C5+J#'*7F:CW4= N:/P7A@C HBI&^K1Y-%.II,@
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MKW/GQ4S$,CVR+G\XQ>%D"3=U.:!:ZH8 3I@ &&B,Z@9$%J9VTH(Y>55O@KQ
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MI&_(^]TZ(^+$J?&2B_L1DH9Y-A+56:W%E30NR^E*A89'_^&NT@1\;C_"_2
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M35/+$6X6%-<;YU:/9'E+%<' >V17"54\18?.KH%ZA/]TOGC7;]PBA8L;FV!
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M;!$@;& 'T7;V*+.:5C1@*!ZE"O5]HHH O+QT[)*A$A,!JW?8^5+XD&U*04/
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M0!_&Z"H)J7>$>S+G)SAXXC7DZV&'/C)OX?@9\PX#&"QE%6;&_V=J<OK" 9_
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MQ</FT':JSA .33S]?%69E=F2?Q\LH:ZV##RR)(95S0:$Q82=M$J] &D"A]O
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MCUC\)D9^4TH^L/6R!H1NA<H^P,MJKBF2;TV@_MHB<$N9^'";C7,[>Y:8@X?
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M=2GT */E',QPI:%)>%VTZB7:;PP7ESO,M<7%-H/M0):4\>9RX[@3TNEX:KN
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MU/;R PC)&R\Y\N]E\4B(.L<9Z$?/6RG5.]O;X^Z/]Z&^/ '^C@#^_G@"_)T
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M?]QX5MS%.^PJ@#,2$85_D!,JXX/R*W+S<*F=N)I#9L"09DU&H[,M?Q'![_>
M7WGLC&4#EN;G9(CUL<X7+[V_W>S49?5GM7<?_D&:J?R,2:S./,%:()ME7XZ$
MI;V)5$D5FE6^-PW5*^ D&1^-@"7B*\DD-"TBG_9@$C245,^RR7-Y)+_&P^ZO
M"K#0G##.0L(:XNW9#F3<04T6.'$B;/MCC)%1=6WK6\ZI!NI/!!]!NB#2]C,.
MJC9^;:D)Z%!%(#MV4M='I@NM)M">2B&F5.A-,H;VV8U7)VU,YXLWWH'MM;)%
M0<BRV4+-C-NJ<ED+,C!R!%24MVP=(8ST(&5DY#W&S2\!O[<!:/4S5K%%]R>%
M<GN<P#^?<"+\Q^<G\,\)_',"_WSVI<C3< PM8H6[ZP&U#BLGD_1M(943^2]H
M%'_R9P*1Z-$)NR2Z^94;ET-SJ:Z_]Y&O^Y6$9'K6;+Q=4_K]F$L;/]"Q%] 4
MU%L.PUTOJ9.<-)?Z^*S&VU'+]<G9U$?"?OY];-JZ,%URA/]]*R7R%RD"]SN<
MJ-\BR4H]+VV##L\W]<Y;O?%QA0H?F\,P91OF-MK9*I3M8!QW^Y52ZQ3U78W\
M@LZ+(?/->K#.\AXLB\<GK]/@)+ ]V)NR5X\*RD6=9'9%A 1Z3MW9HIB*\"6K
M$,Z/8,C?!\[^0,$"D6UXR"H"?:R2K3YY FA"RWKF9.<"3D/@N<#-M"DF4_R9
M4[ N,+\':0615 C7-X@0 EK0*SRI;-%W\TA^83(*"B 9BQOGB>\4?T^*S?(3
MB@HK;0O.6@W&>NW ]D613KT\5,*ZN_C@W!9?]TO6,:D1U3=JJ//*2A/@_JX9
M\7=J9^KY(2CG'ZMZDNA'%.4C2PY@0;]>23DW%M^I*\I=2ZPEJUM8XFF$2,@Y
MQLYV]?LUMS3\4=/^=;G"JS<7(9-9,T_WC!PT;;E=0KWEPW,E065A,-,0CB<+
MQL-_^/KE7U]_??&O__+L3W_X@ME<7G_U[KO__HX_D4!H-0=Z8@(T5)),P[95
M,,FY!NV"@E&;?RWZL:6ZRC)\C$95I3RPK^R8"G'QYN)" 7DTD&0CD_>4#YY#
MN\MO!_8K_/M<O/E6L&'-#J4H;\$X7J7EO1K\!O,/]M*_,52@GG_^["\I<H3S
M//P$K&HG$&DSKW3W9)2#$=]1@47=I7I%&3U5T>;]%03'[$-__[OO\>"$A-@/
M-D%1.(ZF-Y<Z6$C!3H3OP":2GD0EI.%4N34TX/1=>V"6 B>R[@UPXDUG68K'
M_99VFUXOX4%)4"%7Y7>+JO&\2S5'G6K?'4V0H4(W$I<PO:KF:>4(?U)GP#M4
MD$&",EE#<JX'34-#%A4[VF:9'T"<GLUWEIC9@2YP(&C8G'V@=:SIO:'> @2V
MB"I^@&^-E-92^L')\@SX)#Y=>/'( 7.^".]?\%VT!#(["DFNY[+?[Y(GB$>;
MT#M(5EB)S)%ADBNEW_7_)5@#;T^$356%50OC=!!"RZGE-3G-4/VMM*",W;KI
M5W".")JGW] V;QH%F!D&F'512P*=X2P7XG<ZDM7\:_*/^Y^;98;IBQV1?M<L
M#>0>JP>$$U3X#WYO83&BHBTTF4J%8IH@]^-C*]'>@P=6EA2=O$>&SL^)?Z_K
MN[ATJBQTH>F!5-R&C@WF=6W6B?):&AK!>])8H,)W=?)(K4-3Q(SP%XB.'^ ;
MLO8I'(3;-M#'6L- ."XQT@Y!_2-Q*]&67BE?K=8DH+VC[:(%LS &8HZ$,[44
MV9$\-"UG*XEM]?W\%/;^A9?Q*G+.N\X_<#SGP\#Y5Z4.I9%)U]2K9)(?<Y4I
M7TZPAM$-TA<SQVAEH%(Q8).S-NRFP?T4[8^?!W,!9F!5[];XIL<=4@7)1.P0
MU3H&IQ1ZR1/HXM4@.')*L$8?G)6$_5"=OT!#87DLR'[@Q %_A07JD-\3##J0
M1%BAB5Y$/,.JN*J#]9)T0(;[HG6K[;^12S=@O5@W1!<]O*D[29)4#<U/6:7L
M4M'LE8PBF+NF#MD%L<!-OSX7_1,&9\.'0/ H<42H+X=R5PB+5*Y>86OH' PW
M(:/<[#:QM6IP4;@:7W(1:B L'Z8IZ 8=)T_*EE\L*<CU,]4>JF,]3\:C+N1A
MDLT=KH*TBZI=:#W3+)^Y/$J::X(Z!^L9J:[7C+<1<#>G3,P_E*S\^CY!7M,%
M>NR4*_HVZ;]*N_Q@BIC7AB_)&3:4LY.K/+(9N!,YA:Z[3)8U,%[$\9.#[-4/
MBB'6F#H9O"--DWO26.,Y'5G'IY10C@@W)6_M]GXW]M*FJZ=/XB-$VF$^P=/#
M=D7K"=Z4:F3'DUN=,?&)[.$HAQ-?,64%+)@4IH/WL<"0^70"\,1Y,/FY35?Q
MC4KA6/!WYUBCK;8!/$3H1[0!?EU4I(@&-'V*G%UKPP2G.F)'J*OCD8RYOC3G
MWAJ.5[.YW \C%\Q,W[PQJ9,?(8>I?.S\%(?Y)E.-^[+9.9Z*FQ_6@I W>??2
MJONKI^:JC\W-*83G?S$K%X<!36\V\D[[@^)R0^[7',7)^.1/62DD!?CMJJBM
M/D!.T<);PN5-PGK5BP* M+W9[]P[]TPWR^Q=PN5Y>4"K?"E9<62=_7,>#>3D
MX?T35'\NIKE.N#%34QR%0+BC(J8JX_>*+-W)T5$'SWS^>#WA?8[@?9Z=\#XG
MO,\)[^.CQN"BR7GPMWWGN%CV_/<5G8M_Y##.$3Z=@<9I"O _O9%;>7_@II<8
M 'U[('AT3,O"CFXE#5Z@[/">G?AN];CX:J"$&Q7L2+) TMPHO! UIKOJI95G
MK$KW;4EB57QI>OZZVY,Y_?TS>OKGGQ-B7A,'?/37MY0Y48QO0GP9!3S(441&
M3E1Q@J>@UUW\&ZH7*RRC_19NRFW/&<Y_/U^\;,;E'BE^(C7:W:J45?;P6B7W
MS\YI+W^$4 >!/]S)V^V7>Z&>H2XJ*9^9MP -JM3:PZ-;_#*);N/"H,;Q3TR>
M?7M(FP"$'8?_H^*,?DV]$SM:,)P>XB[O<&7H=>&:#%U>>7^!0C]_>6I7INZ[
M#C>GEWL[D+__AL2=" #.4E^HO:CD56%D LA#H?H\W.)C3:?ITAUZ^3-]S3\T
MS_[K->%_[WI\ZT#+SV=NI.M%F^Q-XZB)^+R!ZGK"IJV:<=AO8SJT,!:H#WW$
M@$AFD_3($G^F5:1\4#5]]<.3BK[?-5UH[@S#LA[JC0L,"1D+A!5T* QY4++]
M^[YF+0+%EMCR']"*Y>M64^"7<0R%XUFR[9:+D]M+<[#)D1L!VD\,;9HE]@:%
M15N:F]#[:DH$;'*GG#9"%;.+9)=):N"*%B]W)%!.W2D%>52,2>L#LV".XGAS
MQAE)R0P;!M3!(M&246Q974Q2T^A%!GYZ$'EC3<>3^$B59;CF\ H?\PXT"+^3
M4%"2.YKHOC./B=AG>=TX:<G0'EU_[W6CPD^V[X*[6*1#PQO=Y7(_6 80$3\V
MR79N :<!EHZ8(#=>2I4<?4/_=O-9W)0TR1C)5IH$C]$H/26;E?!]<PSZ:D\=
M@'4N5JCGH#:"PXDB!V32:R+=SLC-PFDAJ97D5*#H5;AGJ+.$?G0+.4E6.\SV
MBJW=:6/UC1LK!0/%_FLI.^K&JJ5#.F^/YA?("[_]<#Q)S:N]D"] +7/.E/T:
M-R^G231S];B6Z\>6&"Z\PTID.]Y=_R# S FZ49,>K&I)Z"Y7JT!>#3_(5L+[
M83&M6=OZJV1P*Z+6X&Q/@T[!)-DS5[&GYZ($SN.:M3O+$H4$L^MJRJ!US25#
MB6YZ_6< :<Y,+7*=-L^99C@)7@@GP9OV2SZZD:2ENX3LI[+'QG0DGVR+U;"_
MXOJ[ (/*F=4%#4:_%T+MM3M3!F[:N=YK8B(0D =(*[NZ)[C!ROE0E#A==H+)
MBD1?X-U8#50CV'N'>L>I-_^'SKF58NC12CF]217O +H7P1BP\C3]DK9#>50C
M7 +!"8%I+/+A]MK!%O<#MA+Y#V#9+5^LHDC2Q58%PCO#K>">UR7ZU*=[@[ [
M?N4W2H:"<EYR6;NE!3F1/ [%\8E,W=1OTM3GW).;O+>I51=-1; $4RMAB@N5
M'&#L"OW_[;UK<]M&MB[\5U">/;-G3E&R*/F:O#M5BAQ/G)W$+LLS.=_> HFF
MB!@$&%PD<W[]Z77K7@V DJQQ)B+5I^KL<2A<&MVK5Z_+LYYEUXKKC.V2PJ>X
MM%;CEP &('[VMEU@GY^W,K.-]]N":R 2G125/15K@3!R<PQ =E"A!B1>'-XQ
M_#H[J:L]4U6?3]3H#(U>_?KV6NNJ7@,U#>]TOQQ8,.S_I-M6B2V+?PCK&"9Z
M)V75A)9:W^S;>+GJ8A0C<00@8X0E:RB<N6_$#;K*OO!AV;SOMR9AL 2I9^&%
M*+TA[I#,Y0EK)%IK4L%<(Y$CN>Z\X;0I)4.L.FY6D-7EH\OJ_[6XQ\BRX,6D
MT2'$M_3[*Y"2TWG;5XCR>I^\!3<T%$C2&QAOQ/^N:C=&?^A!.!'.,_!AL61J
M]+#A#*=.66=F00#)AKHR]3X. 9#F"K\F!;KMHXE=[8 (,BW+CK/?PRG?-W/W
M>DG]NTPKG29N4;E5Z58]$R2<^;PC,X,Z-6\IM>"J6\$JPD\NAPU&P?AQ+(/*
MPQ[6J41&$1@^TJE/Q$?0TXW353P4M%5"M966Y!$&'U#H ;?":RW#HA_A;(3@
M$8W) 4O@5E#=/%2@N4%=RT#A;5CC5E]""H >Z7QGK9WYX0R(( XXG*(F_Z0@
MR6[$_L1>&=/2M,RMD@+/DLZ)[<=+ONBOB4>1%AL7RBDPU,\ =HP:ZP$'5@/M
MI1Q"[&^WG%V"LZR@"?A"GSZPFM*$6MLH@)XQ3<N,=_X+@(U?^=! 0^K _/QD
MS05#K"!R^+(+IF"SOW6 W!GBIP$>9:<6?R.K>N!$X"BW:3Z-3D!YH<:<?47;
M./2+U],@!<'VY$N0'W6!(96V)[LLT-Z34'-,+6XS/;<%TMXI"1#C#LZ<#H6Q
M=B <.@F:9755,AT*A)CK28]LC\#*'T'\[?_^2G/A \/(4TNJ?IY"JX&'I*3?
MELEI=P$8*4I8/J?%/K/;!YVX-1!I96[%WIL@\ ZG.&6+X$;RT-Z?'M+_3!CB
MYBAFD&MS7F6X(>61KC;(:M(#UR-"Q3!"</>$ K*$'V=ZG\!C5+XIZ1Y74<[2
MPSNJ)^XD3XUJKNU$EXP!SY_M0&%X8R#EP9[+%9Y1W+8M!C3I7VB]"TU)FD(8
M^I K$:8F)Q"Z5;V8@*N*S//N# TK4"NK67[1T8!5^53JS6NHZ[TH 2$#O_#
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MRDCS,/02<RC+@%(,Z. 62W)V77R<S<>G" 5!P0P UW75K:PVGY'J" "V!%B
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MX^N"F,:BJCWAD3":$CFC!VO;)Q\F;\LA5ITPR(TGJ!?(.K&!J$)VDBVJI\%
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M18M]W'?M$N//LZ[EAD5P>E (2;4MLG.5H16UX<.G59ZFFEW7(13<K'G:,:F
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M#ELM<8B6^U9QTZ/AC3V+>,8.(2X9MK&#Z!,R",-0\\:;D,*F112)[GU;H7F
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M@M>@?2B H;H:K5/JWLH="N*:[_*:XT)7<PA%$ERXC]&%/ =4R,U9!!*SSA%
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M*6F?!*]+5P"GN?VZ3H2KYX:*W(?+N1*4'?HU#&;'!06YD%'5(6L6HVKM</#
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MLC 98O[@$VK'9X$I'4R3$C?P^+R/;2\TOT./GJ'%/=N$=]RX?4(#Y$7J:?!
M3_:X=.FD'7T>G9_<X0BL9;IV#N5YK>Z^)N<(O2VX+2W%;[>_4.R#0AXLJ>)_
MS%#>6-1 [%4F!WJ5J/# Z%C]R1.>@GNF?NZ4SI'^<TYB<<:E=LK00<;K0,BO
M:E8P;LQMUE^M#]5D0J$=M&U*Y_,:LNL,/]FS*;_1?\<LO,=\P-Z3OE=EMS(U
M@"E0<32>_<9*=@WT1Z(S?7ZD&E^Q'/1JC5E]=)'3H.45+ +QJN .<HJ)-[Y
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MT9 2   !U0  $0   &%G:6\M,C R,# S,S$N>'-D[5U;;^,V%G[OK^#Z9;M
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M0*="#UD?%N1Y9"-<ZXU>%1'_H](!H>L27Z#P)]&S]1J[<Q(^8(^X&9W&MO2
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MDRLLCS3'TV(F%9+O8I@)6[Y5IJL (0\R; 1_5*&1?3);T%4:R[^Z-A,97T%
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M9' L1<#<7;:0;@N6(87K/7EPG=Y]-5\Q0C\YF4TW4'@I'=.0".=!H53"8)Z
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M6#G96K?[/GZ"=#J!65Z_U2,9V*79.OK8%7>E$/_*A?%"><=XI"2EG(B4(I+
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M3S1<;3&SB"(RE-H4AY;K+-IL)_>@>BI*,9SH[^J%W%<O_H$3&O,987N1STG
M=;R+\6>\@F=,DH[GQ RX3%NGI*TLA,BD-5H(379_;&)U/H#KJ>C&D.*_JQUJ
MB$VDKF178Q[9)# J;9C48)GV9-1X)8"9+'WD.0BO;*NMXR:0I\+_7@*^2[@>
MS'1\-4EDWKZ>SN>CF % &L>\J>/34K% KCY92\$6I84WIHE/O0'+TS$7=Y1O
M@QW@U>0SSA=UB)>87DT6.*.?C"*B<,%H0E,,X;*DB@#(;(DI>^-1%M>"]VV
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M7'?@-)6*+RQ'$#$[$>!PJ4N/);^[M?KTX>18^=U%2!VC%$S8N@1[0!9TXJP
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M3HHE5VK\+-.622LB2]+RFND;L*@GHBKW%' >2U-Z"'_PBW#PK"9G7UT (ER
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M3/[TWQ?$X*L)^2H72Z:7ET/]]A$FJR*,ZWS<FUU7-99B'"96E$SU1"+0+FZ
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M_7]_>YP'7T55%^7B/_X0_3G\0R 6K.3%XOX__O#KE[< _>%__^>__,N__U\
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MM0UD+5N@A3,W_?:PNOSB#47 \WMGIKS52W=*TRO>N;WA1GOE3BFQ^\:=_/O
MJ^>#R^W]3MP[(3\_5V5=_[JH!)D7_R.XCH+[2<BR$E_(MQFC,B-<YB!B+ 60
M4@E02!%(""8,IF'(,%E?EAG>7;N0:\#]F>?7?2MH$T=H:R6Z62W#"_315F R
ML3HWP6[P9Z-7<+!BNFB:UBU0RCF\RW>)M=-0 ">"C1M)X!++HT $IX,/H^Q/
M.JY\U=QIW2^*QK6WX*^%%%4E>/='RY1^FR$G]$IWD@4[<C>Q"&O)@_4'?*3]
M#\',Y:MI-?^H;^ 09 Y?M$%C#'N?7A<UFY?UJA(?Y:[#O,O.U=WTZL9=3G?<
MY;9%,ZZ;9$+OW,DKLIVRA#Y>-3?@N7SYKI1HU-?1#7J'+ZBC48>]LC^+A:C(
M7)<1X8_%HM"#ZKRI-]^T'.MLFBA%".=Y"DBLHR>2.-.G$@IHCM2RHCPFG-CX
MI(UFG9J#X;.8SYO:G_>M],T&2?;D#T2K@-U9Q&P-S-C1.;*>2?#G'2SW)0XZ
MD3TD-5F!Y)+LS"8>E=.LL#BD+KLO#P@V;M*CFHS.YE:][MX%SK)8IDD,<@1S
M ",8 QR&#'">1#A,$I*G1BF6/7-,C7W:!,I&S#:0QB;L] R,_93B"!S?UV%'
MN%PF#//GS#SZ]GJ@1HJQM7B0[*)N^Q'HC:T]\]7Q(FC[9=^+D[WPT6%FV'M1
MUT*<N5=<FWRO5T)'XKY5C\*,H2C,<IJ#C%+=,"@/ 2*0@PSG&"4B8ABG-A:9
MK0!3HT?U3"5V5I<UY&8&F$\@/5-I*_I-<#["X&9]4*UO J5#FQ"AM7!GFPW%
MSZ699BW#J!;;4(0.C;?!XPRDN&U 3Y=6L''\Y#&.<88RD.0)!I!&$J@#)0$R
MPQ2G211GS*IBQOFIID9;Z\RBG6BGOUC2V'E8#0G+"5B^J6DKY#8=RX>#[#(:
M3HGF_&SC4LI%K8_(X_(W!M[)Z/CHC_+76C2IJA_IDA0+777]S3?VH'VC;\OJ
M7(A?B&"4LI@!%F&D*Z/K4)>4@SS,6,0$EI!8E6.\0I:I$4U/>&5 JJ+6?]'/
M15 V2NH?RX.O#$DTOV8U#2_<QEDCW_=O6@M02J#T"!I%@K4F.CEFK4L@R^K0
M//,1_^D 5*<7=%>(,^Y]W?6X'5W?.1ARY$:$NGCF\OG=0NT'C4.C;H[,7Y2T
M75:,$EF*8KE2;]!!/LS/:O#E:[(4;TE1_97,5V(6IDD..84 A1%3QF$< YQ1
MI#B>("&E2&.[KD/34&MJ^\-11N>]%CG@2N9 *J&#KUKJFZ#3<8S$SG$>+[-=
M9AK"3FC#<M!8KX4FV,&FJQ*X5.ALLT1W #J1'=J %&B4 @U3T. T@;9\7M9]
M$KW\W&HVK:3245?36== /](-*0WT>5DNQ*;33G>)(@F$G/ (J&U<UT.-"<!4
MJF<24RHY3HC(C$YEYZ>8VF;:"CFH9]5I" TNZJX&QO.&<5(^5_5>^G3O+^IR
M\ILC5F[IDWR_/$OO)Z^,?WULC_QWHE('S$==BNHCG1?W[;5GGF:Q"-4+2S$A
M .)<US..(P!SG@DB4)XDT,JK8C+KU%[IC;3!JB'F6A:BL7W7H@?E1G9+%XG1
M(A@Z0UQ#Z]OMT<I[$VSAW1$YV,I\$]P^EJL>)AT>=&P"E9=HX]Z)7R;,V 2+
ML_'%1E]V5'"P*9QWNZF;=[O@77VJ>H9D'J820I#$/%5TE3% XPR!!+*(8HH$
MU.;&%74&S\]M15JCE1>LV@4"ZU9CZ_J"5Y:MZUD"$W/%&["^[9@S-0);K+?2
M!TK\=:U CU!?61_0#>3??W7 RSA8UP;L&?)E*P->UO5B74"#(89V6^L24YH
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MT_&GCN5$_;X\I[[<I5?[2%T%/>R4(GZWN&O(8I:$4$C%L  F6 *(9 Z459Z
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M7<9S^UX9M]'@WJ0=.9;<-^K'D>C>9[0O6?Q>/9[SNX=R(3ZL&H<7S6$6,LI
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MEXDR,$#B;)2!R7<'LE.Q4..JP;:^TEV/:NL<U[YQ4<\0I%"$G(-,B A  A-
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MG-9)<ZEYP'*]6LQE93E5*W!]7*K':=[6E6L0R\N\=I9N\=1?IC%<[_-]M&^
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MD>.!ZPJ6=TM-*I5SM:XJM%>MENOPL/>KJ@*FDG5;YAE)XHA)E)IB:::-;UQ
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MI:K.<1K;A"2,*J3Y.B.IA%@0#)G"&<PSBG(JXUQ%]LSM-/34&%S;!!G8RNC
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M\#O]T__^;^UO]!^F,,?__F__/U!+ P04    " #H39Y00')0:>MU    E@4
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M[%S#1-D(^#I4*QV ;"-A_>AY;VF[Z)(MF)))9CH5"$49B!A%,,P9(9M45^Q
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M+T%SE8I'E75N.?%W)R*/-U<W:OB"+Q:+NB&K^%]-E^ELOKQ8;$R:*T&9D$@
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M;Q;O<?&%=O^Z3 FYQ^)))JA5!E5*'7#",V2;N%'H2G:#E05O(V!<# VGVOF
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M_*V9,F1WO;Q<+F\%+SAGO":@%:^ST1PQSSLT$+TL,5>3E&\YD'77(_2'JET
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MPN<@Z4 ./[JHRW:=Q-M_<QI_^#" :LG^R=_.Q\AZMUS$G-/J*F]_?I[C=6W
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M;IC 12C6Z0)!2@,J,P9.HH>$SCARPA+W37;MCD[)44]YGS)NM1\F>G F]F3
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M2"^D=@9<L!YT#BD(EKUK,RAJ^!Z9(UCG. @)3^Z1&2*6#C"U.^.>F#*=(\/
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MH*!]8FGS?]1?ZDS __D__C]02P,$%     @ Z$V>4,99N@T<#0  .$0  !H
M  !E>&AI8FET,3 Q+6QE='1E<F%G<F5E+FAT;>U<^W,;MQ'^O7\%(J>./<.G
MJ ?UB&9LR6F5L6.-)=?CGSK@'<B#=:\".%&7O[[?+G#D418=5\TD<DO/F$,>
M@<6^L/OM M3Q=V=O3Z\^7KP2B<M2<?'^Y>OS4['5[?<_C$[[_;.K,_'WJS>O
MQ4YO,!171N96.UWD,NWW7_VR);82Y\K#?G\^G_?FHUYA9OVK=WTBM=-/B\*J
M7NSBK9-C>H)7)>.3OQQ_U^V*LR*J,I4[$1DEG8I%974^$Q]B9:]%MQM&G19E
M;?0L<6)[L#T0'PISK6^D_]YIEZJ3ALYQWW\^[O,BQY,BKD^.8WTC=/SCEC[8
M'ZF1W!N-MJ?CG5$T&$]V1N/][<DTCO<&XX/HGT,PV<=P/\>Z.E4_;B6*UC[<
MWR[=T5S'+CD<#@9_/=KB02?'TR)W6,E@IG^[('!RK+.9D*G#TIF<J<&P]ZF<
M;0EKHKM/5E;:W2UOPTK;@P.\WUHANF;!WQZQ^*Y9;R*CZYDIJCSN1D5:F$,S
MFSS;WMWM-/_%H#=X?N2_>S+@?T=$H#N5F4[KPQ^N=*:L^$7-Q;LBD_D/'0O?
MZ%IE]-0/M/I7=3@DU?''N9=P!W12G:MND'BXS0I]&[EBHHS8[\#2PX,UW-\O
M62.34[>N*U,]RP\_5=;I:4WJ>\Q2OS15I,2I- ^0Z:&Z^*/G/5;=GREI!!N@
ML]'&R;F0F2A3)2U"L2L$!% YOZN+2D@1@03B,P7L8CK%1IT61KA$B;+P"0&/
MQ6FBU51<1AK#]%1'XNT4KQ@LG7@QTX45%XDTF8Q4Y70D4]L1YWG4$\^(T-,G
MX^WMP=%ID94RK_G3\.AY1QA5%H;6)F8R)>;:)6#(.FF<B)$Z:.6?95Y)4XN]
M#B>*GA ?P?9<IRGF1TK?*)JB,MW-($B2UL+*E"9@[O?;@\YX-.J-=L0\T5$B
MM!7J7Q7R3$KB8M7O=P>##@S0&^X)F6.E-*U[02)>HS3%C8X5UDJ+2+(ZI+4:
M/.;8WZ0J:-&(K  ?H$?BOBRLHV'(?E#N#<P&"?'!(K=.TA52$89:B'0^96/
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M8CZPT-X&C$L >AP%WKCC8PT+![Z"ILG<OX^N+^[J^L4]#/-(XFN94TEPCN6
M)@J9-\9X^%2SQUK9F*.J=DXM.+L/'PGQOF0LGL-V&<.A!1^M:-](2WVBAES
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M9K9ZJURFDOQM/?M7_B[^ E!+ P04    " #H39Y0OLPF'?\2  !P@   &@
M &5X:&EB:70Q,#,M86=I;W-C<W1O;F4N:'1M[5WI4QLY%O^^?X66U&9AR^8,
M(0$V50R0B:<2H(#9U'Z:DKME6T.[VR.I<3Q__;Y#ZL,7QR8U-C"52<"MUO'.
MWWMZD@__?G)^?/W?BU/1<_U$7/SZT^?6L5AI;FQ\W3G>V#BY/A&?KK]\%F_6
M-[?$M9&IU4YGJ4PV-D[/5L1*S[G!_L;&<#A<'^ZL9Z:[<7VY@5V]V4BRS*KU
MV,4K'P[Q$_A;R?C#WP[_WFR*DRS*^RIU(C)*.A6+W.JT*[[&RMZ(9M.W.LX&
M(Z.[/2>V-[<WQ=?,W.A;R<^==HGZ$/HYW.#?#S=HD,-V%H\^',;Z5NCXWRMZ
M9V^O(]])]2Y6FV_:T:9\O[W7B=7.[N[;K3>[F^W?MF"2&]"<W[%NE*A_K_04
MCKW_9G?@#H8Z=KW]K<W-?QRL4*,/AYT,YN^;MF5TTS59GL;-*$LRLV^Z[=7M
MW=U&^%]LKF^N'?"S5YOTWP%VT.S(ODY&^_^\UGUEQ9D:BLNL+]-_-BP0NVF5
MT1UN:/6?:G]K&^9"OP[]Y*"?1*>JZ2>[M4TS%(<;V"HL:F)I3GUS39GH;KH?
M ?F4P54M\H*.E7%2I\!.F*[N:! 9G78RTY<HCZ(GK6@KE8J^-#?T3+B>$NI;
M3[>U@T>1S*T2\*.&AIGKB56])M+,P0NP>BT3(=,8/H1/AUF>Q"+1-RH9"7XO
MROH#!1*F;Q4,9?K"9=3_,7PNTU%#Z(X8Y.U$1_!*K&V4@.S'ZW4F+#/Y3S)8
MG1+2(K'LC17 ALPID?6UM<  .[E67A"HHODPX]FB+O;UJZVWFP</_?OTFXIR
M$D8T6_=A/9FVP/GIA)HM,"#H79TV73;@=?G?0;9=UN>/%D6F]J:3^>C+Z=D)
M_'\M6L]JW=?GSVJY "A.SZY.Q='/EZ>GR.X?LOI[J(].T7?L[[R%MRI#_9Y;
M<"BC9:+T#+MU!$@H)E350@?U60,5P7D==8U2]/&JZX'[>_WJW?;VYD$@UN*N
MB)@4JR@SY.3W!<Q+&6Q67>SBKP,]"I!\ZV"M(6)"NX!6LH[XJ-HFEV8DWC88
MX*XBIGAB[!&GG8Z*"#F=P-H7?UE5;K5'! O;R@T17!YU=6;%!2) &2EP]I%,
M;$.TTFA=K#X1ON$2%W\-)9.(0<=7+DO5.&>>"D^\(5\JW5D7XE1&/31SK#7(
MIK 0"+I&H%3"J(XR!NPA>*N>,@JB-K",,IC "VG<R'=([S^H)UARPH8'8C+H
MMF);L6.M[+KO^YG#AJ^?3B]/CZX:T\A+,(SB:2"LG (IV)/]DH/V;>^B&]MZ
M]Z3<6%CHXJ^CU+W7KW;?OPBU%VJ41:_OHB<!A<0*1+H/;X"QZ$GG<T*QLMI(
MS'%T,C--$T#^HZQI!UEJH4'DTU&?,W TXLKE,?1/=,>W7F@_27LB,)%1(C0D
MXD:)A!%&!34')KO5E$Y"HX)OEX;&J 3T,^U29%.E.IH@JQSRS?4X\0?\+/#G
M'4FX)\^,L_.O#7&-'/EX?GG:$.094ZO!QG'JU%-Z8%1?6\52CQ_T<Y<#E:/L
M5J4R=19?0RZ!WK"';5!35)<,VAO1S3)FZZU,<E*EVD U<<!Y.."09RAX\$1U
M90*>NHVD:] 0B+Z1_\CA#GCS;(@J]NX.T_;4&+BUOE"^9VJ69XX/'<@8N=Q,
M5,?M;^\1O4]41Z>TD;04H<82,*"RX[,0DYRUBR,'VH&"_HG.%[RP%;F%']NY
MH[V8&.6BL"_"]L BL-,F@Z1D"I*$!C\RNLU@W^809'!7?L^G<!GWL_Q-,OTU
M*7VZSF!["43Y@;:D</06Q6&I\#K$R-=5=.I='L&C.O@9<X!"/%:T][:?JFC+
M)R7:ZV_?$<F/L^85AQRVIP>(U6K8=Z&6/%_*67X1[Z70\15F9@!\8EW):F\-
M(S O_AJB+>-"RJ&N!KK?5[&6#C,Z97^UOKIK^(Y166<^5'PF6N&S,$!BWJ3^
MJB%&,LH.@&9H+Q7FZ$J1&@&F[X W)>2>)XXCA"&^A,!>#C!"@[; )^3,+R?'
M8M7F[=]];_@9B#>%<,V^O$'NU&.Z(S!U$40&K59KC4('\M^U"7#LS;X_A-N3
MK6A./NTK(PH,I:U&Z'XZP%24G &&_ [%RD\=EI+HB**41 XYZC&JFR>T9)KK
MZU?OMP[^]2_X9^= K"*E&F5N<J$T[Z'&IFI7@"05PB[4LNY.,5_590]"56.I
M7LP'M;]<'1-G05 ;92JG@BM1%3!(;>M$NQ%))+X'XA_GD9NPMQBV1DE.8>L,
M$E(K2BN!$ TQV+:.YJ"^#7#X!FM$[--/#2I$D@1>YO4X-GE&R[#6%*PA=#^B
MZ-R )N"2E#2@+[-M7\95?/N<4[E5U>HV3^L];]RFO2;;-DMRIPZ\(=Q<\NJX
M><5*U;][IO0>7=5L&R5OFF0O]V4RE".[\M#RP7G543,G\_R\6&:Z$/K]R=YH
M(3?U'F&!+\\7:@5W;;.BP\T@3N]H P8M:V,J$,T@N6MLM;5W((8&G2QG&,'M
M@ION:;!$8Q_3IAU:L+8"DH 6V2P%3SRB,7HJB068X1ALTTC%$^92APU%:IPE
ML2536PZIG;>1_L72=!)F /BBT=7CH*MV#8>"5R-EZ#?FT @71I@C#((?@#,H
M!BEW(WFLKI$IV_RP1I@G]> [!X1AP%#',9AG6\*08FZ4#L]2H&Z?GWJZXHX"
M5:4^U$4T!)7$<N%"+?/:5A[M]#'G#J8<X73A"/T.B$J[LDNH"IJ27U6JH$KA
M>6(!8HPN3',U+9++.LEYW8#+=Q&71VM3?1B 1'9?EXR],C,2'\$7P^N QJ2A
MCN2L98^ 7PG0DR:9ITXGGBE8#LR":M2M5D,55_ K_$*KF!@RB&L!<W^ G(:^
M24Z'^L>(:3G(;#DM%LF OQB])VV1M_=D \R3F0%:,<6)B8(45!G-R9?:1C]V
M4LIZU438BD*DGA'0#/$$RHJV4[0 !>QV;9KXR#@;.)(?6(S+P"HBH?I9C+M*
M_#'P/\LME@!@6^BU:(EBCFUF"E<P>343-S :WGLFADZL3M#]_[ K7$HE#3T3
MB985U(WKB*63HJM2Q9*&U2# GBI'H"$#\/+QI.& !PQLLY1S 2X#";K5WWDE
M3/MIZV%;;ITM5B8IX"YV-2OAQ60 KKY%"H3:"X$_QW"+S)C8RJ;=,;^-'62E
M(@\1D ,+H8##$.V.[A%OMWD9W@=\SBQN"-8C:6DT'=7IF*Q/GW>D3G+P;6%M
M8X/"QZW;#,U)JMOBBS]M0;WVE7+CP3@22G?@%P[#94$S4!.(5,PHI'<J%:Y*
M^+"MT@_XI:GK);&)P)[%$G2!-24D)?[3:A6[G\=A&5>\C"()Q385Q&E"GL#C
M)+Q3T3H[L2 O?^0:3<J4H)+/C@2S4W?D#ZI*>E8IWO:32O'R[@5\Q ?JQ$69
M*+NLU#K,1GP+18Q')'\M9VSU6G/U9HW@\?=) ?=>4L#34L#:IX!_!6FJ(CC
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M:-@(1"=KRCCVNH ?G"^8!H@P;1<P$^H7_$:UO"$6&628 M!4I\OMILYY#J"
MYI3QB !.@FB*1+).@N>MR3#KJE&1TK>4DC*>3$7"BJG'"?):YJSZN#P>%$N2
M<G+O?>!&[?8(S,TETC_W1(DQ($/=(%-C?:UYJ2^TU(FV+XIR,ZXH;+:J<1M%
M'(4=9TG&\;*<:%W<R!$#V&8&%<FF"EZN9GSI.<#EJI\IT.?D6+*C$/XCMN,:
M]CSI )8<\/%!D*6N3AC8MX$]/A4U;M)CDW=#5[[CF5AU2M()5W/%;Y]@WO/T
M6P1:T*W&NGQ6F,]6;=+9JO?U UECQU.K#O<EB31#0*,GE40*=8(_HX-)4;H6
M:G6SLT(A8[.SOK6Y*M<FS_OH>D&LC^+C.,"L>DHI2NB>'MRND)Q3QB+:$ "&
MP5:K5J@(C =H>N(Y[_$98PL!_$T8?0BZ'$K!X&$XI%KO'[P733=,#C>QJIFI
MT$%Q;HSF7_6#08U?ZGTG9"A^4GI,]&[!TWY:).,6:GUW:K(56SMX21R*,?ZT
M/:G2E11OT&G>9K,N;/C!"QJ+#YPVBK(T!-AD?.\C8,]$^I>F!FKE0S"^)!Z,
M#1=_VG-+M\;TM,A)+-2R9BML-9N@_5(@-,/=?[K<KJBHB55'5?.Y5 L"\=!1
M!] R>CG;"%E5;0(TQHM>8M!>#$#A>09M(X4_A9+RU.%K747_EL$J#ZGZ@R0;
M*5CPPEXB\'!Y*0CH!<>IY=B\*VK_.'V&B8NNU*GEY$'8>;FF'#[=U0&H21-7
M$ZG[R&7V# V0))A-##^$(@E*;OF*:!(#B^_%L@^"0>U!:K1*(VI7C<( LB5<
MEK!:EF)7=K,DF'"3JE%1K]-1/$!N7!@&XB]*;?&C8M#?\[C;9['$8X@LD+(/
M_, DC=3DH*QR+B%WMO94*E&YS&.A%G&70-9+4LJLCZ]8P>T:"-YSRI-A=('R
MBIL!?"$-7Q!0P))*F5F; 'IU*ZXAOL@TQ\TEJG$Q>.5G7YE(XRG6V@'Z(A>$
MEX(BS82O+QM/$N& F)P#QZ' "'="]H#M<LCDE=)-G?/"BNH8S,"5EQY(.U9C
M5]8B@<B.;8YC)52#CMRJ;U.&"%M=GGI3*K!F9CFPT(43UH7% T)[[>7DVGW\
M#=-AD!N;8[$BO%6%$-L-G,-JQ)P"Z8274]6%,6@#$J>@DZ23)Z*O;27+7E*X
MM,+@#,_&BE8YM#2JFU%!:-57XD8F;QI"5Z5-JBVK7M1;L??31'8LH>49\+*7
M^ C+L/.RE_AD8IN:]48=N:]Z3]&[8(/G&?_PVO/)W=\C4MM^JI':,EVF-[F=
M<7__^1*L/4YDQC'"<@'CN9$: XS&=T?/96&!M[9X#!5WY7QE.%97,>R=MNE,
MX],U^WCU8SD.MFVES8DK!_]JF#ZQYUXB]9+(_P^,G@G-OQ_Z?S2"GN)B[P;1
M4PH"[X6C)U3Q_B#ZT1AB?,S[  AZYWX[KDL+&6;A[J>W"_,%9$(EB4Q5EB^%
M\9]^C9 _1N>= =ZBQR>*\&2>WWSAE@U__=^\JQ?I'!3\ 9VA<W.^TE?1U=Y%
M9>WX&V3/-9N$BI[[_LO2P%;UD!/J(4T>--K52ALJ&TDT8/66Q^F+J+8HSLJI
M6W!+1+/:8U\II.A;/$(Q5HZQ+Y8G8[;2ZS]G.(KS4C'."3>RP%)HT%X\=8D6
M'!\7K5W6553PS*\AN@+?D>,7J*2JH)\%QF"UES/TG48PQX\RLKJ/QXJXRA&<
MFS\W6?[J\%N9_.4FMUJ*]4'<*:?G_/<KX4$J/[_*RS#$)R5CNE6-;F(+MS ;
M/@$&$P6F:#:;:3*J''Q#*^Z/X$$P+"2+@C_GA$N( K.A'YR(O%$IEZW4[Y\D
MR4(RXXZ?=Q[E'6YW774UTZ"^G;"G;Q??G#[T.V=><D6/(/*;ORY7=+\O(WLS
MY\O(B&D_*+_TP MQEU+#6F?B:^OZ[/3J2M UQ><?IUP13='(N(OA+U6IN@BN
M<8=H.L[1-.:N!R;VSRF5Z#_"A,W_PIL ;*B\?K^Y^VY]=_%Y<_1SZ_Q*7'PZ
MNOQR='SZZW7K^.CS54.TSHZ7 &4&X[U0,YUU#>O5]?G9Z3BE'V06'RO!BQW4
M;.XB>7X:<7G>8K,2YSHWD_7ZU9N] TM_BZ,T-C#B)VULU%O\=:U\^*WZ'VM6
M8,MOORW^ N[-F)\0\OXWEPM>[3>%*24;)HS"TEN ,XC$GHBP+9_JBW'%?T+<
M6&)UOR_6W'ZWOE<J_3+: /\UG?B%TLLA=G=?-MC3JB,^:CPA@B>KSGFC;_%7
M%820#4&%)8L_]7LPY,KA35==3JO]%$[<+AES?I1=N"/ ?4EPS<DBOM\ZN I)
M7G&!YW3QNQ'N^'I8.G'T_7-C&^TL'L$_/==//OP/4$L#!!0    ( .A-GE L
M5'9"=A$  ,&/   :    97AH:6)I=#$P-"UA9VEO<V-S=&]N92YH=&WM75%3
MXS@2?K]?H6/JYL*6$Y(  P-S5&4@L\/>#%"0/6Z?MA1;2;0X5LZ2R>1^_76W
M9,<F"82IW3T[,+4+)+9DM;K5_76KU?[PU[/+T]XO5UTV,N.07?W\\<OY*=NJ
M[^S<[I[N[)SUSMCGWM<O;*_1;+%>S",MC501#W=VNA=;;&MDS.1H9V<ZG3:F
MNPT5#W=ZUSO8U=Y.J)06C< $6R<?\!OX*7AP\I</?ZW7V9GRD[&(#/-CP8T(
M6*)E-&2W@=!WK%YW=YVJR2R6PY%A[6:[R6Y5?"?ON;UNI G%2=K/AQW[^<,.
M/>1#7P6SDP^!O&<R^,>6;#:;P<'A0(BV$'O[_@$_>+<OWN^U#@]W6_W6P=ZO
M+1CD#MQNVV@S"\4_MD8"GWVTMS\QQU,9F-%1J]G\V_$6W73R8: B T^*H:7]
MTW:PT(T1WTR=AW(8'?DP5!%C#]@BO:'/_;MAK)(HJ/LJ5/%1/.S7VOO[7OH_
M:S::V\?VVILF_3O&#NH#/I;A[.CO/3D6FEV(*;M68Q[]W=/ J;H6L1S8&[7\
MKSAJM8$0^CAUE$$_H8Q$W5'::A-YIR(V7$8P=3!<.9# 'AD-5#SFR'LVXIKU
MA8C8F,=W=(V9D6#BVTCVI8%+/D^T8/"GA!N5&;&:W&:1,M  J)<\9#P*X$OX
M=JJ2,&"AO!/AC-EVOAI/!'!3W@MX5#QF1E'_I_ ]CV8>DP,V2?JA]*%)(+4?
M@IP%#5;D0I7G_TP!>8)QC;.E[S0#/B@CF!I+K8$#NK$.K;1P4E*7R.D:K<HZ
M0=UOPD](%E%#_'&3X<0%Y'PHH[I1$SM"]QE$VZBQ_:HL$W:P?,(Z7[L79_!_
MCYV?ORC">Y?/T0O5IQ>L=_?BILLZ/UYWN\CPYVO%-5:'C- R'.V^@T'E^ODM
MT6 N9E6:QA4*IC<"T]4!8!$02#D_1R/T1<)$@8'J#&,AZ/N:P?O>OCELMYO'
MZ925ERYB52!\%9,A/V(P+A'C;:@B4FK+3\?6"4UYZWC;8P&A1T D:L"^\M@?
ML;9GT6(-0<.&\89U!P/A$S0Z \++3U:>5;!4QCP0!/Y(XQ!VA(75G]%W?6&F
M""L[0ZDTNT+LQWT!=M[GH?;8>>0W/,8!'\83-TL,' X>P6@"V^DW"0H(W B:
M.P*-(9^2:)P)^(O'@DTEX%'.)K&,?#D!*#H)X2%X2Q]=$*$UXX8='K(;&41B
MQFX,+';CL5,^[L<R& J/?>VP9KNU^Y[5-D2Z<+[+3\-<E(C9IS=&16)13+Y3
M0,C#X#,8)#O7(=P,73E9B<50:BNN/ AB)R)7C<L&^ZB^L=U6J_7>8S_&^(0K
M?B]#>+#'/H,SI/U$LUL./LMAL\UNA3;L(Y_!7/ @;6"?Z;%__M*J YG[WH-1
M;(J0.>-9*9758*S+P:* >%B=A Q+"0%=-@.5!=(Q$#'*!BBR$0@)>,-@C?B&
M6)XK'IM9^6G(>$8L>A:S8(2A-:GA##FW.:@!>2=%)31[P['OA;L=MY^[U]W.
MC;=,@@N(B2]Q1BP&_BD!H]C>1PS<.F0U5$4('@48')U,)B'="]VHF"D0]7@J
MH9.Q"FR8SXQ@-H8C#\"0H8@=H*0P"<!D>K0P$&W3PE$#;X-62C:)Y:=C;IW>
MOME_?_Q$=./EK!@41J?P +?I$6IXDGRZ,E\E\+65:0$(/QIR0(H8:643:)OB
MP![8"&E43/; F8E)K.XE+",[Z[ R7_C$7US>>JR'L__I\KKK,;*DD88I2I&W
MG<M)+,:@8JPRPR_&B4G [?+5O8AX9#0VP]T&T#YVJCVZ=9 J*#94RJ+W>QXF
M' /CA0<56(_C,,!TQ/CH6 *^%T,>@F7OX]1Y] AT-U$>D+L#L/YJJH&KA^L9
MGSJQ= *. #RC'HK!)C.YU2B50EP:\WQ$L1>XU#Z@^3X3 QG1'F8U@%&I!KDB
MZ,Q*-<A5FYI\(@TL4(P% )(::Y9H^#,%.@'*1::#F!Z!UF C?B^LTA(\ DD"
M+:;]6/:M Z$3\ UM5VX+-#,S3^U&OD1ETJZ +#]3F61Q68WR4"D4^<06\FH!
M/6AOJH#6^';Y.5<4PW;#"F(/E(^%,HA\@LS&.3T&. B:V7V2\I/XJ*MV@[$:
M(*S5:+7+3PK81H>#'_KI]-V*;1TO \O:41LEXSY 8=<NM576]B!(%GP '_+<
MQF6)#/=A&E%@PMGC&/>%K/$RQBN>:XG<CDW.?[T"H0%"KK%Y)6!M&JU%7%6N
M 5<9XN+B+X@"Z 9N&-@UAEN?I]!#C-'N8 T=A '"((G)D;8AD3'NTUK) [B;
M"9]55K7^-KGT,7R:I<')@%W%*DA\XV%O$L9S)NY%J";X/(]]Y5$RX+Y)8GK:
MJ1J/1>Q+Q.@VA.!0]2<IPJ#P3!N$0>@NOKGX)/M)@>N/G?1E9)NOUG7*9K$>
MQ2+D2'$^N]--Z8%39LN:\;Y686+$L5-\S6=DASZ=.6I_CN*Y9AZ*>A]4_%V=
MM/P1#Z=\IK=^AU359Z6QOA + 5 JYI-9<2$U&'M4YZZSH-*PHQDI+5@HR3[+
MJ *:Y5%;U'5IOYUZJ_R4@"+GQG!_Y#Q]H]*=)_;='OOF+@50ZN5GZ4.'J-G.
M/**<'^1PWT]@T70@"52GC(=U6WXJU_2)WE5C#4J=!>+MYB1AB%AH0]E\1L'?
MG)0C@@8\A !+=9:+UZ^A;U_=G8UQ=_*KME2DK./=,.%2B$P^1D/22>=BOG(9
MA90)-@+@ZMEC,3TNIY@5!A_@TV<%^/:?"C?A:_(>F_@\<;@;/F:8Y/NCSIN[
M FI^!6S8VF'G--Z7:GP\EE<;5(#"5Z7_IRO]+'/(1@7Q:-W<Q0YG[%IPK2+:
M4(=)5+'=Q%!]W(PGA]T>Q[/;Z/9KS"*Z%L,$O&;,CNA,,"O"'N>C8WE\,@FE
MCUWB?7+<3V)M@Y[IK1YM[/.%" &RG13E.0(VZ/(\ H5O_7A*Z0/.V8.G^2MI
M(Y"*YZI2ZI44*:M1GB^=7,1  N4&!!0Z(:*6$0RRG,X(#B*GH!_,.FXM\E K
MFWSXGT2ZY$,M)AP6.^8<VHZ6/R:R0]QVRE[FM;TW3\["R(Q-4"$"\+G"%UIS
MZ P6F$J YW"A. !Q1YV.X>$K![ ^8U?P-7.O7BW3@F4**J"WGV&9G..5FJ9W
MC>9>!1PKX,-BX-'IP^U7FU4)FY5GH%A00?KW,A.9A: UH WFI656(AMY83!Z
M^6AR]D*:-#?=7T$H$(A6)&<QR*"L0;0=]Q $S0;2]9A,0[:7:$.8^G$S\ZK!
M5VL.40$-OCIA0(-:!W9K3 B/[!FX\I.S5B#LL-'<K83C]^H6_>DFYA/@U$D2
M3Q0F)=.\ 0><X'AIG+C[S1>3?)#8VB,,Z'AD0\AE "9-H"&EFCLU^V.H^@"&
M;TP2S#R[_7ISUH';4U_ QXYMZF#^7N>$P-CPMTH,[:/2B5.T.!KOJ4D!D 2X
MK9/!0/K2I;/CL0ZPA- @A>FT!A"/+X/T^#W*RAS2+W7&BD;2.0*1-@*/+CI'
M0L^M'HP#E0DVQE.9\(PQ)=:'1L01[;$2#9B=7[-IW3 WT2HBM_-T4=Q,AG@'
ML.L95-(DKT$;W$H00*L0K>M#UN:,M0N\6:Q ZS3GC1&S[2ZAE19W9"!7.L F
MD_[<N&FP"Y"*0&DM<<L<4U!A_K2A<5/QG"AK@R+8.CC6>;KU2L*+Z.*1 ;_:
M]=5VO0H1M;4]LSTPA@7/K/RT;9V !=\#!_G/LX[_UVR1RE:J:K\FMU1*LSEX
M<^XJMMT3A$"[E1DH\),E?(\GV&$ L,[0G&M!E@FCI!&+<559-]D=%X5/W[;Q
M$F?YK3J6,_1OW[QO'?_P _S:/4:#F_^\$#2=@$-,^?1H2PLM)^#Q4N&=_+=_
MVV;C)#02K",>Z)@]A#=S.J!C6O_)!%.C$1XX<FU"&EE^;!P+C(HBXECKZ4$B
M;)>YWE*ELW0<LC@A#<;8IQ26W2L9<.>.!2KIP[@ ' 3SQ#F<OGAN^;->:P .
MLP1@H)2>V9_-)S=#?HNCS#K115[G'*H]3"-\./#G'-NNMPZ70HB2+YG:L )@
MH#"K>VDHUBX@9S_'_$[8Z@8:3"E(T 2L*/#%X4DTJU,>QSRB([1S*;"E4DHU
M!2MR=+,TF!8@GE(->)7O7ZI!KIC56F[KS0K4;28FV^6B8,4T+YS >.CAV:N/
MI7?.LS5SZ8YKG>1(8\\^UP)+,/0!2IC$6-NRNW?\Z'/I#M+;N7L7[\C"%KD$
M:>O;V:9T+3O4[J[96&\6[\BH6M(TNYI>>SB!1&%1H^05RLP^*U=O(L&;-/V.
M OE4/=,7Z8..JF9VYEN &>)XD:9GC^559C87<ZUIRY>E]0\V1(<6BFD\J15?
M%<#3"D!60 $\(PCU[GTA"-4Z &U1?@(!I-6Z%%6:RWXYHE(O8Q6DX(7J\:8,
M\-R>0*R-90!-GZT$6Z@!:W&'V^=\]$[@V5!0N"(+ KAZ]E9=:SPRDH2HO(OG
M1^@J;F/88$?V$.VN>U2MAC"?C?Y;:;!99C2:8ME394_0@7#@HSL#W/F X6J/
M*1NTP?C!B+9C"N7!GFY'X[,MEP%@@*:_X<<Q$(@WNB)?.IF(6(L *:<]#8D[
M%#8!@E.A'6?  5S2AS^='&;CLK;B#P5UBJ3D\^3L>P2B@7VS 2P6,\N+%8TC
M;0V]E4H_/0$]Z T=M=P!RX7CDX725A4P+ELG7BZ+LC\O4^=E:A>W[BK&K\YU
M[_ST2Y?]^_Q?I1INI6,4=#P9=0'^X<[_5D+"MZF( XX8Q5I0VH&MA^WL268F
M8 $['0NWX>LOYK%N5_SLM>C0XOSN;E[1H:^V@-[U$B]Z[F.6BNI5)8@8ZXV>
M# =0R7@0]#2#<[Y3E57ZK6:< *SU6JRLA!Y;+'-C+3=N?\TLQ"R\40/\'SF8
MAX2F@#8I\(.93ZX$&_PW2,)P,5B0Z4G:N31KBA#V:@4EVR2S;R-XTA-K/'4V
M?-.4YMX&*DVI?1&&/!(JT:_!I@TK?986_G5!&1\]/ <(;:57FZ8_+X;M[O1<
MB5IU+^F]:HM:S&8"I+H(X]*^>X$)J8BL4-?#%I@_T9>V$*WJ@[04BN)F@(T5
M,C$PO9$&'TI_'A=X4#V,'IC7I<N)*&C;-!]1W',9/J;.7G.='H&2FY+K]'*U
M7*7KF13QD],[L2L_A-NKF9K)]-@DIQ<?8!^*2L:)W=2V50(IZ\B^\P:Z&V(U
MKVCN9.9?E'-CJ$+8@$C^1<5WGBW$I1$RN9A=JL>H$35V[UP*2?&]VN!*5BI8
M98,+PND.M&5A"JH-GZ".1X%$_.Y\N>E(8K@VE<D ;1Q&TYD"N981'A?'(F]X
M.;L["]3;9KGH.H:2L\*9Z%5($G%;CYE]XKZ6F.?&-,@-QZIS+K0__VCP!<=C
M:7#0]Y*SQB08S(=GW*N*T6-PX\LUAD=\%MP&Q*FR=/HRH-AFWL% P<A+>](J
M"NTKS^;A36D/0X!!8-Q""R3#K5(_!0_0#PZ$WXG(O@BD6'.?D I.<RQ,&N[.
MU:1><S?I832H].9Y'Y?/#PS^V1_KV\97Z+.>0[@IT.=WCGJN_2+A)5V_6^CY
M7?EMU-LWK7?-X_5_GE^PV_/>1??FAM&;6BX_%=_40@7VJ<[(0Z_&U1UY$.J6
M6)04=6=B1J"#L99_/O:#>>MN?W!E,.>/8-<3FL4)'6&UH_K^86.__)SN_'A^
M><.N/G>NOW9.NS_WSD\[7VX\=GYQ6H'@4"JHI1KIJO=2W/0N+[H/9_J[3-AS
M);C<J+A)9OWCK)@(4]ZQ/GHR_>V;O8-C33]9)PIB>.)G&6M_5'ZZMDY^S?^S
M*RMERZ^_EI^ M1GS$3'S+PDO>9'!)4R9LV%!*51> UR *[<APE:]I<\>+OP-
MXD:%E_NZ6+-]2!&:"NL 5Y1=FK B8O=DD9K3D10#]DE&/,+J3>P2BWF(N/Q4
MI4)H%4&.)>4?^AH,N3%876MHXW(?$PW7M*X:<_XHO?#,N,MK6&TMCNU_7UAM
MIZ^"&?P:F7%X\C]02P,$%     @ Z$V>4$,-55<F"   W"T  !@   !E>&AI
M8FET,S$M,7@P,W@S,7@R,"YH=&WM6FU/(SD2_GZ_PAMTLR#E_85 PB"QP&HY
M[<W,(E:C^W1RMZO3%NYVC^U.R/WZJ[([+T!@PLY\(,N,-"'=+MM5KJ>J'CL^
M^>GBX_G-?SY=LM1EBGWZ\Y??K\Y9K=%J?>Z=MUH7-Q?LMYM__\[ZS7:'W1B>
M6^FDSKEJM2X_U%@M=:X8M5JSV:PYZS6UF;1NKELT5+^EM+;0%$[43D_H#7X"
M%Z?_./FIT6 7.BXSR!V+#7 '@I56YA/V68"]98U&)76NB[F1D]2Q;KO;9I^U
MN953'MJ== I.%^.<M,+S2<M/<A)I,3\]$7+*I'A?D_SPL#?HP#$_'@S[PZ/C
MJ"OBY%CT^TG_L#<<]O_;025;*![Z6#=7\+Z6 LT]Z@\*-YY)X=)1I]W^Y[CF
MA4Y/$IT[G,E@S_ U#/!H& =WKL&5G.0C;PP-0!T6[1&/;R=&E[EHQ%II,S*3
M:+\[&-07_UF[V3X8A[:]MO\WI@$:"<^DFH]^OI$96/8!9NQ:9SS_N6[140T+
M1B9!T,K_ 2J/=OC'63!LB.,HF4.C,K33]=9=WJ4RDH[U.LW.?=,V&Q7C^H,9
M9]Q,9-YPNL"!BE=OY?GE]<W5KU?G9S=7'S\\:>9K-:J_V:BK.OL7C[^47,US
M=M9DO^K20IW%8)Q,YLREW+W;&QR-GW>KS 6Z=-3H#G'6@@N!H=E0D%2AL&-K
MTFDNK'V]6MY;Y,YQ<^"7]8JE? K,P%3"#'.D2Z5E?Y3<8+BI.;N&0AO'=(YN
M-AGKM!M_,)VPLXG4EGU*N<EX#*63,5>VSJ[RN(F^/WY3ON_NK.]_X18]CK[-
MYNPVUS,%8H*1["%@@N.%1AURC344I^ R9SR?LS)WI@2T%*NJ+["(",XR?#*2
M*Y;P&%\9IC-,\$X'N4<".<1@+3=S$LGX+>"\:V-:?"=0&9Q2^>J,<Y! + U6
M8Q3+L3MJ(L"P62KCE-F2/E;]9V"@&H0,R*156+:) <RD2]% 6T#L%:1Q"U1-
M"S1SBMT$B^;KR_#F,-W[^V$:6")S1 T!<(62.@(:Q;'9K+7+/,%LQXF%XO=8
ME0+'1"2N0:*.*):4(0L$$L4 Q892*Y!7^+(/IL8X$I[>UDFB5"B R-8(/S^=
M]?K$W*8L47IF%[ W,)'6(3=VC-/+H#=J65]#KUTH\TC;-P?@_LX"^.:>M]_M
M'74[P[&M(%J1+$IB.DDD/GH<7#%NP",.$20C!80,!@CS2$F;DCB)99C *8G3
MLY V5MJ6V(]2N]$J0*\P.@:!KRW;1Z0)0.@&.%W>Q2G/)\#.,&M>EPHE.CW>
MZ SVX<!W[0Q$> J/DAA['B!/XS-*K6N1$)!)NFP]47)OH@0G(CL?Q@=*$*?Y
M)A(Z[.X>YOFN8;Z+,P_]NEZ Q5T>NM\7\:]CLT[\(N:EW;X+%?H($&?53($Z
MZ-+@ )@^I]+ZI(Q2D/MQ:".S2N?K)<& XAZX%7=8@:]>E0MJE)C:41>KE13^
M^,&6D95"<B/) !D8CB]2.8U46F(=/LZMIR@^A6L+J)##DD&="N3E,BX5I\J#
M9GDE5NP%>P0NM$[A\%L$)(C% ?N#^*9BL(N!$>U:8"R+P?VXV#JC/@J/[7/Q
MUE&"D365@L#/K<XY%1UN,7"(F%-$<",6Z,1XD3R22KHY\9E-TU*L>B![C(8P
MNR>Z1NQ];;NK#"I*4V",6,^_XE@;X17P%'\".=(JA:&"+5!0#)((;E]".&"L
MR@++RYL+B'C7 F)5*2ZG7)4^G1)<($F08\LI.MINX,I+]K1%>0B/F^FS#P#L
MB*G=!I(>Z=(]K<$V!8POI8%V(,G7=Z$L6NQM?$Q#6 G4Q^.7)GA+&!:[AN%5
M4@_H>(PR.ENIJ*]OV0CE%Z1R(C ZCDM#6%IC"QM&S;1U^)Z.V7$L&^- 7\(A
M(-M_HDN"08%)]H%TI3CN8,$?"]&)45XN]3H(6J7<+JD5I6<?1"!\W?+K4=64
M.5/R%E1U1O1 OO[-2_3-@;.+6^/!S@;.7]L:^_-ML8BY^BJ+4E)?Q_TJH1)R
M7T"V'FT#EJIQW HX;>R2W_@7.&262>< GBE9D48&1>U"HGY^D'V,#JP0EBH0
M_J4-R2*DX4LI47T?OF4>^Z.D@Q\[X%>HY1.\YDPAQT7.+1&Z=(I!YR&Q!,1:
MQ4V6.]$9\%LB&X'S>KKAV;H_<E^<([X(P=6F,9PA;<B\7&!'"\O$^R3:*XZ/
M71"R2,7K@?%8I#NVS!!,N$S>F*K@;3QQ?9-L9G>WJ&=(6A*#>:V., *?BA&(
M_A>7"K'U4/-E/M5J"E3X<SZI?C@R5?:&K%!Z#M@Z2W5(V?Q>/"!^OPLK:OY=
M?H:_P-7U"9Z=X4Y6O=OK'+;'O78]7&-Y9.635TD>KT"DG=/9Z#"L@?-;^_L2
M'@&\='H19O[.27@38=R#H352O+ P6GP9K]WFH/[C]2@FF[%$%XK/1S+WUOIY
MJRLQQ\?-87OH;\4XU-^)A3[5C9EFN#'3<N)QXV#8/.KVGVY_MO.SC;VC9F=X
MN&7GEE<\*(]+8@N>OZ_U:B]$U\,UG!+I0?I=O0N>>Q"H:^DQN*D3'+O0>8,V
M"WF*A6YQM^Q?(8->?1^%<8(MM5T/Q:\$R]9!=S]6M[2H=OINKX\IQW]NO GS
M*6U>K-+,#^<_Y_PJ6_BD6Z"#Z;"<D4=V#Q8_H/#&\L!Y*B%AEW<0EW0 R#Z&
M;></=W]'=R^9R^NC8>&:[G[U,P)R3%@BH3J .'AP:7<)B)8G-R]D9X4.]Z)'
MX>?'*:S?%UZ_1ES;W(U'F%U+!^/*G>T7WS>N/L.]9W\#^_3_4$L#!!0    (
M .A-GE 'IEWM&P@  #<N   8    97AH:6)I=#,Q+3)X,#-X,S%X,C N:'1M
M[5IM3R,Y$OY^O\(;=+,@Y3V!0,(@L<!HD/9F9E%6H_MT<K>KTQ;N=J_M3LC^
M^JNR.R^0P,+.?B##C#0AW2Z7J^RGJAX[/OWI\O/%^+]?KECJ,L6^_/[+K]<7
MK-9HM;[V+EJMR_$E^SC^SZ^LWVQWV-CPW$HG=<Y5JW7UJ<9JJ7/%L-6:S6;-
M6:^IS:0UOFF1JGY+:6VA*9RHG9W2&_P$+L[^=?I3H\$N=5QFD#L6&^ .!"NM
MS"?LJP![RQJ-2NI"%W,C)ZECW7:WS;YJ<RNG/+0[Z12<+?2<ML+S:<L/<AII
M,3\[%7+*I'A?D]WD&))>^R3N1= _/NI$@R@ZBOJ]$\&[QT?)R?\Z:&0+Q4,?
MZ^8*WM=2H+&'_</"C692N'38:;?_/:IYH;/31.<.1S+8,WP-"C;4.+AS#:[D
M)!]Z9T@!=5BT1SR^G1A=YJ(1:Z7-T$RB_>[A87WQG[6;[8-1:-MK^W\C4M!(
M>";5?/CS6&9@V2>8L1N=\?SGNL6%:E@P,@F"5OX):#SZX1]GP;$!ZE$RAT;E
M:*?KO;NZ2V4D'>MUFMW[KFUW*L;Y!S/*N)G(O.%T@8J*5^_EQ=7-^/K#]<7Y
M^/KSIT?=?*U.];<[=5UGY[DPJ.VC-#9.ZRP&XV0R9R[E[MW>X?'HZ165N<#5
M'#:Z QRPX$)@5#84)%44[-AT=)H+;U^OE?<FN7/2//33>LU2/@5F8"IAANG1
MI=*RWTIN,-+4G-U H8UC.F<?M,E8I]WXC>F$G4^DMNQ+RDW&8RB=C+FR=7:=
MQTU<^Y,WM?;=G5W[7[C%%<>US>;L-M<S!6("]0 !$Q9>:+0AUU@^<0@N<\;S
M.2MS9TI 3[&@^MJ*B. LPR<CN6()C_&583K#W.YTD-L0R"$&:[F9DTC&;P''
M7=-I\9U 8W!(Y0LSCD$"L318B%$LQ^YHB0##9JF,4V9+^ECUGX&!2@DYD$FK
ML&)3\9])EZ*#MH#8&TAZ"S1-"W1SBMT$B^;KT_#F,-W[_C -+)$YHH8 N$))
M'0&-XMALUMIEGF"VXT1 \7NL2H$Z$8EKD*@CBB5ER *!1#% L:'4"N05ONR#
MH3&.A&>V=9(H%0H@LC7"SP]GO3TQMRE+E)[9!>P-3*1U2(L=X_0RV(U6UM?0
M:Q?&;%C[Y@#<WUD C^^M]KN]XVYG,+(51"N214E,)XG$1X^#:\8->,0A@F2D
M@)#! &$>*6E3$B>Q#!,X)7%Z%M+&2ML2^U%J-UH%Z!5&QR#PM67[B#0!"-T
MIZN[..7Y!-@Y9LV;4J%$I\<;G<-]./!=.X<B/(5'260]#Y G_8Q2ZUHD!&22
M+<\>*+DW4((#D9\/XP,EB--\$PD=='</\WS7,-_%D0=^7B_!X@8/E]\7\;_&
M9IWX1<Q+^_PN5.@C0)Q5(P7JH$N#"C!]3J7U21FE(/=Z:".S2N?K)<& XAZX
M%7=8@:]>E0MJE)C:T1:KE13^Y,&6D95"<B/) 1D8CB]2.6DJ+;$.'^?64Q2?
MPK4%-,AAR:!.!?)R&9>*4^5!M[P1*_:"/0(76J=P^"T"$L3B@/U!?%,QV,7
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MFL#9AU=O3\;0,FW[8WMLVY-@ F^"=V^A8SDN!()D!9.,9R2Q[>EI"UJQE/G
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MCS/\I?*Y_3#HDPPBD64LTO49UEPEH!(&'U9$8LC2#5RP7$@%.'@DY!(\U_H
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M,#(P,#,S,5]D968N>&UL4$L! A0#%     @ Z$V>4/.G<4+(M0  =+X' !4
M             ( !BP # &%G:6\M,C R,# S,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( .A-GE! <E!IZW4   "6!0 5              "  8:V P!A9VEO+3(P
M,C P,S,Q7W!R92YX;6Q02P$"% ,4    " #H39Y0QEFZ#1P-   X1   &@
M            @ &D+ 0 97AH:6)I=#$P,2UL971T97)A9W)E92YH=&U02P$"
M% ,4    " #H39Y0@@@8/P$*  ! 4   &@              @ 'X.00 97AH
M:6)I=#$P,BUA9VEO<V%M96YD;2YH=&U02P$"% ,4    " #H39Y0OLPF'?\2
M  !P@   &@              @ $Q1 0 97AH:6)I=#$P,RUA9VEO<V-S=&]N
M92YH=&U02P$"% ,4    " #H39Y0+%1V0G81  #!CP  &@
M@ %H5P0 97AH:6)I=#$P-"UA9VEO<V-S=&]N92YH=&U02P$"% ,4    " #H
M39Y00PU55R8(  #<+0  &               @ $6:00 97AH:6)I=#,Q+3%X
M,#-X,S%X,C N:'1M4$L! A0#%     @ Z$V>4 >F7>T;"   -RX  !@
M         ( !<G$$ &5X:&EB:70S,2TR># S>#,Q>#(P+FAT;5!+ 0(4 Q0
M   ( .A-GE#A?N2U'04  .X7   8              "  <-Y! !E>&AI8FET
M,S(M,7@P,W@S,7@R,"YH=&U02P$"% ,4    " #H39Y0T7+SPA<%   N&
M&               @ $6?P0 97AH:6)I=#,R+3)X,#-X,S%X,C N:'1M4$L%
3!@     .  X P@,  &.$!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774377216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three months ended March 31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2020, our results of operations and stockholders' equity for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6940023520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue</a></td>
<td class="text">Product Revenue<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We sell TIBSOVO&#174;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers in the U.S., or collectively, the Customers. The Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The performance obligation related to the sale of TIBSOVO&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reserves for Variable Consideration</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contractual Adjustments</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Rebates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government rebates consist of Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Returns</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government Rebates</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current provisions relating to sales in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,338&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments relating to prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,072)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,072)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(653)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(677)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,330)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,861&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.976%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Component of accrued expenses </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue-related reserves</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets during the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contract assets</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,624&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,763)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales and.deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767298656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investments &#8211; Debt and Equity Securities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three months ended March 31, 2020 and 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities at March&#160;31, 2020 consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:48.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">208,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(718)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">439,094&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(739)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">439,528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(700)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,701&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(715)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">523,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,520&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,454)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">524,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities at December&#160;31, 2019 consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:48.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(91)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(145)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483,946&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(123)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(268)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020 and December&#160;31, 2019, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.</span></div>As of March&#160;31, 2020 and December&#160;31, 2019, we held 92 and 113 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of March&#160;31, 2020 and December&#160;31, 2019 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2020 and December&#160;31, 2019 was $224.0 million and $345.7 million, respectively. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2020 and December&#160;31, 2019. Given our intent and ability to hold such securities until recovery, and the lack of significant change in the credit risk of these investments, we do not consider these marketable securities to be impaired as of March&#160;31, 2020 and December&#160;31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767343408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock', window );">Schedule of Collaboration Revenue</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Licenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">On-going research and development services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were not considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercialization activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue - related party</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Contract Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets and liabilities during the three months ended March 31, 2020:</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.929%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.724%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Collaboration receivable &#8211; related party </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,539&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,294)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,577&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Royalty receivable &#8211; related party </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue &#8211; related party, current and net of current portions </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57,344)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period and unbilled amounts related to future reimbursable costs. Deductions to receivables relate to collection of receivables during the reporting period.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. </span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(3)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in collaboration revenue from on-going research and development services during the three months ended March 31, 2020 is primarily due to the fact that subsequent to Celgene&#8217;s decision to decline extending the research term, the Company updated its estimate of the future costs that will be incurred to complete one of its performance obligations under the 2016 collaboration Agreement that is recognized overtime using an input method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.561%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.429%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance obligations satisfied in previous periods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock', window );">Schedule of Royalty Revenue</a></td>
<td class="text">During the three months ended March 31, 2020 and 2019, we recognized the following as royalty revenue:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty revenue &#8211; related party</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock', window );">Schedule of Collaboration Revenue Under CStone Agreement</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue -other:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.976%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License and other services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Services performed that were not considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">970&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue - other</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">970&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock', window );">Schedule of Changes in Contract Assets and Liabilities, CStone Agreement</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets during the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.929%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.724%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets (1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration receivable - other</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(888)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,033&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)     Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition Multiple deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763967520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory, which consists of commercial supply of TIBSOVO&#174;, consists of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.697%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767228656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant accounting policies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses (Topic 326),</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent accounting pronouncements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6949413104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,256)<span></span>
</td>
<td class="num">$ (93,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(128)<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (40,384)<span></span>
</td>
<td class="num">$ (91,391)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777764688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AGIOS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0662915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">88 Sidney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-8600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,889,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6949161552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">$ 8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractwithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">27,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(24,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">$ 11,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractwithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractwithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6765804416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in the contract liability at the beginning of the period</a></td>
<td class="nump">$ 59,248<span></span>
</td>
<td class="nump">$ 16,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "agio-20200331.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 147,
   "dts": {
    "calculationLink": {
     "local": [
      "agio-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "agio-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "agio-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "agio-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agio-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "agio-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 392,
   "entityCount": 1,
   "hidden": {
    "http://agios.com/20200331": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 7
   },
   "keyCustom": 60,
   "keyStandard": 266,
   "memberCustom": 25,
   "memberStandard": 22,
   "nsprefix": "agio",
   "nsuri": "http://agios.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://agios.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value Measurements",
     "role": "http://agios.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Marketable Securities",
     "role": "http://agios.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Inventory",
     "role": "http://agios.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - Leases",
     "role": "http://agios.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Accrued Expenses",
     "role": "http://agios.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Product Revenue",
     "role": "http://agios.com/role/ProductRevenue",
     "shortName": "Product Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Collaboration and License Agreements",
     "role": "http://agios.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Share-Based Payments",
     "role": "http://agios.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148111 - Disclosure - Loss per Share",
     "role": "http://agios.com/role/LossperShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Policies)",
     "role": "http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://agios.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://agios.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://agios.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Inventory (Tables)",
     "role": "http://agios.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Leases (Tables)",
     "role": "http://agios.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://agios.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Product Revenue (Tables)",
     "role": "http://agios.com/role/ProductRevenueTables",
     "shortName": "Product Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Collaboration and License Agreements (Tables)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://agios.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349309 - Disclosure - Loss per Share (Tables)",
     "role": "http://agios.com/role/LossperShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Overview and Basis of Presentation - Additional Information (Details)",
     "role": "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
     "shortName": "Overview and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i6d7da42c6aea42a087aa27c849a90448_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i52ec527d6f6d4826938dd1bfd0f12b90_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i52ec527d6f6d4826938dd1bfd0f12b90_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Marketable Securities - Additional Information (Details)",
     "role": "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)",
     "role": "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "role": "http://agios.com/role/InventoryScheduleofInventoryDetails",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419407 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://agios.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)",
     "role": "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails",
     "shortName": "Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "role": "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426410 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails",
     "shortName": "Product Revenue - Schedule of Product Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i2cf9de214c744ef3b0f288fbe6cce148_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
     "shortName": "Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i2cf9de214c744ef3b0f288fbe6cce148_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails",
     "shortName": "Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i2cf9de214c744ef3b0f288fbe6cce148_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails",
     "shortName": "Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ie585f0844fac40089fdc45382188ce5a_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "agio:RevenueRecognitionMilestoneMethodEligibleReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432414 - Disclosure - Collaboration and License Agreements - Celegene Purchase Agreements (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails",
     "shortName": "Collaboration and License Agreements - Celegene Purchase Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ie585f0844fac40089fdc45382188ce5a_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "agio:RevenueRecognitionMilestoneMethodEligibleReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Collaboration and License Agreements - Collaboration Revenue (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
     "shortName": "Collaboration and License Agreements - Collaboration Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i6d50ef5ca59c4f6d94a83843d5742328_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i2cf9de214c744ef3b0f288fbe6cce148_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
     "shortName": "Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icc256153a0dc460d8411bbd9eb5fbb40_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails",
     "shortName": "Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ie585f0844fac40089fdc45382188ce5a_I20200331",
      "decimals": "INF",
      "lang": null,
      "name": "agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ieb4111aca4884f158039e11aeb841e7d_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
     "shortName": "Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "if6726df3a7204f6b9e2e0d1efc7914f1_D20180601-20180630",
      "decimals": "-5",
      "lang": null,
      "name": "agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
     "shortName": "Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ib54283dcee9d43cf9fb07a1481b6d9dc_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i2cf9de214c744ef3b0f288fbe6cce148_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
     "shortName": "Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i57f90389d1054ec5a3f958cb88835d5a_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Share-Based Payments - Additional Information (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
     "shortName": "Share-Based Payments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i2cf9de214c744ef3b0f288fbe6cce148_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails",
     "shortName": "Share-Based Payments - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "i2cf9de214c744ef3b0f288fbe6cce148_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ia72433a7819146b3a0daa5c98f8ffa28_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails",
     "shortName": "Share-Based Payments - Summary of Unvested RSUs Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ia72433a7819146b3a0daa5c98f8ffa28_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ibc7485735e584ad183fa3ab8df167007_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
     "shortName": "Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ibc7485735e584ad183fa3ab8df167007_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
     "shortName": "Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "id544e772704d4df68d5aafeb2c9bb919_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
     "shortName": "Share-Based Payments - Expenses Related to Equity-Based Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ifc2e58225fba4370abf79603604d587c_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "shortName": "Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ic8958bd3f29941f2aa800c1928252121_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "ic8958bd3f29941f2aa800c1928252121_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Overview and Basis of Presentation",
     "role": "http://agios.com/role/OverviewandBasisofPresentation",
     "shortName": "Overview and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://agios.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200331.htm",
      "contextRef": "icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "agio_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "AccruedResearchAndDevelopmentCostsCurrent",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_Agreement2010Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Agreement2010Member",
        "terseLabel": "2010 Agreement"
       }
      }
     },
     "localname": "Agreement2010Member",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CStoneAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CStoneAgreementMember",
        "terseLabel": "CStone Agreement"
       }
      }
     },
     "localname": "CStoneAgreementMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CStonePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CStonePharmaceuticalsMember",
        "terseLabel": "CStone Pharmaceuticals"
       }
      }
     },
     "localname": "CStonePharmaceuticalsMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CashEquivalentsAndAvailableForSaleSecurities",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CelgeneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CelgeneMember",
        "terseLabel": "Celgene"
       }
      }
     },
     "localname": "CelgeneMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ChangeInContractWithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Contract With Customer, Asset [Roll Forward]",
        "label": "Change In Contract With Customer, Asset [Roll Forward]",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetRollForward",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration Receivable, Due From Related Parties, Current [Member]",
        "verboseLabel": "Collaboration receivable - other"
       }
      }
     },
     "localname": "CollaborationReceivableDueFromRelatedPartiesCurrentMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CollaborationReceivableDuefromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborationReceivableDuefromRelatedPartiesCurrent",
        "terseLabel": "Collaboration receivable \u2013 related party"
       }
      }
     },
     "localname": "CollaborationReceivableDuefromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborationReceivableDuefromRelatedPartiesCurrentMember",
        "terseLabel": "Collaboration receivable \u2013 related party"
       }
      }
     },
     "localname": "CollaborationReceivableDuefromRelatedPartiesCurrentMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CollaborationReceivableOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborationReceivableOtherCurrent",
        "terseLabel": "Collaboration receivable \u2013 other"
       }
      }
     },
     "localname": "CollaborationReceivableOtherCurrent",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CollaborationRevenueOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration Revenue, Other [Member]",
        "terseLabel": "Collaboration revenue \u2013 other"
       }
      }
     },
     "localname": "CollaborationRevenueOtherMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CollaborationRevenueRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration Revenue, Related Party [Member]",
        "terseLabel": "Collaboration revenue \u2013 related party"
       }
      }
     },
     "localname": "CollaborationRevenueRelatedPartyMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CommercializationActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercialization Activity",
        "label": "Commercialization Activity [Member]",
        "terseLabel": "Commercialization activities"
       }
      }
     },
     "localname": "CommercializationActivityMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ContractWithCustomerAllowanceAndReservesLiability": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Allowance And Reserves, Liability",
        "terseLabel": "Component of accrued expenses"
       }
      }
     },
     "localname": "ContractWithCustomerAllowanceAndReservesLiability",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock",
        "terseLabel": "Schedule of Changes in Contract Assets and Liabilities, CStone Agreement"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset And Liability",
        "label": "Contract With Customer, Asset And Liability [Line Items]",
        "terseLabel": "Contract with Customer, Asset and Liability [Line Items]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityLineItems",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Assets and Liabilities, Product Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset And Liability",
        "label": "Contract With Customer, Asset And Liability [Table]",
        "terseLabel": "Contract with Customer, Asset and Liability [Table]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTable",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ContractWithCustomerAssetProceedsFromCollectionOfReceivables",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetProceedsFromCollectionOfReceivables",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerAssetRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Asset, Revenue Recognized",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRevenueRecognized",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Current Year",
        "negatedLabel": "Contractual adjustments, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesCurrentYear",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Prior Year",
        "negatedTerseLabel": "Contractual adjustments, payments/returns relating to sales in the prior year"
       }
      }
     },
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesPriorYear",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractualAdjustmentReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contractual Adjustment Reserve",
        "periodEndLabel": "Contract adjustments, ending balance",
        "periodStartLabel": "Contract adjustments, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerContractualAdjustmentReserve",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerCurrentYearReserveProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Current Year Reserve Provisions",
        "totalLabel": "Total allowances and reserves, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerCurrentYearReserveProvisions",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerCurrentYearReserveRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Current Year Reserve Recoveries",
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerCurrentYearReserveRecoveries",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Liability, Increase From Cash Receipts",
        "terseLabel": "Initial payment received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerPriorYearsReserveProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Prior Years Reserve Provisions",
        "totalLabel": "Total allowances and reserves, adjustments relating to prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPriorYearsReserveProvisions",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerPriorYearsReserveRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Prior Years Reserve Recoveries",
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPriorYearsReserveRecoveries",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Rebate Reserve",
        "periodEndLabel": "Government rebates, ending balance",
        "periodStartLabel": "Government rebates, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserve",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Current Year",
        "negatedLabel": "Government rebates, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserveRecoveriesInCurrentYear",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Prior Years",
        "negatedTerseLabel": "Government rebates, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserveRecoveriesInPriorYears",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Right To Recover Product, Current Year Recoveries",
        "negatedLabel": "Returns, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductCurrentYearRecoveries",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Right To Recover Product, Prior Year Recoveries",
        "negatedTerseLabel": "Returns, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductPriorYearRecoveries",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Right To Recover Product, Reserve",
        "periodEndLabel": "Returns, ending balance",
        "periodStartLabel": "Returns, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductReserve",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerTotalAllowancesAndReserves": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Total Allowances And Reserves",
        "totalLabel": "Total revenue-related reserves"
       }
      }
     },
     "localname": "ContractWithCustomerTotalAllowancesAndReserves",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractualAdjustmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contractual Adjustments [Roll Forward]",
        "terseLabel": "Contractual Adjustments [Roll Forward]"
       }
      }
     },
     "localname": "ContractualAdjustmentsRollForward",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ContractwithCustomerAssetRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ContractwithCustomerAssetRevenueRecognized",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractwithCustomerAssetRevenueRecognized",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CurrentAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CurrentAssetMember",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentAssetMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CurrentYearProvisionForContractualAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Current Year Provision For Contractual Adjustments",
        "terseLabel": "Contractual adjustments, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "CurrentYearProvisionForContractualAdjustments",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CurrentYearProvisionsForRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Current Year Provisions For Rebate Reserve",
        "terseLabel": "Government rebates, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "CurrentYearProvisionsForRebateReserve",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_DeferredRevenueCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "DeferredRevenueCurrentMember",
        "terseLabel": "Deferred revenue \u2013 related party, current and net of current portions"
       }
      }
     },
     "localname": "DeferredRevenueCurrentMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_EmployeePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeePurchasePlanMember",
        "terseLabel": "Employee stock purchase plan shares"
       }
      }
     },
     "localname": "EmployeePurchasePlanMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_EmployeeStockPurchasePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeeStockPurchasePlan2013Member",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2013Member",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_GovernmentRebatesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Government Rebates [Roll Forward]",
        "terseLabel": "Government Rebates [Roll Forward]"
       }
      }
     },
     "localname": "GovernmentRebatesRollForward",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Increase (Decrease) in Contract with Customer, Liability, Related Party",
        "terseLabel": "Deferred revenue \u2013 related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Liability",
        "label": "Increase (Decrease) In Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent",
        "negatedLabel": "Collaboration receivable \u2013 related party"
       }
      }
     },
     "localname": "IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseinCollaborationReceivableOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseinCollaborationReceivableOtherCurrent",
        "negatedTerseLabel": "Collaboration receivable \u2013 other"
       }
      }
     },
     "localname": "IncreaseDecreaseinCollaborationReceivableOtherCurrent",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent",
        "negatedTerseLabel": "Royalty receivable \u2013 related party"
       }
      }
     },
     "localname": "IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Six",
        "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Six",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due Year Six",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Six",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Remaining Lease Term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "agio_MarketBasedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market-Based Stock Units",
        "label": "Market-Based Stock Units [Member]",
        "terseLabel": "Market-Based Stock Units"
       }
      }
     },
     "localname": "MarketBasedStockUnitsMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_MasterResearchAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MasterResearchAndCollaborationAgreementMember",
        "terseLabel": "2016 Agreement"
       }
      }
     },
     "localname": "MasterResearchAndCollaborationAgreementMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_NonCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NonCurrentAssetsMember",
        "terseLabel": "Non-current"
       }
      }
     },
     "localname": "NonCurrentAssetsMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Amortization",
        "label": "Operating Lease, Right-Of-Use Asset, Amortization",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_OptionExerciseFeeReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "OptionExerciseFeeReceivable",
        "terseLabel": "Option exercise fee receivable"
       }
      }
     },
     "localname": "OptionExerciseFeeReceivable",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_OtherStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Stock Awards",
        "label": "Other Stock Awards [Member]",
        "terseLabel": "Other Stock Awards"
       }
      }
     },
     "localname": "OtherStockAwardsMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceBasedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance-Based Stock Unit",
        "label": "Performance-Based Stock Unit [Member]",
        "terseLabel": "Performance-Based Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedStockUnitMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PerformanceStockUnitMember",
        "verboseLabel": "Performance-based stock units"
       }
      }
     },
     "localname": "PerformanceStockUnitMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Unit, Not Probable Of Meeting Vesting Criteria",
        "label": "Performance Stock Unit, Not Probable Of Meeting Vesting Criteria [Member]",
        "terseLabel": "Performance Stock Unit, Not Probable of Meeting Vesting Criteria"
       }
      }
     },
     "localname": "PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceStockUnitProbableOfMeetingVestingCriteriaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Unit, Probable Of Meeting Vesting Criteria",
        "label": "Performance Stock Unit, Probable Of Meeting Vesting Criteria [Member]",
        "terseLabel": "Performance Stock Unit, Probable of Meeting Vesting Criteria"
       }
      }
     },
     "localname": "PerformanceStockUnitProbableOfMeetingVestingCriteriaMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication",
        "terseLabel": "Potential milestone payment"
       }
      }
     },
     "localname": "PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram",
        "terseLabel": "Milestone payment upon achievement of a specified commercial milestone event"
       }
      }
     },
     "localname": "PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram",
        "terseLabel": "Milestone payments upon achievement of specified regulatory milestone events"
       }
      }
     },
     "localname": "PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PriorYearProvisionForContractualAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Prior Year Provision For Contractual Adjustments",
        "terseLabel": "Contractual adjustments, adjustments relating to prior year"
       }
      }
     },
     "localname": "PriorYearProvisionForContractualAdjustments",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PriorYearProvisionsForRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Prior Year Provisions For Rebate Reserve",
        "terseLabel": "Government rebates, adjustments relating to prior years"
       }
      }
     },
     "localname": "PriorYearProvisionsForRebateReserve",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProceedsFromStockOptionsExercisedInOtherCurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ProceedsFromStockOptionsExercisedInOtherCurrentAssets",
        "terseLabel": "Proceeds from stock option exercises in other current assets"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedInOtherCurrentAssets",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProductReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Product Returns [Roll Forward]",
        "terseLabel": "Product Returns [Roll Forward]"
       }
      }
     },
     "localname": "ProductReturnsRollForward",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ProvisionForRightToRecoverProductInCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Provision For Right To Recover Product In Current Year",
        "terseLabel": "Returns, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "ProvisionForRightToRecoverProductInCurrentYear",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProvisionForRightToRecoverProductInPriorYears": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Provision For Right To Recover Product In Prior Years",
        "terseLabel": "Returns, adjustments relating to prior years"
       }
      }
     },
     "localname": "ProvisionForRightToRecoverProductInPriorYears",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ResearchServicesMember",
        "terseLabel": "On-going research and development services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable",
        "terseLabel": "Potential future milestone payments"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Contracts With Customers, Milestone Revenue Recognized",
        "label": "Revenue From Contracts With Customers, Milestone Revenue Recognized",
        "terseLabel": "Milestones achieved"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomersMilestoneRevenueRecognized",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Revenue From External Customers, Royalty Revenue [Table Text Block]",
        "terseLabel": "Schedule of Royalty Revenue"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_RevenueRecognitionMilestoneMethodEligibleReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueRecognitionMilestoneMethodEligibleReceivable",
        "terseLabel": "Milestone-based receivable payments, eligible to be received"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodEligibleReceivable",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition Multiple deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement",
        "label": "Revenue Recognition Multiple deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement [Table Text Block]",
        "terseLabel": "Schedule of Collaboration Revenue Under CStone Agreement"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
        "terseLabel": "Schedule of Collaboration Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions",
        "terseLabel": "Number of allowable special case extensions"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm",
        "terseLabel": "Special case extension term"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement",
        "terseLabel": "Term of agreements"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "agio_RoyaltyPercentageRemitted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Royalty Percentage Remitted",
        "terseLabel": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentageRemitted",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "agio_RoyaltyReceivableDuefromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "RoyaltyReceivableDuefromRelatedPartiesCurrent",
        "terseLabel": "Royalty receivable \u2013 related party"
       }
      }
     },
     "localname": "RoyaltyReceivableDuefromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RoyaltyReceivableDuefromRelatedPartiesCurrentMember",
        "terseLabel": "Royalty receivable \u2013 related party"
       }
      }
     },
     "localname": "RoyaltyReceivableDuefromRelatedPartiesCurrentMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]",
        "terseLabel": "Schedule of Revenue Related Reserves"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Market-Based Units Activity",
        "label": "Schedule Of Market-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Market-Based Units Activity"
       }
      }
     },
     "localname": "ScheduleOfMarketBasedUnitsActivityTableTextBlock",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_TwoThousandAndThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandAndThirteenStockIncentivePlanMember",
        "terseLabel": "2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndThirteenStockIncentivePlanMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember",
        "terseLabel": "2007 Plan and 2013 Plan"
       }
      }
     },
     "localname": "TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_UpfrontPaymentAgreementExtensionFeeReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "UpfrontPaymentAgreementExtensionFeeReceivable",
        "terseLabel": "Upfront payment agreement extension fee receivable"
       }
      }
     },
     "localname": "UpfrontPaymentAgreementExtensionFeeReceivable",
     "nsuri": "http://agios.com/20200331",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r91",
      "r129",
      "r132",
      "r219",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion of premium and discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r33"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r137",
      "r139",
      "r163",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r139",
      "r158",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r19",
      "r93",
      "r109"
     ],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Allowance for Doubtful Accounts Receivable [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total common stock equivalents excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r204",
      "r214"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r40"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r98",
      "r112"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value",
        "terseLabel": "Aggregate fair value of debt securities in an unrealized loss position"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r95",
      "r99",
      "r112"
     ],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0
      },
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Total marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r97",
      "r112"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r97",
      "r112"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investment positions in available-for-sale investments that have been in a continuous unrealized loss position for greater than or equal to a year for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year",
        "terseLabel": "Debt securities in an unrealized loss position"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r140",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Additions to property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r28",
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r68",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r185"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized; 68,789,925 and 68,401,105 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r121",
      "r123",
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Contract assets, ending balance",
        "periodStartLabel": "Contract assets, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r121",
      "r123",
      "r130"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r121",
      "r122",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Contract liabilities, ending balance",
        "periodStartLabel": "Contract liabilities, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r121",
      "r122",
      "r130"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue \u2013 related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r121",
      "r122",
      "r130"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion \u2013 related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amounts included in the contract liability at the beginning of the period",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r134",
      "r136",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r33",
      "r186"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Financing lease liabilities"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r35",
      "r186"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Financing lease liabilities, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r116"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Product Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share \u2013 basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r78",
      "r79",
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period to recognize compensation expense (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense for options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r175",
      "r183",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r176",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r178",
      "r179",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r176",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r176",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r176",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r180",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Fair value of assets (liabilities)"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r189",
      "r192"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on financing lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Financing lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r92",
      "r109",
      "r110",
      "r111",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r20",
      "r114"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r39",
      "r113"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets",
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r22",
      "r114"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r21",
      "r114"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r60",
      "r89"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r203",
      "r213",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Undiscounted Minimum Rental Commitments Under Uncancelable Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Undiscounted minimum rental commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remaining 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r205",
      "r216"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Licenses",
        "verboseLabel": "License and other services"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r48",
      "r51",
      "r55",
      "r67",
      "r79",
      "r209",
      "r218"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Significant and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r191",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r190",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r195",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r194",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Overview and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r54",
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r140",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March 31, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r62",
      "r161"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Net proceeds from stock option exercises and employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities and sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r117",
      "r217"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r166",
      "r227"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r120",
      "r215"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r128",
      "r129"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Product Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining unsatisfied performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r193",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Financing lease liabilities arising from obtaining financing lease assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r193",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining operating lease assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue \u2013 related party"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Product Revenue Allowance and Reserves"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Excluded from Calculation of Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r139",
      "r157",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Allocated Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r23",
      "r24",
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Performance-Based Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Unvested Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r140",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r142",
      "r153",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ServiceOtherMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other.",
        "label": "Service, Other [Member]",
        "terseLabel": "Other services"
       }
      }
     },
     "localname": "ServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested shares end of period (in shares)",
        "periodStartLabel": "Unvested shares beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value, Unvested shares end of period (in usd per share)",
        "periodStartLabel": "Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Opportunity to purchase of common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of stock options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of stock options, forfeited/expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of stock options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r144",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of stock options, outstanding, ending balance (in shares)",
        "periodStartLabel": "Number of stock options, outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, outstanding, ending balance (in usd per share)",
        "periodStartLabel": "Weighted-average exercise price, outstanding, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of stock options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r138",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, forfeited/expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r12",
      "r13",
      "r119",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under 2013 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r119",
      "r120",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of stock options, exercised (in shares)",
        "terseLabel": "Common stock issued under stock incentive plan and ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued under stock incentive plan and ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r94"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelegenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r134",
      "r136",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2013 basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(d))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r228": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r229": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r231": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r232": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r233": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6764263680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Product Revenue</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Product Revenue Allowance and Reserves</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government Rebates</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current provisions relating to sales in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,338&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments relating to prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,072)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,072)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(653)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(677)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,330)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,861&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock', window );">Schedule of Revenue Related Reserves</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.976%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Component of accrued expenses </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue-related reserves</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock', window );">Schedule of Changes in Contract Assets and Liabilities, Product Revenue</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents changes in our contract assets during the three months ended March 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contract assets</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,624&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,763)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales and.deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763960144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities at March&#160;31, 2020 consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:48.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">208,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(718)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">439,094&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(739)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">439,528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(700)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,701&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(715)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">523,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,520&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,454)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">524,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities at December&#160;31, 2019 consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:48.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(91)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(145)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483,946&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(123)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(268)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781292976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 87,098<span></span>
</td>
<td class="nump">$ 30,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">91,256<span></span>
</td>
<td class="nump">95,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">38,501<span></span>
</td>
<td class="nump">31,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">130,290<span></span>
</td>
<td class="nump">127,710<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,192)<span></span>
</td>
<td class="num">(97,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">2,936<span></span>
</td>
<td class="nump">4,405<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,256)<span></span>
</td>
<td class="num">$ (93,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share &#8211; basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted (in usd per share)</a></td>
<td class="nump">68,608,279<span></span>
</td>
<td class="nump">58,453,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 22,674<span></span>
</td>
<td class="nump">$ 9,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember', window );">Collaboration revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">60,097<span></span>
</td>
<td class="nump">17,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember', window );">Collaboration revenue &#8211; other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,334<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6940066560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Overview and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Overview and Basis of Presentation</a></td>
<td class="text">Overview and Basis of Presentation<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">References to Agios</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our Board of Directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company committed to the fundamental transformation of patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect. We are located in Cambridge, Massachusetts.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of presentation</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three months ended March 31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2020, our results of operations and stockholders' equity for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had cash, cash equivalents and marketable securities of $613.1 million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and </span></div>marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781217520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Celegene Purchase Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($) </div>
<div>extension</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 17, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMilestoneMethodEligibleReceivable', window );">Milestone-based receivable payments, eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram', window );">Milestone payments upon achievement of specified regulatory milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram', window );">Milestone payment upon achievement of a specified commercial milestone event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_MasterResearchAndCollaborationAgreementMember', window );">2016 Agreement | Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement', window );">Term of agreements</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions', window );">Extension period | extension</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions', window );">Number of allowable special case extensions | extension</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm', window );">Special case extension term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_UpfrontPaymentAgreementExtensionFeeReceivable', window );">Upfront payment agreement extension fee receivable</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_OptionExerciseFeeReceivable', window );">Option exercise fee receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_OptionExerciseFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_OptionExerciseFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMilestoneMethodEligibleReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMilestoneMethodEligibleReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_UpfrontPaymentAgreementExtensionFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_UpfrontPaymentAgreementExtensionFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_MasterResearchAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_MasterResearchAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_CelgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_CelgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6949391024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining unsatisfied performance obligation</a></td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized', window );">Milestones achieved</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication', window );">Potential milestone payment</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>agio-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:agio="http://agios.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="agio-20200331.xsd" xlink:type="simple"/>
    <context id="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i862ee064d0b64106a97a0864c5e2a292_I20200424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="ieb4111aca4884f158039e11aeb841e7d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2cf9de214c744ef3b0f288fbe6cce148_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35fda49bee8b485999b812e174739a48_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i68cad50d747b48a7b8ceb77216e8aa02_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6e999092fe5a47b995df7486ab8722ad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i02db62d3a5c6475eb891c555c988387c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i41094e12553647d993f3c81751f72fe6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i54eae18cd0904e9d906affdbfe7dceef_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic82eaa651b994a398eb65997f0b11e71_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if879b8d640fd4528a046bfb43e105676_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib37208e30fc641978c63e725033d8b60_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0d4ece46885443dfb8b45982f5c1d81a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id37911106fe1449f9034156faa5eb2a6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic89fcca3dd5745338d1cfd3260db99f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae2b4e4df79d4fe1bf3634518d64c589_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib08167bb5f1945769d6ee3657f77ca59_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0449bd3f63554820bbdfb7c723787243_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5089bb6eb61f47bd86313de5659a1590_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i05cbd70b0ea74776a5302b8c60f708dd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7f5ad1c314b54412beee6289ce701979_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i06129accabc84db1998139916e3bfdce_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie9781e5291b34a4b96ee6b85750b185a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie22c76c636c44318bd5ddf5c65c4945e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic8958bd3f29941f2aa800c1928252121_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6db96c6a87374048ace2fc1cb33ea464_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6b788f2270d84d63a475d1b2aecbeaf8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5c76a8d5c9f047fdb64349f6cebc1f11_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i62be91ce449047f7b038e5f03bcc8373_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1a5f41773d3e4ddd9bceaac90793a7ee_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i64beb8c427754afbbeb4323e2204e1ce_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="idfdf8a5d4f2b461cbcd4e7f10715380a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3c9a056637214d5796f17b4822cda10e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8a0427dc88004cdb9ad5b111ee121e8a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6971d4a30427440ba662d8d10de5fd9a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8b9f97f0add14e97ac35d6c17a93e045_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8d5f65c2dfb44ce892a2a2a36fc23f81_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4edbcb8341ca4ae9a52de4dfbc7f3fa9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic285bdb5cfff4f9bb6e8c6aa8bd0aef6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id2896d589cf7469a8775ecf2af7fef57_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7d69f26b53ee4c3e8ba4149462acd30a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2a5ae1f4e6da4a40ab90e89f131655fc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i980609409a6b4e13b07d000c6cdd7d2c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i237b15fb46da4b59a1a6fac0feae116a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6d7da42c6aea42a087aa27c849a90448_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i852744abdf2745b18e0f60fa3df00339_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1f8f8fda49a94e84b0a5c8d9bd24a8ef_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i635947295b764abfbbdea991d6fe54fc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ief6cbec674e741b4a873e845b45a4e31_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia4fdeb9348b94b618851880b5c977d5d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id9f32329914f4f5ba7b80bae3b347fda_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i474102d2baee43179a37e278bb04cf73_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i244896107f9d40bd82157d3c93e71bad_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id3fe9a6e1ebc48a49cc37d47c38c8288_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9e239c737d2f45488edacb7ef4b2bb95_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i689b528c68d6471cbeca1282d66876f7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibe05f5bb5bf340819df84fa9a1e20a30_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0502aed7c32c4db0853962e904c21847_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i108de68f38fd4fabbe1b522da2bfee56_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i85ccd9c5271946ae8ea7524c2ea81976_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i554916221ecb43d4bad1bebdd455085e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaba4c2b9d8104e2092c8a1578a072d33_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia264a24d96044bba896491152779474a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i74269132e8824b1d9ae169ad9bcfd579_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf88bf362c84475c8e9b943d30632f1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if4917f73e8bc4c0d8651d34dc493d64d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f2183ebcadc4450b714435b21b5ba17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2021a05d78884df3b63427ad0ed8fbef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i985faa780d224792b8352dc1688c2523_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibae56b3854004a2ab8062e84d6051194_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie585f0844fac40089fdc45382188ce5a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="icf8e4931186847f7af3d6555eddb2ef4_I20160517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-17</instant>
        </period>
    </context>
    <context id="i7d39d16372b54ef7b70c6ceb2f6802c9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic8cc725b4829480fa6c29d3f371c5ae3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6d50ef5ca59c4f6d94a83843d5742328_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i91175df5ecdd49638bd57d0783c41bdc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i108d62e896fc49d1b83a96231e5bc13e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if3447e34e86e4a2ea996f1ad6af3f411_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="icc256153a0dc460d8411bbd9eb5fbb40_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa2a9618801f42c48cc8313f6b4cd731_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i53c90550dda24d7eb8b02c2f2c2f719e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6d243dbfb39c481597c75558a4b5ffa9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d106c4df9564a3caf0ba3be633967df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i811057ddd1de4d0eb6492cfeadecbf6a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i096066d9ee4641e1b8faebda2ab34627_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if84fd2a101824c788fae2a197d74ffa9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id04eae8cb5824809b789766bea430fe0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if6726df3a7204f6b9e2e0d1efc7914f1_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i3da6969fb0f94cae987375f25efa45d4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9b95111b950c47f2a99d64f7549560da_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if9319d12250d4cd4816f3f7f9a1a58ec_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ib54283dcee9d43cf9fb07a1481b6d9dc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieda041072edb42d2a45ab6f7a35301cf_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6c9f069f49404c26883dc94c9bf8bf4b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id57699cbaff4472d9cf3ea62c0cbb2fb_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id861975ff87f4dbc8890a79d84ea157e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie310e674843d43f68873f2b9cc63f547_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i57f90389d1054ec5a3f958cb88835d5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i280f176668304207a8331664a7bf1e74_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iae5252cae278436a972c726382d0b31e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i269bc734bdc446a984c9d2c5b91a592c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic38711366192418d8c09c3d6abfa8e66_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i93e49459503f4101adaa3ac89788c0cc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i39e8393880f542d281e86b6aff922c87_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ida454044d7e04cf78a0d3ed1df7dd45d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i04dd698bbbf04386be79177cadfcb551_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia72433a7819146b3a0daa5c98f8ffa28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibc7485735e584ad183fa3ab8df167007_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i458a6e5895e2457b9575fb921714653a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idfe0ad5afa984d16ba94c0190f3a7bb7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibc517a1325e3471bb6ee91315080f545_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i13ac445102f7441f9e4b8ba54ae46f21_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1d0177361b9c4b0b90dc4288e2d48078_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i256d78b2b36e45f28bd9b75429058398_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i899a9e83495b4f28b410853e4bd3e1a9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i28d21d465e804cd7be91d92333466787_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic8dacf8900174e15a3112799baf17da0_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3e96f9d80bf045189e770a60c9426d0f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id544e772704d4df68d5aafeb2c9bb919_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i00295454cded4864b99639e493192cdc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ida2a85e29bc44bb4b78adcee2aa8a238_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2b778fd9cd91494abee392de786ad04e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3964e595953c4f299314ea4efb11d354_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9b1c325e2dd54b6aa424bba94309ad67_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i02d3013b6a4c4bdbae10be0d1e36aeec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id4533663f1404a6c94d173dbdd0d8fe6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifc2e58225fba4370abf79603604d587c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i85f2e56eb9624864a6a945bcd372afda_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic09bbe0bec9644d0bdb9f127f396b6ee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib2c6cd3484924f04bded7e03913923fb_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i63d93efc8a284556ab8f020edd3dc6e0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0a127ee084474fe89e94f05cb952f47b_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i091c1b621ade4bb9a85dbc64bfb48525_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7729db14fc3848fe915720a14a4de566_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8a6e57a772564177acc7f7a661b71d0f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic07875a2aa9f4507b1f46ea8b5fed18d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2c7313c325334ec4b2e51b1fbd9a8afb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i429a7cb2f66d4ba1976785a1a8199946_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="security">
        <measure>agio:security</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="extension">
        <measure>agio:extension</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGFibGU6YTA5MzYxNTgwMmQxNGNjZDgxYWNmMTk4NDI2ZGI5ZGEvdGFibGVyYW5nZTphMDkzNjE1ODAyZDE0Y2NkODFhY2YxOTg0MjZkYjlkYV8zLTEtMS0xLTA_95a75c41-b3e2-41b4-a3e6-105dcad1302d">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGFibGU6YTA5MzYxNTgwMmQxNGNjZDgxYWNmMTk4NDI2ZGI5ZGEvdGFibGVyYW5nZTphMDkzNjE1ODAyZDE0Y2NkODFhY2YxOTg0MjZkYjlkYV80LTEtMS0xLTA_f5dd56ba-816f-4afb-9b8b-1a203deabf84">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGFibGU6YTA5MzYxNTgwMmQxNGNjZDgxYWNmMTk4NDI2ZGI5ZGEvdGFibGVyYW5nZTphMDkzNjE1ODAyZDE0Y2NkODFhY2YxOTg0MjZkYjlkYV81LTEtMS0xLTA_e4f67d33-6980-44c3-8332-cee4f46f779b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGV4dHJlZ2lvbjplMDM0ZDI3NjRkZTA0MmVhYmNiYjVjZjZjNjBkZWZhOF84Ng_5555295e-b5d3-4b42-9c44-d48ac15a0aca">0001439222</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180L2ZyYWc6ZTAzNGQyNzY0ZGUwNDJlYWJjYmI1Y2Y2YzYwZGVmYTgvdGV4dHJlZ2lvbjplMDM0ZDI3NjRkZTA0MmVhYmNiYjVjZjZjNjBkZWZhOF84OA_17f3fd28-3dbb-4085-9a10-a42bfdc9c3d5">--12-31</dei:CurrentFiscalYearEndDate>
    <agio:RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement
      contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzI5ODUzNDkxMzg3MA_e91388f5-9090-44e2-9f63-c9d6bd473913">P4Y</agio:RevenueRecognitionMultipledeliverableArrangementsTermOfAgreement>
    <agio:RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm
      contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQ4NQ_1f9fa6ea-bf2b-47b0-80ab-ef3b836dafa9">P1Y0M0D</agio:RevenueRecognitionMultipledeliverableArrangementsSpecialCaseExtensionTerm>
    <dei:DocumentType
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY184Mg_f709a33e-75e7-454d-b0d8-3e9ea89d7cdc">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6MzcxNDk4YmY2NjU4NDViZThhMTQxOWRlZGUxYWFhYjkvdGFibGVyYW5nZTozNzE0OThiZjY2NTg0NWJlOGExNDE5ZGVkZTFhYWFiOV8wLTAtMS0xLTA_06fa7edd-394c-4800-a0ea-55caf19df8a8">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xMzE_ebb92f6e-40ad-47b8-8fa8-c5d2455fe964">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6YWI5NWY1NjJjMzM1NGI1NWIzNjg1YmU4OTNlODczMjgvdGFibGVyYW5nZTphYjk1ZjU2MmMzMzU0YjU1YjM2ODViZTg5M2U4NzMyOF8wLTAtMS0xLTA_0412f77c-6f3f-4d4d-bcc1-5c0f329a5b5f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xNjI_63f10415-149c-4ef9-bbd6-15bc16a47db6">001-36014</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xNjc_d3d03e58-fc41-4137-b425-3347180673d2">AGIOS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8wLTAtMS0xLTA_6e37b1f5-9434-4d9f-b046-e394a351d169">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8wLTMtMS0xLTA_32648baa-cc24-4794-9728-90fa5aacefc1">26-0662915</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiN2UxZGU3NDI5ZTE0ZjM5OTQ3ZmViNzkxYWNlZjBiZl80_96101a1f-e460-4545-b6ec-44a9f8e13d1a">88 Sidney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiN2UxZGU3NDI5ZTE0ZjM5OTQ3ZmViNzkxYWNlZjBiZl84_3e6c99d3-d0e2-4749-b029-9d804cde53d8">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiN2UxZGU3NDI5ZTE0ZjM5OTQ3ZmViNzkxYWNlZjBiZl8xMg_cd825cf1-f90c-4171-84c4-c51a0c5e2526">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzRmNDA5OGNiY2Q4NGVjZmI2YzliZDNlYzg3NGEyMmQvdGFibGVyYW5nZTo3NGY0MDk4Y2JjZDg0ZWNmYjZjOWJkM2VjODc0YTIyZF8zLTMtMS0xLTA_ed55a258-2b65-4174-a501-159c5a678217">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18yMzE_7e61a7bc-fb32-49f1-a787-389aba284827">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18yMzU_d0a59a0b-48ad-401a-88f1-091aa0d656e8">649-8600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzhmNTg4MTQ0NGNhNGYxZDg4YjhmZjIwMjY2NjNjNzYvdGFibGVyYW5nZTo3OGY1ODgxNDQ0Y2E0ZjFkODhiOGZmMjAyNjY2M2M3Nl8xLTAtMS0xLTA_e60bd73c-cdee-4d9d-8304-be0b59c4d2ab">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzhmNTg4MTQ0NGNhNGYxZDg4YjhmZjIwMjY2NjNjNzYvdGFibGVyYW5nZTo3OGY1ODgxNDQ0Y2E0ZjFkODhiOGZmMjAyNjY2M2M3Nl8xLTEtMS0xLTA_7eb3611d-5b53-4ef2-a1ac-dfce3988f28a">AGIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzhmNTg4MTQ0NGNhNGYxZDg4YjhmZjIwMjY2NjNjNzYvdGFibGVyYW5nZTo3OGY1ODgxNDQ0Y2E0ZjFkODhiOGZmMjAyNjY2M2M3Nl8xLTItMS0xLTA_88c4646e-061d-42fa-93ef-94c5b724bd59">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY183ODg_370b909f-8568-4613-8401-9dcfd35fb5a2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xMTE1_a16acab4-fa5f-42a1-b679-7e7cc33fe382">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzNhZTE1ODA2MmZiNDc1NzhlNmFiMjk1MjcwZWZhYTMvdGFibGVyYW5nZTo3M2FlMTU4MDYyZmI0NzU3OGU2YWIyOTUyNzBlZmFhM18wLTAtMS0xLTA_dc87e081-8298-4ae4-b185-981176c1a9ec">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzNhZTE1ODA2MmZiNDc1NzhlNmFiMjk1MjcwZWZhYTMvdGFibGVyYW5nZTo3M2FlMTU4MDYyZmI0NzU3OGU2YWIyOTUyNzBlZmFhM18xLTMtMS0xLTA_f474078a-b6eb-43b4-be31-2efb2ecaee47">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGFibGU6NzNhZTE1ODA2MmZiNDc1NzhlNmFiMjk1MjcwZWZhYTMvdGFibGVyYW5nZTo3M2FlMTU4MDYyZmI0NzU3OGU2YWIyOTUyNzBlZmFhM18yLTMtMS0xLTA_8875a33c-17b9-44d0-8c6b-13bf9c16a4fa">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xODU3_d4eccb1a-bca4-4a51-90d5-877f80d728f8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i862ee064d0b64106a97a0864c5e2a292_I20200424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xL2ZyYWc6MDkxZGQ5MDdkMDg2NDc2NjhlODZlY2E5ODdkZmNkMWMvdGV4dHJlZ2lvbjowOTFkZDkwN2QwODY0NzY2OGU4NmVjYTk4N2RmY2QxY18xOTU5_07044b9a-0634-4ce0-b0d5-c157d0ec7a41"
      unitRef="shares">68889380</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMy0xLTEtMS0w_c8e58068-2fb8-4c96-a656-00b4d2f0287e"
      unitRef="usd">89093000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMy0zLTEtMS0w_eb3b624b-fc53-45a0-8409-24cb93e802db"
      unitRef="usd">80931000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNC0xLTEtMS0w_986b6370-ba1e-4178-83f1-2839b2cdf0a0"
      unitRef="usd">439528000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNC0zLTEtMS0w_0d8eead6-5525-4d1c-bf37-b77d72ca66b5"
      unitRef="usd">483946000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNS0xLTEtMS0w_7ff21d76-742d-4604-b6c2-08baad7e1b44"
      unitRef="usd">11813000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNS0zLTEtMS0w_aea298f3-8d49-4a94-8b16-79724cb21d5c"
      unitRef="usd">8952000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <agio:CollaborationReceivableDuefromRelatedPartiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNi0xLTEtMS0w_36bab38a-6ed6-43e5-b9b8-16044eacd462"
      unitRef="usd">2577000</agio:CollaborationReceivableDuefromRelatedPartiesCurrent>
    <agio:CollaborationReceivableDuefromRelatedPartiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNi0zLTEtMS0w_114b4a7c-2913-4a37-bf2f-b8f5e4b16c67"
      unitRef="usd">1539000</agio:CollaborationReceivableDuefromRelatedPartiesCurrent>
    <agio:CollaborationReceivableOtherCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNy0xLTEtMS0w_8d4fb11e-24de-4df2-a695-018d68a0bb02"
      unitRef="usd">2033000</agio:CollaborationReceivableOtherCurrent>
    <agio:CollaborationReceivableOtherCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfNy0zLTEtMS0w_92308c6e-7965-4a15-813c-1eb6699a45b9"
      unitRef="usd">1928000</agio:CollaborationReceivableOtherCurrent>
    <agio:RoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOC0xLTEtMS0w_3ef0c084-ebd2-4410-9cca-768c683e3bf8"
      unitRef="usd">3300000</agio:RoyaltyReceivableDuefromRelatedPartiesCurrent>
    <agio:RoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOC0zLTEtMS0w_3efea33f-023c-4ba7-ae14-e423b88b85f0"
      unitRef="usd">2900000</agio:RoyaltyReceivableDuefromRelatedPartiesCurrent>
    <us-gaap:InventoryNet
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOS0xLTEtMS0w_f83b8471-d5d1-487c-ae78-9b0e58dcb64f"
      unitRef="usd">9778000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfOS0zLTEtMS0w_f1b569cf-9a9c-4609-bca0-aa30cf9b1249"
      unitRef="usd">7331000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTAtMS0xLTEtMA_98e83f59-2eb3-4eb5-a9e5-fad10e6e637c"
      unitRef="usd">29152000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTAtMy0xLTEtMA_426fea81-d61d-448f-a102-1f2b29c94c1a"
      unitRef="usd">24177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTEtMS0xLTEtMA_8501b195-ffd1-44cf-a07e-bfaa7de145c6"
      unitRef="usd">587274000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTEtMy0xLTEtMA_c4245eda-51b2-4468-8f8e-02a4462e2401"
      unitRef="usd">611704000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTItMS0xLTEtMA_8883f5c1-a920-4dee-bc9e-720aedc2f6f1"
      unitRef="usd">84503000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTItMy0xLTEtMA_0226e0c6-cb9b-431d-82a2-a9d858b3e4b8"
      unitRef="usd">152929000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTMtMS0xLTEtMA_0bc2b746-dfb2-44ae-a910-db630b07914e"
      unitRef="usd">91440000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTMtMy0xLTEtMA_2a7e08bd-fd85-403e-b6ef-9273d4e5112b"
      unitRef="usd">93643000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTQtMS0xLTEtMA_f4e4b858-5fdc-4008-ac38-078d6fe2b969"
      unitRef="usd">33840000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTQtMy0xLTEtMA_a459bed0-84e6-42ca-8fc1-a2e2a5ae7dae"
      unitRef="usd">31472000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTUtMS0xLTEtMA_5c6fafc8-74a9-43df-b9d0-2e4971b8d2b9"
      unitRef="usd">881000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTUtMy0xLTEtMA_ec8b245e-2868-4b60-8173-f72bf0c0a334"
      unitRef="usd">993000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMS0xLTEtMTc4OA_3bc150ed-2784-407d-8ea4-1ae667f1106c"
      unitRef="usd">1800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMy0xLTEtMTc5MQ_af26638a-3043-460d-9196-91f2145841a3"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMS0xLTEtMA_46256270-4fa9-4418-a6ee-9e92e6c0aba8"
      unitRef="usd">799738000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTYtMy0xLTEtMA_ba54614b-4610-41f4-ad09-98ee00872dde"
      unitRef="usd">890741000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTktMS0xLTEtMA_85f0569e-9cdc-4b92-9e21-b75e1844cc4b"
      unitRef="usd">18707000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMTktMy0xLTEtMA_73e8e8ad-350a-4752-93b2-c27268279603"
      unitRef="usd">21896000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjAtMS0xLTEtMA_30c8951c-db79-4660-be3d-79bfbe1a33a9"
      unitRef="usd">39631000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjAtMy0xLTEtMA_c66f959b-87f6-4862-98bf-a9089da98354"
      unitRef="usd">53142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjEtMS0xLTEtMA_7b192c58-0c1c-4efb-88ad-d4a4eefb15a3"
      unitRef="usd">4748000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjEtMy0xLTEtMA_8b39017a-6565-4b5a-b2db-471da12ae715"
      unitRef="usd">10933000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjItMS0xLTEtMA_5149c70e-320d-4237-b74c-a2391c98e54c"
      unitRef="usd">6466000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjItMy0xLTEtMA_46a29e11-da0d-4742-b25d-567a6c06e0b0"
      unitRef="usd">6642000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjMtMS0xLTEtMA_8538fd9c-c358-45ab-b481-8b9c547b25ab"
      unitRef="usd">306000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjMtMy0xLTEtMA_32ed4e1c-ce22-499c-ba23-0301269294b4"
      unitRef="usd">273000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjQtMS0xLTEtMA_71c1fb77-59bc-4ed8-bbd3-86ab3761cb26"
      unitRef="usd">69858000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjQtMy0xLTEtMA_e3a20fe5-813e-4e85-89fa-3c6348b374f0"
      unitRef="usd">92886000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjUtMS0xLTEtMA_96a25983-6892-442c-a374-9ec5044910a2"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjUtMy0xLTEtMA_06193a65-471a-4ddd-9566-68ee90ba90ba"
      unitRef="usd">50580000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjYtMS0xLTEtMA_394fdc87-e860-4b51-af5d-51112463074e"
      unitRef="usd">104010000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjYtMy0xLTEtMA_9d0a2c2e-49e2-4f0f-a08e-e8f4bfad21ed"
      unitRef="usd">106074000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjctMS0xLTEtMA_fa2b0837-7506-4561-8b5d-d103d75074f1"
      unitRef="usd">571000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjctMy0xLTEtMA_0a2c02a6-ec8e-41ca-91ca-f82f90bfd4cb"
      unitRef="usd">673000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjgtMS0xLTEtMA_39d627af-26fb-4e09-a3b8-ff5ee501a6fd"
      unitRef="usd">174439000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMjgtMy0xLTEtMA_4e09f38b-1125-4cff-a395-7076a42c1cc1"
      unitRef="usd">250213000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzIx_02e1e0c9-8178-4651-8c6a-25bebb492513"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzIx_3e785395-7102-4574-9c39-30d95596d0f5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzM1_87d790af-cf2a-49b2-837c-a7cbb0ec7158"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzM1_da41ba03-6816-4869-a1ca-36a76ac10b81"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_06606bc1-f91e-442a-9750-46f57c07388b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_08b276db-0e5c-40da-9e8a-ea4a71788517"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_6d34a51b-f8b7-47d9-8f3c-134621ccbb11"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjY1OGQ5N2FhOTUxODQzM2Y5YWE4MDU1YjMyNzc4ZDQ3XzU3_ee55b380-1eca-4b0f-9e10-714596013e36"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMS0xLTEtMA_f3112198-d3af-4ab2-aa63-4a2c5c4d8dec"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzAtMy0xLTEtMA_e8e161fe-f2b3-4294-9a94-867adf9eefb8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzE4_8306a027-359b-4b94-972b-abad230695dc"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzE4_c4c1d208-f3c3-48dd-9c34-95943f8ebc48"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzMy_c3b22cbc-9f20-4603-8f20-1e29929f2f27"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzMy_f9a8116a-5570-4b02-a3d0-2e1fc8678d5d"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzU0_4202f64b-d01d-46eb-90a6-e78032b05527"
      unitRef="shares">68789925</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzU0_b1852341-1adb-4dcd-b67b-1ba09dc74f80"
      unitRef="shares">68789925</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzYx_27f8fe79-ddb8-48e5-9928-cfa576628539"
      unitRef="shares">68401105</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2NzNmODNhZDhlNTQwYWY5ZDgyZWEwZWQ1NzI1NDJmXzYx_48e28be4-8943-4369-a8d1-043d637d8d83"
      unitRef="shares">68401105</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMS0xLTEtMA_0f94b124-c890-4ecc-acf4-2f30faff2a4b"
      unitRef="usd">69000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzEtMy0xLTEtMA_4f7d4f1e-16b2-4d9f-976c-fa6b630f95b5"
      unitRef="usd">68000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzItMS0xLTEtMA_89cd6f6b-0f82-4908-9057-7cb90c4bc3a4"
      unitRef="usd">2181517000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzItMy0xLTEtMA_2eaf27da-2d66-4b27-8e55-f0884f867c59"
      unitRef="usd">2156363000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzMtMS0xLTEtMA_516ef55e-714c-41ef-bfd0-ee5bd9a1ccc8"
      unitRef="usd">74000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzMtMy0xLTEtMA_0740660b-7260-4478-aa24-80d6f0aa502e"
      unitRef="usd">202000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzQtMS0xLTEtMA_5f2aa7aa-9782-4dae-8b35-f7667a3fcd6e"
      unitRef="usd">-1556361000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzQtMy0xLTEtMA_edb358ce-d9f1-4a23-b923-2aa298f4a34f"
      unitRef="usd">-1516105000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzUtMS0xLTEtMA_4a203df8-e4c8-4070-b510-65bc139c4229"
      unitRef="usd">625299000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzUtMy0xLTEtMA_6ebaa8d4-de30-4f84-bba9-98678b0798f0"
      unitRef="usd">640528000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzYtMS0xLTEtMA_af6df1bb-10c0-4cab-81b5-4ca9a69ccb5a"
      unitRef="usd">799738000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xNi9mcmFnOjQ3NWJkYTQ4Nzk5NDQ4YTY5MTZmNzFiZTUxMTE1MjMyL3RhYmxlOmFkYWRjODNkMmNmODRmNTA5NzY5OWIzZmUxYWFiYjIxL3RhYmxlcmFuZ2U6YWRhZGM4M2QyY2Y4NGY1MDk3Njk5YjNmZTFhYWJiMjFfMzYtMy0xLTEtMA_e37b83ba-ee01-41b5-ac3e-b6d2cdd4b05a"
      unitRef="usd">890741000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35fda49bee8b485999b812e174739a48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMy0xLTEtMS0w_e76ea54d-49c3-4221-8fd1-2116f8e5df71"
      unitRef="usd">22674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68cad50d747b48a7b8ceb77216e8aa02_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMy0zLTEtMS0w_771cb60d-38b7-48a7-9e8f-a5a074c1a4cf"
      unitRef="usd">9138000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e999092fe5a47b995df7486ab8722ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNC0xLTEtMS0w_430bb797-dd93-4cb2-bad0-56ddb8529096"
      unitRef="usd">60097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02db62d3a5c6475eb891c555c988387c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNC0zLTEtMS0w_6b85b29e-bb9e-43e9-baa3-29c9e22c095b"
      unitRef="usd">17919000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41094e12553647d993f3c81751f72fe6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNS0xLTEtMS0w_926cbf29-6574-4b7b-9735-379d29563624"
      unitRef="usd">993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54eae18cd0904e9d906affdbfe7dceef_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNS0zLTEtMS0w_24bb7d3a-6097-4caf-9431-e92e01b47398"
      unitRef="usd">970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic82eaa651b994a398eb65997f0b11e71_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNi0xLTEtMS0w_4c01b13c-2171-4d5a-a43d-45b2d37a8cc0"
      unitRef="usd">3334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if879b8d640fd4528a046bfb43e105676_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNi0zLTEtMS0w_3743b21c-3e05-4c84-8168-272d35f4cf83"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNy0xLTEtMS0w_8a601348-d4a7-4d1e-88c3-678cf237d2c3"
      unitRef="usd">87098000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfNy0zLTEtMS0w_f4cf1a94-e1e6-40b4-88d2-5e015afe3466"
      unitRef="usd">30227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfOS0xLTEtMS0w_47d09b68-cfeb-487c-9b44-5cda6415f28d"
      unitRef="usd">533000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfOS0zLTEtMS0w_42f866ff-b0af-42a6-b36b-9267b7b3c246"
      unitRef="usd">334000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTAtMS0xLTEtMA_9a6bc720-8e24-490e-9cf4-52277ae33f6d"
      unitRef="usd">91256000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTAtMy0xLTEtMA_50472083-d5fc-47bd-a1f9-c8d8279a0502"
      unitRef="usd">95585000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTEtMS0xLTEtMA_e44d3b46-a953-4031-afab-d7fa725c5e79"
      unitRef="usd">38501000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTEtMy0xLTEtMA_720d6cf3-f185-46b0-a13e-f829197b78a6"
      unitRef="usd">31791000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTItMS0xLTEtMA_bb4e5eda-c1f2-4079-828b-34666e0f6a7a"
      unitRef="usd">130290000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTItMy0xLTEtMA_0057b71f-3fdd-46f7-8b84-f3755f48adaa"
      unitRef="usd">127710000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTMtMS0xLTEtMA_53c07f43-7b49-428b-9017-865e8faa66be"
      unitRef="usd">-43192000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTMtMy0xLTEtMA_467773de-022c-41ff-ac06-60d0c176e796"
      unitRef="usd">-97483000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTQtMS0xLTEtMA_cd44194a-6f78-419a-a5c4-3a7d4a795779"
      unitRef="usd">2936000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTQtMy0xLTEtMA_d60473ea-c9c8-4722-b4c7-868f93fbc1cf"
      unitRef="usd">4405000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTUtMS0xLTEtMA_cecf5592-de19-43d9-baf5-b1010ebcb09e"
      unitRef="usd">-40256000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTUtMy0xLTEtMA_8da73c4a-f678-442c-9b4f-bbef609d45b5"
      unitRef="usd">-93078000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTYtMS0xLTEtMA_0eeaa883-0db9-4eb6-bb2f-91986730993b"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTYtMy0xLTEtMA_59887939-9492-40f0-b59a-d6ac62de65eb"
      unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTctMS0xLTEtMA_30f0bbed-2d12-4f5b-9ff4-0ffa6c435ffe"
      unitRef="shares">68608279</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18xOS9mcmFnOjkyY2RhM2QwNGQ0YTQ4OTBhYjI3ODYwNDFmMjg3ZTBhL3RhYmxlOjQxMmYzZThiMWVmOTRlYzdhMjk0YTk4ZmU4YzhhZDdhL3RhYmxlcmFuZ2U6NDEyZjNlOGIxZWY5NGVjN2EyOTRhOThmZThjOGFkN2FfMTctMy0xLTEtMA_6caf9831-83de-4ddd-8a44-e5e57087cd69"
      unitRef="shares">58453918</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfMi0xLTEtMS0w_cecf5592-de19-43d9-baf5-b1010ebcb09e"
      unitRef="usd">-40256000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfMi0zLTEtMS0w_8da73c4a-f678-442c-9b4f-bbef609d45b5"
      unitRef="usd">-93078000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNC0xLTEtMS0w_af5a40ea-562c-4651-b2a2-1c8296ada092"
      unitRef="usd">-128000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNC0zLTEtMS0w_5ef49a94-0eb9-4b1f-bf05-f89dbaae59e4"
      unitRef="usd">1687000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNS0xLTEtMS0w_ff560841-a7c0-4167-b93c-0099069d5941"
      unitRef="usd">-40384000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yMi9mcmFnOjM1NmNhNTUzM2U1ZjQwMDZiNGU2NGQwOTU4ZTI0NWY3L3RhYmxlOjk4NzZhMDdhNGFiMDRlNThiMGI0YjMwMDlkYTU0YWYwL3RhYmxlcmFuZ2U6OTg3NmEwN2E0YWIwNGU1OGIwYjRiMzAwOWRhNTRhZjBfNS0zLTEtMS0w_2d984111-410f-4e0e-b0e8-2030b16a9123"
      unitRef="usd">-91391000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i0d4ece46885443dfb8b45982f5c1d81a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi0xLTEtMS0w_302c4626-8088-4778-a136-8287b2991133"
      unitRef="shares">68401105</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0d4ece46885443dfb8b45982f5c1d81a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi0zLTEtMS0w_da2fff5c-e1d1-451f-92a6-92678fa9b244"
      unitRef="usd">68000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id37911106fe1449f9034156faa5eb2a6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi01LTEtMS0w_d7e235eb-39bf-43db-ab94-49b74e98e8f9"
      unitRef="usd">2156363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic89fcca3dd5745338d1cfd3260db99f1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi03LTEtMS0w_5dee418b-f0e0-4ede-aeed-e78009d5455e"
      unitRef="usd">202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae2b4e4df79d4fe1bf3634518d64c589_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi05LTEtMS0w_0d5188f7-d085-4410-b2d7-066e23800006"
      unitRef="usd">-1516105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfMi0xMS0xLTEtMA_01bc103d-cae2-4c89-bd04-5eafaae2d15a"
      unitRef="usd">640528000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib08167bb5f1945769d6ee3657f77ca59_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC0xLTEtMS0w_572bd038-82a0-41cd-97f2-57da155902f2"
      unitRef="shares">388820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib08167bb5f1945769d6ee3657f77ca59_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC0zLTEtMS0w_ec28894d-6b95-4b38-b568-5c3f9fa2d9a6"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0449bd3f63554820bbdfb7c723787243_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC01LTEtMS0w_49b5bd8a-e9c9-4435-8673-b18eb8b2099c"
      unitRef="usd">5464000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNC0xMS0xLTEtMA_7966cbc8-679b-47dc-8711-fccf94107732"
      unitRef="usd">5465000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0449bd3f63554820bbdfb7c723787243_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNS01LTEtMS0w_e840a15b-badf-48e6-b3f4-1eca1a2aacc4"
      unitRef="usd">19690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNS0xMS0xLTEtMA_b50f8ccc-be0e-4fe9-9513-04069340a537"
      unitRef="usd">19690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5089bb6eb61f47bd86313de5659a1590_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNi03LTEtMS0w_3ec63b0d-0a70-487f-acf1-9204e77c32b8"
      unitRef="usd">-128000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNi0xMS0xLTEtMA_f549ac0e-2b5c-45c3-b274-dd35ee154f4d"
      unitRef="usd">-128000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i05cbd70b0ea74776a5302b8c60f708dd_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNy05LTEtMS0w_8272c8c7-6933-4591-ac29-e393b881886b"
      unitRef="usd">-40256000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfNy0xMS0xLTEtMA_40725a29-ff72-4f01-b382-ee722295f263"
      unitRef="usd">-40256000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7f5ad1c314b54412beee6289ce701979_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS0xLTEtMS0w_b270b2f0-a6b8-4f5b-80ef-50a8521fb873"
      unitRef="shares">68789925</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7f5ad1c314b54412beee6289ce701979_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS0zLTEtMS0w_e37c43ca-f34d-4787-862e-1a495553b880"
      unitRef="usd">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06129accabc84db1998139916e3bfdce_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS01LTEtMS0w_a4aebdfe-3402-4e77-88f8-969975bf29d7"
      unitRef="usd">2181517000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9781e5291b34a4b96ee6b85750b185a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS03LTEtMS0w_f493fa9e-dd59-491c-8d84-7819774b0386"
      unitRef="usd">74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie22c76c636c44318bd5ddf5c65c4945e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS05LTEtMS0w_df460be7-eabe-4498-9067-eb96ce1d185d"
      unitRef="usd">-1556361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOjFkNzNkYzQ2MmQ2OTQyY2U4NTA0M2IwODEzN2EyYTM5L3RhYmxlcmFuZ2U6MWQ3M2RjNDYyZDY5NDJjZTg1MDQzYjA4MTM3YTJhMzlfOS0xMS0xLTEtMA_87ed2230-016a-4111-bdbb-766cb60ceb66"
      unitRef="usd">625299000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ic8958bd3f29941f2aa800c1928252121_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi0xLTEtMS0w_b2016883-c841-4edb-9e40-616449bf19b2"
      unitRef="shares">58218653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic8958bd3f29941f2aa800c1928252121_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi0zLTEtMS0w_5a282dd2-e551-4aea-81ff-9acf62e56812"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6db96c6a87374048ace2fc1cb33ea464_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi01LTEtMS0w_f31bd5ff-4f98-4875-88a7-1e03d15fa862"
      unitRef="usd">1794283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b788f2270d84d63a475d1b2aecbeaf8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi03LTEtMS0w_2f4d7d6e-5a98-4e62-99c7-befee8c4eb3f"
      unitRef="usd">-2171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c76a8d5c9f047fdb64349f6cebc1f11_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi05LTEtMS0w_2c26a86d-726c-473e-af25-eb5ba1ff9bcf"
      unitRef="usd">-1104633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62be91ce449047f7b038e5f03bcc8373_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMi0xMS0xLTEtMA_51903e74-36b4-488e-85c4-a45cf665995e"
      unitRef="usd">687537000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1a5f41773d3e4ddd9bceaac90793a7ee_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC0xLTEtMS0w_ffbe0ae5-505c-4a64-b450-e4e6b3f1dd4f"
      unitRef="shares">441168</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1a5f41773d3e4ddd9bceaac90793a7ee_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC0zLTEtMS0w_4ccde987-080a-4d0e-8bd2-64ccb06b040b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i64beb8c427754afbbeb4323e2204e1ce_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC01LTEtMS0w_206dc9f7-8383-49af-8611-e81a9c076773"
      unitRef="usd">6002000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNC0xMS0xLTEtMA_a78f4cb1-f80b-4648-b9da-fb3b8b286973"
      unitRef="usd">6003000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i64beb8c427754afbbeb4323e2204e1ce_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNS01LTEtMS0w_b6da4e2b-156f-4230-8897-3a016b3ed778"
      unitRef="usd">18108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNS0xMS0xLTEtMA_949baabe-2621-465e-a6d7-70e26e515cbb"
      unitRef="usd">18108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idfdf8a5d4f2b461cbcd4e7f10715380a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNi03LTEtMS0w_aa4012b3-66a7-41f8-9e73-04ba857400bd"
      unitRef="usd">1687000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfNi0xMS0xLTEtMA_9485cf39-9819-4464-be5e-5979bd32e4ba"
      unitRef="usd">1687000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3c9a056637214d5796f17b4822cda10e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfOS05LTEtMS0w_955b3949-236a-4b00-a6cc-6d329003945b"
      unitRef="usd">-93078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfOS0xMS0xLTEtMA_fd04e914-e170-43cd-8823-d265f8d0a319"
      unitRef="usd">-93078000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i8a0427dc88004cdb9ad5b111ee121e8a_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtMS0xLTEtMA_542313c7-3dab-4609-91bd-89b9bd26ed11"
      unitRef="shares">58659821</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8a0427dc88004cdb9ad5b111ee121e8a_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtMy0xLTEtMA_1097e6d4-3b0a-4e62-9a4b-025e762d949e"
      unitRef="usd">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6971d4a30427440ba662d8d10de5fd9a_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtNS0xLTEtMA_5777dbf4-1194-4ce8-82e2-7bc31ac0488f"
      unitRef="usd">1818393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b9f97f0add14e97ac35d6c17a93e045_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtNy0xLTEtMA_701ed571-3412-4f51-97c5-430aff66445d"
      unitRef="usd">-484000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d5f65c2dfb44ce892a2a2a36fc23f81_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtOS0xLTEtMA_c6a824d7-8dfb-42a9-bcfb-86f724c0003a"
      unitRef="usd">-1197711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4edbcb8341ca4ae9a52de4dfbc7f3fa9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yNS9mcmFnOjE2YTFmMTE2YzVmMzQ2MTA5OGZkYmU2ODNmOTYxYzJkL3RhYmxlOmM1YWI4NTcwYmEzZjQzZmI4NTgyY2Y2NzRhOTg3M2U4L3RhYmxlcmFuZ2U6YzVhYjg1NzBiYTNmNDNmYjg1ODJjZjY3NGE5ODczZThfMTEtMTEtMS0xLTA_e7e89cec-6190-4aff-8cd7-ab2220eec031"
      unitRef="usd">620257000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMy0xLTEtMS0w_1b92ce9b-3730-480a-8a61-a98c8f44f2e3"
      unitRef="usd">-40256000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMy0zLTEtMS0w_c838272e-da2f-4ba1-adba-67aa29e8501e"
      unitRef="usd">-93078000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNS0xLTEtMS0w_aabdf972-97d5-4a1e-bc96-28da41ba4e63"
      unitRef="usd">2474000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNS0zLTEtMS0w_057b7908-3c67-4fb6-8980-673409fcf1f9"
      unitRef="usd">2005000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNi0xLTEtMS0w_f30580d6-4099-4f35-86be-9b53eeb396b5"
      unitRef="usd">19690000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNi0zLTEtMS0w_c7b4f56b-ab47-4332-a653-ebaaa4181643"
      unitRef="usd">18108000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNy0xLTEtMS0w_b3697149-fbf2-483d-8635-e66291dc8137"
      unitRef="usd">-126000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNy0zLTEtMS0w_5228e1ff-868c-463c-a480-f590730b9d38"
      unitRef="usd">1131000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <agio:OperatingLeaseRightOfUseAssetAmortization
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfOS0xLTEtMS0w_820a3724-2c48-4579-842d-459096c051ba"
      unitRef="usd">2203000</agio:OperatingLeaseRightOfUseAssetAmortization>
    <agio:OperatingLeaseRightOfUseAssetAmortization
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfOS0zLTEtMS0w_00137c90-9ddd-4752-a2b4-5da5a8d49ecb"
      unitRef="usd">2085000</agio:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTEtMS0xLTEtMA_a6c2de4a-5059-4c71-a86e-4e8de04f82df"
      unitRef="usd">2861000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTEtMy0xLTEtMA_9505698d-e7f5-4528-b6c6-ab01920dd4d5"
      unitRef="usd">-721000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <agio:IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTItMS0xLTEtMA_e4689313-1c5a-4ae1-b6ab-fecd228009b9"
      unitRef="usd">1038000</agio:IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent>
    <agio:IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTItMy0xLTEtMA_1b42e52d-0208-4ff1-9dca-3107b87848db"
      unitRef="usd">-143000</agio:IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent>
    <agio:IncreaseDecreaseinCollaborationReceivableOtherCurrent
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTMtMS0xLTEtMA_b847f5ff-de00-423d-8cd9-84cae6cbe835"
      unitRef="usd">105000</agio:IncreaseDecreaseinCollaborationReceivableOtherCurrent>
    <agio:IncreaseDecreaseinCollaborationReceivableOtherCurrent
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTMtMy0xLTEtMA_b2a6aa8e-3152-4222-9bae-c8b2741debe6"
      unitRef="usd">970000</agio:IncreaseDecreaseinCollaborationReceivableOtherCurrent>
    <agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTQtMS0xLTEtMA_4c441501-d764-45a2-9280-a09ad32e3489"
      unitRef="usd">400000</agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent>
    <agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTQtMy0xLTEtMA_0448889e-87e1-42c1-b176-0547bc475048"
      unitRef="usd">-34000</agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTUtMS0xLTEtMA_272ec9ce-5e17-4609-aae4-ad073bd059ff"
      unitRef="usd">2447000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTUtMy0xLTEtMA_7a1ee955-6371-4123-8fea-f52e55d34761"
      unitRef="usd">1459000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTctMS0xLTEtMA_1aaf201c-a0c9-4e3c-812e-dd3b434a496f"
      unitRef="usd">6774000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTctMy0xLTEtMA_ad2b932f-a128-4321-8c1e-35be91ffd6fb"
      unitRef="usd">2173000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTgtMS0xLTEtMA_b0392e79-3fb4-4121-9c28-9dc9f5dc32d4"
      unitRef="usd">-2009000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTgtMy0xLTEtMA_b4f0d2ca-cc20-462a-925a-99a726c4bb90"
      unitRef="usd">-4939000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTktMS0xLTEtMA_20c462b5-21ae-4acc-aee4-e76f4d2ba754"
      unitRef="usd">-14967000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMTktMy0xLTEtMA_da7987f2-92c4-4188-bcd6-453c6b3aac7c"
      unitRef="usd">-5097000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjAtMS0xLTEtMA_69a287d6-57a0-47be-b7e4-ed1699719d94"
      unitRef="usd">-56765000</agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty>
    <agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjAtMy0xLTEtMA_5aea0b56-4dce-4ae7-8c2f-36bac23a4341"
      unitRef="usd">-15391000</agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty>
    <agio:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjEtMS0xLTEtMA_bc64a9c4-201c-46b4-a4b8-bd1992f478c8"
      unitRef="usd">-2229000</agio:IncreaseDecreaseInOperatingLeaseLiability>
    <agio:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjEtMy0xLTEtMA_2f716df8-e0b4-43ed-bc81-8c629745f234"
      unitRef="usd">-2129000</agio:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjMtMS0xLTEtMA_1981a037-bc92-42e9-9d46-87f9635f01b5"
      unitRef="usd">-105358000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjMtMy0xLTEtMA_df855812-cf9c-47db-b5b9-0bb57f2cc8a1"
      unitRef="usd">-103271000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjUtMS0xLTEtMA_7aa665aa-6314-43e4-880c-ab96d244eca3"
      unitRef="usd">54911000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjUtMy0xLTEtMA_16ad0419-2a5e-49c2-b5e9-f4e22d8e306d"
      unitRef="usd">77421000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjYtMS0xLTEtMA_5ac3ef8f-420a-47f7-8a2c-4b1dbe61d50e"
      unitRef="usd">167501000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjYtMy0xLTEtMA_0fc80ba7-932f-4ded-b0c8-9c5f8e423d44"
      unitRef="usd">210811000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjctMS0xLTEtMA_f5aa15ba-dc89-4157-b24a-39ee6466f511"
      unitRef="usd">4455000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjctMy0xLTEtMA_c952c7ca-7339-41d6-bf44-5080cd09935e"
      unitRef="usd">2038000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjgtMS0xLTEtMA_74c66762-9474-4b23-ad01-63d94a17515a"
      unitRef="usd">108135000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMjgtMy0xLTEtMA_fcff0b29-8b00-4ea4-969e-44f251d421dc"
      unitRef="usd">131352000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzAtMS0xLTEtMjE4OQ_40bd0ea0-9dba-4b9d-b94b-fb4ed7085585"
      unitRef="usd">80000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzAtMy0xLTEtMjU0NA_1059aa23-b413-4ea1-977f-1a14c62f8bf5"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzItMS0xLTEtMA_8525ea46-29db-4b32-8709-55214f7b5c17"
      unitRef="usd">5465000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzItMy0xLTEtMA_1f2c0ad7-fd57-4af1-b5be-77685693df74"
      unitRef="usd">4860000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzMtMS0xLTEtMA_7690e077-e845-439c-bf40-116c958e1a22"
      unitRef="usd">5385000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzMtMy0xLTEtMA_a74ff30e-e1d2-472b-ac3c-0e1b64bd36c1"
      unitRef="usd">4860000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzQtMS0xLTEtMA_342dc0a6-aeef-42aa-9f0f-27e5bf534eeb"
      unitRef="usd">8162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzQtMy0xLTEtMA_a23e8a04-bf3c-4dd5-aa00-e679e1d7a9ae"
      unitRef="usd">32941000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzUtMS0xLTEtMA_7df61483-5324-4833-b320-8fca168a2491"
      unitRef="usd">80931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i62be91ce449047f7b038e5f03bcc8373_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzUtMy0xLTEtMA_e26d75bf-53a2-481e-88ba-b6e4a682e34f"
      unitRef="usd">70502000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzYtMS0xLTEtMA_69382c70-f410-4cc3-915f-0cb68a4bb82c"
      unitRef="usd">89093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4edbcb8341ca4ae9a52de4dfbc7f3fa9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzYtMy0xLTEtMA_8105afb6-8775-48fe-a655-67a0c93dbf37"
      unitRef="usd">103443000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzgtMS0xLTEtMA_b87943f0-7ea0-4eeb-96d8-ec45d15f401f"
      unitRef="usd">5444000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzgtMy0xLTEtMA_c9ed3a96-e1d4-45e4-9292-2263f7a7990f"
      unitRef="usd">727000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <agio:ProceedsFromStockOptionsExercisedInOtherCurrentAssets
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzktMS0xLTEtMA_4f3da7f8-25fd-464d-b7e8-a3e9e20c6c2f"
      unitRef="usd">0</agio:ProceedsFromStockOptionsExercisedInOtherCurrentAssets>
    <agio:ProceedsFromStockOptionsExercisedInOtherCurrentAssets
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfMzktMy0xLTEtMA_f30d2428-3e88-47b2-9ca6-8cf98541245a"
      unitRef="usd">1149000</agio:ProceedsFromStockOptionsExercisedInOtherCurrentAssets>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDEtMS0xLTEtMA_af6a943b-170b-45d6-b94e-6d6eaef0979b"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDEtMy0xLTEtMA_c1d5a930-73c4-492c-b4fa-69dd37048f90"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDItMS0xLTEtMTgzMQ_671bc326-9815-4457-ae25-8095add9f559"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18yOC9mcmFnOjI1ZTkwNjRhZWNjZTQwNWI4Y2EwNmM4MmZhNDkyMWJmL3RhYmxlOjRkNWQ4ZDJiMTRhMTQxYWI5ZDNlOWY2ODBiYjg0OTk3L3RhYmxlcmFuZ2U6NGQ1ZDhkMmIxNGExNDFhYjlkM2U5ZjY4MGJiODQ5OTdfNDItMy0xLTEtMTgzNA_d1b5ef75-0ca3-44bf-b9bf-54cb6bd1e3b5"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMjY3NA_c96aeccf-b1a0-40b6-9dd7-6d56cce3c0da">Overview and Basis of Presentation&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;References to Agios&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our,&#x201d; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#x201c;our Board of Directors&#x201d; refers to the board of directors of Agios Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are a biopharmaceutical company committed to the fundamental transformation of patients&#x2019; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect. We are located in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three months ended March 31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2020, our results of operations and stockholders' equity for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, we had cash, cash equivalents and marketable securities of $613.1 million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and &lt;/span&gt;&lt;/div&gt;marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMzI5ODUzNDg4OTczNA_39bf2e50-fbaa-4c39-a685-0f6365758e27">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed consolidated balance sheet as of March&#160;31, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three months ended March 31, 2020 and 2019, and the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2020, our results of operations and stockholders' equity for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMzI5ODUzNDg4OTczNQ_7097e3b7-43a2-41f3-8381-cadce56568a4">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNC9mcmFnOmI2YjE0MDJiZDQ0NjQxYzFhMmY0NWExNjcyNzI4NmVhL3RleHRyZWdpb246YjZiMTQwMmJkNDQ2NDFjMWEyZjQ1YTE2NzI3Mjg2ZWFfMjM1OQ_f9b7db24-4aa0-45c3-ba7d-ac5346d137d4"
      unitRef="usd">613100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNy9mcmFnOmQyNjEzYmMxNDM5MDQyNDA4ODEzMWFmNWY3MDYwM2QwL3RleHRyZWdpb246ZDI2MTNiYzE0MzkwNDI0MDg4MTMxYWY1ZjcwNjAzZDBfMzY0Mg_e3f9ed2d-a7df-4475-836d-a8cb6ec7a705">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses (Topic 326),&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN18zNy9mcmFnOmQyNjEzYmMxNDM5MDQyNDA4ODEzMWFmNWY3MDYwM2QwL3RleHRyZWdpb246ZDI2MTNiYzE0MzkwNDI0MDg4MTMxYWY1ZjcwNjAzZDBfMzI5ODUzNDg5ODU0MA_873d8a61-f835-45d1-8fc1-5bc436f68f07">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses (Topic 326),&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTk3OQ_695dc427-a01e-473a-91cb-0b2e44c031ef">Fair Value Measurements&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of March&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;524,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;524,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;544,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;598,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of March&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;There have been no changes to the valuation methods during the three months ended March 31, 2020. We evaluate transfers between levels at the end of each reporting period. We have no financial assets or liabilities that were classified as Level 3 at any point during the three months ended March 31, 2020.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTk3NQ_a0a98a13-2cd2-412f-aabf-00108d8df90d">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTk3Ng_33f7bc06-507b-42fd-84b1-475700aaab69">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of March&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;524,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;524,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;544,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;598,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic285bdb5cfff4f9bb6e8c6aa8bd0aef6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS0xLTEtMS0w_d98554b4-731e-452f-97f7-c92fbc127144"
      unitRef="usd">54853000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id2896d589cf7469a8775ecf2af7fef57_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS0zLTEtMS0w_f429283f-34ce-42a9-852d-b35c46660441"
      unitRef="usd">19979000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7d69f26b53ee4c3e8ba4149462acd30a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS01LTEtMS0w_263894de-08f2-4bbf-86e7-e2d1d32b88cb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2a5ae1f4e6da4a40ab90e89f131655fc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMS03LTEtMS0w_5e349fee-f8f5-4ec7-a499-60e11275a121"
      unitRef="usd">74832000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i980609409a6b4e13b07d000c6cdd7d2c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi0xLTEtMS0zNzc_8558079c-0adf-4a2d-a616-faee64eacdd0"
      unitRef="usd">54853000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i237b15fb46da4b59a1a6fac0feae116a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi0zLTEtMS0zNzc_3199eb9d-57f7-489a-8265-24799b821d52"
      unitRef="usd">19979000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi01LTEtMS0zNzc_0484a5c6-9884-4a9d-a761-d092a0dbe32a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d7da42c6aea42a087aa27c849a90448_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfMi03LTEtMS0zNzc_93e7af31-e19f-4c0d-a077-394cbc9a470a"
      unitRef="usd">74832000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i852744abdf2745b18e0f60fa3df00339_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC0xLTEtMS0w_d2b46754-2214-487f-b408-f1365358c645"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f8f8fda49a94e84b0a5c8d9bd24a8ef_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC0zLTEtMS0w_e357e5d1-74aa-4f71-9280-e6df31a852e1"
      unitRef="usd">163878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i635947295b764abfbbdea991d6fe54fc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC01LTEtMS0w_f3e8f7d1-3a64-4b4f-8f4b-b3af87cdd7e2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief6cbec674e741b4a873e845b45a4e31_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNC03LTEtMS0w_28fe0a29-badf-4de4-9b28-d7a3bf6d8c97"
      unitRef="usd">163878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4fdeb9348b94b618851880b5c977d5d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS0xLTEtMS0w_693bf8ad-31d2-4889-8d0e-d50f5698a927"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9f32329914f4f5ba7b80bae3b347fda_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS0zLTEtMS0w_b55a5eb4-2772-4381-8e88-d1673a861778"
      unitRef="usd">100492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i474102d2baee43179a37e278bb04cf73_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS01LTEtMS0w_067610d8-918b-4831-a4db-3bb228b74ec1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i244896107f9d40bd82157d3c93e71bad_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNS03LTEtMS0w_cceceb1d-5307-43c0-bfd0-d5760bc2aa7d"
      unitRef="usd">100492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3fe9a6e1ebc48a49cc37d47c38c8288_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi0xLTEtMS0w_3183f581-9152-4733-af37-fa71e0277db5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e239c737d2f45488edacb7ef4b2bb95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi0zLTEtMS0w_4caf435d-a6ea-46f5-a4d9-ee03a524eb14"
      unitRef="usd">259661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i689b528c68d6471cbeca1282d66876f7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi01LTEtMS0w_fb50a935-c914-4267-b2af-cfd6078c8644"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe05f5bb5bf340819df84fa9a1e20a30_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNi03LTEtMS0w_1c0977a6-8774-4b6d-b97b-33894ea3afc9"
      unitRef="usd">259661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i980609409a6b4e13b07d000c6cdd7d2c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS0xLTEtMS0zODE_f8ed362b-db0d-4b2f-bd6a-c62c6c4f888a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i237b15fb46da4b59a1a6fac0feae116a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS0zLTEtMS0zODE_e28a5387-81c2-4acd-9086-dea841d3fc08"
      unitRef="usd">524031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS01LTEtMS0zODE_88255756-959a-4a20-aeb1-b21aeded1d48"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d7da42c6aea42a087aa27c849a90448_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfOS03LTEtMS0zODE_3e2cf275-7b11-42eb-bce2-0aa0a2322d61"
      unitRef="usd">524031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i980609409a6b4e13b07d000c6cdd7d2c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy0xLTEtMS0w_6a9279c8-3000-4cc8-8a3e-3137f61034df"
      unitRef="usd">54853000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i237b15fb46da4b59a1a6fac0feae116a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy0zLTEtMS0w_5cc914ff-a675-4330-aea4-9698120650ff"
      unitRef="usd">544010000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy01LTEtMS0w_a91cd460-a0df-4d0d-bcee-ea0bc74638ca"
      unitRef="usd">0</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i6d7da42c6aea42a087aa27c849a90448_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RhYmxlOmE2YTFlZjhhYWMzNTQ3OWNhMjMzZDcxZDYwZmQwYjY0L3RhYmxlcmFuZ2U6YTZhMWVmOGFhYzM1NDc5Y2EyMzNkNzFkNjBmZDBiNjRfNy03LTEtMS0w_09c418b9-11d6-4fc2-b197-6c5e479c0003"
      unitRef="usd">598863000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i52ec527d6f6d4826938dd1bfd0f12b90_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180MC9mcmFnOmI4MTVmMTJiYTU1ZDRhYzc5ZWY1OGNiMmNmOWViZTUzL3RleHRyZWdpb246YjgxNWYxMmJhNTVkNGFjNzllZjU4Y2IyY2Y5ZWJlNTNfMTg4MQ_01240fd6-7ef8-46a4-a951-aec39aea5e30"
      unitRef="usd">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTc2NA_45ac4ec8-ee23-4b85-aa44-1a1f2281c318">Marketable Securities&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities at March&#160;31, 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;208,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;439,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(739)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;439,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;523,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;524,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities at December&#160;31, 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;483,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;483,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020 and December&#160;31, 2019, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.&lt;/span&gt;&lt;/div&gt;As of March&#160;31, 2020 and December&#160;31, 2019, we held 92 and 113 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of March&#160;31, 2020 and December&#160;31, 2019 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2020 and December&#160;31, 2019 was $224.0 million and $345.7 million, respectively. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2020 and December&#160;31, 2019. Given our intent and ability to hold such securities until recovery, and the lack of significant change in the credit risk of these investments, we do not consider these marketable securities to be impaired as of March&#160;31, 2020 and December&#160;31, 2019.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTc1OQ_a3dda6d1-c7a2-44a9-9e55-3c8cfa147a11">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfNTUw_9dbd18c4-67d5-47d6-b715-7d6ff5d95660"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfNTUw_a1d11a58-4d41-4816-8a83-6b12d0d9c7f2"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTc2MQ_8495b195-dfd5-4813-8ee1-f1540481e343">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities at March&#160;31, 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;208,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;439,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(739)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;439,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;523,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;524,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities at December&#160;31, 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.750%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;483,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;483,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0502aed7c32c4db0853962e904c21847_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy0xLTEtMS0w_e3fd1b15-ca82-4d59-b561-8517ffaaba0f"
      unitRef="usd">141490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0502aed7c32c4db0853962e904c21847_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy0zLTEtMS0w_f99cb0af-029a-4c13-945e-0b23a0d06942"
      unitRef="usd">835000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0502aed7c32c4db0853962e904c21847_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy01LTEtMS0w_621fac69-cd58-4118-a1d8-718cc36ceb41"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0502aed7c32c4db0853962e904c21847_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMy03LTEtMS0w_f180685b-f736-48d5-9953-b8cbc2993486"
      unitRef="usd">142325000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC0xLTEtMS0w_f7a6b918-599f-4e92-8316-1ad3d03ed8fb"
      unitRef="usd">89008000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC0zLTEtMS0w_f07c0411-2ed9-42c4-9416-b58bf278ed20"
      unitRef="usd">256000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC01LTEtMS0w_b53fbfa7-22be-4f8c-82d0-3e601a698d26"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i108de68f38fd4fabbe1b522da2bfee56_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNC03LTEtMS0w_80aafb86-e1b2-4200-9a9a-4e7eb406d552"
      unitRef="usd">89243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS0xLTEtMS0w_922f443a-c013-4ddb-8467-d407ca6e1f9c"
      unitRef="usd">208596000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS0zLTEtMS0w_a9669c26-88b5-447f-8172-ff24baa81329"
      unitRef="usd">82000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS01LTEtMS0w_068feccc-3f01-408b-b73f-4531c2a97ef4"
      unitRef="usd">718000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85ccd9c5271946ae8ea7524c2ea81976_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNS03LTEtMS0w_7fe00876-84ed-40c5-8a1c-e1eb4b6366c4"
      unitRef="usd">207960000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi0xLTEtMS0zOTI_8f11cc43-38d3-4d67-bcc5-556d8ea25430"
      unitRef="usd">439094000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi0zLTEtMS0zOTI_39fdfd89-455f-48ab-9bff-5ba370c506e8"
      unitRef="usd">1173000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi01LTEtMS0zOTI_ae570c11-a2c1-4a19-9d4c-458ed17d170d"
      unitRef="usd">739000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i554916221ecb43d4bad1bebdd455085e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfNi03LTEtMS0zOTI_ce1e985a-2e8e-4033-a96d-136720b39fad"
      unitRef="usd">439528000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMS0xLTEtMzk3_a7bab8a9-907c-49c1-8cc6-235cfd6aea83"
      unitRef="usd">21282000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMy0xLTEtMzk3_ec440f48-5204-4699-8349-462dbaf972a8"
      unitRef="usd">271000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNS0xLTEtMzk3_9dc0e243-37af-452c-b7f2-9231d5bcc0f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c83103f8a9a4a869b0f015b8764c2bf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNy0xLTEtMzk3_767d0075-4b77-4e76-a490-cb4a7d1ebb8e"
      unitRef="usd">21553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS0xLTEtMS0w_4047013e-7ec5-4b0e-bc21-40d2fee3a8f9"
      unitRef="usd">11260000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS0zLTEtMS0w_57348bad-f855-4e3e-a729-709ca2cec8b1"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS01LTEtMS0w_ce69225e-f8f4-4612-a023-f3d09450fbbd"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaba4c2b9d8104e2092c8a1578a072d33_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfOS03LTEtMS0w_0817c174-5239-429d-9ddb-c57fe747e466"
      unitRef="usd">11249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia264a24d96044bba896491152779474a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtMS0xLTEtMA_550a1286-8ef1-4547-a45c-0943ea2ce393"
      unitRef="usd">52329000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia264a24d96044bba896491152779474a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtMy0xLTEtMA_ad30c9bb-efda-4f9a-9792-9b417324a7e8"
      unitRef="usd">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia264a24d96044bba896491152779474a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtNS0xLTEtMA_9e1c86ba-8882-4907-a276-42618055464b"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia264a24d96044bba896491152779474a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTAtNy0xLTEtMA_1f99195d-e481-44cb-9bc8-b5c3920b47b7"
      unitRef="usd">51701000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtMS0xLTEtNDAw_1dc93b65-d85d-4618-a3b3-633c8b86ed62"
      unitRef="usd">84871000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtMy0xLTEtNDAw_3de9da7c-9d7a-46dc-a014-85da77848b35"
      unitRef="usd">347000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtNS0xLTEtNDAw_efefcdc3-8e3b-4f3a-85b0-fae34a7e4644"
      unitRef="usd">715000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74269132e8824b1d9ae169ad9bcfd579_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTQtNy0xLTEtNDAw_5ef2d85c-3923-4cb9-9dda-614191c7dcc4"
      unitRef="usd">84503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMS0xLTEtMA_22b79d52-6301-4002-9ef5-664f04858b96"
      unitRef="usd">523965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtMy0xLTEtMA_ba6939de-1fca-44e0-b502-a756bdc57962"
      unitRef="usd">1520000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNS0xLTEtMA_c6dae1b2-3755-42a7-8b68-d9ff78d48531"
      unitRef="usd">1454000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmRhODg3Mzk5NGRhYjQzZmE4MjhmYjcwZDQ5MzdmYjk0L3RhYmxlcmFuZ2U6ZGE4ODczOTk0ZGFiNDNmYTgyOGZiNzBkNDkzN2ZiOTRfMTEtNy0xLTEtMA_8aa23d9c-eaf7-4331-834d-168e01e2b74e"
      unitRef="usd">524031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy0xLTEtMS0w_b1474d10-e2f3-4b21-a7bd-ff0427781902"
      unitRef="usd">178721000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy0zLTEtMS0w_000c9f5e-76ee-44d7-acab-03d93f529867"
      unitRef="usd">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy01LTEtMS0w_d10056f7-703c-44be-aa0a-88f9b2080440"
      unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a8863eb18ec4b8f8127c6b5ba3364f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMy03LTEtMS0w_160328f3-d9d5-4f93-bc1d-a6b18252d9e1"
      unitRef="usd">178741000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC0xLTEtMS0w_65c235db-8e53-4eb6-bbf0-3106369eba0f"
      unitRef="usd">80228000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC0zLTEtMS0w_3880df84-0974-41d5-9a57-aa42ca3fe7c8"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC01LTEtMS0w_639ae3d7-c33b-4a45-b4bb-3ed9f76b606e"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf88bf362c84475c8e9b943d30632f1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNC03LTEtMS0w_3488ebad-b7a0-4d6b-8dfc-27ff13214845"
      unitRef="usd">80229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0xLTEtMS0w_b2d6679e-8cbd-40bd-a6d6-c6acae9b2fe7"
      unitRef="usd">224928000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0zLTEtMS0w_4142722a-ce6f-4df5-8110-bf45f48b0a98"
      unitRef="usd">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS01LTEtMS0w_1eeab8ab-33a9-46b5-9be0-a6400a2dd63a"
      unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e5ed8a6b14f456e9a5eb9bc557b6ccf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS03LTEtMS0w_86efdb45-6d40-4a02-94b9-9eb557f549ac"
      unitRef="usd">224976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0xLTEtMS00MTM_7ff57bdd-abe7-4d05-b620-7f62efb57bb3"
      unitRef="usd">483877000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS0zLTEtMS00MTM_4c5f0e6c-597c-43a0-a83b-cc6e7b1affc3"
      unitRef="usd">214000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS01LTEtMS00MTM_66464e96-f911-48c0-aef8-f9bab41cd8e6"
      unitRef="usd">145000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if4917f73e8bc4c0d8651d34dc493d64d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfNS03LTEtMS00MTM_ec4d7c1b-a2fd-40cc-bf6e-e65b6b0e3333"
      unitRef="usd">483946000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC0xLTEtMS0w_1458fa27-775d-470d-9937-e36afaf256b9"
      unitRef="usd">35296000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC0zLTEtMS0w_1fe623d7-59a8-4413-98eb-5206672ae841"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC01LTEtMS0w_0fb10abb-413e-42e0-8edc-07d1ed0c05d6"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f2183ebcadc4450b714435b21b5ba17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOC03LTEtMS0w_4c2b631b-5656-4187-b1d6-56b088e308bc"
      unitRef="usd">35286000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS0xLTEtMS0w_4d02fad1-6cfe-4c12-bb76-d65b6ec5b66f"
      unitRef="usd">17587000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS0zLTEtMS0w_584b43fe-449d-4488-9f8c-74e118d48d96"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS01LTEtMS0w_022caca0-d26f-4ef4-aba6-51df4f844ab3"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2021a05d78884df3b63427ad0ed8fbef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfOS03LTEtMS0w_e60d69a8-c5a8-454e-9e65-828a5962a7f6"
      unitRef="usd">17591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i985faa780d224792b8352dc1688c2523_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtMS0xLTEtMA_6f70e7f0-5e39-4f3b-b047-8f949b9a3cc3"
      unitRef="usd">99913000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i985faa780d224792b8352dc1688c2523_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtMy0xLTEtMA_cde877e4-f9b6-483f-86fc-d664c320c7f2"
      unitRef="usd">239000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i985faa780d224792b8352dc1688c2523_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtNS0xLTEtMA_ad09b79a-4c5c-474f-be00-fa9f31b5475b"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i985faa780d224792b8352dc1688c2523_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTAtNy0xLTEtMA_7b62b2c3-7a8b-4d00-9862-d3eba26ae5d2"
      unitRef="usd">100052000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItMS0xLTEtNDE3_109db86b-1b93-4f5f-88c5-5055ea1e31ee"
      unitRef="usd">152796000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItMy0xLTEtNDE3_0796451a-bedd-4ecb-8558-b975dd4c54e4"
      unitRef="usd">256000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItNS0xLTEtNDE3_9dfb23bd-f02e-48a2-a2d6-e7e91eb27279"
      unitRef="usd">123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibae56b3854004a2ab8062e84d6051194_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTItNy0xLTEtNDE3_06d06a86-da5e-4dbb-b6c7-74cd6c5ef24b"
      unitRef="usd">152929000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtMS0xLTEtMA_6a8004c0-1695-4037-9f9c-22eaab98d014"
      unitRef="usd">636673000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtMy0xLTEtMA_b943977f-d267-4d92-bb40-1af35ee915d2"
      unitRef="usd">470000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtNS0xLTEtMA_291a685b-985b-4d5f-8f47-1dc4af32d0e7"
      unitRef="usd">268000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RhYmxlOmVmMmM2NzUxMDQ4ZTQ1NTA5MTZkNmRkYzg5NGMyMTg4L3RhYmxlcmFuZ2U6ZWYyYzY3NTEwNDhlNDU1MDkxNmQ2ZGRjODk0YzIxODhfMTEtNy0xLTEtMA_45f849c6-97fd-485f-bdf2-59ebf4584b5d"
      unitRef="usd">636875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTE4Ng_e06709df-16ca-4448-b3ef-e2f7dc694967"
      unitRef="security">92</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTE5Mw_e41d6ef1-aee0-455d-b3f5-596d8a27f82a"
      unitRef="security">113</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMzI5ODUzNDg4ODI4Mg_b552168f-7c27-4c0a-b93b-b12d1e0c823d"
      unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMzI5ODUzNDg4ODI4Mg_d4e53e83-e285-4730-97fa-af2d8e629ff4"
      unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTM4NA_a09b8dd2-61ea-4fa8-84ca-9ae8fceb8e8e"
      unitRef="usd">224000000.0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180My9mcmFnOjA4YTViMzk4NGIyYTQ0NTNhMjhhODdlNmFiZGYwNzM5L3RleHRyZWdpb246MDhhNWIzOTg0YjJhNDQ1M2EyOGE4N2U2YWJkZjA3MzlfMTM5MQ_6883d7a7-a3fc-4abc-8941-7e18ff697cf6"
      unitRef="usd">345700000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RleHRyZWdpb246NWExYTRhOTA3Zjk2NGI0M2JmNzUxNmJjYmEwMjA0YmVfMTM1_e76639e6-1f7b-4d15-ac01-daef09c87bcf">Inventory&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventory, which consists of commercial supply of TIBSOVO&#xae;, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.697%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RleHRyZWdpb246NWExYTRhOTA3Zjk2NGI0M2JmNzUxNmJjYmEwMjA0YmVfMTM2_d98e4fff-902e-47f5-95a8-3971cbf86e4e">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventory, which consists of commercial supply of TIBSOVO&#xae;, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.697%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMS0xLTEtMS0w_89b6024f-d045-4d4a-b700-f4e96a4ef140"
      unitRef="usd">180000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMS0zLTEtMS0w_bceedcf9-98d6-49af-880e-1d24ba10d242"
      unitRef="usd">180000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMi0xLTEtMS0w_c20a9073-8bc1-43cf-93fc-be025b785744"
      unitRef="usd">8589000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMi0zLTEtMS0w_bdb58a9d-2ac8-4aec-8e9b-d77f9e5fa87e"
      unitRef="usd">6808000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMy0xLTEtMS0w_c030c654-3854-4264-b18e-64ec159cb77f"
      unitRef="usd">1009000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfMy0zLTEtMS0w_148da32f-67ea-45ce-8ccc-dea4ebec4e6b"
      unitRef="usd">343000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfNC0xLTEtMS0w_35c80f33-d9e3-4448-b5e6-11f7e95a82de"
      unitRef="usd">9778000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180Ni9mcmFnOjVhMWE0YTkwN2Y5NjRiNDNiZjc1MTZiY2JhMDIwNGJlL3RhYmxlOmRmN2EwM2E4NTUzYTRiY2NhYTllMDlhNGRiY2ZjZjczL3RhYmxlcmFuZ2U6ZGY3YTAzYTg1NTNhNGJjY2FhOWUwOWE0ZGJjZmNmNzNfNC0zLTEtMS0w_649ba84f-d722-44c9-80d2-93141b09f69f"
      unitRef="usd">7331000</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjY2Mw_670c670c-e193-4dfd-8d25-1c0ed7339c41">Leases&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of eight years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal option is not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. Operating lease costs for the three months ended March 31, 2020 and 2019 were $3.8 million and $3.1&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2020 and 2019 were $3.9 million and $3.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have not entered into any material short-term leases or financing leases as of March&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.317%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.683%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;In arriving at the operating lease liabilities as of March&#160;31, 2020 and December&#160;31, 2019, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 7.9 years and 8.2 years, respectively.</us-gaap:LesseeOperatingLeasesTextBlock>
    <agio:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMTM4Mw_369127c7-2623-40f5-b9ad-1e54e69941f6">P8Y</agio:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMTczMw_25fe6934-75ba-462e-b2da-38b5f96e301a"
      unitRef="usd">3800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfNDM5ODA0NjUxNTQyNA_6f1f679c-5e46-429a-ad65-0fc08127b434"
      unitRef="usd">3100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMTg1OQ_e49a7743-bd28-4166-bff9-7a887c605e0f"
      unitRef="usd">3900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfNDM5ODA0NjUxNTQzOA_5202a1aa-bd3d-4202-a3af-1a492a731bfd"
      unitRef="usd">3100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMzI5ODUzNDg4NzU3NA_5533b289-5d58-4a8b-9ff3-4bd5fc5e7e98">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.317%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.683%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMC0xLTEtMS0w_dd92a5a5-d502-4b17-be06-10d5cd17851b"
      unitRef="usd">9395000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMS0xLTEtMS0w_fbe1ac83-73e8-4f23-99ab-e130a3a3c587"
      unitRef="usd">14380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMi0xLTEtMS0w_2deee499-4dc5-458d-b972-5ef2e3d10be9"
      unitRef="usd">16773000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMy0xLTEtMS0w_2ad14f7e-51f1-4bd3-bd97-569ff2d3c4e9"
      unitRef="usd">18126000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNC0xLTEtMS0w_ebbf73a4-3f1a-4811-bc4a-36c5d13eb27b"
      unitRef="usd">18660000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <agio:LesseeOperatingLeaseLiabilityPaymentsDueYearSix
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNS0xLTEtMS0w_9a08440b-35c2-4385-8842-56bcf6b2aef2"
      unitRef="usd">19507000</agio:LesseeOperatingLeaseLiabilityPaymentsDueYearSix>
    <agio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNi0xLTEtMS0w_6dca8f61-ca28-4b98-ab9e-4aab1f674411"
      unitRef="usd">44385000</agio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfNy0xLTEtMS0w_cb74dadf-6313-4af9-98ab-6cc4c3aace3a"
      unitRef="usd">141226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfOS0xLTEtMS00NDc_0b8bcbcd-e14f-4663-bbf5-547770c2e7b2"
      unitRef="usd">30750000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RhYmxlOmY4NjM4OWJlNzhkNzQ4NzFhODVhMWZhMzZiOWUzZTdjL3RhYmxlcmFuZ2U6Zjg2Mzg5YmU3OGQ3NDg3MWE4NWExZmEzNmI5ZTNlN2NfMTAtMS0xLTEtNDQ3_f4368644-7073-4caf-be1f-bbdf78c61f8c"
      unitRef="usd">110476000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjI1NQ_1e2f251c-e01f-4738-9704-de93eb573b82"
      unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjI1NQ_b1e6f403-7f09-4087-9f91-9b01fa282ba3"
      unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfMjMwNg_522ea7e9-0b2e-44cc-9350-cedff6d96fe9">P7Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN180OS9mcmFnOjkwNGI4ZTUwMjAyZTQwMjg5MjU2M2Q2M2FiOGM3NThmL3RleHRyZWdpb246OTA0YjhlNTAyMDJlNDAyODkyNTYzZDYzYWI4Yzc1OGZfNDM5ODA0NjUxNTQ4Mw_7c0d631b-6736-459d-bbbe-fe234727a674">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RleHRyZWdpb246NmRjMGIyNzAxMGFhNDkxZWE5MmUyYWM0YTY3ZDY5YTdfODQ_a6f5a987-5b9f-4b7e-a520-fe58acc4e38f">Accrued Expenses&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RleHRyZWdpb246NmRjMGIyNzAxMGFhNDkxZWE5MmUyYWM0YTY3ZDY5YTdfODc_88ea273e-b4fe-419b-84e0-8cf6a833a358">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMS0xLTEtMS0w_73a38568-f7e6-4f36-a5ab-98bac53cf466"
      unitRef="usd">7006000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMS0zLTEtMS0w_582c58d1-f882-4194-8772-df33426d16e5"
      unitRef="usd">18982000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMi0xLTEtMS0w_1e0805d6-3344-4591-9810-641b767c38d1"
      unitRef="usd">18661000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMi0zLTEtMS0w_6cbb47ea-1988-4700-bd6f-10dbac8d4f33"
      unitRef="usd">21777000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMy0xLTEtMS0w_86732bbb-47ed-4d51-a469-9b3e244786be"
      unitRef="usd">9238000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfMy0zLTEtMS0w_009a1986-d0cb-4a4c-be78-2c39c8ac2b14"
      unitRef="usd">8335000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNC0xLTEtMS0w_8fa3cde2-f598-43f8-b131-5fd04901e5bf"
      unitRef="usd">4726000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNC0zLTEtMS0w_f7519c1e-5905-4290-9df9-3b01dded9172"
      unitRef="usd">4048000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNS0xLTEtMS0w_9301c1a6-1505-4f19-97b6-1c5f3897737d"
      unitRef="usd">39631000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181Mi9mcmFnOjZkYzBiMjcwMTBhYTQ5MWVhOTJlMmFjNGE2N2Q2OWE3L3RhYmxlOjJjOTY3ZDE0NjA1ODRhN2RhODQ1MzUxZThkYzgwNjEyL3RhYmxlcmFuZ2U6MmM5NjdkMTQ2MDU4NGE3ZGE4NDUzNTFlOGRjODA2MTJfNS0zLTEtMS0w_40781783-d5d8-4e30-aaad-8ad8c68dccb3"
      unitRef="usd">53142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3MA_7d8da548-e5bf-45b3-bb32-a38f97efea52">Product Revenue&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We sell TIBSOVO&#xae;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers in the U.S., or collectively, the Customers. The Customers subsequently resell TIBSOVO&#xae; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The performance obligation related to the sale of TIBSOVO&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contractual Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Government rebates consist of Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.976%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents changes in our contract assets during the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contract assets&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales and.deductions to contract assets primarily relate to collection of receivables during the reporting period.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzI5ODUzNDg5MjA4NQ_e8add603-cd1c-43ce-86f7-1fb61f267d5e">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We sell TIBSOVO&#xae;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers in the U.S., or collectively, the Customers. The Customers subsequently resell TIBSOVO&#xae; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The performance obligation related to the sale of TIBSOVO&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contractual Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Government rebates consist of Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzI5ODUzNDg5MjMxOQ_a9d6266b-2c96-4a37-b4e3-6ce1544cb19d">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35fda49bee8b485999b812e174739a48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQ0NmIxOWU3N2Y2MDQwYTA5OWM2NzA0MTdiZGYwN2VlL3RhYmxlcmFuZ2U6NDQ2YjE5ZTc3ZjYwNDBhMDk5YzY3MDQxN2JkZjA3ZWVfMi0xLTEtMS01NjQ_e76ea54d-49c3-4221-8fd1-2116f8e5df71"
      unitRef="usd">22674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68cad50d747b48a7b8ceb77216e8aa02_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQ0NmIxOWU3N2Y2MDQwYTA5OWM2NzA0MTdiZGYwN2VlL3RhYmxlcmFuZ2U6NDQ2YjE5ZTc3ZjYwNDBhMDk5YzY3MDQxN2JkZjA3ZWVfMi0zLTEtMS01NjQ_771cb60d-38b7-48a7-9e8f-a5a074c1a4cf"
      unitRef="usd">9138000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3Nw_5655f450-d35e-4fd3-9ebd-faca6f6daf51">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <agio:ContractWithCustomerContractualAdjustmentReserve
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS0xLTEtMS0w_565d5b5d-5c78-4995-9b39-701e0b345805"
      unitRef="usd">874000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS0zLTEtMS0w_0e99affc-23e2-4945-afad-fb65b4e4c50b"
      unitRef="usd">1124000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS01LTEtMS0w_da73ec52-3292-4c3d-b38b-1a485ba25cc7"
      unitRef="usd">1798000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMS03LTEtMS0w_8b7858f6-3617-43c0-bb29-520bfa16f0d1"
      unitRef="usd">3796000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:CurrentYearProvisionForContractualAdjustments
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi0xLTEtMS0w_606d5d47-5066-4ff4-b295-bddcc5bcc373"
      unitRef="usd">3000000</agio:CurrentYearProvisionForContractualAdjustments>
    <agio:CurrentYearProvisionsForRebateReserve
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi0zLTEtMS0w_a78d4192-915e-4317-80a1-01badaf3615b"
      unitRef="usd">1338000</agio:CurrentYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInCurrentYear
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi01LTEtMS0w_1998cbf2-3763-46b9-9c0e-43b8de547df4"
      unitRef="usd">537000</agio:ProvisionForRightToRecoverProductInCurrentYear>
    <agio:ContractWithCustomerCurrentYearReserveProvisions
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMi03LTEtMS0w_4c27d376-dad0-4012-84a8-c52b5727ea7c"
      unitRef="usd">4875000</agio:ContractWithCustomerCurrentYearReserveProvisions>
    <agio:PriorYearProvisionForContractualAdjustments
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy0xLTEtMS0w_33ddf8be-235a-4db4-bc85-620b734c192b"
      unitRef="usd">-3000</agio:PriorYearProvisionForContractualAdjustments>
    <agio:PriorYearProvisionsForRebateReserve
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy0zLTEtMS0w_ffe99a33-4aac-4b60-8ee6-a34694bfcc1b"
      unitRef="usd">76000</agio:PriorYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInPriorYears
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy01LTEtMS0w_f485006f-4aef-4218-a66e-d76a87e905cb"
      unitRef="usd">0</agio:ProvisionForRightToRecoverProductInPriorYears>
    <agio:ContractWithCustomerPriorYearsReserveProvisions
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfMy03LTEtMS0w_6fc820f3-f32f-4de2-9558-988f59318812"
      unitRef="usd">73000</agio:ContractWithCustomerPriorYearsReserveProvisions>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC0xLTEtMS0w_e20428c2-4687-4de7-ac95-13e925e2c182"
      unitRef="usd">2072000</agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC0zLTEtMS0w_2ebb7da3-f3ee-4120-86d9-7fdb5c6553d5"
      unitRef="usd">0</agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear>
    <agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC01LTEtMS0w_d31cc8cb-bbaf-4699-aea1-449279b32455"
      unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries>
    <agio:ContractWithCustomerCurrentYearReserveRecoveries
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNC03LTEtMS0w_afb44d16-ac55-42b7-95b2-2954bc940cfa"
      unitRef="usd">2072000</agio:ContractWithCustomerCurrentYearReserveRecoveries>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS0xLTEtMS0w_38f68be0-cfe6-4905-92ff-2a55d39e1680"
      unitRef="usd">653000</agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS0zLTEtMS0w_65e99be4-4c9a-4bfa-9a25-e19aac737c0d"
      unitRef="usd">677000</agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears>
    <agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS01LTEtMS0w_eb03fa4f-92e1-4385-a20c-6bd88e487119"
      unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries>
    <agio:ContractWithCustomerPriorYearsReserveRecoveries
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNS03LTEtMS0w_5b1b6990-fd2d-42a2-80e8-0cd6997f42d2"
      unitRef="usd">1330000</agio:ContractWithCustomerPriorYearsReserveRecoveries>
    <agio:ContractWithCustomerContractualAdjustmentReserve
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi0xLTEtMS0w_b7a87a68-a06e-4f67-b9c3-e28d891ab574"
      unitRef="usd">1146000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi0zLTEtMS0w_439ff12b-6835-4082-85a5-f9cc82490935"
      unitRef="usd">1861000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi01LTEtMS0w_13087572-3810-4f0e-897f-c4a59ba4dc25"
      unitRef="usd">2335000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjliY2M5NmJkMTY4NTRkZDU4YzA0M2E5NDM1MGZhODNjL3RhYmxlcmFuZ2U6OWJjYzk2YmQxNjg1NGRkNThjMDQzYTk0MzUwZmE4M2NfNi03LTEtMS0w_53bd9da9-2264-4f7b-87b3-b285718f822c"
      unitRef="usd">5342000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3Mg_f9c36564-88b3-4cd9-ad94-eb404eb2fb6d">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.976%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMS0xLTEtMS0w_aa5b4d82-14e0-4396-b5f5-6558756c84dd"
      unitRef="usd">707000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMS0zLTEtMS0w_23323756-fb6d-4628-ae3f-ea4ad7adbeb7"
      unitRef="usd">540000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <agio:ContractWithCustomerAllowanceAndReservesLiability
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMi0xLTEtMS0w_45ae59de-3ac2-4fd1-84da-d141799dedfd"
      unitRef="usd">4635000</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerAllowanceAndReservesLiability
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMi0zLTEtMS0w_c3c460a2-bc82-4f00-b6ed-6c7f65544cdb"
      unitRef="usd">3256000</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMy0xLTEtMS0w_ef3ef620-abe5-464d-af57-8863dbceb0dc"
      unitRef="usd">5342000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjQzZDQ4MDQ0ZDMxNTQ5MzI4NGIxZWZhNTYzZDI3OTA3L3RhYmxlcmFuZ2U6NDNkNDgwNDRkMzE1NDkzMjg0YjFlZmE1NjNkMjc5MDdfMy0zLTEtMS0w_46f6c9bb-97d0-4f9a-b842-c7b1ce7641e9"
      unitRef="usd">3796000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RleHRyZWdpb246ZTc5MjhkOTljZjVhNGQ1YmFjZGZmM2QwZTIxNDI0MGNfMzk3Mw_deb6e75a-f775-4504-a748-8c5098255b68">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents changes in our contract assets during the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contract assets&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales and.deductions to contract assets primarily relate to collection of receivables during the reporting period.</agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi0xLTEtMS0w_ca25bb8a-20cb-4996-9927-65750f62a0f5"
      unitRef="usd">8952000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractwithCustomerAssetRevenueRecognized
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi0zLTEtMS0w_af1bb924-eccc-4f65-bd8f-397e68240f35"
      unitRef="usd">27624000</agio:ContractwithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi01LTEtMS0w_a03936de-dfce-4dfc-8a10-45d05bf9c7b2"
      unitRef="usd">24763000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181NS9mcmFnOmU3OTI4ZDk5Y2Y1YTRkNWJhY2RmZjNkMGUyMTQyNDBjL3RhYmxlOjY1MjYwNDQyMzk1MjRjMDU4MmRhZWU0YzQzMjIzZjJkL3RhYmxlcmFuZ2U6NjUyNjA0NDIzOTUyNGMwNTgyZGFlZTRjNDMyMjNmMmRfMi03LTEtMS0w_3845b5a1-6512-4ed4-bd62-cc8b6792169b"
      unitRef="usd">11813000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxOTA_95948be6-48e3-4810-a1fe-3ae170fc99d2">Collaboration and License Agreements &lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Accounting analysis and revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our collaboration and license agreements typically involve us granting licenses of our intellectual property and performing research and development services in exchange of upfront fees, milestone payments and royalty payments. Since December 31, 2019, there have been no material changes to the key terms of our collaboration or license agreements. For further information on the terms and conditions of our existing collaboration and license agreements, please see the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the appropriate amount of revenue to be recognized, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For arrangements that include sales-based royalties and sales-based milestones and in which the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Milestone revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At each reporting period we evaluate whether milestones are considered probable of being reached and, to the extent that a significant reversal would not occur in future periods, estimate the amount to be included in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are considered constrained and are excluded from the transaction price until those approvals are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Celgene Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have entered into the following collaboration agreements, or collectively, the Collaboration Agreements, with Celgene, a wholly-owned subsidiary of Bristol-Myers Squibb Company, or BMS, which is a related party through ownership of our common stock: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;In April 2010, we entered into a discovery and development collaboration and license agreement focused on cancer metabolism, or the 2010 Agreement, which was amended in October 2011 and July 2014. The discovery phase of the 2010 Agreement expired in April 2016. On August 15, 2016, we terminated the 2010 Agreement as to the program directed to the isocitrate dehydrogenase 1, or IDH1, target, for which ivosidenib was the lead development candidate. Accordingly, the sole program remaining under the 2010 Agreement is IDHIFA&#xae; (enasidenib), a co-commercialized licensed program for which Celgene leads and funds global development and commercialization activities. Under the remaining terms of the 2010 Agreement, we are eligible to receive up to $80.0&#160;million in potential milestone payments for the enasidenib program. The potential milestone payments are comprised of: (i) up to $55.0 million in milestone payments upon achievement of specified ex-U.S. regulatory milestone events, and (ii) a $25.0 million milestone payment upon achievement of a specified ex-U.S. commercial milestone event, as well as royalties at tiered, low-double digit to mid-teen percentage rates on net sales of IDHIFA&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;In April&#160;2015, we entered into a joint worldwide development and profit share collaboration and license agreement with Celgene, and our wholly owned subsidiary, Agios International Sarl, entered into a collaboration and license agreement with Celgene International II Sarl, or collectively, the AG-881 Agreements, to establish a worldwide collaboration focused on the development and commercialization of vorasidenib products. Under the AG-881 Agreements, we and Celgene split all worldwide development costs for vorasidenib, subject to specified exceptions. The AG-881 Agreements were terminated effective September 4, 2018, upon which we received sole global rights to vorasidenib. In connection with the termination of the AG-881 Agreements, Celgene will be eligible to receive royalties from us at a low single-digit percentage rate on worldwide net sales of products containing vorasidenib.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;"&gt;In May&#160;2016, we entered into a master research and collaboration agreement with Celgene, or the 2016 Agreement, focused on metabolic immuno-oncology, or MIO. The initial &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzI5ODUzNDkxMzg3MA_e91388f5-9090-44e2-9f63-c9d6bd473913"&gt;four&lt;/span&gt;-year research term of the 2016 Agreement ends May 2020. On March 25, 2020 Celgene declined the option to extend the research agreement for up to two, or in specified cases, up to four additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQ4NQ_1f9fa6ea-bf2b-47b0-80ab-ef3b836dafa9"&gt;one&lt;/span&gt;-year terms which would have required the payment of a $40.0&#160;million extension fee. Further, on April 10, 2020 Celgene notified us that they will be declining to elect any program as a continuation program under the 2016 agreement. Celgene had designated AG-270, our inhibitor of  methionine adenosyltransferase 2a,  or MAT2A, as a development candidate under the 2016 Agreement. On March 25, 2020, Celgene notified us of their decision to decline their option to enter into a Development &amp;amp; Commercialization Agreement with respect to the MAT2A program under the 2016 Agreement which would have required the payment of a $30.0&#160;million fee. As a result of the decisions, the research services will be fully satisfied as of May 17, 2020, no additional performance obligations remain under the 2016 Agreement and we are no longer eligible for any milestone payments for the 2016 agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;On-going research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were not considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercialization activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total collaboration revenue - related party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents changes in our contract assets and liabilities during the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.724%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Collaboration receivable &#x2013; related party &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Royalty receivable &#x2013; related party &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue &#x2013; related party, current and net of current portions &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(57,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period and unbilled amounts related to future reimbursable costs. Deductions to receivables relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(3)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The increase in collaboration revenue from on-going research and development services during the three months ended March 31, 2020 is primarily due to the fact that subsequent to Celgene&#x2019;s decision to decline extending the research term, the Company updated its estimate of the future costs that will be incurred to complete one of its performance obligations under the 2016 collaboration Agreement that is recognized overtime using an input method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.561%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.429%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $10.5 million. This amount is expected to be recognized as performance obligations are satisfied through September 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As the underlying performance obligation, or delivery of the enasidenib license, had been satisfied as of June 2014, royalty revenue is recognized as the related sales occur. During the three months ended March 31, 2020 and 2019, we recognized the following as royalty revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalty revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Milestone revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;No milestones were achieved during the three months ended March 31, 2020 or 2019. The next potential milestone expected to be achieved under our Collaboration Agreements is the first regulatory approval of enasidenib in any of China, Japan or a major European country, which would result in a milestone payment of $35.0 million under the 2010 Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;CStone Pharmaceuticals &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, we and CStone Pharmaceuticals, or CStone, entered into an exclusive license agreement, or the CStone Agreement, to grant CStone specified intellectual property licenses to enable CStone to develop and commercialize certain products containing ivosidenib in mainland China, Hong Kong, Macau and Taiwan, or the CStone Territory. We retain development and commercialization rights for the rest of the world. On March 2, 2020, we amended the CStone Agreement to include Singapore as part of the CStone Territory. Pursuant to the CStone Agreement, CStone will initially be responsible for the development and commercialization of ivosidenib in acute myeloid leukemia, or AML, cholangiocarcinoma, and, at our discretion, brain cancer indications. CStone is responsible for all costs it incurs in developing, obtaining regulatory approval of, and commercializing ivosidenib in the CStone Territory, as well as certain costs incurred by us. Pursuant to the CStone Agreement, we received an initial upfront payment in the amount of $12.0 million and are entitled to receive up to an additional $407.0 million in milestone payments upon the achievement of certain development, regulatory and sales milestone events. We &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;will also be entitled to receive tiered royalties, ranging from 15% to 19% percent, on annual net sales, if any, of ivosidenib in the CStone Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue -other:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.976%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;License and other services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were not considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total collaboration revenue - other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents changes in our contract assets during the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.724%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract assets (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Collaboration receivable - other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(888)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)     Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $0.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The license was determined to be the predominant item to which sales-based royalties and sales-based milestones relate. As the license was delivered in June 2018, we will recognize royalty revenue when the related sales occur. To date, no royalties have been received under the CStone Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Milestone revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;No milestones were earned during the three months ended March 31, 2020 and 2019. The next potential milestone expected to be achieved under the CStone Agreement is the dosing of the first patient in a local study in a solid tumor indication in mainland China. Achievement of this event will result in a milestone payment of $5.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <agio:RevenueRecognitionMilestoneMethodEligibleReceivable
      contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzM3Mg_2093716c-c878-4bd0-a361-b1004acab565"
      unitRef="usd">80000000.0</agio:RevenueRecognitionMilestoneMethodEligibleReceivable>
    <agio:PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram
      contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzQ5Ng_b9ba858f-1ea5-4d89-a898-6468123b4c5a"
      unitRef="usd">55000000.0</agio:PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram>
    <agio:PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram
      contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMzU5OQ_59d3a993-6dd5-4ad9-9b2e-eb98ca155b34"
      unitRef="usd">25000000.0</agio:PortionOfPotentialMilestonePaymentReceivableForSpecifiedCommercialMilestoneEventProgram>
    <agio:RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions
      contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQzOA_b6a7d8c7-adb6-47f1-b5a5-906e2d0d8223"
      unitRef="extension">2</agio:RevenueRecognitionMultipledeliverableArrangementsNumberOfExtensions>
    <agio:RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions
      contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDQ3MQ_f494155b-f722-4f4f-90ae-efbe6c1485f6"
      unitRef="extension">4</agio:RevenueRecognitionMultipledeliverableArrangementsNumberOfSpecialCaseExtensions>
    <agio:UpfrontPaymentAgreementExtensionFeeReceivable
      contextRef="ic29657cd87054e66a92e25fb2303af80_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NDcwNw_ad68be27-2c7b-4e5a-a911-9204b4eaad1e"
      unitRef="usd">40000000.0</agio:UpfrontPaymentAgreementExtensionFeeReceivable>
    <agio:OptionExerciseFeeReceivable
      contextRef="icf8e4931186847f7af3d6555eddb2ef4_I20160517"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMjE5OTAyMzI4NTAxNA_3b044564-15a6-43cb-96ea-8b20a2e9a393"
      unitRef="usd">30000000.0</agio:OptionExerciseFeeReceivable>
    <agio:RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODQ_1dc97677-7d4a-49db-ba63-9688f35f22c3">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;On-going research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were not considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercialization activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total collaboration revenue - related party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:RevenueRecognitionMultipledeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d39d16372b54ef7b70c6ceb2f6802c9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfMy0xLTEtMS0w_430cfc76-8f1d-473d-93b9-9c28021e2f25"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8cc725b4829480fa6c29d3f371c5ae3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfMy0zLTEtMS0w_32a5a377-fe8b-4351-97c5-ff6d792e525a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d50ef5ca59c4f6d94a83843d5742328_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfNC0xLTEtMS0w_68bfc607-426c-43a7-a2c0-abff45e3b93b"
      unitRef="usd">59220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91175df5ecdd49638bd57d0783c41bdc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfNC0zLTEtMS0w_0470c8c5-7ac5-4e9d-bc18-bc70b80ad1f8"
      unitRef="usd">17065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i108d62e896fc49d1b83a96231e5bc13e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOC0xLTEtMS0w_4966991f-dc09-43fb-a90d-6c374cfb8718"
      unitRef="usd">877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3447e34e86e4a2ea996f1ad6af3f411_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOC0zLTEtMS0w_fbdcad45-a7d9-40c7-836c-19ebcc9b8258"
      unitRef="usd">854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e999092fe5a47b995df7486ab8722ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOS0xLTEtMS0w_344adac4-2ca3-49c8-bab9-c382888bbd39"
      unitRef="usd">60097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02db62d3a5c6475eb891c555c988387c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmU3ZmNlYjZjNWU1NzRkNzNiNTJiYTdlMzQ4OWM2OWE2L3RhYmxlcmFuZ2U6ZTdmY2ViNmM1ZTU3NGQ3M2I1MmJhN2UzNDg5YzY5YTZfOS0zLTEtMS0w_24db0331-e78d-493b-ac51-0bbd6ebaf847"
      unitRef="usd">17919000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODI_6a71e26a-87dc-4161-8bf3-5c265e809a84">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents changes in our contract assets and liabilities during the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.724%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Collaboration receivable &#x2013; related party &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Royalty receivable &#x2013; related party &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue &#x2013; related party, current and net of current portions &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(57,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period and unbilled amounts related to future reimbursable costs. Deductions to receivables relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(3)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The increase in collaboration revenue from on-going research and development services during the three months ended March 31, 2020 is primarily due to the fact that subsequent to Celgene&#x2019;s decision to decline extending the research term, the Company updated its estimate of the future costs that will be incurred to complete one of its performance obligations under the 2016 collaboration Agreement that is recognized overtime using an input method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.561%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.429%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="icc256153a0dc460d8411bbd9eb5fbb40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi0xLTEtMS0w_be30e61d-2bfc-436f-a52e-f3da530c9b68"
      unitRef="usd">1539000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractwithCustomerAssetRevenueRecognized
      contextRef="iaa2a9618801f42c48cc8313f6b4cd731_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi0zLTEtMS0w_926ce05e-e27a-4e68-8571-bf4accc7e1da"
      unitRef="usd">3332000</agio:ContractwithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="iaa2a9618801f42c48cc8313f6b4cd731_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi01LTEtMS0w_9a0b2d50-325a-442e-9d77-8d53c8d7336b"
      unitRef="usd">2294000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i53c90550dda24d7eb8b02c2f2c2f719e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMi03LTEtMS0w_0a55254e-d1e4-40cc-a71a-137a148767e0"
      unitRef="usd">2577000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i6d243dbfb39c481597c75558a4b5ffa9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy0xLTEtMS0w_56e41d67-4c13-4634-9035-0cd32c2e3858"
      unitRef="usd">2900000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractwithCustomerAssetRevenueRecognized
      contextRef="i2d106c4df9564a3caf0ba3be633967df_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy0zLTEtMS0w_4a5b678e-bdd7-4e40-b00a-8433bedb29a7"
      unitRef="usd">3334000</agio:ContractwithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="i2d106c4df9564a3caf0ba3be633967df_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy01LTEtMS0w_72b81c0d-762e-447e-9397-d2acdaaef4f9"
      unitRef="usd">2934000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i811057ddd1de4d0eb6492cfeadecbf6a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfMy03LTEtMS0w_e9c82770-ccbc-41f9-929d-7f8136d6e480"
      unitRef="usd">3300000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i096066d9ee4641e1b8faebda2ab34627_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS0xLTEtMS0w_7afd03c4-52a3-4309-9cdb-c82274a9bce3"
      unitRef="usd">61513000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if84fd2a101824c788fae2a197d74ffa9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS0zLTEtMS0w_fd1e0039-de9c-40ab-aa13-30db9f8dc6cd"
      unitRef="usd">579000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="if84fd2a101824c788fae2a197d74ffa9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS01LTEtMS0w_b874c8f8-ce30-4a17-8ef6-39b611e02e0b"
      unitRef="usd">57344000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id04eae8cb5824809b789766bea430fe0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjA4MjdmNjA0Y2VkYjQ1MGZiMDJhMTEwNGYzYTA1M2NlL3RhYmxlcmFuZ2U6MDgyN2Y2MDRjZWRiNDUwZmIwMmExMTA0ZjNhMDUzY2VfNS03LTEtMS0w_d2878363-dee8-4f3c-837e-5d8f2d5bc0ec"
      unitRef="usd">4748000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMi0xLTEtMS0w_56f36364-a7a6-4bca-b9de-21f90732e639"
      unitRef="usd">59248000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMi0zLTEtMS0w_882caabc-6c46-4dc6-bcfb-cc3925e99e0b"
      unitRef="usd">16410000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMy0xLTEtMS0w_8974963d-4519-4dd0-b23f-6c667df07b23"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmFhMzk4MmZhNzBjOTQ2ZDVhYzYxNDAwNGY0ZDhhNWNjL3RhYmxlcmFuZ2U6YWEzOTgyZmE3MGM5NDZkNWFjNjE0MDA0ZjRkOGE1Y2NfMy0zLTEtMS0w_6bd12df7-dca5-4aca-94ab-a0c14bf4147d"
      unitRef="usd">21000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNjY5OQ_fb721016-b7e2-4323-b625-77e3bcd5253f"
      unitRef="usd">10500000</us-gaap:RevenueRemainingPerformanceObligation>
    <agio:RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODc_9fd4559c-e1c4-4371-a36c-90b5735fd479">During the three months ended March 31, 2020 and 2019, we recognized the following as royalty revenue:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalty revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</agio:RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic82eaa651b994a398eb65997f0b11e71_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmQxZmIzNzJhMGY3ZTRlNGZhYjY1ODU5NTJhZDdkMWNmL3RhYmxlcmFuZ2U6ZDFmYjM3MmEwZjdlNGU0ZmFiNjU4NTk1MmFkN2QxY2ZfMi0xLTEtMS0w_1763d017-c0f7-467c-9341-c4014160072a"
      unitRef="usd">3334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if879b8d640fd4528a046bfb43e105676_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOmQxZmIzNzJhMGY3ZTRlNGZhYjY1ODU5NTJhZDdkMWNmL3RhYmxlcmFuZ2U6ZDFmYjM3MmEwZjdlNGU0ZmFiNjU4NTk1MmFkN2QxY2ZfMi0zLTEtMS0w_8ad11453-c7ec-4567-b356-7ca760f9b2fb"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_455247b0-9c63-4498-a4ed-ca455c5a0bab"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_89f9cea3-12ef-4965-802d-c83ed7c135a7"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_c8c8fa33-4b2f-4f5a-bdea-27e38d3da9c5"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzQ5Mw_fb7726c3-6d23-4808-95dc-960aa612fe79"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication
      contextRef="ie585f0844fac40089fdc45382188ce5a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfNzc2Ng_9c7566ff-4657-4e2a-8175-2fae29a63e34"
      unitRef="usd">35000000.0</agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication>
    <agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts
      contextRef="if6726df3a7204f6b9e2e0d1efc7914f1_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODcyNQ_14b8807f-8318-40f5-b855-a8dbca76f7ce"
      unitRef="usd">12000000.0</agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts>
    <agio:ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable
      contextRef="i3da6969fb0f94cae987375f25efa45d4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODc3Ng_b5077ee2-5085-402f-90f2-ba1853c9eb55"
      unitRef="usd">407000000.0</agio:ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable>
    <agio:RoyaltyPercentageRemitted
      contextRef="i9b95111b950c47f2a99d64f7549560da_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODk1Mg_3d2d898f-4a6d-46dd-a310-162fe157d87a"
      unitRef="number">0.15</agio:RoyaltyPercentageRemitted>
    <agio:RoyaltyPercentageRemitted
      contextRef="if9319d12250d4cd4816f3f7f9a1a58ec_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfODk1OA_88f755eb-98b5-4ef6-a872-18a52d4f73aa"
      unitRef="number">0.19</agio:RoyaltyPercentageRemitted>
    <agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxODE_bd9a983e-e95d-4ea9-87ee-4b084ddea319">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020 and 2019, we recognized the following collaboration revenue -other:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.976%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.721%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;License and other services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Services performed that were not considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total collaboration revenue - other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54283dcee9d43cf9fb07a1481b6d9dc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfMy0xLTEtMS0w_eba2a649-6e20-4694-8c62-9c0d7589fd7f"
      unitRef="usd">192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieda041072edb42d2a45ab6f7a35301cf_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfMy0zLTEtMS0w_a9ccbb9d-7478-49b6-95d1-879bd042253f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c9f069f49404c26883dc94c9bf8bf4b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNS0xLTEtMS0w_1d172814-670c-450f-b005-163110c92655"
      unitRef="usd">801000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id57699cbaff4472d9cf3ea62c0cbb2fb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNS0zLTEtMS0w_4fccab86-0c9e-4f42-87e3-7e353bbc1b79"
      unitRef="usd">970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id861975ff87f4dbc8890a79d84ea157e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNy0xLTEtMS0w_d9518e77-d57f-4ee9-83a1-e214af3ec1bc"
      unitRef="usd">993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie310e674843d43f68873f2b9cc63f547_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjE2NzFmYTNmNzU4YTRmZDA4MzA0YWM2MDJkNjU4NTJiL3RhYmxlcmFuZ2U6MTY3MWZhM2Y3NThhNGZkMDgzMDRhYzYwMmQ2NTg1MmJfNy0zLTEtMS0w_21214cac-9bc6-40db-8701-bdf8918227ec"
      unitRef="usd">970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxOTI_c5135c1a-9eae-487e-96e1-bd43454c6013">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents changes in our contract assets during the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.724%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract assets (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Collaboration receivable - other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(888)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)     Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;</agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i57f90389d1054ec5a3f958cb88835d5a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi0xLTEtMS0w_f5abff5f-5a9e-478f-afc8-2d80c8b29a72"
      unitRef="usd">1928000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized
      contextRef="i280f176668304207a8331664a7bf1e74_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi0zLTEtMS0w_5d766226-c13b-45e9-a0c6-86a21ad98e3c"
      unitRef="usd">993000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="i280f176668304207a8331664a7bf1e74_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi01LTEtMS0w_6b0e7621-46aa-49b6-be38-c6a812a8f09f"
      unitRef="usd">888000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iae5252cae278436a972c726382d0b31e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RhYmxlOjdmOWU0MDc0MDkwODQyODhhODM5YzZiMDdkMDhiZmFjL3RhYmxlcmFuZ2U6N2Y5ZTQwNzQwOTA4NDI4OGE4MzljNmIwN2QwOGJmYWNfMi03LTEtMS0w_892bfb84-4a17-496f-9ee9-57060a06d167"
      unitRef="usd">2033000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i269bc734bdc446a984c9d2c5b91a592c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfOTU1Mg_de925a42-7883-4f6f-af92-3aaa23d90a1e"
      unitRef="usd">500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic38711366192418d8c09c3d6abfa8e66_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfOTgwOA_d4694334-56fc-4a33-b76c-1c8b91ac8722"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="i93e49459503f4101adaa3ac89788c0cc_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfOTg4Ng_6fd3563b-df93-4d48-b312-811a6843477e"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable
      contextRef="i269bc734bdc446a984c9d2c5b91a592c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN181OC9mcmFnOjVlZjQ2MjlkNTM3MjQ2MTU5ZDM0YTIzOGU1OWJhOGRmL3RleHRyZWdpb246NWVmNDYyOWQ1MzcyNDYxNTlkMzRhMjM4ZTU5YmE4ZGZfMTAxNzk_6569f526-2898-452a-bf96-5fe30d0626cd"
      unitRef="usd">5000000.0</agio:ResearchandDevelopmentArrangementContracttoPerformforOthersPotentialMilestonePayable>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5NA_4a5e11b2-cfbe-41b5-ab4e-35a91d17b67a">Share-Based Payments&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2013 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based stock units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of March&#160;31, 2020, the total number of shares reserved under the 2007 Plan and the 2013 Plan was 11,030,628, and we had 2,708,920 shares available for future issuance under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents stock option activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.061%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,201,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;792,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(133,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(110,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,749,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,874,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,749,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At March&#160;31, 2020, there was approximately $104.0 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents RSU activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;766,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;744,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(192,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,290,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, there was approximately $58.3 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Performance-based stock units &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents PSU activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.736%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.766%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.768%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#x2019;s best estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, there was approximately $0.5&#160;million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, which we expect to recognize over a weighted-average period of 0.1 years, and $11.3 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Market-based stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.838%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.787%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.385%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.790%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of March&#160;31, 2020, there was approximately $0.5 million of total unrecognized compensation expense related to MSUs, which we expect to recognize over the remaining derived service period of 0.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2013 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued 62,694 and 32,410 shares of common stock during the three months ended March 31, 2020 and 2019, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 836,363 shares of our common stock. As of March&#160;31, 2020, we had 528,952 shares of common stock available for future issuance under the 2013 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.707%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.283%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i39e8393880f542d281e86b6aff922c87_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfNzQ1_a2a23d35-18ca-408f-971c-d4271e3d5a94"
      unitRef="shares">11030628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ida454044d7e04cf78a0d3ed1df7dd45d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfNzYw_e56e3cee-0cf0-4d57-b79e-2de1b1664233"
      unitRef="shares">2708920</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5Nw_8a55dc06-9e02-4ec7-903e-cd63091f8ccb">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents stock option activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.061%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,201,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;792,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(133,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(110,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,749,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,874,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,749,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMS0xLTEtMS0w_84588446-d7c7-4be0-a74c-1f83e47f000d"
      unitRef="shares">6201485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2cf9de214c744ef3b0f288fbe6cce148_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMS0zLTEtMS0w_70aa8203-c851-4386-aa38-31f37e9333f8"
      unitRef="usdPerShare">58.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMi0xLTEtMS0w_d27fc860-5376-4769-9226-e8dbbbedd4ad"
      unitRef="shares">792048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMi0zLTEtMS0w_dec39b47-aab5-448c-a259-c5a25d8ef22c"
      unitRef="usdPerShare">51.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMy0xLTEtMS0w_910114c9-ab08-45f2-b944-e40801b0f562"
      unitRef="shares">133256</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfMy0zLTEtMS0w_b5e9dcd8-17ce-4767-82c7-0bab56b7289d"
      unitRef="usdPerShare">25.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNC0xLTEtMS0w_8d9e465d-20aa-41e7-8d02-a29cd1012d66"
      unitRef="shares">110904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNC0zLTEtMS0w_75ed00a7-b1d4-4840-b683-5e9d94c3e663"
      unitRef="usdPerShare">69.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNS0xLTEtMS0w_93215256-8435-4f30-b6d8-22d10192ee40"
      unitRef="shares">6749373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNS0zLTEtMS0w_5b1ef647-d9e3-41fa-be4e-9b3d31098619"
      unitRef="usdPerShare">58.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNi0xLTEtMS0w_8eab27e0-2bb8-4bd6-994b-d3b616056a52"
      unitRef="shares">3874135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNi0zLTEtMS0w_f0e37852-cf53-4daa-8581-b5577363991e"
      unitRef="usdPerShare">59.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNy0xLTEtMS0w_e0dd6936-fd96-401b-aac5-8144df57457c"
      unitRef="shares">6749373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ieb4111aca4884f158039e11aeb841e7d_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjU0MjI0OTcxNTVhYTQ0ZDU5YWFlZTQwMGJkNzI0NWMwL3RhYmxlcmFuZ2U6NTQyMjQ5NzE1NWFhNDRkNTlhYWVlNDAwYmQ3MjQ1YzBfNy0zLTEtMS0w_af9784e8-f364-43ba-a2da-dbd3dd570d61"
      unitRef="usdPerShare">58.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ida454044d7e04cf78a0d3ed1df7dd45d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfOTMx_c269ada4-c584-4179-9027-36e5736cde31"
      unitRef="usd">104000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i04dd698bbbf04386be79177cadfcb551_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTA5NQ_6fc929f4-af3a-458e-b9ff-83b2db3e3a03">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5OQ_265a33af-9d77-4ae6-889c-097bfcdc31f1">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents RSU activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;766,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;744,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(192,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,290,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia72433a7819146b3a0daa5c98f8ffa28_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMS0xLTEtMS0w_02eda3ab-c408-458e-ac63-5a12b46003fb"
      unitRef="shares">766953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia72433a7819146b3a0daa5c98f8ffa28_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMS0zLTEtMS0w_027429a7-0dd7-48ce-91fa-3f2a4e58f1f1"
      unitRef="usdPerShare">63.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMi0xLTEtMS0w_7e08e8f0-ce2a-4d39-b9fb-93d8216389f7"
      unitRef="shares">744447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMi0zLTEtMS0w_143ace7b-1ffe-4419-a344-2de86efb560b"
      unitRef="usdPerShare">51.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMy0xLTEtMS0w_7556ed26-0f60-4a60-812e-c2756f40b9a8"
      unitRef="shares">192870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfMy0zLTEtMS0w_97fb3c6d-d8ce-42ea-aa6a-8be68ce9d5c9"
      unitRef="usdPerShare">70.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNC0xLTEtMS0w_c65638a8-61c9-465a-ac81-2f5ee674ea93"
      unitRef="shares">27655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNC0zLTEtMS0w_46fdcb68-0c8d-451e-909d-f0aa9483cce9"
      unitRef="usdPerShare">66.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNS0xLTEtMS0w_e481cbd2-9f71-4b14-afaf-58962e3a1273"
      unitRef="shares">1290875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjRjOTM5N2JkOTllOTQyMzRiYjlhNzAwNzg1NGMwN2FlL3RhYmxlcmFuZ2U6NGM5Mzk3YmQ5OWU5NDIzNGJiOWE3MDA3ODU0YzA3YWVfNS0zLTEtMS0w_b7b06cc2-c3e2-4fab-9b33-e092fc4dae08"
      unitRef="usdPerShare">55.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ibe6c61fdedc249b5beea3a844fe1d6f1_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTIzOQ_989c83d2-1bc6-49a7-93d5-5ee1f6038308"
      unitRef="usd">58300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTM3OQ_3dc4418f-c0f5-4ae8-80fd-1842c8ccf7ac">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzUwMg_60fbae04-6b31-4816-bd00-5cab3943a3d2">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents PSU activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.736%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.766%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.768%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibc7485735e584ad183fa3ab8df167007_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMS0xLTEtMS0w_2e947c41-3ec4-42b0-9abc-890fb18795bc"
      unitRef="shares">218143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibc7485735e584ad183fa3ab8df167007_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMS0zLTEtMS0w_d3b49498-db8a-418a-a04a-6eab49af64c1"
      unitRef="usdPerShare">55.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMi0xLTEtMS0w_aa1e41b1-420b-4f63-9e17-787093792a91"
      unitRef="shares">20622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMi0zLTEtMS0w_07cd9dbf-4c46-48e6-a0cf-d896b739a89d"
      unitRef="usdPerShare">48.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMy0xLTEtMS0w_1f8bed30-6d72-4d91-88dd-e5a12c7e3a90"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfMy0zLTEtMS0w_afe1bd3e-868a-4c8d-8299-09ad86c04b65"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idfe0ad5afa984d16ba94c0190f3a7bb7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfNS0xLTEtMS0w_f332c0ac-e464-41f5-8a3e-88a5cd821d2a"
      unitRef="shares">238765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idfe0ad5afa984d16ba94c0190f3a7bb7_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjZmZTViZjQ4N2NmMTRiODA5MmY4N2Q0ZWNhMTRkNGI4L3RhYmxlcmFuZ2U6NmZlNWJmNDg3Y2YxNGI4MDkyZjg3ZDRlY2ExNGQ0YjhfNS0zLTEtMS0w_49ee1917-8b06-43f2-ac60-4c18aaaff081"
      unitRef="usdPerShare">55.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibc517a1325e3471bb6ee91315080f545_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTczMA_5b9b01ad-62b6-4d89-b93b-36daa7cc6020"
      unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i13ac445102f7441f9e4b8ba54ae46f21_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTk0MA_371f2534-0add-438a-bcaf-ba71cb080198">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1d0177361b9c4b0b90dc4288e2d48078_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMTk0OA_91f318c2-9f97-4532-a51d-af6d2df88b12"
      unitRef="usd">11300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <agio:ScheduleOfMarketBasedUnitsActivityTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzUwMw_f82b98e0-a044-4696-a98d-a30606ad7554">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.838%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.787%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.385%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.790%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested shares at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:ScheduleOfMarketBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i256d78b2b36e45f28bd9b75429058398_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMS0xLTEtMS0w_843eef46-f8e2-4f6a-9e54-4fe07e8c7298"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i256d78b2b36e45f28bd9b75429058398_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMS0zLTEtMS0w_de3935c9-829b-465a-91ca-5cc0292bf35c"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMi0xLTEtMS0w_4e8c1b82-768d-430f-9286-4b7ccb33c968"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfMi0zLTEtMS0w_8662c291-8dd0-4bc0-b4ff-5f2c73ff4d0c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i899a9e83495b4f28b410853e4bd3e1a9_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfNS0xLTEtMS0w_59dd50e3-383c-4120-a7fb-f42220ab17d5"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i899a9e83495b4f28b410853e4bd3e1a9_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmNiMTNkNDhhYmQ5MDRhZDNiYzExYWUyY2Q0ZTY4MTY1L3RhYmxlcmFuZ2U6Y2IxM2Q0OGFiZDkwNGFkM2JjMTFhZTJjZDRlNjgxNjVfNS0zLTEtMS0w_8aecc0ef-b832-4cb5-bd7e-78eff02f1e73"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i899a9e83495b4f28b410853e4bd3e1a9_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjUxMA_11e83fd4-96e7-40cb-a75a-560dfee778e7"
      unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ida5205279d0f406f88eb5f89f7706211_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjY0Nw_5d5fa787-9f52-4be6-a0b7-d0e3430b9834">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i28d21d465e804cd7be91d92333466787_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjg0Mg_0d7ed0a4-ac83-4ff9-b9ff-a42d83edce89"
      unitRef="shares">62694</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic8dacf8900174e15a3112799baf17da0_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMjg0OQ_f84d3e5c-9893-4bd8-a75a-506ba5ca33a5"
      unitRef="shares">32410</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i28d21d465e804cd7be91d92333466787_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzAzNA_48ecac9c-6a90-4104-b573-5b214e37f458"
      unitRef="shares">836363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3e96f9d80bf045189e770a60c9426d0f_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzA4Mg_abf001da-f9b4-4d5d-bd1b-f8e93c3043e4"
      unitRef="shares">528952</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzQ5NQ_204a286e-f1c9-4b1b-801a-f809d64134ce">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id544e772704d4df68d5aafeb2c9bb919_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMi0xLTEtMS0w_043a1a0f-3ac7-4319-b711-e1eea5cc120c"
      unitRef="usd">11603000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00295454cded4864b99639e493192cdc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMi0zLTEtMS0w_fffd50d4-0a5d-4ee8-acc4-2075a71a8203"
      unitRef="usd">13046000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8227bb95e18c4d24bc3a21bc02f8d1f4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMy0xLTEtMS0w_0fa14b50-7e11-4459-967e-18ba3e9b521c"
      unitRef="usd">6132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida2a85e29bc44bb4b78adcee2aa8a238_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfMy0zLTEtMS0w_80b03a3d-3f5e-4355-9f7a-90d53fbc46d9"
      unitRef="usd">4548000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i458a6e5895e2457b9575fb921714653a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0xLTEtMS0xNzU3_7c25b58a-7994-48e5-b1a7-3d5a4c1a43ba"
      unitRef="usd">1388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b778fd9cd91494abee392de786ad04e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0zLTEtMS0xNzU3_274dffd8-4e5e-4d03-8619-da1d8682a565"
      unitRef="usd">186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3964e595953c4f299314ea4efb11d354_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0xLTEtMS0w_4c8644f4-5756-415d-a94c-6424e9bf7314"
      unitRef="usd">297000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b1c325e2dd54b6aa424bba94309ad67_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNC0zLTEtMS0w_6c88c562-924d-4f41-b769-14b4585ef969"
      unitRef="usd">328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i02d3013b6a4c4bdbae10be0d1e36aeec_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNS0xLTEtMS0w_54b10d6c-e07d-4eb0-817b-635d46167ee1"
      unitRef="usd">270000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4533663f1404a6c94d173dbdd0d8fe6_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNS0zLTEtMS0w_89a1a4ab-9818-4d61-b4e6-3ab153767956"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNi0xLTEtMS0w_34037a9f-24c6-4637-a618-37cc72e4ed75"
      unitRef="usd">19690000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOjc4Yzg5OTAwMWZhYzQzMGI5OWExNjg0ZDFiMWFhMGUzL3RhYmxlcmFuZ2U6NzhjODk5MDAxZmFjNDMwYjk5YTE2ODRkMWIxYWEwZTNfNi0zLTEtMS0w_9d0b7654-d060-4fd1-a6dc-d9c2e04d346d"
      unitRef="usd">18108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RleHRyZWdpb246MzBhYjMwN2Q3YTkyNDNlYjg2YmYwMzAyMDBmNGNiNTVfMzUwNA_15322ca2-1088-48e3-aeee-5efc1f9f67c6">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.707%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.283%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifc2e58225fba4370abf79603604d587c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMi0xLTEtMS0w_a63e32e6-446a-43f9-8662-1d0e329c9b80"
      unitRef="usd">9564000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i85f2e56eb9624864a6a945bcd372afda_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMi0zLTEtMS0w_abfb35df-7430-4dd7-840d-df32542bfee6"
      unitRef="usd">10042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic09bbe0bec9644d0bdb9f127f396b6ee_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMy0xLTEtMS0w_08329712-a71c-434e-af64-9786072a7e2b"
      unitRef="usd">10126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2c6cd3484924f04bded7e03913923fb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfMy0zLTEtMS0w_f676ebd7-e071-4f53-ac36-6f7747a8dad9"
      unitRef="usd">8066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfNC0xLTEtMS0w_c287f6d1-efe2-457f-8c78-9b6028c8ce02"
      unitRef="usd">19690000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182MS9mcmFnOjMwYWIzMDdkN2E5MjQzZWI4NmJmMDMwMjAwZjRjYjU1L3RhYmxlOmU0MmE4YzAwNmJkNjRjZmZhMzgzMjM5NTA0MzcxZDZlL3RhYmxlcmFuZ2U6ZTQyYThjMDA2YmQ2NGNmZmEzODMyMzk1MDQzNzFkNmVfNC0zLTEtMS0w_5cbb40a6-ec59-482a-b5a9-7dec47417a27"
      unitRef="usd">18108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RleHRyZWdpb246MjljM2RjYWYxNDNjNDAzODlmZjMzY2Y0MDNiNDZlMDBfMTI2NQ_6c218006-38a0-4a9a-b105-d8df0094f48d">Loss per Share&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March&#160;31, 2020 are not considered to be common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Since we had a net loss for all periods presented, the effect of all potentially dilutive securities is anti-dilutive. Accordingly, basic and diluted net loss per share was the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.834%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.215%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,749,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,482,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,290,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,132,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,198,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RleHRyZWdpb246MjljM2RjYWYxNDNjNDAzODlmZjMzY2Y0MDNiNDZlMDBfMTI2Ng_756451b7-7a4c-44be-a21a-ef971dcdcf0a">March&#160;31, 2020 are not considered to be common stock equivalents.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RleHRyZWdpb246MjljM2RjYWYxNDNjNDAzODlmZjMzY2Y0MDNiNDZlMDBfMTI2OA_0996eb76-5298-4855-8a87-827859333a9f">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.834%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.215%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,749,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,482,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,290,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,132,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,198,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i63d93efc8a284556ab8f020edd3dc6e0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0xLTEtMS0w_821fe710-4750-481e-8899-c0fe40168c64"
      unitRef="shares">6749373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i63d93efc8a284556ab8f020edd3dc6e0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0xLTEtMS0w_969e42c3-2bdf-4f0c-b610-ff61d4856024"
      unitRef="shares">6749373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0a127ee084474fe89e94f05cb952f47b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0zLTEtMS0w_c6e8dcb6-a85f-4068-88c7-0d021d27f662"
      unitRef="shares">6482873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0a127ee084474fe89e94f05cb952f47b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMi0zLTEtMS0w_cb63dd71-d57c-44af-9d83-5ea5874ca1ee"
      unitRef="shares">6482873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i091c1b621ade4bb9a85dbc64bfb48525_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0xLTEtMS0w_36bd97bf-3ccc-4248-a313-8f4b990b6372"
      unitRef="shares">1290875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i091c1b621ade4bb9a85dbc64bfb48525_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0xLTEtMS0w_438eb214-2c20-413d-bbfd-fb1c4f24d1f6"
      unitRef="shares">1290875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7729db14fc3848fe915720a14a4de566_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0zLTEtMS0w_08b66426-1d37-4980-b63b-e45a726be979"
      unitRef="shares">709162</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7729db14fc3848fe915720a14a4de566_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfMy0zLTEtMS0w_58c611d0-57d0-4b4f-956f-d8b50b6641fc"
      unitRef="shares">709162</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a6e57a772564177acc7f7a661b71d0f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0xLTEtMS0w_cc2114b1-b7f6-4540-a22e-ff68a336d5e3"
      unitRef="shares">78920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a6e57a772564177acc7f7a661b71d0f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0xLTEtMS0w_eb3b1973-5441-47f2-8478-f5849a21f979"
      unitRef="shares">78920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic07875a2aa9f4507b1f46ea8b5fed18d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0zLTEtMS0w_7823d8e7-37ad-465b-89d4-2d7a5b074bc7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic07875a2aa9f4507b1f46ea8b5fed18d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNC0zLTEtMS0w_ce9daf8f-ffb2-4d4a-b122-fa259f29cc58"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c7313c325334ec4b2e51b1fbd9a8afb_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0xLTEtMS0w_56f7031e-03b2-4871-9315-0f0748409904"
      unitRef="shares">13430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c7313c325334ec4b2e51b1fbd9a8afb_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0xLTEtMS0w_d24cd8bf-ad1d-41a1-82e3-1f98654259a9"
      unitRef="shares">13430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i429a7cb2f66d4ba1976785a1a8199946_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0zLTEtMS0w_1a02028c-9ca4-48af-a3a4-8a6f7105edc3"
      unitRef="shares">6778</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i429a7cb2f66d4ba1976785a1a8199946_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNS0zLTEtMS0w_54337ea6-d076-43d5-b70f-2d8aef74d4d9"
      unitRef="shares">6778</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0xLTEtMS0w_1974ece4-d5d6-44c7-8e8d-c513494b150e"
      unitRef="shares">8132598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icdfe999b2ec0463f862b8e809b32b0cf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0xLTEtMS0w_958a914e-11a4-459b-9da2-63a8d5167b9c"
      unitRef="shares">8132598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0zLTEtMS0w_4629ce3e-8097-4643-ac73-1ec4f54c091e"
      unitRef="shares">7198813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib37208e30fc641978c63e725033d8b60_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNzFjOWE3YTUzZDQ4NDU4YTk2OWRmMWE3Y2QwNWE3L3NlYzo3YzcxYzlhN2E1M2Q0ODQ1OGE5NjlkZjFhN2NkMDVhN182NC9mcmFnOjI5YzNkY2FmMTQzYzQwMzg5ZmYzM2NmNDAzYjQ2ZTAwL3RhYmxlOjk0ZWQzNGEwZTZhNDQxZjFiNjczOGU4MzRkMGQ1MjMwL3RhYmxlcmFuZ2U6OTRlZDM0YTBlNmE0NDFmMWI2NzM4ZTgzNGQwZDUyMzBfNi0zLTEtMS0w_6000a024-9656-4e08-8664-b03c7380c0c3"
      unitRef="shares">7198813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782630688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Expenses Related to Equity-Based Awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,690<span></span>
</td>
<td class="nump">$ 18,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">9,564<span></span>
</td>
<td class="nump">10,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,126<span></span>
</td>
<td class="nump">$ 8,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6947846960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options, outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">6,201,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options, granted (in shares) | shares</a></td>
<td class="nump">792,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of stock options, exercised (in shares) | shares</a></td>
<td class="num">(133,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock options, forfeited/expired (in shares) | shares</a></td>
<td class="num">(110,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options, outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">6,749,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options, exercisable (in shares) | shares</a></td>
<td class="nump">3,874,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of stock options, vested and expected to vest (in shares) | shares</a></td>
<td class="nump">6,749,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 58.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised (in usd per share) | $ / shares</a></td>
<td class="nump">25.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited/expired (in usd per share) | $ / shares</a></td>
<td class="nump">69.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">58.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">59.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">$ 58.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6655930112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gain (loss) on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear', window );">Debt securities in an unrealized loss position | security</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Aggregate fair value of debt securities in an unrealized loss position</a></td>
<td class="nump">$ 224,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments that have been in a continuous unrealized loss position for greater than or equal to a year for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762699376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining 2020</a></td>
<td class="nump">$ 9,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">14,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">16,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">18,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">18,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix', window );">2025</a></td>
<td class="nump">19,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix', window );">Thereafter</a></td>
<td class="nump">44,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted minimum rental commitments</a></td>
<td class="nump">141,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="num">(30,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 110,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due After Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseLiabilityPaymentsDueYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763955328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.721%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763955328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of March&#160;31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:48.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.750%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">524,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">524,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,853&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">544,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">598,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of March&#160;31, 2020.</span></div>There have been no changes to the valuation methods during the three months ended March 31, 2020. We evaluate transfers between levels at the end of each reporting period. We have no financial assets or liabilities that were classified as Level 3 at any point during the three months ended March 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6940135968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text">Loss per Share<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March&#160;31, 2020 are not considered to be common stock equivalents.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since we had a net loss for all periods presented, the effect of all potentially dilutive securities is anti-dilutive. Accordingly, basic and diluted net loss per share was the same for all periods presented.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:70.834%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.215%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.217%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,749,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,482,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,290,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709,162&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance-based stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,132,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,198,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1.5pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
